
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:6b34b432-c0a0-452f-ac73-317c12512b86,g:c0d24525-6b97-4eba-9dda-a8971b8c6054,d:ad55818e5d094e70a171c29f2aae2512--><meta http-equiv="Content-Type" content="text/html">


<title>myov-20210331</title><div style="display:none"><ix:header><ix:hidden><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityCentralIndexKey" id="fact-identifier-0" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80L2ZyYWc6OThiNzMyNzdjNzIzNDQ2MWJhZTgyOWY2ZjhmMzJmZDcvdGFibGU6ODVjMzI4NGE2OGVlNGE5MDliZDZhNjI2NWFkMzMzN2YvdGFibGVyYW5nZTo4NWMzMjg0YTY4ZWU0YTkwOWJkNmE2MjY1YWQzMzM3Zl8zLTEtMS0xLTA_b49de6e0-ab66-4306-aadf-d7d49ad1803e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0001679082</ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:AmendmentFlag" id="fact-identifier-1" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80L2ZyYWc6OThiNzMyNzdjNzIzNDQ2MWJhZTgyOWY2ZjhmMzJmZDcvdGFibGU6ODVjMzI4NGE2OGVlNGE5MDliZDZhNjI2NWFkMzMzN2YvdGFibGVyYW5nZTo4NWMzMjg0YTY4ZWU0YTkwOWJkNmE2MjY1YWQzMzM3Zl80LTEtMS0xLTA_1420e027-6f45-4e03-b3ae-b0cc3bf4f9c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">false</ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:DocumentFiscalYearFocus" id="fact-identifier-2" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80L2ZyYWc6OThiNzMyNzdjNzIzNDQ2MWJhZTgyOWY2ZjhmMzJmZDcvdGFibGU6ODVjMzI4NGE2OGVlNGE5MDliZDZhNjI2NWFkMzMzN2YvdGFibGVyYW5nZTo4NWMzMjg0YTY4ZWU0YTkwOWJkNmE2MjY1YWQzMzM3Zl82LTEtMS0xLTA_0c6aafb1-648c-44da-8542-f9bf1e3b3561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">2021</ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:DocumentFiscalPeriodFocus" id="fact-identifier-3" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80L2ZyYWc6OThiNzMyNzdjNzIzNDQ2MWJhZTgyOWY2ZjhmMzJmZDcvdGFibGU6ODVjMzI4NGE2OGVlNGE5MDliZDZhNjI2NWFkMzMzN2YvdGFibGVyYW5nZTo4NWMzMjg0YTY4ZWU0YTkwOWJkNmE2MjY1YWQzMzM3Zl83LTEtMS0xLTA_37a486cb-7491-4fee-ab25-bcc8265fcf60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">FY</ix:nonnumeric></span><ix:nonnumeric id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTY2MzQ0Ng_bf18bf41-873f-4c43-905e-ef781ff57372">P3Y</ix:nonnumeric><span><ix:nonfraction unitref="number" contextref="i70c22e7ba07e49bca70d22170efedbfc_D20200401-20210331" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="0" id="fact-identifier-4" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMzQyL2ZyYWc6OGIzMDQyNDdmMjg1NDIwYmEyNWRlMWJkYzJhZjg5MTAvdGV4dHJlZ2lvbjo4YjMwNDI0N2YyODU0MjBiYTI1ZGUxYmRjMmFmODkxMF81NDk3NTU4MTM5MzY1_5d4d7668-fd26-419b-887e-db6b5af46f30" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">0.3333</ix:nonfraction></span><span><ix:nonfraction unitref="number" contextref="i70c22e7ba07e49bca70d22170efedbfc_D20200401-20210331" decimals="3" name="myov:ShareBasedCompensationArrangementByShareBasedPaymentAwardQuarterlyAwardVestingRightsPercentage" scale="0" id="fact-identifier-5" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMzQyL2ZyYWc6OGIzMDQyNDdmMjg1NDIwYmEyNWRlMWJkYzJhZjg5MTAvdGV4dHJlZ2lvbjo4YjMwNDI0N2YyODU0MjBiYTI1ZGUxYmRjMmFmODkxMF81NDk3NTU4MTM5Mzg5_cf0ccf62-9cbc-4011-a74f-ac44d5ecf456" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="false" iscustomonly="true">0.125</ix:nonfraction></span><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="fact-identifier-6" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMzA0L2ZyYWc6NGM3OGZhMDhiNmVmNDJmM2E2MjkwNzdjMjA2NGYwNDAvdGV4dHJlZ2lvbjo0Yzc4ZmEwOGI2ZWY0MmYzYTYyOTA3N2MyMDY0ZjA0MF81NDk3NTU4MTM5MzQ5_b2a766a8-df17-4824-a192-9c4b2a287106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">50</ix:nonfraction></span><span><ix:nonnumeric contextref="ide7e9364c9d14ffaa6a10a9d7d4471ed_I20210331" format="ixt-sec:durmonth" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="fact-identifier-7" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82NC9mcmFnOmZhMWRmOWJlYzFkYTRkODFiZmQzOWRiNWNkZGI5YTE2L3RleHRyZWdpb246ZmExZGY5YmVjMWRhNGQ4MWJmZDM5ZGI1Y2RkYjlhMTZfNTQ5NzU1ODEzODkzMA_100cf032-e6e3-41f9-a097-1adf84843b2c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="true" isstandardonly="true" iscustomonly="false">12</ix:nonnumeric></span></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="myov-20210331.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9a8ff5c82bc340319c0983d9fcd15cbe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2f7fd4366b954df29a9e99de5dc2ed36_I20210506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4958360cbf8427f96c2932708912fc8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e16053900e4008a01ad86b6cb3f057_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0779d6358d4c59af7d0b42d81c8e3e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide85e32a24044ffc979f12f625b7267c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="iffc37857417e4a9f8b585b4b4ca869dc_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if10a70d569d04a69ae8cd6c0fd2d95b3_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieb70d87d00f54750a09b71cd219de7d5_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i64014c60d448460e85581076c2cd76d0_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic265aae726454c4089f67ca1ee78a7a7_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i160c41394db246a5882746745393046e_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i476d00d6d1d74cb3bf79fd01cf60745a_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8cf1a2d33619471aa16d38eb9243e185_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:ProductAndRoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8b4a4133e70b4c39a775c1259ddb1bcd_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:ProductAndRoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i34570be86f5c4d238bc3375d7a2642fa_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:ProductAndRoyaltyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2fca78b28e13473bbba9cab0265c782f_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:CollaborationAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i054c7fc8b51e4b05a98a285ed6f44dce_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:CollaborationAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9641067803a1427698e5ea7056683ff2_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:CollaborationAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3c23f8eed98b444c9c9270d7a5adc3e3_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCoLtdAndSunovionPharmaceuticalsIncMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if349c6471a15451d8608a9388e4a832b_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2321815be65048179f59af7408ba61d4_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i61d0175b2e42410da8d8b92684250864_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68945742841b40e68e0478668b632941_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9dcc325cc19453e834f9bdedc5ff57e_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956394f3bf6348cca5d26f889b906891_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaaac77afb624e62b09f40c92b485ea0_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2976f6ca9974c84a27bd4800eb31e6a_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie385a303d391492087df1a4e47452b8a_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ada8c2f2f3b4d69b0a3fe2eb9295c9d_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0137e39b3dca4703939d787a21b30d7b_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i90226e0502534a7687a95bbda83d0759_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5db119d101d64f3fa903075699a23d4b_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if307d320921b49eaa929b311c7c0587c_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idaeb13ab941f462f8dd689170cd64c01_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e33c24894de473e812d75848df1f2b4_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i497ad0ffa4584983bacd47a8166fb918_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99ca3e98a7d04bb797aeb3113f6ce0db_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3db108d1008d4bf089c98bfaa7f9a1c7_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:NovaQuestCapitalManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06cfff86bba34830a947e138a4da05a6_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:NovaQuestCapitalManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie8ce49038ae1495195d828b434b81c44_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:NovaQuestCapitalManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i28ca06d3712d432e89160d8b9d21b785_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a218cb0267c4d579e747d655e88b3a1_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i45f4aa5653414da7ae04aa838147d6cc_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562afd9841c148ca9384190c6e0102cd_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66ce50bb7a0c498d9ea0450a13c6e803_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ac1aba889714a8984ad9d9a6bd42a72_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0db7a698575433cb3c4c18d7405a592_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9617fb45d9424787a8eafd2ba4e4de52_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2273728e14114fa392000925352b6a83_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4a859c7761234c979689270973d3badc_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b4f10066b2947649f8511819ee273e0_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0a287ab55ddc4ea8843a5299da4de0d2_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id670791c2abf4c7590246e9218224792_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib6e12f6acf3147a5a74844e2373b7c41_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i19fdc1f929614896983285ba13d2fe37_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8fda2b40754b4565bba683c66721b63f_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib0c4217a5fc141e0bb845d65ef5ac4be_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i18069b355e1c466c9d9d58d5de4fd598_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01aa3463454442781e4dcad06c1fd71_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0c80634e601403fa4e2efd8a7f3492f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibefe2a474ee14ff3975172141efdb176_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6e48627d4625437a8773e7da5c3ce588_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia6fe03c315034c978a108ee01765c807_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i78be8e9dc90f48a78cf2ec4656e47a13_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7e3a32c9a2a5400a8e24118bf404b14d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41653fb53f874e489854f639ad2a842e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f5a48a02db4820b68629ff4c7ef6f1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i157c79b0fe854791ae5956a9797a6af4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bdf6a726fa9489bbf814c38dbe12bb1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>myov:segment</xbrli:measure></xbrli:unit><xbrli:context id="ie7c3c15401904be1bb4d741769a60966_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734cf075e84444f4acaa76dbe31c5fc1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id065c50329c0435a88678e4da94aabf5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b3e2c62d8349449f7511695df8a9c7_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6a4d7bea8057460ea21e7aed4564004b_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e17d3c7464149bc9fdb25c557e46a14_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i131004c9c7534d6096944aef3ce9f4a7_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i278b998c8dd24659b492f5d16d108ab9_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib6e5a3d7a6124d999c6a0938694445bc_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8a5c8a215cac437da65fb0d335451cdb_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i627594ceb5664d49be7e2a6b91d8f7cc_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8ee355aa008e4b919ff1f014345b7efa_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8bc94df2f5824d348f6acdeca26456cd_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i171aa1d8fad04b9b8343dd08b02f156d_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie4704b12df0247899d9b7694353be980_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i807d21c1ce3b49c4b1f962e6d45a953a_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50492cdba76f4a2c989a79fba0f76dd7_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2fca2879d16d43a79b79683f7c737832_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3231f0283b4c4951a38d1fb1ad37ef99_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i57ae0204ce764ee4a4aa18b6e29aa73e_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i11d3054f377c4832b8baae30c9d29217_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic2a1fcaa43dd4ba09f221ca93334cbd5_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i885de4632f2f4f5e81aacf1de28d14a0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c683190990845059125c172f9b1fa01_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f73bf49238419393cd4e679f52d393_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf49e669868a4e9ab6d2c55a04639227_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i891fd5fe3ae841a08bdba3fe0440ddb0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if96e2b8e3f0a4faa80c9b4b7ee6ef3b9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b5762808e6471e8285272362002aee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58410d84411e4228b07957f367d15604_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2cf551e1ada45db84803530ba43d154_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb614ae82ff40b89b4a9bf367375a2b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a26269ffc74aa6aa735e6580e255c5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6fa0e7020d04c22a2ca3474cd2425d6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AgencySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56aaf6c9864e4e498d30ad564413e854_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9e7b4057c44456b5e16d5ff9659b19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a5784f2341d4e5496417b3db6a6e72a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4927fb5b0049f485113a70c734f1bd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01ec2294762e4a2eafc8e26ccee9cdd4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1321682262914bc28a3678c5f5ceaf28_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29bd15f1b5a64babba09049ab611472c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857193c97d064fabb83622b2b3184d72_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72948c6873ba49259e4cfdb9658da1eb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63472d3e281749c888b95118c532c344_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a459494ae548db92ec3041a7cba918_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64fe2b17225542d5a0739c08fe62ea19_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d22f0608d204604b314c21ac395dc56_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5d3b9559f684ecdbfde2c64fa129619_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e7e8729d8f4b65897a8a049c08a7ef_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50255dd008f84caabcc561482fa93d44_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4ca920475ba4c73a2da8f88212c5ab5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e334f346fa842e1b7fe7fb7067eacc2_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae280cc9cfa444ffa7de102360134b36_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb23059f75734fc9814e788938085e12_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fbe8fefb4d4af99e6fed0a9798c21e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib688a00110d44bcf8d9419108d0490eb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf108e4e3337490982bc5fb425e92241_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cfe925475f6445a816ad4aa1f7a2bfd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i578f0e94f204426a8c8544dd95205d25_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdc539f16644461d991f2f9544dbf5a4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibacbcb1b777a4bf0a7ac6c7fa8ba001a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i484fef3f009e468296994707b244cc57_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50395313737f4a87bae3709486199473_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">myov:DeferredCompensationShareBasedArrangementsLiabilityCurrentAndNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b59a0f9a234053ad56fc8afab847da_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">myov:DeferredCompensationShareBasedArrangementsLiabilityCurrentAndNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iadaccd1fd0144ec59b82072c231826a9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByLiabilityClassAxis">myov:DeferredCompensationShareBasedArrangementsLiabilityCurrentAndNoncurrentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b6b4d80d01b4760b029dda88ffcfc72_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10aa586237574aa5b94b40ab6b856730_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90aad34de6084b32a181ae0a496e7ca6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if429dd30dbc445c78cf10e392deda5dd_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b42ffe7d5247a48d2613a2ba51c318_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaad3b7e595a4db6ab4652ce0ba17288_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87704afbd47e4c3fbcee55bdac8de957_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9360b3da6344330938a4422d2b0310e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b6dccd158e48bab7ae301a7d31dab4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb9c7aa071245da888c0085e5e94393_I20191227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31619c59bc56433da9b58960beb6deb1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b6f9c4aba04aed805c0ad1552c617f_I20191227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6da7876d2d984f1989f9551f9414c11d_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-30</xbrli:startdate><xbrli:enddate>2019-12-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia132fcc98f8344e48bc0ade25c62e279_D20191227-20191227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-27</xbrli:startdate><xbrli:enddate>2019-12-27</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>myov:day</xbrli:measure></xbrli:unit><xbrli:context id="ic8506fd4deba4888887e458f53b8d9eb_D20191227-20191227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-27</xbrli:startdate><xbrli:enddate>2019-12-27</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia3918c63054242939eeae92e8a94c3fc_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5987f96b69294f2a974591d09ad4090e_I20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:NewLetterAgreementWithSumitomoDainipponPharmaCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8d8416cdebc49a890e4f715ae8dd36f_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:NewLetterAgreementWithSumitomoDainipponPharmaCoLtdMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-08-05</xbrli:startdate><xbrli:enddate>2020-08-05</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="director"><xbrli:measure>myov:director</xbrli:measure></xbrli:unit><xbrli:context id="i5756aa52883647099d0210d84468a1de_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SumitovantConsultingAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2424089909134b219d8b45206607f606_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SumitovantOtherExpensesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i098be655fd164bf8bb18c9e6456e5b1d_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SunovionPharmaceuticalsIncMarketAccessServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13eeda6118504b7587cf747dc8a8c35b_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SunovionPharmaceuticalsIncMarketAccessServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3bc1b689495d4b0ea89f1121a0f7efed_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SunovionPharmaceuticalsIncMarketAccessServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1448dada7e44c119525efcd8834611b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SunovionPharmaceuticalsIncMarketAccessServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3491bf2316473eac9c17ba0357696f_D20200801-20200801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SunovionPharmaceuticalsIncMarketAccessServicesAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:SumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-08-01</xbrli:startdate><xbrli:enddate>2020-08-01</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib86468a4aec1412fa885b2c37c4d74f4_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:ServiceAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1ef90652a2774279a6894949a90858ce_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:ServiceAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i26ee01ab67dc4d45a073e3ba7692b58d_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SharebasedCompensationExpenseAllocatedtoCompanyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4edf3e64c51546e9a494ccfb75044950_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SharebasedCompensationExpenseAllocatedtoCompanyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i89a0be85f2a94755a4b41da13a0951d4_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">myov:SharebasedCompensationExpenseAllocatedtoCompanyMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i583dba94ffec43e3a6c5b60504593422_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2018-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3ac1ba231f864c0ba68c62cd4ac8c6fa_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aeedb3fe99b483c96f39fb1ee6667d0_D20190604-20190604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-06-04</xbrli:startdate><xbrli:enddate>2019-06-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9151d09e403a4f679ee57f92a9e435db_I20190604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">myov:FormerMajorityShareholderMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6ec7b5f521a49cfbdf29d3e1054fe6d_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:NovaQuestSecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb7af4431d74692aeea06e9b6f26b22_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:NovaQuestSecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-10-01</xbrli:startdate><xbrli:enddate>2017-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i511b27955033485ca29467861a8a30c1_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:NovaQuestSecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-12-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3c6a7e43a07a445bb6ee43204163e121_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:NovaQuestCapitalManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-10-01</xbrli:startdate><xbrli:enddate>2017-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i17c9577c2c374eb9b251cc212818a8ce_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PrivatePlacementOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:NovaQuestCapitalManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-12-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2b181681ceba475a83f43380db82ff1e_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae586a67793b4c4081bca0c227d89254_D20181201-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PrivatePlacementTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:NovaQuestCapitalManagementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-12-01</xbrli:startdate><xbrli:enddate>2018-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibb34819b1fb34ad7a90edd9186712354_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:NovaQuestSecuritiesPurchaseAgreementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-31</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if31bc18712f54ed5b7976efc86b9431a_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:HerculesLoanAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a537794db3241879fd7283f5a37d6e0_I20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:HerculesLoanAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b353bff16f4f979281cb0eeb5bd76b_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:HerculesLoanAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2017-10-01</xbrli:startdate><xbrli:enddate>2017-10-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6a9698cfea346919d3afa18e9509386_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i517a68709a264788ae218910401dd878_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19cc100bd7eb48298cf42e393b74368c_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia28abb24d77e4e27941b5b8085f308a4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10afd77d191141b282bd2f6c59d14a68_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:HerculesLoanAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-31</xbrli:startdate><xbrli:enddate>2019-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib32c3f94129e4d8dbefac7fa4eab5150_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">myov:LetterAgreementwithSumitomoDainipponPharmaCo.Ltd.Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i047d00c0aa49447f86371a50ead75251_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if8d0c33fa7d641b3a55d026773e9791f_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba5f1ef5b53f477382efecb52f98ad5b_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0bc872e5bed54456af67853bb6d75ea5_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i397ea0b6bb4c48888fb9e05fb2d644a8_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie717b325af6b452c9511eec4b94e1d0f_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i117e18ee6bd0423daab8385d7f6a7dd5_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">myov:OtherGeographicalAreaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i836bc805fa8a40eabe761ae065cc0ac2_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">myov:OtherGeographicalAreaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9ed39e866d0540169f628f2b8a83e88b_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">myov:OtherGeographicalAreaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i90a89ad745cc4430a45ae443473d907e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b05c42fa7946719c0649d510655f73_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia050f9c6320246b68eaaa2414e7bf09d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14cb036be58049a5a1e6ef1933f1f5d9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27c0afbf0b9429b90af8a081e74358f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="class"><xbrli:measure>myov:class</xbrli:measure></xbrli:unit><xbrli:context id="idbe6fbaf66b8452f81c58753e6162dbe_I20160202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b15f058a9d4ed3a6aad08a0a1f4339_D20190604-20190604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-06-04</xbrli:startdate><xbrli:enddate>2019-06-04</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i31ea3c0b682048259654ea71d2e26d84_I20190604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">myov:PublicStockOfferingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99c173fc4a03493fa8326c6e2dc82492_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2018-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c2361102bdb408e86893b0add5297f9_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RoivantSciencesLtd.Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b87553fb87b4999b2ca0bcb634c4d5a_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4e1aedd77242baab4668c4efdf0daa_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c23fa554dc24d70ab6393e0fd1f4b90_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8399c5bfe14297aeae28b517791725_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:CowenandCompanyLLCMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>myov:plan</xbrli:measure></xbrli:unit><xbrli:context id="i32426dc54f2e4f90a2e28216c0ba82f3_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">myov:A2020InducementEquityAwardPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8b6bed0cf54930a7276e9765285fb2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">myov:A2020InducementEquityAwardPlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c956a8a25046c3a5d7c63adaa2143e_I20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">myov:A2016EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5241b229576a4e2cbf7ec1780e27f524_D20200401-20200401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">myov:A2016EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2020-04-01</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i75760b3f086640beb44c84b01be1dfd6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">myov:A2016EquityIncentivePlanMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f7e93d9c2ac463186f432b565e4eff3_D20190826-20190826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-26</xbrli:startdate><xbrli:enddate>2019-08-26</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i28fc3cb4eabd47658f50a411778d7d2a_I20190826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb854f2f89245be9c6674d2122cd54a_I20190826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">myov:ExecutivesSubjecttoExerciseRestrictionPeriodMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba9dbf39a9ec48f08ffc4b4c6f83da16_D20190826-20190826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">myov:ExecutivesSubjecttoExerciseRestrictionPeriodMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-08-26</xbrli:startdate><xbrli:enddate>2019-08-26</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib1cbbf17f4a349698c18de77532fec91_I20190825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7811a97ef23b4fd2a2148d9e87cb4926_I20190825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id71ac72af0e646d9abe133492e4c342b_I20190825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia096d573ae55428e8102aa9304361433_I20190825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:SharebasedPaymentArrangementOptionRepricedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MedianMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb05b7ba93bf4df3b372ea71154cc993_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">myov:EmployeeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i70c22e7ba07e49bca70d22170efedbfc_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36f53a993a4146c1888a0c675b260515_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i90720c8c13874fdfa2b23bc51da1625c_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-11</xbrli:startdate><xbrli:enddate>2021-01-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i96bf59ca87ae4224a3f6fafdb761f652_D20191227-20191227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-27</xbrli:startdate><xbrli:enddate>2019-12-27</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1058bec0d4b47e691d283c4993b14c8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:RestrictedStockandRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:RestrictedStockandRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1737e566bd44f8b8435e57c4feba528_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:RestrictedStockandRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i304044cb65b442898864be253c282710_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i58f241cf3fa24ccea9c80d6ec35d1efe_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i50fc65ab07b54ae597dfaf23f929a717_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id805a53b9e34474c87c15f68904f6e27_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i24619cb8370c4b89881651dafb755384_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d57aa4bb3604940926187a3dc104911_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ebbcc65387e437fa11813698fd3cc6f_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">myov:RestrictedStockandRestrictedStockUnitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-11</xbrli:startdate><xbrli:enddate>2021-01-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9149eff2546a482b9623ca978c96029e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9282900d85f4e61a6640fa57fa2d94e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aebd06af1e64f6886dbabbe89d571c9_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f8caf25584b4da188a7de5664bd00e8_D20210111-20210111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-11</xbrli:startdate><xbrli:enddate>2021-01-11</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9a71c67d637d45b4aae1044295a0d400_D20191227-20191227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-12-27</xbrli:startdate><xbrli:enddate>2019-12-27</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9363e7bcddf6409d9aeaee3886fe120a_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b0ef5ffb409492c9f1ad8de38a11d0f_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i55758c0b672b4d2190b469f98d727337_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0b349076eee24e72985f2f7149553ff4_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa4b19acee2240339519e89669f21fb1_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib810827a8c0640e9be2f9040c365c032_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i9869138a4ffc4913b7c3be038c825154_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">myov:BrisbaneCaliforniaOfficeSpaceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4171948bbae41ff91528d566150c7fa_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">myov:AdditionalBrisbaneCaliforniaOfficeSpaceMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4569e20bd4b438cb3359b35b3188cb9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15ef4be74c044cfa83fb759b9e4b67a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i548d8ee3aebb4ee2b6dee329307a72d2_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a36b0d7806242bb988c0664ee8df284_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2020-04-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5cadb7c1daa7462598ef501d9080b3db_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b63da2c0ef541a290ca09a7f8a95eb2_D20190401-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2019-04-01</xbrli:startdate><xbrli:enddate>2020-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9657129676304a97b4d602ca97c7f65a_D20180401-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-04-01</xbrli:startdate><xbrli:enddate>2019-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9e2f61c09c543a3824cb5ffdba7b10d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:typedmember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain>2021-04-01</us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain></xbrldi:typedmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:RichterMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a9e43d4547546e58bff6661329d1f19_I20201226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedbcb7ee89d145d38a3c70f01ca35893_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-12-01</xbrli:startdate><xbrli:enddate>2020-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if88b1311809844dc8de95731d40742f4_D20201226-20201226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-12-26</xbrli:startdate><xbrli:enddate>2020-12-26</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia215322f49eb490fa54bee4a811c68fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i85080f48e14b4807a46e2a1d09c8d3b0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46646f25f2014144b1e98e9522ea3954_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida9dd4331929457f91d25ee1d11bdf22_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:CollaborationAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i273b2f938fcd4cc28208ee0ff9943fc0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">myov:CollaborationAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">myov:PfizerMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ide7e9364c9d14ffaa6a10a9d7d4471ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:typedmember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain>2021-04-01</us-gaap:revenueremainingperformanceobligationexpectedtimingofsatisfactionstartdateaxis.domain></xbrldi:typedmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ab6df641ef14f30bb72bfffdd621f0a_D20200401-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SupplyCommitmentAxis">myov:CommercialManufacturingandSupplyAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2020-04-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i05ed7cbc4a1b443fa804b7e7dd5511ce_D20180530-20180530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001679082</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SupplyCommitmentAxis">myov:CommercialManufacturingandSupplyAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2018-05-30</xbrli:startdate><xbrli:enddate>2018-05-30</xbrli:enddate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNy0xLTEtMS0w_b12d24f9-f1f7-4f8a-ab59-1f6f569e84bf id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNi01LTEtMS04NzYz_5c8ec08c-52b0-4f1d-8244-926c951a39bd id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNy0zLTEtMS0w_3c65709b-03e0-467c-9ca1-2f669a52ae2b" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RleHRyZWdpb246YWEyNTUyNTYxYTIxNDdmZjkwN2Q2MWE0NDJmMzBiMTRfNDMy_eda06ed6-16ec-4c45-ac18-6ffec5e9e12c" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNy01LTEtMS04Nzcw_34827c18-f930-4feb-9d9c-3a29b6c2d7ec id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOC0zLTEtMS0w_681525c6-da84-48ab-9691-ad9fc0495b17 id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOC0xLTEtMS0w_badf4d3f-9a79-4f28-8b2e-9e0bdc502c07" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RleHRyZWdpb246YWEyNTUyNTYxYTIxNDdmZjkwN2Q2MWE0NDJmMzBiMTRfNDMx_90314d1e-1b3d-47a2-bd5d-d5f50ab487f2" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTEtOS0xLTEtMjU2NA_b84b8186-4408-466a-a00b-0d5a9b15ff58 id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTEtNy0xLTEtMA_992cac55-5caa-47ac-8f7d-57eefc826d5f id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTEtNS0xLTEtMA_929d3519-b4de-43b6-a251-e155438f33a9" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNzU4_35e53685-1e4c-44d0-a67e-84fabb7b160d" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy01LTEtMS0w_bfa657ec-8b27-4d75-8ed3-01c621126e81 id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy03LTEtMS0w_bc3f3fb9-6923-438a-9201-3664bcd15781 id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy05LTEtMS0yNTYx_c58ca93d-8a7a-46f4-b531-0db490a1dbc5" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNTQ5NzU1ODE0MTE4NA_fe39f7c2-85a4-4f1c-9b5b-85baf19f27ec" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromrefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC03LTEtMS0w_957b1efc-e204-4659-94bd-1935601fdfb4 id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC05LTEtMS0yNTYx_11bfd018-24fe-455f-9780-bcbdf9fb54bb id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC01LTEtMS0w_f18b3b75-a3be-45e9-888d-f145380909b4" linkrole="http://www.xbrl.org/2003/role/link" torefs="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNzU3_42e42f1e-cd52-4ac4-8835-0f71a5002afb" order="1"></ix:relationship></ix:resources></ix:header></div><div id="iad55818e5d094e70a171c29f2aae2512_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.005%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:DocumentType" id="fact-identifier-8" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTgz_b68666ec-0772-4962-9503-918de3b62f50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10-K</ix:nonnumeric></span></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.005%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark&nbsp;One)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="fact-identifier-9" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTg0_c8641cb3-6853-4afa-b7c6-2f617b205775" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="fact-identifier-10" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMzI_f6ffc9e2-cb52-4ecc-b5ff-199f8ef3595c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="fact-identifier-11" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMzI_972ab29a-cd9d-42fd-a4a2-bb04207b0dfe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">March&nbsp;31</ix:nonnumeric></span>, 2021</ix:nonnumeric></span></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="fact-identifier-12" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTg3_237ea55d-a00f-488b-9f57-fe112f393c8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF&nbsp;1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _______ to&nbsp;_______&nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number&nbsp;<span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityFileNumber" id="fact-identifier-13" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTg1_aa178ec3-a271-4455-860e-d2dbb37afdc3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">001-37929</ix:nonnumeric></span> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.005%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityRegistrantName" id="fact-identifier-14" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTg4_ed755e07-e2b0-4439-bf61-c7170a7d031f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Myovant Sciences Ltd.</ix:nonnumeric></span> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.005%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="fact-identifier-15" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N18wLTAtMS0xLTA_0fc21870-5d0f-4b53-a2b7-7847104b0889" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Bermuda</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityTaxIdentificationNumber" id="fact-identifier-16" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N18wLTItMS0xLTA_fbc94202-7493-4dbc-bd7d-5d2e391dae35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">98-1343578</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityAddressAddressLine2" id="fact-identifier-17" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N18yLTAtMS0xLTA_6bad93a7-3dbe-45f0-9d49-d356c1e72a36" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Suite 1, 3rd Floor</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityAddressAddressLine1" id="fact-identifier-18" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N18zLTAtMS0xLTA_f0cb924f-80c0-4270-978d-0b6881568990" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11-12 St. James’s Square</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityAddressCityOrTown" id="fact-identifier-19" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N180LTAtMS0xLTA_6fe29c77-4535-4172-971c-f2c3addc7ab1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">London</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityAddressPostalZipCode" id="fact-identifier-20" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N181LTAtMS0xLTA_6f0cbe3c-c69f-4155-8794-d3a13c0008cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">SW1Y 4LB</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry" id="fact-identifier-21" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6MjU1ODk1NmIxNzZhNGQxYWJhZjhlYWUxNTkwNjk5NzcvdGFibGVyYW5nZToyNTU4OTU2YjE3NmE0ZDFhYmFmOGVhZTE1OTA2OTk3N182LTAtMS0xLTA_f74fa86b-2d24-43e7-9162-e23c2afb7d39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">United Kingdom</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant’s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+<span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:CountryRegion" id="fact-identifier-22" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTg5_5e540781-6179-4370-b932-8f0a81d38e2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">44</ix:nonnumeric></span> (<span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:CityAreaCode" id="fact-identifier-23" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTg2_cfea98e0-741e-49bc-b15a-64d71a89db1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">207</ix:nonnumeric></span>) <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:LocalPhoneNumber" id="fact-identifier-24" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8yMTkw_94da5c89-a1fd-4c71-be3d-dfcaa0120e61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400 3351</ix:nonnumeric></span> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:44.005%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.198%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:Security12bTitle" id="fact-identifier-25" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6YTZhYTVhZjRmMjNhNDNhMTg0MDM2YzQ2ZDNhNzBjMzcvdGFibGVyYW5nZTphNmFhNWFmNGYyM2E0M2ExODQwMzZjNDZkM2E3MGMzN18xLTAtMS0xLTA_d35294a9-93db-4a98-b2fc-077d916189eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Common Shares, $0.000017727 par value per share</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:TradingSymbol" id="fact-identifier-26" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6YTZhYTVhZjRmMjNhNDNhMTg0MDM2YzQ2ZDNhNzBjMzcvdGFibGVyYW5nZTphNmFhNWFmNGYyM2E0M2ExODQwMzZjNDZkM2E3MGMzN18xLTItMS0xLTA_6032f408-6642-492c-923d-4318bca6b828" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">MYOV</ix:nonnumeric></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="fact-identifier-27" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6YTZhYTVhZjRmMjNhNDNhMTg0MDM2YzQ2ZDNhNzBjMzcvdGFibGVyYW5nZTphNmFhNWFmNGYyM2E0M2ExODQwMzZjNDZkM2E3MGMzN18xLTQtMS0xLTA_bf52a9b0-2258-41a6-8c4a-f434c17f5e09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">New York Stock Exchange</ix:nonnumeric></span></span></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:   None</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.   <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityWellKnownSeasonedIssuer" id="fact-identifier-28" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTU0MDYz_b4be9792-4ac0-46b3-9222-388ce01cb930" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span>  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ý </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.   Yes  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityVoluntaryFilers" id="fact-identifier-29" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTUzODky_7326fe91-91f8-43ec-a06c-a7d7841c2db6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonnumeric></span></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> ý</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityCurrentReportingStatus" id="fact-identifier-30" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTUzODk0_6647b6ee-a71a-431d-a3fb-c3504919f3a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> ý </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:EntityInteractiveDataCurrent" id="fact-identifier-31" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTUzODk1_9c51d8d3-c077-44f6-b893-982f2ace0de8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Yes</ix:nonnumeric></span></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> ý </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” ”accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule&nbsp;12b-2&nbsp;of the Exchange Act</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">☐</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&nbsp;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">☐</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="fact-identifier-32" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6Njg2NTIxNDVmOTk5NDIxY2EzMDBlYTAxZmYyZjQ0MDQvdGFibGVyYW5nZTo2ODY1MjE0NWY5OTk0MjFjYTMwMGVhMDFmZjJmNDQwNF8xLTAtMS0xLTA_e079e19f-3d74-4f12-81f5-9a58275eb9d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Non-accelerated filer</ix:nonnumeric></span></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">☒</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&nbsp;reporting&nbsp;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="fact-identifier-33" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6Njg2NTIxNDVmOTk5NDIxY2EzMDBlYTAxZmYyZjQ0MDQvdGFibGVyYW5nZTo2ODY1MjE0NWY5OTk0MjFjYTMwMGVhMDFmZjJmNDQwNF8xLTMtMS0xLTA_860933e4-a28d-42c0-a4dd-a34cca4443f6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☒</ix:nonnumeric></span></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth&nbsp;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;padding-right:2.25pt;text-align:justify"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="fact-identifier-34" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGFibGU6Njg2NTIxNDVmOTk5NDIxY2EzMDBlYTAxZmYyZjQ0MDQvdGFibGVyYW5nZTo2ODY1MjE0NWY5OTk0MjFjYTMwMGVhMDFmZjJmNDQwNF8yLTMtMS0xLTA_f6e5495d-777e-403f-a3d7-53ab0810fc3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></div></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (§ 15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="fact-identifier-35" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTU0MDY4_cba138b0-cb2b-4ee5-a9c9-ca59341ad88c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">☐</ix:nonnumeric></span></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">☐</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="fact-identifier-36" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTUzODkx_42ce2d72-9505-4b06-929b-8ea9012ca019" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">ý</ix:nonnumeric></span></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of voting common shares held by non-affiliates of the registrant as of the end of the registrant’s most recently completed second fiscal quarter ended September&nbsp;30, 2020 was approximately $<span><ix:nonfraction unitref="usd" contextref="i9a8ff5c82bc340319c0983d9fcd15cbe_I20200930" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="fact-identifier-37" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8xMDk5NTExNjQyMDEy_88095321-c6f4-4f45-bb89-649a2dfe33da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">559,121,548</ix:nonfraction></span> based on the last reported sale price of the registrant’s common shares as reported on the New York Stock Exchange on September&nbsp;30, 2020 of $14.05 per common share. Common shares held by our majority shareholder, Sumitovant Biopharma Ltd. and each officer and director have been excluded in that such persons, on such dates, may have been deemed to be affiliates. This determination of affiliate status is not a conclusive determination for other purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of the registrant’s common shares, $0.000017727 par value per share, outstanding on May&nbsp;6, 2021, was <span><ix:nonfraction unitref="shares" contextref="i2f7fd4366b954df29a9e99de5dc2ed36_I20210506" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="fact-identifier-38" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl8xMDk5NTExNjQyMDI4_e110f850-1f62-4b9c-b6a2-fd616edc69bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,480,278</ix:nonfraction></span>.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="fact-identifier-39" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xL2ZyYWc6ZGQ5NTMwNzMxY2ZlNDljZGI0NjU5MWM2MWU3NWYwM2IvdGV4dHJlZ2lvbjpkZDk1MzA3MzFjZmU0OWNkYjQ2NTkxYzYxZTc1ZjAzYl81NDk3NTU4MTUzODk2_48172460-4604-47d2-912c-1b3857b0acca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Portions of the registrant’s definitive proxy statement for the 2021 Annual General Meeting of Shareholders (the “2021 Proxy Statement”) to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.</ix:nonnumeric></span> </span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM&nbsp;10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE FISCAL YEAR ENDED MARCH&nbsp;31, 2021</span></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1049" tabindex="18">Item 1.  Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1049" tabindex="18">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_94" tabindex="18">Item 1A.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_94" tabindex="18"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_94" tabindex="18"> Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_94" tabindex="18">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1064" tabindex="18">Item 1B.  Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1064" tabindex="18">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1070" tabindex="18">Item 2.  Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1070" tabindex="18">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_91" tabindex="18">Item 3.  Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_91" tabindex="18">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1077" tabindex="18">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1077" tabindex="18">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_130" tabindex="18">Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_130" tabindex="18">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_133" tabindex="18">Item 6.  Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_133" tabindex="18">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_76" tabindex="18">Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_76" tabindex="18">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1199" tabindex="18">Item 7A. </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1199" tabindex="18"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1199" tabindex="18">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1199" tabindex="18">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_13" tabindex="18">Item 8.  Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_13" tabindex="18">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1155" tabindex="18">Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1155" tabindex="18">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1150" tabindex="18">Item 9A.  Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1150" tabindex="18">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1145" tabindex="18">Item 9B.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1145" tabindex="18">123</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART III.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1169" tabindex="18">Item 10.  Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1169" tabindex="18">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1175" tabindex="18">Item 11.  Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1175" tabindex="18">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1181" tabindex="18">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1181" tabindex="18">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1187" tabindex="18">Item 13.  Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1187" tabindex="18">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1193" tabindex="18">Item 14.  Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1193" tabindex="18">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_142" tabindex="18">Item 15.  Exhibits</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_142" tabindex="18"> and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_142" tabindex="18">Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_142" tabindex="18">124</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1130" tabindex="18">Item 16.  Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1130" tabindex="18">128</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_145" tabindex="18">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_145" tabindex="18">129</a></span></div></td></tr></tbody></table></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&nbsp;I.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information Relating to Forward-Looking Statements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (“Annual Report”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”). These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements appearing in several places throughout this Annual Report include, but are not limited to, statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our and our collaboration partners’ ability to successfully plan for and commercialize ORGOVYX, as well as any other product candidates such as relugolix combination tablet, if approved; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success and anticipated timing of our clinical studies for our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated start dates, durations and completion dates of our ongoing and future nonclinical and clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated designs of our future clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated future regulatory submissions and the timing of, and our ability to obtain and maintain, regulatory approvals for our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to procure sufficient quantities of commercial relugolix drug substance and drug product from approved third party CMOs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve commercial sales of any approved products, whether alone or in collaboration with others;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain reimbursement and coverage from government and private payers for our products if commercialized;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of any approved products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to initiate and continue relationships with third-party clinical research organizations and manufacturers and third-party logistics providers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to quickly and efficiently identify and develop new product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire and retain our management and other key personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and enforce intellectual property rights for our products and product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding our results of operations, financial condition, liquidity, capital requirements, access to capital, prospects, growth and strategies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to continue to fund our operations with the cash, cash equivalents, and marketable securities currently on hand, including our expectations for how long these capital resources will enable us to fund our operations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding potential future payments that we are eligible to receive from Richter under the Richter Development and Commercialization Agreement and Pfizer under the Pfizer Collaboration and License Agreement;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to borrow under the Sumitomo Dainippon Pharma Loan Agreement;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third party collaboration partners’ abilities to perform their obligations under our agreements with them; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital if needed, on terms acceptable to us; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry trends;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments and projections relating to our competitors or our industry;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competing drugs that are or may become available; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of pandemics, epidemics or outbreaks of infectious diseases, including the effect that the COVID-19 pandemic and related “shelter-in-place” orders and other measures will have on our business operations, financial conditions and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors known and unknown that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, particularly in the section titled “Risk Factors” set forth in Part I. Item 1A. of this Annual Report, and in our other filings with the United States Securities and Exchange Commission (“SEC”). These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks and Certain Terms</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report, references to “Myovant,” the “Company,” “we,” “us,” and “our” refer to Myovant Sciences Ltd. and its wholly-owned subsidiaries on a consolidated basis, unless the context otherwise provides. All brand names or trademarks appearing in this Annual Report are the property of their respective owners. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the material factors that make an investment in our common shares speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under the heading “Risk Factors” in Item 1A of Part 1 of this Annual Report. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under “Risk Factors” in Item 1A of Part I of this Annual Report as part of your evaluation of an investment in our common shares. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Commercialization of ORGOVYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (relugolix) for the treatment of adult patients with advanced prostate cancer</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends in part on the successful commercialization of ORGOVYX, which received approval in December 2020 from the U.S. Food and Drug Administration (the “FDA”), for the treatment of adult patients with advanced prostate cancer. To the extent ORGOVYX is not commercially successful, our business, financial condition and results of operations will be materially harmed.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORGOVYX may fail to achieve the degree of market acceptance by physicians, patients, third-party payers or others in the medical community necessary for commercial success, which would negatively impact our business. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and Pfizer are unable to effectively market and sell ORGOVYX, the commercialization of ORGOVYX will not be successful and our business will be harmed. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to successfully obtain coverage and reimbursement for ORGOVYX in the United States, or the availability of coverage only at limited levels, would diminish our ability to generate net product revenue. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition in the commercialization of ORGOVYX, and our operating results will suffer if we fail to compete effectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Requirements</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not have adequate funds to cover our development and commercialization activities, we may have to raise additional capital or curtail or cease operations. We may not be able to obtain funding through public or private offerings of our capital shares, debt financings, collaboration or licensing arrangements, or other sources. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to meet certain terms and conditions to draw down funds under the Sumitomo Dainippon Pharma Loan Agreement. If we are unable to meet such terms and conditions, we may not be able to access funding from the Sumitomo Dainippon Pharma Loan Agreement. Further, we may be obligated to repay the loans prior to their scheduled maturity date under certain circumstances.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of the Sumitomo Dainippon Pharma Loan Agreement place restrictions on our operating and financial flexibility.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of drug substance and drug product. If these third parties do not perform as we expect, do not maintain their regulatory approvals, or become subject to other negative circumstances, it may result in delay in our ability to develop and commercialize our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical studies are very expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes. Clinical study failures can occur at any stage of clinical studies, and we could encounter problems that cause us to suspend, abandon or repeat clinical studies. We cannot predict with any certainty the timing for commencement or completion of current or future clinical studies.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of our clinical studies may not support our proposed claims for our product candidates. The results of previous clinical studies may not be predictive of future results, and interim or top-line data may be subject to change or qualification based on the complete analysis of data.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are not able to obtain required regulatory approvals, we will not be able to commercialize relugolix combination tablet, relugolix monotherapy tablet, or MVT-602, and our ability to generate net product revenue will be materially impaired.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Relugolix combination therapy, relugolix monotherapy and MVT-602 may cause adverse effects or have other properties that could halt, delay or prevent their commercialization, regulatory approval or limit the scope of any approved label or market acceptance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent upon our relationships with collaboration partners to further develop, fund, manufacture and commercialize ORGOVYX, relugolix combination tablet and our other product candidates. If such relationships are unsuccessful, or if a collaboration partner terminates its collaboration agreement with us, it could negatively impact our ability to conduct our business and generate net product revenue. Failure by a collaboration partner to perform its duties under its collaboration agreement with us (e.g. financial reporting or internal control compliance) may negatively affect us.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are reliant on third parties to conduct, manage, and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Being a Controlled Company</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with Sumitovant, our majority shareholder, and with Sumitovant’s parent, Sumitomo Dainippon Pharma, and their affiliates, including Sunovion, that may be perceived to create conflicts of interest which, if other investors perceive that Sumitovant or Sumitomo Dainippon Pharma will not act in the best interests of all of our shareholders, may affect the price of our common shares and have other effects on our company. </span></div><div id="iad55818e5d094e70a171c29f2aae2512_1049"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Business</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. ORGOVYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (relugolix) was approved by the U.S. Food and Drug Administration (“FDA”) in 2020 as the first and only oral gonadotropin-releasing hormone (“GnRH”) receptor antagonist for the treatment of adult patients with advanced prostate cancer. Relugolix is also under regulatory review in Europe for men with advanced prostate cancer. In addition, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in the U.S. and Europe for women with uterine fibroids, has completed Phase 3 registration-enabling studies for women with endometriosis, and is being assessed for contraceptive efficacy in healthy women ages 18-35 years who are at risk for pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for the treatment of female infertility as a part of assisted reproduction.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our efforts to identifying and in-licensing our product candidates, organizing and staffing our company, raising capital, preparing for and advancing the clinical development of our product candidates, preparing for and achieving regulatory approvals, and preparing for and executing on commercialization of our product candidates. Since our inception, we have funded our operations primarily from the issuance and sale of our common shares, from debt financing arrangements, and more recently from the upfront and milestone payments received from Pfizer Inc. (“Pfizer”) and Gedeon Richter Plc. (“Richter”). We launched our first product, ORGOVYX, in the U.S. in January 2021 and began generating product revenue, net from sales of ORGOVYX in the U.S. in January 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our majority shareholder is Sumitovant Biopharma Ltd. (“Sumitovant”), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo Dainippon Pharma”). As of March 31, 2021, Sumitovant directly, and Sumitomo Dainippon Pharma indirectly, own 48,641,181, or approximately 53.5%, of our outstanding common shares.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to be a leading biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. The key elements of our strategy to achieve this goal include the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully commercialize ORGOVYX in the U.S. for the treatment of adult men with advanced prostate cancer and seek regulatory approval to commercialize relugolix monotherapy tablet in other markets;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approval and prepare for potential commercialization of relugolix combination tablet for the treatment of women with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uterine fibroids a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd for women with pain associated with endometriosis;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leverage our collaboration with Pfizer to maximize the commercial potential of ORGOVYX and relugolix combination tablet in the U.S. and Canada, while continuing to invest in the clinical development of relugolix for additional potential indications;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">leverage our collaboration with Richter to seek regulatory approval and commercialize relugolix combination tablet for the treatment of uterine fibroids and endometriosis in certain territories outside of the U.S.;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance assessment and potential clinical development of MVT-602;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our product portfolio and pipeline by advancing our existing product candidates and/or acquiring or in-licensing additional clinical-stage product candidates or commercial-stage products in a capital-efficient manner; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deliver operational excellence while upholding the highest ethical and compliance standards in our business practices; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foster our values-based culture that embraces diversity, and attract and retain highly skilled employees that value and contribute to the advancement of our patient-focused mission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product and Product Candidates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the status of our product and product candidates and is followed by detailed descriptions of each program.</span></div><div style="margin-top:9pt;text-align:center"><img alt="myov-20210331_g1.jpg" style="height:559px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" data-src="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331_g1.jpg" src="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/myov-20210331_g1.jpg"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Relugolix in General</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (“GnRH”) receptor antagonist that binds to and inhibits GnRH receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of gonadotropins (luteinizing hormone (“LH”) and follicle-stimulating hormone (“FSH”)), thereby decreasing the downstream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a GnRH receptor antagonist, relugolix has a clinically-validated mechanism of action in each of our programs: advanced prostate cancer; heavy menstrual bleeding associated with uterine fibroids; pain associated with endometriosis; and prevention of pregnancy. The direct and rapid action of relugolix on the pituitary-gonadal axis is distinct from approved luteinizing hormone-releasing hormone (“LHRH”) agonists which are administered as depot injections and result in an initial surge in levels of gonadotropins, and estrogen and progesterone or testosterone, before resulting in pituitary desensitization and a fall in hormone levels over weeks. Approved LHRH agonist injections such as leuprolide acetate are used in women to treat the symptoms of uterine fibroids and endometriosis, but the adoption and duration of use is limited due to bone mineral density loss and vasomotor symptoms (such as hot flushes).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Uterine Fibroids </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uterine fibroids, also known as uterine myomas or leiomyomas, are non-cancerous tumors that develop in the muscular wall of the uterus and are among the most common reproductive tract tumors in women. In addition to an individual’s genetic predisposition, estrogens are well known to play an important role in the regulation of fibroid growth. Although uterine fibroids are benign tumors, they may cause debilitating symptoms such as heavy and prolonged menstrual bleeding, heavy or painful periods, anemia, abdominal pain, backache, increased abdominal girth and bloating, urinary frequency or retention, constipation or painful defecation, pregnancy loss, painful intercourse and, in some cases, infertility. These symptoms can also lead to loss of productivity at work, limitations in normal activities of daily living, and social embarrassment. For most women, uterine fibroids and associated symptoms resolve at menopause when estrogen and progesterone levels fall. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that over 25% of women of reproductive age in the U.S., or approximately 19 million women, have uterine fibroids. Of those, approximately five million women are estimated to experience symptoms of uterine fibroids, approximately three million of whom are inadequately treated by current medical therapy and require further treatment.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current approach to treating uterine fibroids includes both medical and surgical options. The recommended treatment for a given patient is dependent on factors such as the patient’s desire to become pregnant in the future, the importance of uterine preservation, symptom severity, and tumor characteristics. Medical options include oral contraceptives, GnRH antagonists, tranexamic acid, and LHRH agonists. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current standard of care for the treatment of patients with mild symptoms includes the use of oral or other hormonal contraceptives or nonsteroidal anti-inflammatory drugs (“NSAIDs”), which are generally prescribed at the time of initial diagnosis. These therapeutic options, however, often do not provide sufficient relief to the many patients with more moderate-to-severe symptoms. These women require additional treatment to relieve excessive bleeding and pain. Tranexamic acid, an antifibrinolytic agent, is approved for use to treat heavy menstrual bleeding. LHRH agonists are used for short-term therapy and may involve low-dose estradiol and progestin hormonal combination therapy to mitigate the side effect of bone mineral density loss and reduce vasomotor symptoms generally associated with LHRH agonists. Recently the GnRH antagonist elagolix in combination with estradiol and a progestin, was approved for the management of heavy menstrual bleeding associated with uterine fibroids providing one new medical treatment option. However, treatment requires twice daily dosing and is associated with hot flashes and progressive bone loss. Other invasive procedures such as endometrial ablation and uterine artery embolization may also be tried. Surgical intervention, such as myomectomy or hysterectomy, are often used to treat the heavy bleeding and symptoms associated with uterine fibroids; however, these procedures may result in post-operative complications, complications with future pregnancy, or as is the case in hysterectomies, preclude the potential for future pregnancies. Even if a future pregnancy is not desired, many women prefer to avoid surgical intervention. However, heavy menstrual bleeding associated with uterine fibroids is a leading cause of hysterectomy, resulting in approximately 250,000 hysterectomies per year in the U.S. alone.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Endometriosis</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Endometriosis is an estrogen-dependent, inflammatory disease in which tissue similar to the lining of the uterus is found outside the uterine cavity. Endometriosis lesions commonly appear in the lower abdomen or pelvis or on ovaries, the bladder, or the colon. During the menstrual cycle, the lesions grow, differentiate, and shed into the abdomen, thereby inducing a cascade of inflammatory events. Endometriosis may cause debilitating symptoms such as dysmenorrhea (menstrual pain), non-menstrual pelvic pain, dyspareunia (painful intercourse), heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that endometriosis affects approximately 10% of women of reproductive age and, in the U.S., can take approximately 4-11 years from the onset of symptoms to accurately diagnose, often leading to unnecessary or inappropriate treatment. We estimate that approximately six million women in the U.S. suffer from symptomatic endometriosis, approximately one million of whom are inadequately treated by oral contraceptives and require additional treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to uterine fibroids, lowering estrogen levels has been shown to reduce pain associated with endometriosis, and there are a variety of medical and surgical treatments available. Initial treatment usually involves over-the-counter pain medications, including NSAIDs, because pain is the primary symptom. Hormonal contraceptives are also commonly used. In more severe cases, LHRH agonists such as leuprolide are used for short-term treatment and may involve hormonal add-back therapy with an estrogen and/or a progestin. The FDA has approved Lupaneta Pack (leuprolide administered with norethindrone acetate (5 mg)) to treat pain associated with endometriosis while lowering the side effect of bone mineral density loss and reducing vasomotor symptoms. The GnRH antagonist, elagolix, is approved for the management of moderate to severe pain associated with endometriosis. The low dose of elagolix is associated with limited efficacy but is generally well tolerated and can be used for up to two years. The high dose is more efficacious but is associated with a high incidence of hot flashes and progressive loss of bone density and, therefore, can only be used for six months. For many patients, surgical intervention, typically laparoscopy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ablation of endometriotic lesions, is ultimately undertaken to relieve pain, and opioid medications are frequently needed to control pain both before and after surgery. After treatment with hormonal therapy or laparoscopic procedures, recurrence of endometriosis and related symptoms is common, resulting in repeated procedures for many women. In addition, approximately 100,000 endometriosis-related hysterectomies are performed each year in the U.S., although hysterectomy is not a cure for endometriosis and pain associated with endometriosis will not necessarily subside following hysterectomy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Prevention of Pregnancy</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uterine fibroids and endometriosis occur in premenopausal women who may desire to prevent pregnancy while receiving treatment for their heavy menstrual bleeding or pelvic pain. However, when using medical options like LHRH agonists or GnRH antagonists, the use of effective contraceptives such as combined hormonal contraceptives is not recommended. Their use may reduce the efficacy of treatment with LHRH agonists or GnRH antagonists and, in some cases, the efficacy of the contraceptives may be reduced, and the concomitant use of these therapies may increase the risk of severe and serious adverse events including thromboembolic events. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Phase 1 dedicated ovulation inhibition study, treatment with relugolix combination therapy inhibited ovulation in 100% of patients from the first cycle.  In addition, ovulation or menses returned in 100% of patients once treatment was discontinued.  Based on these data, relugolix combination tablet may provide a treatment option for women with uterine fibroids or endometriosis which also provides reliable prevention of pregnancy. Our Phase 3 SERENE study was recently initiated to demonstrate the contraceptive efficacy of relugolix combination tablet. Although the target population for relugolix combination tablet are women with uterine fibroids or endometriosis, to properly assess the contraceptive efficacy in a fertile population at risk of pregnancy, the SERENE study is being conducted in healthy premenopausal women 18 to 35 years of age. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advanced Prostate Cancer</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prostate cancer is a potentially lethal disease that starts in the prostate gland in men. Prostate cancer usually grows slowly and is confined, or localized, to the prostate gland. Cancer cells can grow beyond the prostate gland and spread to nearby tissues, also called metastasis. Prostate cancer is the second most prevalent form of cancer in men and the second leading cause of death due to cancer in men in the U.S. Approximately three million men diagnosed with prostate cancer are alive in the U.S., and approximately 250,000 men are newly diagnosed each year, according to the National Cancer Institute. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If prostate cancer is diagnosed at a stage where it is confined to the prostate gland and immediate surroundings, it is generally treated by surgical removal of the prostate gland (prostatectomy) or with radiation. Often, these procedures are successful in curing men of their disease. Men whose disease progresses after prostatectomy or radiation are said to have advanced prostate cancer. Advanced prostate cancer is defined as any of the following: PSA biochemical relapse following primary surgical or radiation therapy of curative intent; newly diagnosed metastatic prostate cancer; or advanced localized disease for which immediate radiation or surgical therapy is not indicated.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First-line treatment for advanced prostate cancer typically involves treatment with androgen deprivation therapies (“ADT”), which are therapies that substantially reduce testosterone. This is because androgens, such as testosterone, promote the growth of cancerous prostate cells by binding to and activating the androgen receptor which, once activated, stimulates prostate cancer cell growth. ADT consisting of either medical castration or surgical castration (removal of the testes which produce testosterone) can be successful in delaying prostate cancer progression. As prostate cancer progresses, men remain on ADT while other therapies are added, typically until death. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most commonly prescribed ADTs are LHRH agonists, such as long-acting leuprolide depot injections. LHRH agonists initially stimulate a testosterone surge, but with chronic stimulation of the LHRH receptors, the pituitary gland desensitizes and luteinizing hormone decreases with a resultant reduction in testosterone three to four weeks after the initiation of therapy. The initial stimulation of testosterone can cause an initial worsening of symptoms, or clinical flare. LHRH agonists are often given as depot formulations, requiring injections every month, three months or six months, and testosterone may remain suppressed for weeks and months after cessation of therapy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORGOVYX</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;18, 2020, the FDA approved ORGOVYX for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Review by the FDA, is the first and only oral GnRH receptor antagonist for men with advanced prostate cancer. The approval is based on efficacy and safety data from our Phase 3 HERO study of ORGOVYX in men with advanced prostate cancer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Phase 3 HERO study, ORGOVYX met the primary endpoint and achieved sustained testosterone suppression to castrate levels (&lt; 50 ng/dL) through 48 weeks in 96.7% (95% confidence interval [CI]: 94.9-97.9) of men, compared with 88.8% (95% </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CI: 84.6-91.8) of men receiving leuprolide acetate injections, the current standard of care. ORGOVYX also achieved several key secondary endpoints compared to leuprolide acetate, including suppression of testosterone to castrate levels at Day 4 and Day 15 (56% versus 0% and 99% versus 12%, respectively) and profound suppression of testosterone (&lt; 20 ng/dL) at Day 15 (78% versus 1%). ORGOVYX lowered prostate-specific antigen (“PSA”), on average, by 65% at Day 15 and by 83% at Day 29. In a substudy, 55% of men treated with ORGOVYX achieved normal testosterone levels (&gt; 280 ng/dL) or returned to baseline within 90 days of treatment discontinuation. The most frequent adverse events reported in at least 10% of men in the ORGOVYX group, were hot flush, musculoskeletal pain, fatigue, constipation, and mild to moderate diarrhea. In May 2020, efficacy and safety data from the Phase 3 HERO study were published online in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX became commercially available through authorized specialty distributors in the U.S. in early January 2021. Our oncology sales force began promoting ORGOVYX to target prescribers in early January 2021 and the uro-oncology sales force of our collaboration partner, Pfizer, began actively promoting ORGOVYX to target prescribers in early February 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are </span><span style="color:#253746;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">committed to ensuring that men in the U.S. who are prescribed ORGOVYX can achieve fair and timely access to ORGOVYX and receive the support they may need throughout their treatment journey. As part of this commitment, we have launched the ORGOVYX Support Program which provides insurance verifications, prior authorizations, copay support for commercially-insured patients, free trial for up to two months of therapy, and patient assistance for qualifying uninsured patients.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2021, we announced that the European Medicines Agency (“EMA”) validated our previously submitted Marketing Authorization Application (“MAA”) for relugolix for the treatment of men with advanced prostate cancer. The validation of the application confirmed that the submission is sufficiently complete for the EMA to begin the formal review process. We currently expect the European Commission decision on this application in calendar year 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partner, Pfizer, may conduct additional clinical studies to support the commercial potential of relugolix monotherapy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Relugolix Combination Tablet</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing relugolix combination tablet administered orally once-daily, with the goal of maintaining estrogen levels in the low normal range to achieve the long-term benefit of relugolix on symptoms of uterine fibroids and endometriosis, while maintaining bone health and mitigating side effects from a low-estrogen state, such as vasomotor symptoms. We have successfully completed a bioequivalence study, which demonstrated the bioequivalence of relugolix combination tablet with relugolix combination therapy, the co-administered regimen used in the LIBERTY and SPIRIT clinical programs (one relugolix 40 mg tablet plus one tablet containing estradiol 1.0 mg and norethindrone acetate 0.5 mg). We expect to launch in the women’s health indications, if approved, with our single-tablet regimen.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lowering estrogen and progesterone levels has been demonstrated, including in our two replicate Phase 3 LIBERTY studies and our long-term extension studies, to effectively decrease heavy menstrual bleeding and pain in women with uterine fibroids. These studies were designed to provide data on the safety and efficacy of treatment with relugolix combination therapy for up to two years. Similarly, relugolix combination therapy has been demonstrated in our two replicate Phase 3 SPIRIT studies and our SPIRIT long-term extension study to reduce pelvic pain associated with endometriosis over one year (52 weeks) with minimal and stable bone mineral density loss. Relugolix combination therapy achieved these results while maintaining a generally well-tolerated safety profile. We believe our combination approach has the potential to have a better safety and tolerability profile than the currently approved LHRH agonist therapies and has the potential to be used longer-term. We further believe our single tablet combination approach also has certain benefits over other oral GnRH antagonist therapies that are currently approved or in development. The goal of relugolix combination tablet is to provide women with uterine fibroids and endometriosis a once-daily oral medical alternative to hysterectomy and other invasive procedures often recommended to treat these conditions that is suitable for long-term use. In April 2021, we and Pfizer announced that the first patient has been dosed in the Phase 3 SERENE study, which is designed to assess the potential of relugolix combination tablet to prevent pregnancy, and may complement data from our Phase 3 LIBERTY and SPIRIT programs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Phase 3 Program for the Treatment of Heavy Menstrual Bleeding Associated with Uterine Fibroids</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase 3 clinical program in January 2017, evaluating relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids. The program consisted of two multinational, replicate pivotal clinical studies (LIBERTY 1 and LIBERTY 2). Women in the LIBERTY 1 and LIBERTY 2 studies underwent a screening period requiring up to two menstrual cycles to document heavy menstrual bleeding and were randomized in a 1:1:1 ratio to one of three groups. Women received treatment either with relugolix combination therapy for 24 weeks, relugolix 40 mg once-daily monotherapy for 12 weeks followed by relugolix combination therapy once-daily for an additional 12 weeks, or placebo once-daily for 24 weeks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enrolled 388 women in LIBERTY 1 and 382 women in LIBERTY 2. To be enrolled, women must have had a monthly menstrual blood loss volume of at least 80 mL in two consecutive cycles or 160 mL in one cycle, measured by the alkaline hematin method, a quantitative measure of menstrual blood loss from an assessment of collected menstrual products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible women who completed the LIBERTY 1 or LIBERTY 2 studies were offered the opportunity to enroll in an active treatment extension study in which all women received relugolix combination therapy for an additional 28-week period for a total treatment period of 52 weeks, designed to evaluate the safety and sustained efficacy of longer-term treatment. Upon completion of this 52-week total treatment period, eligible women could elect to participate in a second 52-week randomized withdrawal study designed to provide two-year safety and efficacy data on relugolix combination therapy, and to evaluate the need for maintenance therapy.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary efficacy endpoint for LIBERTY 1 and LIBERTY 2 was the proportion of all women enrolled who achieved a menstrual blood loss volume of less than 80 mL and at least a 50% reduction in menstrual blood loss volume from baseline during the last 35 days of the 24-week treatment period as measured by the alkaline hematin method. The secondary endpoints included the proportion of women who achieved amenorrhea (defined as no or negligible blood loss) during the last 35 days of treatment, reduction in pelvic pain, reduction in fibroid volume, reduction in uterine volume, percent change from baseline to week 24 in menstrual blood loss, increase in hemoglobin, and an assessment of the impact of therapy on quality-of-life. Safety, including bone mineral density changes as measured by dual-energy x-ray absorptiometry (“DXA”), was also assessed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the results and status of our LIBERTY program as well as certain recent publications and presentations: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 14, 2019 and July 23, 2019, we announced positive top-line results for the LIBERTY 1 and LIBERTY 2 studies, respectively. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On February 10, 2020, we announced positive safety and efficacy data from the Phase 3 LIBERTY long-term extension study. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 9, 2020, we announced the submission of a MAA to the EMA for relugolix combination tablet for the treatment of women with moderate to severe symptoms associated with uterine fibroids. This application has completed validation and is now under evaluation by the EMA. We currently expect the European Commission decision on this application in mid-calendar year 2021. If approved, this commercial launch would be executed by Richter, our commercialization partner for relugolix combination tablet for the uterine fibroids and endometriosis indications in Europe and certain other international markets.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we submitted an NDA to the FDA for relugolix combination tablet for the treatment of women with heavy menstrual bleeding associated with uterine fibroids, which has been accepted by the FDA with a target action date of June 1, 2021. If approved, we and Pfizer expect to launch relugolix combination tablet for the treatment of uterine fibroids in the U.S. in June 2021.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On September 14, 2020, we announced additional data on bone mineral density in women with uterine fibroids from the LIBERTY program and from a prospective observational study.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On October 21, 2020, we presented one-year efficacy and safety data from the LIBERTY long-term extension study at the American Society for Reproductive Medicine (“ASRM”) 2020 Virtual Congress. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2021, we and our collaboration partner, Pfizer, announced publication in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy in women with uterine fibroids.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 24, 2021, we and Pfizer announced positive safety and efficacy data from the LIBERTY randomized withdrawal study.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LIBERTY 1</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 14, 2019, we announced that LIBERTY 1 met its primary efficacy endpoint and six key secondary endpoints. The distribution of the change in bone mineral density, including outliers, was similar for the relugolix combination therapy and placebo groups at 24 weeks, as assessed by DXA.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the primary endpoint analysis, 73.4% of women receiving relugolix combination therapy achieved the responder criteria compared with 18.9% of women receiving placebo (p &lt; 0.0001). On average, women receiving relugolix combination therapy experienced an 84.3% reduction in menstrual blood loss from baseline, a clinically relevant secondary endpoint. A significantly </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">greater proportion of women suffering from moderate-to-severe pain from uterine fibroids at baseline experienced no pain or minimal pain during the last 35 days of treatment with relugolix combination therapy compared with women on placebo (p &lt; 0.0001).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIBERTY 1 achieved six key secondary endpoints with statistical significance compared to placebo, including mean change in menstrual blood loss from baseline to week 24, reduction in pain in women with pain at baseline, improvement in quality of life, amenorrhea (defined as no or negligible blood loss), improvement in anemia in those women with anemia at baseline, and reduction in uterine volume. The seventh key secondary endpoint, reduction in uterine fibroid volume, did not achieve statistical significance. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall incidence of adverse events in the relugolix combination therapy and placebo groups was comparable (62% vs. 66%). In the relugolix combination therapy group, 5% of women discontinued treatment early due to adverse events compared with 4% in the placebo group. The only adverse event in the relugolix combination therapy arm occurring in at least 10% of women and more frequently than in the placebo arm was hot flash (11% vs. 8%). There were no pregnancies in the relugolix combination therapy group and one in the placebo group. There were two serious adverse events related to the study drug: one fibroid expulsion and one for pelvic pain.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LIBERTY 2</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, we announced that LIBERTY 2 met its primary efficacy endpoint and the same six key secondary endpoints as were achieved in LIBERTY 1. Changes in bone mineral density were comparable between the relugolix combination therapy and placebo groups at the end of treatment as was the distribution of the change in bone mineral density, including outliers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the primary endpoint analysis, 71.2% of women receiving relugolix combination therapy achieved the responder criteria compared with 14.7% of women receiving placebo (p &lt; 0.0001). On average, women receiving relugolix combination therapy experienced a highly significant 84.3% reduction in menstrual blood loss from baseline to week 24 (p &lt; 0.0001). In addition, a significantly greater proportion of women suffering from moderate-to-severe pain from uterine fibroids at baseline experienced no pain or minimal pain during the last 35 days of treatment with relugolix combination therapy compared with women on placebo (p &lt; 0.0001).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIBERTY 2 achieved six key secondary endpoints with statistical significance compared to placebo, including mean change in menstrual blood loss from baseline to week 24, reduction in pain in women with pain at baseline, improvement in quality of life, amenorrhea (defined as no or negligible blood loss), improvement in anemia in those women with anemia at baseline, and reduction in uterine volume. The seventh key secondary endpoint, reduction in uterine fibroid volume, did not achieve statistical significance. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall incidence of adverse events in the relugolix combination therapy and placebo groups was comparable (60.3% vs. 58.9%). In the relugolix combination therapy group, 1.6% of women discontinued treatment early due to adverse events compared with 4.7% in the placebo group. There were no adverse events in the relugolix combination therapy group reported by at least 10% of women and more frequently than in the placebo group. The incidence of hot flashes in the relugolix combination therapy group was similar to placebo (5.6% vs. 3.9%). There were no pregnancies in the relugolix combination therapy group and one in the placebo group. There were no serious adverse events related to study drug reported in this study.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LIBERTY Long-Term Extension Study</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2020, we announced positive one-year safety and efficacy data from the Phase 3 LIBERTY long-term extension study of relugolix combination therapy in women with heavy menstrual bleeding associated with uterine fibroids.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the primary endpoint analysis, 87.7% of women achieved the responder criteria. The primary endpoint result in the one-year Phase 3 LIBERTY long-term extension study was consistent with the 24-week primary endpoint data from the pivotal LIBERTY 1 and LIBERTY 2 studies, demonstrating a durability of response through one year. In addition, women experienced, on average, an 89.9% reduction in menstrual blood loss from baseline at one year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in bone mineral density through one year, as assessed by DXA every three months, demonstrated maintenance of bone density and were consistent with those in LIBERTY 1 and LIBERTY 2. The adverse events over one year were consistent with those observed in LIBERTY 1 and LIBERTY 2, with no new safety signals. Adverse events reported in more than 10% of women treated with relugolix combination therapy for one-year and more frequently than those reported in the placebo group after 6 months included only hot flashes (11% vs. 6%). There were no pregnancies reported in the relugolix combination therapy group. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we presented a poster at the ASRM 2020 Virtual Congress describing a validated exposure-response model simulating long-term effects of relugolix combination therapy on bone mineral density at the lumbar spine. Simulations from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this model were well correlated with the effect of relugolix combination therapy observed in the Phase 3 LIBERTY program and projected maintenance of bone mineral density for at least three years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">LIBERTY Randomized Withdrawal Study</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2021, we and Pfizer announced positive safety and efficacy data from the LIBERTY randomized withdrawal study. The LIBERTY randomized withdrawal study (N = 229) was a Phase 3 double-blind, placebo-controlled study that enrolled eligible women who completed the LIBERTY long-term extension study. Eligibility criteria included meeting the responder criteria at one year. Responder criteria were defined as a menstrual blood loss volume of less than 80 mL and a 50% or greater reduction from baseline in menstrual blood loss volume during the last 35 days of treatment measured using the alkaline hematin method. Women were randomized at Week 52 to once-daily relugolix combination therapy or placebo for a one-year double-blind treatment period. Women on placebo with relapse of heavy menstrual bleeding during the study were offered re-treatment with open-label relugolix combination therapy. This study, together with the LIBERTY 1, LIBERTY 2, and LIBERTY long-term extension studies, was designed to provide data on the safety and efficacy of treatment with relugolix combination therapy for up to two years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The LIBERTY randomized withdrawal study met its primary endpoint with 78.4% of women who continued on relugolix combination therapy achieving the sustained responder rate (menstrual blood loss &lt; 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment and initiated placebo at Week 52 (p &lt; 0.0001). All three key secondary endpoints in the LIBERTY randomized withdrawal study were also achieved, including sustained responder rate at two years (Week 104), time to relapse of heavy menstrual bleeding, and amenorrhea rate (all p &lt; 0.0001). Through two years, 69.8% of women who continued on relugolix combination therapy remained responders. 88.3% of women who discontinued treatment at Week 52 relapsed with heavy menstrual bleeding, with a median time of return to heavy menstrual bleeding of 5.9 weeks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bone mineral density was maintained through two years in the subset of women continuously treated with relugolix combination therapy (N = 31). The incidence of adverse events over one additional year of treatment was consistent with those observed in prior studies, with no new safety signals observed. The most commonly reported adverse event in at least 10% of women treated with relugolix combination therapy was nasopharyngitis (inflammation of the nose and pharynx).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Observational Bone Mineral Density Study</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This prospective observational study was designed to characterize the longitudinal natural history of bone mineral density in 262 premenopausal women with uterine fibroids over 52 weeks. Women with documented uterine fibroids by imaging who were not receiving treatment with GnRH agonists or antagonists were enrolled contemporaneously from U.S. centers that participated in the LIBERTY studies. Bone mineral density was assessed by DXA at baseline, week 24 and week 52. Mean bone mineral density at the lumbar spine showed minimal changes over the 52-week observational period (0% at week 24 and -0.41% at week 52) and did not appear to be influenced by race or body mass index.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Phase 3 Program for the Treatment of Pain Associated with Endometriosis</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a Phase 3 clinical program in June 2017, evaluating relugolix combination therapy in women with pain associated with endometriosis. The program consisted of two multinational, replicate pivotal clinical studies (SPIRIT 1 and SPIRIT 2). Each study randomized women 1:1:1 to one of three treatment arms. Women received treatment either with relugolix combination therapy for 24 weeks, relugolix 40 mg once-daily monotherapy for 12 weeks followed by relugolix combination therapy once-daily for an additional 12 weeks, or placebo once-daily for 24 weeks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enrolled 623 and 638 patients in the SPIRIT 2 and SPIRIT 1 studies, respectively. To be enrolled, women must have had a surgical diagnosis of endometriosis in the last 10 years and moderate-to-severe dysmenorrhea (menstrual pelvic pain) and non-menstrual pelvic pain.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eligible women who completed the SPIRIT 1 or SPIRIT 2 studies were offered the opportunity to enroll in an active treatment long-term extension study in which all women received relugolix combination therapy for an additional 80-week period, resulting in a total treatment period of up to 104 weeks, designed to evaluate the safety and sustained efficacy of longer-term treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The co-primary efficacy endpoints for the SPIRIT 1 and SPIRIT 2 studies were the proportion of all women enrolled with reductions in both dysmenorrhea and non-menstrual pelvic pain, as assessed by an endometriosis-specific patient questionnaire based on the Numerical Rating Scale (“NRS”) completed daily on an electronic patient diary, with no increase in background pain medication. The NRS is an 11-point scale with 0 representing “no pain” and 10 representing “the worst pain you can imagine.” Secondary endpoints included additional questionnaires assessing functional changes associated with endometriosis-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific pain and quality of life, and the use of pain medications to treat endometriosis, including opioid medications. Safety, including bone mineral density changes as measured by DXA, was also assessed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the results and status of our SPIRIT program as well as certain recent publications and presentations:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 22, 2020 and June 23, 2020, we announced positive top-line results from the SPIRIT 2 and SPIRIT 1 studies, respectively. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On October 20, 2020, data from the Phase 3 SPIRIT studies were presented at the ASRM 2020 Virtual Congress and the presentation was named the Prize Paper by the Endometriosis Special Interest Group.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 26, 2021, we and Pfizer announced positive one-year safety and efficacy data from the Phase 3 SPIRIT long-term extension study.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. regulatory submission to the FDA for relugolix combination tablet for the treatment of women with endometriosis-associated pain is expected in the second quarter of calendar year 2021. We currently expect to submit an MAA to the EMA for relugolix combination tablet for the treatment of women with endometriosis-associated pain in calendar year 2021. Richter will be the MAA sponsor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SPIRIT 1</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2020, we announced that SPIRIT 1 met its co-primary efficacy endpoints and all seven key secondary endpoints. In addition, relugolix combination therapy was generally well-tolerated and resulted in minimal bone mineral density loss over 24 weeks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relugolix combination therapy achieved both co-primary endpoints by demonstrating clinically meaningful pain reductions for 74.5% of women with dysmenorrhea (menstrual pain) and 58.5% of women with non-menstrual pelvic pain, compared to 26.9% and 39.6% of women in the placebo group, respectively (p &lt; 0.0001). On average, women receiving relugolix combination therapy had a 73.3% reduction on the 11-point (0 to 10) NRS for dysmenorrhea from 7.3 (severe pain) to 1.8 (mild pain).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All seven key secondary endpoints measured at week 24 and compared to placebo achieved statistical significance, including changes in mean dysmenorrhea and overall pelvic pain, impact of pain on daily activities as measured by the EHP-30 pain domain, greater proportions of women not using analgesics (p-values &lt; 0.0001), changes in mean non-menstrual pelvic pain (p = 0.0002), greater proportions of women not using opioids (p = 0.0005), and changes in mean dyspareunia (painful intercourse) (p = 0.0149).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall incidence of adverse events in the relugolix combination and placebo groups was similar (71.2% vs. 66.0%). In the relugolix combination therapy group, 3.8% of women had adverse events leading to discontinuation of treatment versus 1.9% in the placebo group. The only reported adverse events in at least 10% of women in the relugolix combination group were headache and hot flashes. There was one pregnancy in the relugolix combination group and three in the placebo group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SPIRIT 2</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, we announced that SPIRIT 2 met its co-primary efficacy endpoints and six key secondary endpoints. In addition, relugolix combination therapy was generally well-tolerated and resulted in minimal bone mineral density loss over 24 weeks.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the co-primary endpoint analysis, 75.2% of women achieved a clinically meaningful reduction in dysmenorrhea versus 30.4% of women in the placebo group (p &lt; 0.0001). For non-menstrual pelvic pain, relugolix combination therapy achieved a clinically meaningful reduction in 66.0% of women versus 42.6% of women in the placebo group (p &lt; 0.0001). On average, women receiving relugolix combination therapy had a 75.1% reduction on the 11-point (0 to 10) NRS for dysmenorrhea from 7.2 (severe pain) to 1.7 (mild pain).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six key secondary endpoints measured at week 24 and compared to placebo achieved statistical significance, including changes in mean dysmenorrhea and overall pelvic pain, impact of pain on daily activities as measured by the EHP-30 pain domain, a greater proportion of women not using opioids (all p-values &lt; 0.0001), changes in non-menstrual pelvic pain (p = 0.0012), and dyspareunia (painful intercourse) (p = 0.0489). An endpoint evaluating change in analgesic use did not achieve statistical significance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall incidence of adverse events in the relugolix combination therapy and placebo groups was similar (80.6% vs. 75.0%). In the relugolix combination therapy group, 5.3% of women discontinued treatment early due to adverse events versus </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9% in the placebo group. The most frequently reported adverse events, reported in at least 10% of women in the relugolix combination therapy group, were headache, nasopharyngitis, and hot flashes. There were three pregnancies in the relugolix combination therapy group and five in the placebo group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SPIRIT Long-Term Extension Study</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 26, 2021, we and Pfizer announced positive one-year safety and efficacy data from the Phase 3 SPIRIT long-term extension study of relugolix combination therapy in women with endometriosis. Another analysis will be conducted at week 104. A total of 802 women enrolled in the extension study, all of whom receive relugolix combination therapy regardless of their treatment assignment in SPIRIT 1 and SPIRIT 2.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the primary endpoint analysis, 84.8% and 73.3% of women receiving relugolix combination therapy over one year achieved clinically meaningful pain reductions in dysmenorrhea and non-menstrual pelvic pain, respectively. On average, women reported an 82.8% reduction on the 11-point Numerical Rating Scale (0-10) for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bone mineral density remained stable through week 52 in women treated with relugolix combination therapy after minimal, non-clinically meaningful bone loss through week 24. The incidence of adverse events over one year was consistent with that observed in the SPIRIT 1 and SPIRIT 2 studies, with no new safety signals observed. The most commonly reported adverse events in at least 10% of women treated with relugolix combination therapy were headache, nasopharyngitis, and hot flashes. There was one pregnancy reported in the relugolix combination therapy group (n = 278).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect that results from the Phase 3 SPIRIT long-term extension study will be included in our U.S. regulatory submission for relugolix combination tablet for the treatment of women with endometriosis, anticipated to be submitted to the FDA in the second quarter of calendar year 2021. Results from the 52-week analysis of the Phase 3 SPIRIT long-term extension study are expected to be submitted for presentation at a future scientific meeting and publication in a medical journal.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Bioequivalence Study of Relugolix Combination Therapy and Relugolix Combination Tablet</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2019, we announced that a separate clinical study of relugolix combination tablet met all required and pre-specified criteria for bioequivalence to the two tablets (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) used in our Phase 3 uterine fibroid and endometriosis clinical studies, providing data necessary to include the once-daily dosing regimen of relugolix combination tablet in our NDA and MAA submissions for the treatment of heavy menstrual bleeding associated with uterine fibroids and endometriosis. In December 2019, we successfully completed one-year stability studies, which are required for FDA approval of relugolix combination tablet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Phase 3 SERENE Study</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 12, 2021, we and Pfizer announced that the first patient has been dosed in the Phase 3 single-arm, open-label SERENE study evaluating the contraceptive efficacy of relugolix combination tablet in healthy women ages 18-35 years who are at risk for pregnancy. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SERENE study is designed to enroll 900 sexually active, healthy women ages 18-35 years with presumed normal fertility. The primary efficacy endpoint is the at-risk Pearl Index, defined as the number of on-treatment pregnancies per 100 women-years of treatment. On-treatment pregnancies are pregnancies with an estimated conception date between the first day of study intervention intake up to and including seven days after the last intake of study medication. Women will receive once-daily relugolix combination tablet for 13 28-day at-risk cycles. Safety data will also be collected during the study. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive data from the SERENE study could further differentiate relugolix combination tablet by potentially adding the benefit of prevention of pregnancy for women taking relugolix combination tablet for the treatment of uterine fibroids and endometriosis, if approved for these indications.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The findings of our Phase 1 ovulation inhibition study demonstrated that relugolix combination therapy inhibited ovulation in all the study participants and provided the basis for the SERENE study to evaluate whether relugolix combination tablet has the potential to prevent pregnancy in women receiving therapy. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we announced results from a Phase 1 single-arm, open-label ovulation inhibition study to assess the effects of relugolix combination therapy on ovulation inhibition, per the Hoogland-Skouby assessment scale (score &lt; 5). In 67 healthy women over an 84-day treatment period (three cycles), relugolix combination therapy achieved 100% ovulation inhibition and was generally well tolerated. Furthermore, 100% of women resumed ovulation or menses upon discontinuation of treatment, with an average time to ovulation of 23.5 days. Data from this study were previously presented at the ASRM 2020 Virtual Congress. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MVT-602</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our license agreement with Takeda, we acquired the worldwide rights to MVT-602, our second product candidate, which previously had been evaluated in over 150 men. MVT-602 is an oligopeptide kisspeptin-1 receptor agonist. Kisspeptin, the ligand, is a naturally occurring peptide that stimulates GnRH release and is required for puberty and maintenance of normal reproductive function, including production of sperm, follicular maturation and ovulation, and production of estrogen and progesterone in women and testosterone in men. MVT-602 is being developed as a potential treatment for female infertility in women as part of assisted reproduction, such as in vitro fertilization (“IVF”). Approximately 1.5 million assisted reproduction cycles are performed each year worldwide. Further, approximately 25% of women suffering from infertility have problems achieving ovulation, including the inability to produce fully matured eggs or the failure to ovulate, most commonly resulting from hormonal dysfunction in the GnRH-luteinizing hormone/follicle-stimulating hormone axis. We believe MVT-602 has the potential to be a safer alternative to human chorionic gonadotropin as a part of assisted reproduction for the treatment of female infertility.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that MVT-602, an analog of the naturally-occurring kisspeptin peptide in humans, may mimic natural physiology by inducing a luteinizing hormone surge during IVF and other assisted reproductive technologies, enhancing the likelihood of successful egg maturation and ovulation at the right time without the serious side effect of ovarian hyperstimulation syndrome (“OHSS”). While assisted reproductive technologies are effective, typically resulting in pregnancy in 20% to 35% of patients, the standard procedure has remained largely unchanged since inception and has potentially serious side effects. The most serious side effect of assisted reproduction is OHSS. Severe OHSS has been reported to occur in up to 2% of the general assisted reproduction population, and in up to 20% of patients at high-risk for developing OHSS, including women with polycystic ovarian syndrome. OHSS is thought to occur as a result of the nonphysiologic elevations in luteinizing hormone that occur as a result of egg maturation triggered with human chorionic gonadotropin and to a lesser extent the GnRH receptor agonists. Symptoms can range from abdominal pain and bloating in milder cases to rapid weight gain, severe abdominal pain, nausea and vomiting, blood clots, decreased urination, kidney failure, and shortness of breath.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By acting upstream in the GnRH-axis to promote the release of physiologically normal levels of key hormones in the assisted reproduction cycle such as luteinizing hormone, kisspeptin agonists, such as MVT-602, may have the potential to trigger egg maturation without causing OHSS. A recently published investigator-sponsored study, where a native kisspeptin peptide (specifically, kisspeptin 54) was used in place of human chorionic gonadotropin as the egg-maturation trigger in the assisted reproduction cycle, showed that none of the 60 high-risk patients developed moderate-to-severe OHSS and resulted in a live birth rate of up to 65.1% at the maximally efficacious dose tested. These results validate the potential use of kisspeptin analogs as an alternative to the standard egg maturation trigger in assisted reproduction protocols. To our knowledge, MVT-602 is the only kisspeptin-1 receptor agonist in clinical development and thus has the potential to become a safe alternative egg-maturation trigger in this space.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we presented data from a Phase 1 study of MVT-602 at the American Society for Reproductive Medicine Annual Congress. Results of the study showed that administration of MVT-602 in healthy premenopausal women in the follicular phase produced a dose-related increase in LH concentrations and expected effects on FSH and estradiol. A total of 24 women were randomized to one of three MVT-602 dose groups (0.3 µg, 1 µg or 3 µg) and then subsequently randomized within the assigned group to receive a single subcutaneous dose of MVT-602 or placebo in a 3:1 ratio. Results showed that administration of single subcutaneous doses of MVT-602 demonstrated dose-related increases in LH concentrations and expected post-dose increases in FSH and estradiol concentrations, with little effect observed on progesterone as expected. No serious adverse events were reported, and no subject discontinued from the study due to an adverse event. Adverse events were similar between the placebo and MVT-602 groups with no apparent dose-related effects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further assessment of the exposure-response profile of MVT-602 was conducted in a Phase 2a study during the pre-ovulatory phase in 75 fertile women following a minimal controlled ovarian stimulation protocol. After ovarian stimulation, women were randomized to one of four MVT-602 dose groups (0.1 µg, 0.3 µg, 1 µg or 3 µg), to triptorelin, 0.2 mg, or to placebo. Top-line results from this Phase 2a study were presented at the European Society of Human Reproduction and Embryology in Vienna, Austria in June 2019. The study demonstrated that MVT-602 was generally well-tolerated and produced the desired LH surge associated with high and dose-dependent rates of ovulation in healthy women following a minimal controlled ovarian stimulation protocol. This study provides information for dose selection for a future study of MVT-602 in infertile women seeking pregnancy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Key Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborations and License Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have collaborations with leading pharmaceutical companies for the commercialization and further development of relugolix. Our collaborations with Pfizer and Richter are described below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pfizer Collaboration and License Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;26, 2020, our subsidiary, Myovant Sciences GmbH (“MSG”), and Pfizer, entered into a collaboration and license agreement (the “Pfizer Collaboration and License Agreement”), pursuant to which we and Pfizer will collaborate to jointly develop and commercialize relugolix in oncology and women’s health in the U.S. and Canada (the “Co-Promotion Territory”). In addition, Pfizer also received an option to acquire exclusive commercialization and development rights to relugolix in oncology outside the Co-Promotion Territory, excluding certain Asian countries (the “Pfizer Territory”).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Co-Promotion Territory, we and Pfizer will equally share profits and certain expenses. We will remain responsible for regulatory interactions and drug supply and continue to lead clinical development for relugolix combination tablet in the women’s health indications, while development for ORGOVYX will be shared equally among the parties. In the Co-Promotion Territory, we will be the principal on all sales transactions with third parties and will recognize 100% of product sales to third parties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Pfizer Collaboration and License Agreement, we received an upfront payment of $650.0 million in December 2020, and remain eligible to receive up to $3.7 billion of additional milestone payments, including two regulatory milestones of $100.0 million upon each FDA approval for relugolix combination tablet in uterine fibroids and endometriosis ($200.0 million in the aggregate), and tiered sales milestones of up to $3.5 billion upon reaching certain thresholds of annual net sales for oncology and the combined women’s health indications in the Co-Promotion Territory. In addition, if Pfizer exercises its option to acquire exclusive commercialization and development rights to relugolix in oncology in the Pfizer Territory, we will receive an option exercise fee of $50.0 million, will also be eligible to receive double-digit royalties on net sales of relugolix in the Pfizer Territory, and Pfizer will bear 100% of costs incurred in the Pfizer Territory.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Pfizer Collaboration and License Agreement, we will bear Pfizer’s share of Allowable Expenses, up to a maximum of $100.0 million for calendar year 2021 and up to a maximum of $50.0 million for calendar year 2022. Any unused portion will carry over into the subsequent calendar years until we have assumed in aggregate $150.0 million of Pfizer’s share of the Allowable Expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Pfizer Collaboration and License Agreement continues until no products are sold and all development activities have terminated in the Co-Promotion Territory and, in the case that Pfizer exercises its option for relugolix in the Pfizer Territory, on the last to expire royalty term with respect to a country in the Pfizer Territory. The Pfizer Collaboration and License Agreement may be terminated early by either party for the uncured material breach of the other party or for bankruptcy or other insolvency proceeding of the other party. In addition, Pfizer has certain other termination rights and may terminate the Pfizer Collaboration and License Agreement early upon providing written notice to us pursuant to the terms of the Pfizer Collaboration and License Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Richter Development and Commercialization Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&nbsp;30, 2020, we entered into an exclusive license agreement with Richter for Richter to commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia, and New Zealand (the “Richter Development and Commercialization Agreement”). Under the terms of the Richter Development and Commercialization Agreement, we received an upfront payment of $40.0 million on March 31, 2020, and are eligible to receive up to $40.0 million in regulatory milestone payments (of which $10.0 million was received in April 2020), $107.5 million in sales-related milestones, and tiered royalties on net sales following regulatory approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Richter Development and Commercialization Agreement, we will continue to lead global development of relugolix combination tablet. We have also agreed to assist Richter in transferring manufacturing technology from our contract manufacturing organizations to Richter to enable Richter to manufacture relugolix combination tablet. We have agreed to supply Richter with quantities of relugolix combination tablet for its territories pursuant to our agreements with our contract manufacturing organizations. Richter will be responsible for all local clinical development, manufacturing, and all commercialization activities for its territories. We have also granted Richter an option to collaborate with us on relugolix combination tablet for future indications in women’s health other than fertility. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Richter Development and Commercialization Agreement shall expire on a country-by-country basis upon expiry of the Royalty Term for the Product in a country in the Richter Territory. The Richter Development and Commercialization Agreement may be terminated in its entirety or on a country-by-country basis by mutual consent of the parties, or by either party for the uncured material breach of other party, for bankruptcy of the other party, and for certain other reasons in accordance with the terms of the Richter Development and Commercialization Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Related Party Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our majority shareholder is Sumitovant, a wholly-owned subsidiary of Sumitomo Dainippon Pharma. We have agreements with Sumitovant, Sumitomo Dainippon Pharma, and their affiliates, including Sunovion Pharmaceuticals Inc. (“Sunovion”), a subsidiary of Sumitomo Dainippon Pharma. These agreements are described below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sumitomo Dainippon Pharma Loan Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, we and our subsidiary, MSG, entered into a Loan Agreement with Sumitomo Dainippon Pharma (the “Sumitomo Dainippon Pharma Loan Agreement”). Pursuant to the Sumitomo Dainippon Pharma Loan Agreement, Sumitomo Dainippon Pharma agreed to make revolving loans to us in the aggregate principal amount of up to $400.0 million, of which $358.7 million was outstanding as of as March 31, 2021. Additional funds may be drawn down by us once per calendar quarter, subject to certain terms and conditions, including consent of our board of directors. In addition, if Sumitomo Dainippon Pharma fails to own at least a majority of our outstanding common shares, it may become unlawful under Japanese law for Sumitomo Dainippon Pharma to fund loans to us, and in which case we would not be able to continue to borrow under the Sumitomo Dainippon Pharma Loan Agreement. Interest is due and payable quarterly, and the outstanding principal amounts are due and payable in full on the five-year anniversary of the closing date of the Sumitomo Dainippon Pharma Loan Agreement. Loans under the Sumitomo Dainippon Pharma Loan Agreement are prepayable at any time without premium or penalty upon 10 business days’ prior written notice.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans under the Sumitomo Dainippon Pharma Loan Agreement bear interest at a rate per annum equal to 3-month London Interbank Offered Rate (“LIBOR”) plus a margin of 3.0% payable on the last day of each calendar quarter. LIBOR is currently expected to be phased out by the end of 2021, and if it becomes unavailable, we and Sumitomo Dainippon Pharma will negotiate in good faith to select an alternative interest rate and, if applicable as a result of such alternative interest rate, margin adjustment that is consistent with industry accepted successor rates for determining a LIBOR replacement. Our obligations under the Sumitomo Dainippon Pharma Loan Agreement are fully and unconditionally guaranteed by us and our subsidiaries. The loans and other obligations are senior unsecured obligations of us, MSG, and subsidiary guarantees. The Sumitomo Dainippon Pharma Loan Agreement includes customary representations and warranties and affirmative and negative covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sumitomo Dainippon Pharma Loan Agreement also includes customary events of default, including payment defaults, breaches of representations and warranties, breaches of covenants following any applicable cure period, cross acceleration to certain other debt, failure to pay certain final judgments, certain events relating to bankruptcy or insolvency, failure of material provisions of the loan documents to remain in full force and effect or any contest thereto by us or any of our subsidiaries and certain breaches by us under the Investor Rights Agreement. Upon the occurrence of an event of default, a default interest rate of an additional 5% will apply to the outstanding principal amount of the loans, Sumitomo Dainippon Pharma may terminate its obligations to make loans to us and declare the principal amount of loans to become immediately due and payable, and Sumitomo Dainippon Pharma may take such other actions as set forth in the Sumitomo Dainippon Pharma Loan Agreement. Upon the occurrence of certain bankruptcy and insolvency events, the obligations of Sumitomo Dainippon Pharma to make loans to us would automatically terminate and the principal amount of the loans would automatically become due and payable. In addition, if it becomes unlawful for Sumitomo Dainippon Pharma to maintain the loans under the Sumitomo Dainippon Pharma Loan Agreement or within 30 days of a change of control with respect to us, we would be required to repay the outstanding principal amount of the loans.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sumitomo Dainippon Pharma Loan Commitment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;5, 2020, we obtained a debt commitment letter from Sumitomo Dainippon Pharma, as amended by a letter dated September 29, 2020, and then further amended by a letter dated December&nbsp;22, 2020, pursuant to which, subject to the terms and conditions set forth therein, Sumitomo Dainippon Pharma committed to enter into a new $200.0 million unsecured, low-interest, five-year term loan facility. The 2020 Commitment Letter expired in March 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Investor Rights Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, we entered into an Investor Rights Agreement with Sumitomo Dainippon Pharma and Sumitovant (the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Investor Rights Agreement”). Pursuant to the Investor Rights Agreement, among other things, we agreed, at the request of Sumitovant, to register for sale, under the Securities Act of 1933, common shares beneficially owned by Sumitovant, subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specified conditions and limitations. In addition, we agreed to periodically provide Sumitovant (i) certain financial statements, projections, capitalization summaries and other information and (ii) access to our books, records, facilities and employees during our normal business hours as Sumitovant may reasonably request, subject to specified limitations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investor Rights Agreement also contains certain protections for our minority shareholders for so long as Sumitomo Dainippon Pharma or certain of its affiliates beneficially owns more than 50% of our common shares. These protections include: (i) a requirement that Sumitovant vote its shares for the election of independent directors in accordance with the recommendation of our board of directors (the “board”) or in the same proportion as the shareholders not affiliated with Sumitovant vote their shares; (ii) a requirement that the audit committee of our board be composed solely of three independent directors; (iii) a requirement that any transaction proposed by Sumitomo Dainippon Pharma or certain of its affiliates that would increase Sumitomo Dainippon Pharma’s beneficial ownership to over 60% of the outstanding voting power of us must be approved by our audit committee (if occurring prior to December 27, 2022) and be conditioned on the approval of shareholders not affiliated with Sumitovant approving the transaction by a majority of the common shares held by such shareholders; and (iv) a requirement that any related person transactions between Sumitomo Dainippon Pharma or certain of its affiliates and us must be approved by our audit committee.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Investor Rights Agreement, we also agreed that at all times that Sumitomo Dainippon Pharma beneficially owns more than 50% of our common shares, Sumitomo Dainippon Pharma, by purchasing common shares in the open market or from us in certain specified circumstances, will have the right to maintain its percentage ownership in our common shares in the event of a financing event or acquisition event conducted by us, or specified other events, subject to specific conditions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Market Access Services Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;1, 2020, our subsidiary, MSG, entered into the Market Access Services Agreement, as amended, with Sunovion. Pursuant to the Market Access Services Agreement, among other things, Sunovion agreed to provide to MSG certain market access services with respect to the distribution and sale of ORGOVYX (“Prostate Cancer Product”) and relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) (“Women’s Health Product,” and collectively with Prostate Cancer Product, the “Products”, and each a “Product”), including, among other things: (i) adding the Products to Sunovion’s agreements with its third party logistics providers; (ii) adding the Women’s Health Product to certain of Sunovion’s contracts with wholesalers, group purchasing organizations and integrated delivery networks and negotiating rates for the Products with certain market access customers; (iii) providing order-to-cash services; (iv) providing certain employees to provide market access account director services; (v) performing activities required in connection with supporting and maintaining contracts between us and market access customers for the coverage, purchase, or dispensing of the Products; (vi) managing the validation, processing and payment of rebates, chargebacks, and certain administrative, distribution and service fees related to the Products; (vii) providing MSG with price reporting metrics and other information required to allow us to comply with applicable government price reporting requirements; (viii) coordinating with MSG and any applicable wholesalers and distributors to address any recalls, investigations, or product holds; (ix) configuring, or causing to be configured, the appropriate software systems to enable Sunovion to perform its obligations under the Market Access Services Agreement; and (x) providing training and certain other ancillary support services to facilitate the foregoing. Pursuant to this agreement, Sunovion will also provide certain services to us to enable us to comply with our obligations under the State Transparency Laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSG, in turn, appointed Sunovion as the exclusive distributor of the Women’s Health Product and a non-exclusive distributor of the Prostate Cancer Product, each in the United States, including all of its territories and possessions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate Sunovion’s provision of these services, MSG agreed, among other things, to: (i) grant Sunovion a non-exclusive license under all intellectual property owned or controlled by MSG, solely for Sunovion’s use in connection with its performance of the contemplated services; (ii) provide Sunovion periodic reports of sales projections and estimated volume requirements, as well as such other information as Sunovion reasonably requests or may need to perform the services; (iii) comply with the provisions of any agreements between Sunovion and third parties pursuant to which the Products will be distributed or sold; (iv) cooperate with certain investigations related to orders and audits of MSG’s quality systems solely related, as reasonably determined by us, to Sunovion’s performance of certain regulatory services, at Sunovion’s costs; and (v) promptly notify Sunovion in the event relugolix is recalled.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the services, MSG has paid and will continue to pay Sunovion an agreed-upon monthly service charge for each of the first two years of the Market Access Services Agreement term and any agreed regulatory and training service charges. After the second year of the Market Access Services Agreement term, the monthly service charges will be determined by the parties. In addition, MSG also agreed to (x) reimburse Sunovion for any pass-through expenses it incurs while providing the services, and (y) establish an escrow fund for use by Sunovion when managing any rebates, chargebacks and similar fees. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Market Access Services Agreement also contains customary representations and warranties by the parties and customary provisions related to confidentiality, indemnification and insurance. The initial term of the Market Access Services Agreement is three years. Thereafter, the term will be automatically extended for one-year periods, unless either party provides notice of its intent not to renew the Market Access Services Agreement at least nine (9) months prior to the expiration of the applicable term. Either party may also terminate the Market Access Services Agreement prior to the end of its term in the event of an uncured material breach by the other party, if there are certain changes of law, or if such other party becomes insolvent or undergoes a change of control. MSG may also terminate the Market Access Services Agreement with respect to one or both Products if Sunovion fails to satisfy certain market access milestones or for convenience upon payment of a break-up fee.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Sumitovant Consulting Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&nbsp;18, 2020, we and Sumitovant entered into a consulting agreement, as amended on November&nbsp;9, 2020, pursuant to which Sumitovant provided consulting services to us to support us in commercial planning, commercial launch activities and implementation. Adele Gulfo, Sumitovant’s Chief Business and Commercial Development Officer and a member of our board of directors, provided services to us on behalf of Sumitovant under this agreement. The term of the consulting agreement with Sumitovant expired on March 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Takeda License Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2016, we entered into a License Agreement with Takeda (as subsequently amended, the “Takeda License Agreement”) pursuant to which Takeda Pharmaceuticals International AG (“Takeda”), a subsidiary of Takeda Pharmaceutical Company Limited (“Takeda Limited”), the originator of relugolix, granted to us an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by Takeda to develop and commercialize relugolix and MVT-602, and products containing these compounds for all human diseases and conditions. The territory for our exclusive license for relugolix covers all countries worldwide, except that Takeda retains exclusive rights to Japan, China, Hong Kong, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam (including, in each case, the territories and possession of each of the foregoing), which we collectively refer to as the Takeda Territory. Takeda has granted us a nonexclusive license in the Takeda Territory to manufacture relugolix and to conduct development of relugolix for prostate cancer solely for the purpose of developing, manufacturing and commercializing relugolix in our territory. The territory for our exclusive license for MVT-602 covers all countries worldwide. Our license includes a right of reference to regulatory materials related to relugolix and MVT-602 controlled by Takeda. On May 31, 2018, Takeda announced that they entered into a licensing agreement granting ASKA Pharmaceutical Co., Ltd. exclusive commercialization rights for uterine fibroids and exclusive development and commercialization rights for endometriosis in Japan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeda License Agreement, we granted to Takeda an exclusive, royalty-bearing license in the Takeda Territory under certain patents and other intellectual property controlled by us to develop and commercialize relugolix and products containing relugolix for all human diseases and conditions, subject to our nonexclusive rights to conduct development and manufacturing as described above. We also granted to Takeda a nonexclusive license in our territory to manufacture relugolix and MVT-602; and to conduct development of relugolix for uterine fibroids and endometriosis solely for the purpose of developing, manufacturing and commercializing relugolix in the Takeda Territory. Takeda’s license includes a right of reference to regulatory materials controlled by us. If Takeda determines not to seek regulatory approval for or to commercialize relugolix in any country in the Takeda Territory, then we have a right of first negotiation to acquire the rights to seek regulatory approval and commercialize relugolix in such country.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are solely responsible, at our expense, for all activities related to the development of relugolix and MVT-602 in our territory and all activities related to the development of relugolix through the receipt of regulatory approval for prostate cancer in certain countries in the Takeda Territory. Pursuant to the terms of the Takeda License Agreement, we are required to use commercially reasonable efforts to develop and obtain regulatory approval of relugolix for the treatment, prevention, cure or control of symptoms associated with uterine fibroids or endometriosis and MVT-602 in our territory, as well as to develop and obtain regulatory approval of relugolix for prostate cancer in Japan and the U.S. We are solely responsible, at our expense, for all activities related to the commercialization of relugolix and MVT-602 in our territory and must use commercially reasonable efforts to do so in each country in our territory in which we obtain regulatory approval. Takeda is solely responsible, at its expense, for all activities related to the commercialization of relugolix in the Takeda Territory, and must use diligent efforts to commercialize relugolix for prostate cancer in the Takeda Territory following receipt of regulatory approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeda License Agreement, we will pay Takeda a fixed, high single-digit royalty on net sales of relugolix and MVT-602 products in our territory, subject to certain agreed reductions. Takeda will pay us a royalty at the same rate as ours on net sales of relugolix products for prostate cancer in the Takeda Territory, subject to certain agreed reductions. Royalties are required to be paid, on a product-by-product and country-by-country basis, until the latest to occur of the expiration of the last </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to expire valid claim of a licensed patent covering such product in such country, the expiration of regulatory exclusivity for such product in such country, or 10 years after the first commercial sale of such product in such country. Under the Takeda License Agreement, there was no upfront payment and there are no payments upon the achievement of clinical development or marketing approval milestones. We have also licensed additional patents and patent applications from Takeda directed to other oligopeptides that target the same pathway as MVT-602.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Takeda License Agreement will expire, on a product-by-product and country-by-country basis, on the expiration of the royalty payment term described above for such product in such country. Either party may terminate the Takeda License Agreement for the other party’s uncured material breach, challenge to the patents licensed under the Takeda License Agreement, or insolvency. Takeda may terminate the Takeda License Agreement with respect to a compound if we cease development or commercialization of such compound. We may terminate the agreement at will, in our sole discretion, in its entirety, or with respect to relugolix for prostate cancer or both endometriosis and uterine fibroids, or on a compound by compound basis for all fields, upon prior notice, with the notice period depending on the compound and field to be terminated and the regulatory status at the time that notice of termination is given. We may also terminate the agreement with respect to a compound for safety reasons or lack of commercial viability. If the agreement is terminated in its entirety or with respect to relugolix for prostate cancer, other than for safety reasons or by us for Takeda’s uncured material breach, prior to receipt of the first regulatory approval of relugolix for prostate cancer in Japan, then we must either reimburse Takeda for its out of pocket costs and expenses directly incurred in connection with Takeda’s completion of the relugolix development for prostate cancer, up to an agreed cap, or complete ourselves the conduct of any clinical studies of relugolix for prostate cancer that are ongoing as of the effective date of such termination, at our cost and expense. If we reimburse Takeda for such costs, then under certain circumstances we may be later reimbursed by Takeda through a royalty on sales of the terminated relugolix product.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Takeda Supply Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, we and one of Takeda’s affiliates, Takeda Limited, entered into an agreement for the manufacture and supply of relugolix. Under this agreement, Takeda Limited supplied us with, and we obtained from Takeda Limited, all of our requirements for relugolix drug substance and drug product that were used under our development plans.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 30, 2018, we entered into a Commercial Manufacturing and Supply Agreement with Takeda (the “Takeda Commercial Supply Agreement”) pursuant to which Takeda agreed to supply us with and we agreed to obtain from Takeda certain quantities of relugolix drug substance according to agreed-upon quality specifications. For relugolix drug substance manufactured or delivered on or after December 31, 2019, we will pay Takeda a price per kilogram of relugolix drug substance to be agreed upon between the parties at the beginning of each fiscal year. Takeda has also assisted with the transfer of technology and manufacturing know-how to a second contract manufacturing organization of our subsidiary, MSG. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Takeda Commercial Supply Agreement began on May 30, 2018, and will continue for five years. At the end of the initial term, the Takeda Commercial Supply Agreement will automatically renew for successive one-year terms, unless either party gives notice of termination to the other at least 12 months prior to the end of the then-current term. The Takeda Commercial Supply Agreement may be terminated by either party upon 90 days’ notice of an uncured material breach of its terms by the other party, or immediately upon notice to the other party of a party’s bankruptcy. Each party will also have the right to terminate the Takeda Commercial Supply Agreement, in whole or in part, for any reason upon 180 days’ prior written notice to the other party, provided that any then-open purchase orders will remain in effect and be binding on both parties. The Takeda Commercial Supply Agreement, including any then-open purchase orders thereunder, will terminate immediately upon the termination of the Takeda License Agreement in accordance with its terms.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Takeda Commercial Supply Agreement also includes customary provisions relating to, among others, delivery, inspection procedures, warranties, quality management, storage, handling and transport, intellectual property, confidentiality and indemnification.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Excella Commercial Manufacturing and Supply Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 4, 2019, we entered into a Commercial Manufacturing and Supply Agreement with Excella GmbH &amp; Co. KG (“Excella”) pursuant to which Excella agreed to manufacture and supply us with certain commercial relugolix active pharmaceutical ingredient (“API”). Subject to and under the terms and conditions of this agreement, Excella shall not develop, manufacture or supply any relugolix API or regulatory starting material, or any product containing relugolix, for or to any third party without our written consent.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a fully integrated commercial team consisting of sales, marketing, market access, and commercial operations functions. Our oncology sales force markets ORGOVYX in the U.S. primarily to oncologists and urologists. In addition to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using customary pharmaceutical company practices, we have also adopted digital marketing technologies to engage with customers. The digital marketing capabilities that we have implemented were particularly important as we launched ORGOVYX in January 2021 during the COVID-19 pandemic, which required us to engage with healthcare providers primarily through virtual interactions in lieu of in-person interactions. In addition to our sales force, the uro-oncology sales force of our collaboration partner, Pfizer, began actively promoting ORGOVYX to target prescribers in early February 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX, is sold in the U.S. through specialty distribution and specialty pharmacy channels, which then distribute product to hospitals and other organizations that provide ORGOVYX to end-user patients. To facilitate our commercialization activities, we and Pfizer also engage with various other third parties such as advertising agencies, market research firms and vendors providing other sales-support related services as needed, including digital marketing and other promotional activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2021, our four largest customers represented 90% of our product revenue, net and each of these customers represented 10% or greater of our product revenue, net. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently establishing a separate women’s health sales force. We expect the majority of the sales representatives and supporting management to be hired in advance of the FDA’s uterine fibroid target action date of June 1, 2021. Should relugolix combination tablet be approved for marketing in the U.S., our women’s health sales force will be supported by that of our collaboration partner, Pfizer, and will focus primarily on gynecology practices. If approved, we and Pfizer expect to launch relugolix combination tablet for the treatment of uterine fibroids in the U.S. in June 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, we entered into an exclusive license agreement for Richter to commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia, and New Zealand. Should relugolix combination tablet be approved for marketing for either of these indications in Richter’s territory, Richter will be responsible for all commercialization activities in Richter’s territory.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Pfizer Collaboration and License Agreement, we granted Pfizer an option to acquire exclusive commercialization and development rights to relugolix in oncology outside the Co-Promotion Territory, excluding certain Asian countries (the “Pfizer Territory”). Pfizer’s decision is expected in mid-calendar year 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Product Supply</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, nor do we expect to own or operate, facilities for drug substance and drug product manufacturing, storage and distribution, or testing of our product or product candidates. We contract with third parties for these activities and expect to continue to do so in the future. We have personnel with extensive technical, manufacturing, analytical and quality experience and strong project management discipline to oversee activities performed by third-party contract manufacturing organizations and testing activities performed by other third parties, and to compile manufacturing and quality information for our regulatory submissions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing of any product or product candidate is subject to extensive regulations that impose various procedural and documentation requirements, which govern recordkeeping, manufacturing processes and controls, personnel, quality control and quality assurance, among others. We expect that all of our contract manufacturing organizations will manufacture relugolix and MVT-602 under current good manufacturing practice (“cGMP”) conditions, which set forth the regulatory standards for the production of pharmaceuticals to be used in humans. However, we do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and other regulations and laws for the manufacture of our product and product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, they may not be able to secure or maintain regulatory approvals for their manufacturing facilities and any applications that we submit to the FDA or other regulatory authorities that list those manufacturing facilities may be negatively affected. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the FDA issued a warning letter to Takeda following a routine inspection of aseptic finished pharmaceuticals (drug product) manufacturing at Takeda’s manufacturing facility located at Takeda 4720, Mitsui, Hikari, Yamaguchi (the “Hikari Facility”). The warning letter indicated that the FDA was not satisfied with Takeda’s response to an FDA Form 483 issued to Takeda following the inspection and cited significant violations of cGMP for finished pharmaceuticals. The Hikari Facility is one of two contract manufacturing organizations included in our initial regulatory filings for the manufacture of relugolix drug substance, with Excella being the other. We have removed the Hikari Facility as a manufacturing site from our NDA submissions and may remove it from other regulatory filings if required until Takeda corrects the violations noted in the warning letter to the satisfaction of the regulatory authorities. We believe we have procured from Excella sufficient quantities of commercial relugolix drug substance to support our U.S. ORGOVYX commercial launch plans and U.S. commercial launch plans for relugolix combination tablet, if approved. We have not experienced any supply constraints to date. We currently do not expect that the issues relating to the Hikari Facility will have an effect on the June 1, 2021 FDA target action date for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relugolix combination tablet for uterine fibroids or the European Commission decision on the uterine fibroids MAA anticipated in mid-calendar year 2021, or any other of our currently planned regulatory submissions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are delays in initiating new relationships with one or more other third-party manufacturers for MVT-602, or if there are delays in completing technology transfer to any of these manufacturers, or if any of our third-party manufacturers experience adverse developments, including with respect to adverse findings during inspections and/or the COVID-19 pandemic, we could experience delays in our future development and commercialization efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical and biopharmaceutical industries are highly competitive and require an ongoing, extensive search for technological innovation. These industries are characterized by rapid and significant technological advancements, intense competition, and a strong emphasis on proprietary products. While we believe that our product, product candidates, knowledge, experience, and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete successfully will significantly depend upon our ability to effectively complete necessary clinical studies and regulatory approval processes, and effectively commercialize approved products. The primary competitive factors that will affect the commercial success of any product candidate for which we have or may receive marketing approval include efficacy, safety and tolerability profile, acceptance by physicians, ease of patient compliance, dosing convenience, price, insurance and other reimbursement coverage, patent position, distribution, and marketing. Our competitors may obtain FDA or other regulatory approvals for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our existing and potential future competitors have significantly greater financial, technical, and human resources to deploy than we do towards the discovery and development of product candidates, as well as obtaining regulatory approvals of those product candidates in the U.S. and in foreign countries. Many of our existing and potential future competitors also have significantly more experience in manufacturing and commercializing drugs that have been approved for marketing. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaboration agreements with larger more established companies. These competitors also compete with us in recruiting and retaining qualified scientific, sales force, and management personnel and establishing clinical study sites and patient enrollment and retention for clinical studies. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a smaller number of our competitors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our competitors may be more successful than us in obtaining regulatory approval for therapies and in achieving widespread market acceptance of their drugs. It is also possible that the development of a cure or more effective treatment method for prostate cancer, uterine fibroids or endometriosis by a competitor could render our product candidates non-competitive or obsolete or reduce the demand for our product candidates before we can recover our development and commercialization expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX (relugolix) is the only oral GnRH receptor antagonist approved for men with advanced prostate cancer. LHRH agonists, such as leuprolide acetate, are the standard of care treatment used to lower testosterone in men with advanced prostate cancer. These have been approved for three decades and are administered by injection on a monthly, quarterly, every four months or every six months basis and are expected to be the direct competitor for ORGOVYX. Degarelix, a depot GnRH antagonist requiring monthly injections, is approved for use to lower testosterone in men with advanced prostate cancer, but clinical use is limited likely by the requirement for monthly high-volume injections with a rate of injection site reactions of approximately 35%. A Phase 3 prospective cardiovascular study evaluating the benefit of degarelix versus LHRH agonist therapy on the incidence of major adverse cardiovascular events in men with pre-existing cardiovascular disease has completed as of March 31, 2021 according to clinicaltrials.gov and results are anticipated to be announced shortly. Other oral medications used for androgen deprivation therapy include androgen receptor inhibitors such as enzalutamide, apalutamide and darolutamide, androgen biosynthesis inhibitors such as abiraterone acetate, and antiandrogens such as bicalutamide and flutamide, each commonly used in combination with a GnRH receptor antagonist or LHRH agonist.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider relugolix combination tablet’s (if approved) most direct competitor for the treatment of heavy menstrual bleeding associated with uterine fibroids to be ORIAHNN™, an oral GnRH receptor antagonist combination therapy (one capsule (elagolix 300 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) in the morning and one capsule (elagolix 300 mg) in the evening), which was approved by the FDA and launched by AbbVie in June 2020 for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. We consider relugolix combination tablet’s (if approved) most direct competitor for the treatment of pain associated with endometriosis to be ORILISSA™ (elagolix), an </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oral GnRH receptor antagonist, which was approved as monotherapy (150 mg once a day or 200 mg twice a day) by the FDA and launched by AbbVie in August 2018 for the management of moderate-to-severe pain associated with endometriosis. AbbVie also has one ongoing Phase 3b study of elagolix in combination with hormonal therapy in women with pain associated with endometriosis. In April 2021, AbbVie posted the results of a Phase 3 study evaluating elagolix 200 mg twice a day with and without hormonal add-back therapy in women with moderate to severe endometriosis associated pain, showing that the study met its primary endpoint. AbbVie has indicated that it plans to submit this study to the FDA in 2021. In addition, ObsEva SA, a Swiss-based clinical-stage biopharmaceutical company, reported in December 2019 and 2020 that each of its two pivotal Phase 3 clinical studies of linzagolix (OBE2109), also an oral GnRH receptor antagonist, in women with heavy menstrual bleeding associated with uterine fibroids met their primary endpoints. A marketing authorization application for a 100 mg dose and a 200 mg dose with hormones based on these studies has been submitted to the European Medicines Agency in the fourth quarter of 2020 and ObsEva indicated they plan to submit a NDA based on these studies in the third quarter of 2021. In May 2019, ObsEva also initiated a Phase 3 program evaluating linzagolix in women with endometriosis-associated pain, evaluating a lower 75 mg monotherapy dose and a higher 200 mg dose with hormones; however, one of the Phase 3 studies being conducted in the U.S. was terminated due to enrollment challenges. We believe the development of multiple GnRH receptor antagonists by other biopharmaceutical companies adds further validation to the therapeutic relevance of GnRH as a target for the treatment of women’s health and endocrine diseases and will help fuel growth in this market which has lacked innovative new medical therapies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to other GnRH receptor antagonists and selective progesterone receptor modulators in active development, we are aware of other biotechnology and pharmaceutical companies as well as academic institutions, government agencies, and private and public research institutions that are developing, and may in the future develop and commercialize, products for gender-specific hormone disorders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries for relugolix, MVT-602 and any future products and product candidates. We seek to protect our proprietary position by, among other methods, filing and in-licensing U.S. and foreign patents and patent applications. We also rely on trademarks, trade secrets and know-how to develop and maintain our proprietary position.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent terms can be adjusted to recapture a portion of delay by the U.S. Patent and Trademark Office (“USPTO”) in examining the patent application (patent term adjustment (“PTA”)) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension (“PTE”)), or both. We cannot provide any assurance that any patents will be issued from our pending or future applications or that any issued patents will adequately protect our products or product candidates. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Takeda License Agreement, we are the exclusive licensee of multiple granted U.S. patents, and pending patent applications, as well as patents and patent applications in numerous foreign jurisdictions relating to relugolix and MVT-602. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For relugolix, we are the exclusive worldwide licensee, excluding the Takeda Territory. These patents and patent applications cover the relugolix molecule and certain analogs and the use of relugolix to treat sex-hormone dependent prostate cancer and hysteromyoma (uterine fibroids); methods of manufacturing; and certain formulations. The patent family directed to the relugolix molecule and its use will expire in 2024, subject to any extension of patent term that may be available in a particular country. We have applied for PTE based on the approval of ORGOVYX for a patent covering relugolix. If granted, the term of the extended patent may be extended for up to five years, or 2029. The patents and patent applications, if issued, directed to methods of manufacturing relugolix will expire in 2033, subject to any adjustment or extension of patent term that may be available in a particular country. The patents and patent applications, if issued, directed to formulations of relugolix will expire in 2036, subject to any adjustment or extension of patent term that may be available in a particular country. We have filed patent applications directed to uses of relugolix combination therapy in treating, among other conditions, heavy menstrual bleeding associated with uterine fibroids and for pain associated with endometriosis. These applications are co-owned with Takeda under the Takeda License Agreement. If issued, they will expire in 2037 not including any adjustments or extensions. We have also filed patent applications directed to the use of relugolix as a monotherapy to treat advanced prostate cancer. The granted U.S. patents, and patent applications in this patent family, if issued, will expire in 2037, not including any adjustments or extensions. These patents and patent applications are also co-owned with Takeda. We have also filed patent applications directed to particular crystalline forms of relugolix and certain relugolix solvates. The patent applications in these families, if issued, will expire in 2040, not including any adjustments or extensions. The relugolix crystalline form application is co-owned with Takeda under the Takeda License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For MVT-602, we are the exclusive worldwide licensee of multiple patents and patent applications in the U.S. and numerous foreign jurisdictions. These patents and patent applications cover the MVT-602 oligopeptide and its use in treating advanced prostate cancer, as well as certain sustained release formulations containing MVT-602. The patent family directed to the MVT-602 molecule and method of use expires in 2028 in the U.S. (because of PTA) and in 2026 ex-U.S., subject to any adjustment or extension of patent term that may be available in a particular country. The patents directed to sustained-release formulations of MVT-602, if issued, would expire between 2030 and 2031, subject to any adjustment or extension of patent term that may be available in a particular country. We intend to apply for PTE for a patent covering MVT-602. If granted, the patent term covering MVT-602 may be extended. We are also the owner of patent applications directed to uses of MVT-602 in treating infertility. If issued, patents in this family will expire in 2037 subject to any adjustment or extension of patent term that may be available in a particular country. We have licensed additional patents and patent applications from Takeda directed to other oligopeptides that target the same pathway as MVT-602.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patents, we also rely upon trademarks, trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position. We maintain both registered and common law trademarks. Common law trademark protection typically continues where and for as long as the mark is used. Registered trademarks continue in each country for as long as the trademark is registered. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial partners and selected consultants. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining patents does not guarantee our right to practice the patented technology or commercialize the patented product. Third parties may have or obtain rights to patents which could be used to prevent or attempt to prevent us from commercializing our product candidates. If third parties prepare and file patent applications in the U.S. that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orange Book Listing</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NDA sponsor must identify to the FDA patents that claim the drug substance or drug product or approved method of using the drug. When the drug is approved, those patents are among the information about the product that is listed in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations, which is referred to as the Orange Book. Any applicant who files an ANDA or a 505(b)(2) NDA must certify, for each patent listed in the Orange Book for the Referenced Listed Drug (“RLD”) that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA, (2) such patent has expired, (3) the listed patent will expire on a particular date and approval is sought after patent expiration, or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. An ANDA or 505(b)(2) applicant may also submit a statement that it intends to carve-out from the labeling of its product an RLD’s use that is protected by exclusivity or a method of use patent. The fourth certification described above is known as a Paragraph IV certification. A notice of the Paragraph IV certification must be provided to each owner of the patent that is the subject of the certification and to the reference NDA holder. The reference NDA holder and patent owners may initiate a patent infringement lawsuit in response to the Paragraph IV notice. We intend to defend vigorously any patents for our approved products. Six patents are currently listed in the Orange Book for ORGOVYX.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Drug Approval Process </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (“FDCA”), and other federal and state statutes and regulations, govern, among other things, the research, development, nonclinical and clinical testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The steps required before a drug may be approved for marketing in the U.S. generally involves the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive nonclinical laboratory tests, animal studies, and formulation studies conducted in accordance with the FDA’s Good Laboratory Practices (“GLP”); </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug application (“IND”) for human clinical testing, which must become effective before human clinical studies may begin; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board (“IRB”), representing each clinical site before each clinical study may be initiated;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practices (“GCP”) to establish the safety and efficacy of the drug for each proposed indication; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the preparation and submission of an NDA to the FDA for commercial marketing, or of a supplemental New Drug Application (“sNDA”);</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA acceptance, review, and approval of the NDA or sNDA, which might include an advisory committee; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of manufacturing facilities at which the active pharmaceutical ingredient (“API”) and finished drug product are produced and tested to assess compliance with cGMP and selected clinical investigators or contract research organizations for their compliance with GCP. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities or an IRB or the study sponsor may suspend a clinical study at any time on various grounds including a finding that the subjects or patients are being exposed to an unacceptable health risk.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical studies include laboratory evaluations of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product candidate. The results of nonclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical study protocol. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the clinical study as outlined in the IND prior to that time. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical study can begin. The FDA may nevertheless initiate a clinical hold after the 30 days if, for example, significant public health issues arise. A separate submission to the existing IND must be made for each successive clinical study conducted during product development. Long-term nonclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. These phases generally include the following: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 - Studies, which involve the initial introduction of the new drug product candidate into humans, are initially conducted in a limited number of subjects to assess pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on effectiveness. Phase 1 studies may also be conducted to assess potential for drug interactions or drug exposure in patients with renal or hepatic impairment.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 - Studies are conducted with groups of patients afflicted with a specified disease in order to provide enough data to evaluate the preliminary efficacy, metabolism, pharmacokinetics, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks.  </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 - Phase 3 studies, also called pivotal or registration studies, are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical study sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical studies to demonstrate the efficacy of the drug. A single Phase 3 clinical study with other confirmatory evidence may be sufficient in rare instances where the study is a large multi-center study demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity, or prevention of a disease with a potentially serious outcome and where confirmation of the result in a second study would be practically or ethically impossible.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may require, or companies may pursue, additional clinical studies after a product is approved. These Phase 4 studies may be deemed a condition to be satisfied after a drug receives approval. Failure to satisfy such post-marketing commitments can result in FDA enforcement action, up to and including withdrawal of NDA approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the U.S. The NDA must include the results of all nonclinical, clinical, and other testing, and a compilation of data relating to the product’s pharmacology, chemistry, manufacture and controls. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">submission of most NDAs is subject to a substantial application user fee, and the manufacturer and/or sponsor under an approved NDA are also subject to annual program user fees. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA sets a user fee goal date that informs the applicant of the specific date by which the FDA intends to complete its review. The FDA’s goal is to review applications within ten months of the filing date or, if the application relates to an unmet medical need in a serious or life-threatening indication and is granted priority review, six months from the filing date. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine, among other things, whether a drug candidate is safe and effective for its intended use and whether its manufacturing is cGMP-compliant. The FDA may refer applications to an advisory committee—typically a panel that includes clinicians and other experts—for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or some of the facilities at which the drug is manufactured or tested. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its API will be produced, it issues either an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of NDA approval, the FDA may require a Risk Evaluation and Mitigation Strategy (“REMS”) to ensure that the benefits of the drug outweigh the potential risks. A REMS can include a medication guide, a communication plan for healthcare professionals, and elements to assure safe use, such as special training and certification requirements for individuals who prescribe or dispense the drug, requirements that patients enroll in a registry, and other measures that the FDA deems necessary to assure the safe use of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug’s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to some of the conditions established in an approved application, including changes in formulation, indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or sNDA before the change can be implemented. An sNDA for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing an sNDA as it does in reviewing NDAs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved drugs that are manufactured or distributed in the U.S. pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, REMS, or surveillance to monitor the effects of an approved product, or restrictions on the distribution or use of the product. In addition, quality-control, drug manufacture, packaging, and labeling procedures must continue to conform to GMP requirements after approval, including for supply chain traceability. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with GMP requirements. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with GMP requirements. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacture of the product, complete withdrawal of the product from the market, or product recalls; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters, or holds on post-approval clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product approvals;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Regulation </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we are subject to regulations of other countries governing clinical studies and the manufacturing, commercial sales and distribution of our products outside the U.S. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical studies or marketing of the product in foreign countries or economic areas, such as the European Union (“EU”). Although many of the issues discussed above with respect to the U.S. apply similarly in the context of foreign countries and the EU, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be shorter or longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Compliance Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future business operations are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting, and physician sunshine laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we have a Code of Business Conduct and Ethics and other corporate compliance policies, but it is not always possible to identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Although the development and implementation of compliance programs designed to establish internal control and facilitate compliance can mitigate the risk of violating these laws, and the subsequent investigation, prosecution, and penalties assessed for violations of these laws, the risks cannot be entirely eliminated. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements, and oversight if we become subject to a corporate integrity agreement or similar agreement, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anti-Kickback Laws</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal laws, including the federal Anti-Kickback Statute, prohibit fraud and abuse involving state and federal healthcare programs, such as Medicare and Medicaid. These federal Anti-Kickback Statutes, among other things, make it illegal for any person or entity, including a prescription drug manufacturer or a party acting on its behalf, to knowingly and willfully solicit, receive, offer, or pay any remuneration, directly or indirectly, that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item, or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term “remuneration” has been broadly interpreted to include anything of value, including cash, gifts or gift certificates, improper discounts, and free or reduced-price items and services. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act (“ACA”), to a stricter intent standard such that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Federal and State Prohibitions on False Claims</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims laws, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the U.S. government. Many states have enacted similar laws modeled after the federal civil False Claims Act that apply to items and services reimbursed under Medicaid and other state healthcare programs, and, in several states, such laws apply to claims submitted to all payers. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Federal Prohibitions on Healthcare Fraud and False Statements Related to Healthcare Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) created new federal civil and criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers. Like the federal Anti-Kickback Statute, the ACA broadened the reach of certain criminal healthcare fraud statutes under HIPAA by amending the intent requirement such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Healthcare Privacy and Security Laws</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous federal and state laws, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use and disclosure of personal information. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”) and their implementing regulations, impose specific requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses and their respective business associates and covered subcontractors that perform services for them that involve the use, or disclosure of, individual identifiable health information, relating to the privacy, security, and transmission of individually identifiable health information. In addition, certain state and foreign laws, regulations, standards and regulatory guidance govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and may continue to conduct, clinical studies or continue to enroll subjects in our ongoing or future clinical studies in certain jurisdictions in which we may be subject to additional privacy restrictions. For example, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the General Data Protection Regulation (“GDPR”), which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data out of the EU, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to the greater of 20 million Euros or 4% of annual global revenue, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Data protection authorities from the different EU member states have issued limited guidance, may interpret the GDPR and national laws differently and may impose additional requirements, which complicates the effort to comply with these laws. Further, the United Kingdom’s vote in favor of exiting the EU, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom (“U.K.”). In particular, it is unclear how data transfers to and from the U.K. will be regulated.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. Some states require the posting of information relating to clinical studies. Additionally, California enacted the California Consumer Privacy Act (“CCPA”), which creates new </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of California consumers and households. The CCPA, which went into effect on January 1, 2020, gives California residents expanded rights to access and requires deletion of their personal information, opting out of certain personal information sharing, and receiving detailed information about how their personal information is collected, used and shared. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. Although the CCPA includes exemptions for certain clinical studies data, as well as HIPAA protected health information, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA has prompted a wave of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs, and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Physician Payments Sunshine Act</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The ACA through the enactment of the Physician Payments Sunshine Act, imposes, among other things, annual reporting requirements for covered manufacturers for certain payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants and certified nurse midwives.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payer, in addition to items and services reimbursed under Medicaid and other state programs. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing, as well as state and local laws that require the registration of pharmaceutical sales representatives. Additionally, to the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Corrupt Practices Act</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the Foreign Corrupt Practices Act of 1977, as amended, (“FCPA”), which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or otherwise influence a person working in an official capacity to obtain a business advantage. The FCPA also requires public companies whose securities are listed in the U.S. to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls. A determination that our operations or activities are not, or were not, in compliance with U.S. or foreign laws or regulations could result in the imposition of substantial fines, interruptions of business, loss of suppliers, vendor or other third-party relationships, termination of necessary licenses or permits, and legal or equitable sanctions. Other internal or governmental investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of products regulated by the FDA or other government agencies. In addition to new legislation, FDA and healthcare fraud and abuse and coverage and reimbursement regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. Further, the 2020 Presidential and Congressional elections and political developments have caused the future state of many core aspects of the current health care marketplace to be uncertain. As a result of the new Biden administration, there may be significant changes to the healthcare environment in the future that could have an adverse effect on anticipated net revenues from any of our products that receive marketing approval. Furthermore, federal agencies, Congress, state legislatures, and the private sector have shown significant interest in implementing cost containment programs to limit the growth of health care costs, including price controls, restrictions on reimbursement and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit coverage for or the amounts that federal and state governments will pay for health care products and services, which could also result in reduced demand for our products or additional pricing pressures and affect our ultimate profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage, Reimbursement and Pricing </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of any products for which we have obtained or, in the future, may obtain regulatory approval, depend, in part, on the coverage and reimbursement status of those products. In the U.S., sales of any products for which we have received or, in the future, may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payers. Third-party payers include government programs including Medicare Part D, Medicaid, TRICARE and the Veterans Administration, as well as private payers including pharmacy benefit managers, health plans, self-insured organizations, and other plan administrators. Other countries and jurisdictions will also have their own unique mechanisms for approval and reimbursement. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining whether a payer will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payer will pay for the product. Third-party payers may limit coverage to specific products on an approved list or formulary which might not include all of the FDA-approved products for a particular indication. Third-party payers may also refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when a less costly generic equivalent or other alternative is available. Further, private payers often follow the coverage and payment policies established by certain government programs, such as Medicare and Medicaid, which require manufacturers to comply with certain rebate, price reporting, and other obligations. For example, the Medicaid Drug Rebate Program, which is part of the Medicaid program (a program for financially needy patients, among others), requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the Secretary of the Department of Health and Human Services under which the manufacturer agrees to report certain prices to the government and pay rebates to state Medicaid programs on outpatient drugs furnished to Medicaid patients, as a condition for receiving federal reimbursement for the manufacturer’s outpatient drugs furnished to Medicaid patients. Further, in order for a pharmaceutical product to receive federal reimbursement under Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the Public Health Service’s 340B drug pricing program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our approved products  unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. Sales of any approved products, will therefore depend substantially on the extent to which the costs the product will be paid by third-party payers. Additionally, the market for any approved products depends significantly on access to third-party payers’ formularies without prior authorization, step therapy, or other limitations such as approved lists of treatments for which third-party payers provide coverage and reimbursement. Additionally, coverage and reimbursement for therapeutic products can differ significantly from payer to payer. One third-party payer’s decision to cover a particular medical product or service does not ensure that other payers will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payer separately and will likely be a time-consuming process.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the prices charged for medical products and services, and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. Additionally, the containment of healthcare costs (including drug prices) has become a priority of federal and state governments. The U.S. government, state legislatures, and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement, and requirements for substitution by generic products, among other controls. Adoption of price controls or other cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could limit our net revenue and results. If these third-party payers do not consider our products to be cost-effective compared to other therapies, they may not cover our products once approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis. Decreases in third-party reimbursement for our approved products or a decision by a third-party payer to not cover our products could reduce or eliminate utilization of our products and have an adverse effect on our sales, results of operations, and financial condition. In addition, state and federal healthcare reform measures have been and will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our approved products or additional pricing pressures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of ORGOVYX will also depend on the acceptance and degree of adoption by institutional treatment pathways and institutional, local, and national clinical guidelines such as the National Comprehensive Cancer  Networks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Practice Guidelines in Oncology, or the NCCN Guidelines, the American Urological Association (“AUA”) guidelines, American Society of Clinical Oncology (“ASCO”) Clinical Practice Guidelines, or other country-specific guidelines. In the U.S., healthcare providers may refer to these guidelines related to patient treatment decisions. To the extent that our current or any future approved products are not included or positioned favorably in such treatment guidelines and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pathways, the full utilization potential of our products may not be reached, which may harm our ability to successfully commercialize our current or any future approved products. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Brexit and the Regulatory Framework in the United Kingdom</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2020, the U.K. and the EU agreed on a trade and cooperation agreement, under which the U.K. and the EU will now form two separate markets governed by two distinct regulatory and legal regimes. The trade and cooperation agreement covers the general objectives and framework of the relationship between the U.K. and the EU, including as it relates to trade, transport and visas. Under the trade and cooperation agreement, U.K. service suppliers no longer benefit from automatic access to the entire EU single market, U.K. goods no longer benefit from the free movement of goods and there is no longer the free movement of people between the U.K. and the EU. Depending on the application of the terms of the trade and cooperation agreement, we and others could face new regulatory costs and challenges.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since a significant proportion of the regulatory framework in the U.K. applicable to our business and certain of our product candidates are derived from EU directives and regulations, Brexit has had, and may continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. or the EU. For example, the U.K. is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be required to market our product candidates in the U.K. It is currently unclear whether the Medicines &amp; Healthcare products Regulatory Agency (“MHRA”) in the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us and our collaboration partners from commercializing our product candidates in the U.K. or the EU and restrict our ability to generate revenue and achieve and sustain profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.K.’s vote to exit the EU could also result in similar referendums or votes in other European countries in which we and our collaboration partners conduct business. Given the lack of comparable precedent, it is unclear what financial, trade and legal implications the withdrawal of the U.K. from the EU will have and how such withdrawal may affect us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Applicable Laws</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the SEC and the regulations of the New York Stock Exchange, on which our common shares are traded.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to various other federal, state, and local laws and regulations, including those related to safe working conditions, and the storage, transportation, or discharge of items that may be considered hazardous substances, hazardous waste, or environmental contaminants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations extend to countries around the world, and many of these jurisdictions have established privacy legal frameworks with which we, our customers, our collaboration partners, or our vendors must comply.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, we had 407 employees, all of whom are full-time employees. Our employees are not represented by labor unions or covered by collective bargaining agreements, and we believe that we have good employee relations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We emphasize a number of measures and objectives in managing our human capital assets, including employee engagement, development and training, talent acquisition and retention, employee wellness, diversity, inclusion, and compensation and pay equity. We provide our employees with competitive salaries, bonuses, opportunities for equity ownership, development opportunities that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off. In addition, we regularly collect employee feedback to ensure two-way communication, measure employee engagement and identify opportunities for improvement. In response to the COVID-19 pandemic and its impact on the workplace, we executed what we believe was a smooth transition to a remote work environment while ensuring that ample resources, support and flexibility were available to our employees.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that developing a diverse and inclusive culture is critical to continuing to attract and retain the top talent necessary to deliver on our business strategy. As such, we are investing in a work environment where our employees feel inspired and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included. We continue to focus on extending our diversity and inclusion initiatives across our entire workforce. In addition, we work to ensure our employees understand and embrace our commitment to our patient community and core values.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an exempted company limited by shares incorporated under the laws of Bermuda in February 2016 under the name Roivant Endocrinology Ltd. We changed our name to Myovant Sciences Ltd. in May 2016. Our principal executive offices are located at Suite 1, 3rd Floor, 11-12 St. James’s Square, London, SW1Y 4LB, United Kingdom, and our telephone number is +44 (207) 400 3351. We maintain additional offices in Brisbane, California and Basel, Switzerland. Our common shares are currently listed on the New York Stock Exchange under the symbol “MYOV.” Our website is www.myovant.com. The contents of our website are not part of this Annual Report on Form 10-K, and our website address is included in this document as an inactive textual reference only. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our filings with the SEC, including our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and all amendments to those reports available free of charge on our website as soon as reasonably practicable after we file such reports with, or furnish such reports to, the SEC. We also show detail about stock trading by corporate insiders by providing access to SEC Forms 3, 4 and 5. The SEC maintains an internet site that contains reports, proxy and information statements, and other information. The address of the SEC’s website is www.sec.gov.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and other interested parties should note that we also use our media and investor relations website (investors.myovant.com) and our social media channels to publish important information about Myovant that may be deemed material to investors. We encourage investors and other interested parties to review the information we may publish through our investor relations website and social media channels, in addition to our SEC filings. The information contained on our websites and social media channels is not included as part of, or incorporated by reference, into this Annual Report on Form 10-K.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_94"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.  Risk Factors</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, in addition to the other information contained in this Annual&nbsp;Report on Form 10-K, including the section of this Annual Report on Form 10-K titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the events described in the following risk factors and the risks described elsewhere in this Annual Report on Form 10-K occurs, our business, operating results and financial condition could be seriously harmed and the trading price of our common shares could decline and you could lose all or part of your investment in our common shares. </span></div><div id="iad55818e5d094e70a171c29f2aae2512_100"></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of ORGOVYX</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (relugolix) for the treatment of adult patients with advanced prostate cancer</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part on the successful commercialization of ORGOVYX, which received approval in December 2020 from the FDA, for the treatment of adult patients with advanced prostate cancer. To the extent ORGOVYX is not commercially successful, our business, financial condition and results of operations will be materially harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested and continue to invest a significant portion of our efforts and financial resources in the development, approval and now commercialization in the U.S. of ORGOVYX for the treatment of adult patients with advanced prostate cancer. Our and/or our collaboration partner, Pfizer’s, ability to generate net product revenues from ORGOVYX will depend upon the size of the markets in the jurisdictions for which regulatory approval is obtained, the number of competitors in such markets and numerous other factors, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully establishing effective sales, marketing, and distribution systems in the jurisdictions in which ORGOVYX is approved for sale;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully establishing and maintaining commercial third-party manufacturers and having adequate commercial quantities of ORGOVYX manufactured at acceptable cost and quality levels, including maintaining current good manufacturing practice (“cGMP”) and quality systems regulation standards required by various regulatory agencies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broad acceptance of ORGOVYX by physicians, patients and the healthcare community;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance of pricing and placement of ORGOVYX on payers’ formularies and the associated tiers;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other approved or used medicines and future compounds in development;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued demonstration of safety and efficacy of ORGOVYX in comparison to competing products, including through differentiated approved labeling; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, enforcing, and defending intellectual property rights and claims.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and/or Pfizer do not achieve one or more of these factors in a timely manner or at all, we and/or Pfizer could experience significant delays or an inability to successfully commercialize ORGOVYX, which would materially harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORGOVYX may fail to achieve the degree of market acceptance by physicians, patients, third-party payers or others in the medical community necessary for commercial success, which would negatively impact our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX may fail to gain sufficient market acceptance by physicians, patients, third-party payers, or others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant net product revenue or become profitable. The degree of market acceptance of ORGOVYX is dependent on a number of factors, including but not limited to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages compared to alternative treatments, including the convenience and ease or duration of administration;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptability of the price of ORGOVYX relative to other treatments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the content of the approved product label and our ability to make compelling product claims;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness and adequacy of our and Pfizer’s marketing efforts;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our and Pfizer’s sales efforts;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient out-of-pocket costs in relation to alternative treatments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the potential patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the breadth and cost of distribution support;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our patient assistance and support programs;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party payer coverage and adequate reimbursement; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether diagnosis and treatment rates change in advanced prostate cancer; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of ORGOVYX together with other medications.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of ORGOVYX will also depend on the acceptance and degree of adoption by institutional treatment pathways and institutional, local, and national clinical guidelines such as the National Comprehensive Cancer Networks</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Clinical Practice Guidelines in Oncology, or the NCCN Guidelines, the American Urological Association (“AUA”) guidelines, American Society of Clinical Oncology (“ASCO”) Clinical Practice Guidelines, or other country-specific guidelines. In the U.S., healthcare providers may refer to these guidelines related to patient treatment decisions. To the extent that our current or any future approved products are not included or positioned favorably in such treatment guidelines and pathways, the full utilization potential of our products may not be reached, which may harm our ability to successfully commercialize our current or any future approved products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and Pfizer are unable to effectively market and sell ORGOVYX, the commercialization of ORGOVYX will not be successful and our business will be harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To successfully market ORGOVYX, we must continue to develop our capabilities in sales, market access, marketing, distribution, and other commercial functions, either on our own or with our third-party collaboration partners. We have made arrangements regarding some of these functions in certain markets with third-party collaboration partners. For example, on August 1, 2020, we entered into a Market Access Services Agreement, as amended, with Sunovion pursuant to which, among other things, Sunovion has agreed to provide to us certain market access services with respect to the distribution and sale of ORGOVYX for prostate cancer and relugolix combination tablet for uterine fibroids and endometriosis. On December 26, 2020, we entered into the Pfizer Collaboration and License Agreement, pursuant to which we and Pfizer will collaborate to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jointly develop and commercialize relugolix in oncology and women’s health in the U.S. and Canada (the “Co-Promotion Territory”). In addition, Pfizer also received an option to acquire exclusive commercialization and development rights to relugolix in oncology outside the Co-Promotion Territory, excluding certain Asian countries (the “Pfizer Territory”). If Sunovion or Pfizer, or any other collaboration partners we may engage in the future, fail to perform or satisfy its obligations under their respective agreements with us or terminate their relationship with us, the sales, market access, marketing and/or distribution of ORGOVYX would be delayed or may not occur. In addition to the third-party collaboration arrangements described above, we continue to develop our own sales, market access, marketing, distribution and other commercial capabilities. There are significant expenses and risks involved with maintaining our own sales, market access, marketing, distribution, and other commercial capabilities, including: (i) our ability to recruit, train, and retain adequate numbers of qualified and effective sales, market access and marketing personnel; (ii) our ability to attain access to adequate numbers of physicians to prescribe any approved drugs; (iii) our ability to negotiate coverage and reimbursement for our products with payers at reasonable rebate or discount levels; (iv) our ability to negotiate competitive provider contracts to ensure access in in-office dispensing pharmacies; and (v) unforeseen costs and expenses associated with creating and sustaining internal sales, market access, marketing, distribution, and other commercial capabilities. The COVID-19 pandemic may negatively impact our and our collaboration partners’ ability to maintain commercial capabilities and may negatively impact our ability to rapidly and effectively educate potential prescribers and, if significant delays result, to commercialize ORGOVYX.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX is a newly approved and marketed drug in the U.S. and is the first and only oral gonadotropin-releasing hormone (“GnRH”) receptor antagonist for adult patients with advanced prostate cancer. Therefore, we and our collaboration partner, Pfizer, have only recently begun to promote ORGOVYX. In addition, we have only recently established our distribution and reimbursement capabilities in the U.S. together with Sunovion, all of which are necessary to successfully commercialize ORGOVYX. As a result, we and/or our collaboration partners will be required to expend significant time and resources to market, sell, and distribute ORGOVYX to physicians and the medical community in a credible, persuasive, and compliant manner consistent with applicable laws. There is no guarantee that the strategies, tactics and marketing messages, or the distribution and reimbursement capabilities, that we or our collaboration partners have developed will be successful. Specifically, for distribution of ORGOVYX, we are heavily dependent on third-party logistics, pharmacy and distribution partners. If we or our collaboration partners are unable to perform effectively, our ability to realize the return on our investment in developing ORGOVYX will suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to successfully obtain coverage and reimbursement for ORGOVYX in the United States, or the availability of coverage only at limited levels, would diminish our ability to generate net product revenue. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and Pfizer’s ability to commercialize ORGOVYX successfully in the U.S. will depend in part on the extent to which coverage and reimbursement for ORGOVYX will be available from third-party payers, including government health administration authorities, Medicare Part D plan sponsors and private health insurers, such as pharmacy benefit managers, health plans, and self-insured organizations. In the U.S., no uniform policy for coverage for products exists among third-party payers. Third-party payers decide which drugs they will pay for, what steps prescribers must take to obtain authorization for patients to fill their prescriptions, and how much patients must pay out of their own pocket. Payer decisions regarding the extent of coverage to be provided for any of our product candidates that obtain marketing approval will be made on a plan-by-plan basis. Additionally, a third-party payer’s decision to provide coverage for a drug does not imply that an affordable out-of-pocket cost for patients will be established. Each third-party payer determines whether or not it will provide coverage for a drug, what amount it will reimburse for the drug, on what tier of its formulary the drug will be placed, and whether to require step therapy or prior authorizations. The position of a drug on a formulary generally determines out-of-pocket costs that a patient will pay to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Coverage from both governmental healthcare programs, such as Medicare Part D and Medicaid, and coverage by private commercial payers are critical to ORGOVYX’s commercial success. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there have been a number of legislative and regulatory proposals to change the healthcare system that may impact drug coverage, reimbursement for drugs, and patient out-of-pocket costs in the U.S. and in some foreign jurisdictions that could affect our ability to successfully commercialize ORGOVYX. These legislative and regulatory changes may negatively impact the coverage for any future drugs, if approved.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition in the commercialization of ORGOVYX, and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of new pharmaceutical products is highly competitive, and we face substantial competition with respect to ORGOVYX. For example, although ORGOVYX is the first and only oral GnRH receptor antagonist for adult patients with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advanced prostate cancer approved by the FDA in the U.S., we may face competition from various drugs approved for the treatment of prostate cancer, such as Lupron Depot</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (AbbVie Inc.), Eligard</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Tolmar Pharmaceuticals) and Firmagon</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Ferring Pharmaceuticals).</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current and potential future competitors may have significantly more resources that they can deploy to commercialize drugs and may succeed in developing, acquiring or licensing, on an exclusive basis, drugs that are more effective or less costly than ORGOVYX or any product candidate that we may develop. Our competitors may succeed in obtaining patent protection, discovering, developing, receiving FDA or other regulatory authority approval for or commercializing medicines before we do, which would have an adverse impact on our business and results of operations. The availability and pricing of our competitors’ products could limit the demand and the price we are able to charge for ORGOVYX or any other product candidate we develop. Mergers and acquisitions in the pharmaceutical and biotechnology industries could result in even more resources being concentrated among a smaller number of our competitors.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inability to compete with existing or subsequently introduced drugs would have an adverse impact on our business, financial condition and prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If manufacturers obtain approval for generic versions of ORGOVYX, or of products with which we compete, our business may suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the U.S. Food, Drug and Cosmetic Act (“FDCA”), the FDA can approve an Abbreviated New Drug Application (“ANDA”), for a generic version of a branded drug without the ANDA applicant undertaking the clinical testing necessary to obtain approval to market a new drug. Generally, in place of such clinical studies, an ANDA applicant usually needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form, route of administration and that it is bioequivalent to the branded product.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA requires that an applicant seeking approval of a generic form of a branded drug certify either that its generic product does not infringe any of the patents listed by the owner of the branded drug in the Orange Book or that those patents are not enforceable. This process is known as a paragraph IV challenge. Upon notice of a paragraph IV challenge, a patent owner has 45 days to bring a patent infringement suit in federal district court against the company seeking ANDA approval of a product covered by one of the owner’s patents. If this type of suit is commenced, the FDCA provides a 30-month stay on the FDA’s approval of the competitor’s application. If the litigation is resolved in favor of the ANDA applicant or the challenged patent expires during the 30-month stay period, the stay is lifted and the FDA may thereafter approve the application based on the standards for approval of ANDAs. Once an ANDA is approved by the FDA, the generic manufacturer may market and sell the generic form of the branded drug in competition with the branded medicine.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner’s patents. If this were to occur with respect to ORGOVYX or products with which it competes, our business would be materially harmed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If patient safety issues were to arise for ORGOVYX, our future sales of ORGOVYX may be reduced, adversely affecting our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data supporting the marketing approval in the U.S. for ORGOVYX and forming the basis for our product label for ORGOVYX were obtained in controlled clinical studies of limited duration. As ORGOVYX is used over a longer period of time by patients, including those taking other medicines, we may continue to identify new issues such as safety concerns, resistance or drug interactions of ORGOVYX, which may require us to provide additional warnings or contraindications on our label or narrow the approved indication, each of which could reduce the market acceptance of ORGOVYX.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities have been moving towards more active and transparent pharmacovigilance and are making greater amounts of stand-alone safety information directly available to the public through websites and other means, e.g., periodic safety update report summaries, risk management plan summaries and various adverse event data. Safety information, without the appropriate context and expertise, may be misinterpreted and lead to misperception or legal action which may potentially negatively impact product sales of ORGOVYX. Further, if serious safety, resistance or drug interaction issues arise with ORGOVYX, sales could be limited or halted by us or by regulatory authorities and our results of operations would be adversely affected. In addition, problems with other drugs marketed by third parties that utilize the same therapeutic target or that belong to the same therapeutic class as ORGOVYX could adversely affect the commercialization of ORGOVYX.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a safety issue emerges post-approval, we may become subject to costly product liability litigation by our customers, patients or payers. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by our insurance. If we cannot successfully defend </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ourselves against claims that ORGOVYX caused injuries, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for ORGOVYX;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize ORGOVYX;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of patients from clinical studies or cancellation of clinical studies of relugolix;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product liability insurance coverage may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to obtain insurance coverage at a reasonable cost or in amounts adequate to satisfy any liability or associated costs that may arise in the future. These events could harm our business and results of operations and cause our common share price to decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our collaboration partner, Pfizer, are found to have improperly promoted unapproved uses of ORGOVYX, we may be subject to restrictions on the sale or marketing of ORGOVYX and significant fines, penalties, sanctions and product liability claims, and our image and reputation within the industry and marketplace could be harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies, including regulatory authorities outside the U.S., strictly regulate the marketing and promotional claims that are made about drug products, such as ORGOVYX. In particular, promotion for a product must be consistent with its labeling approved by the FDA or by regulatory agencies in other countries. For example, in the case of ORGOVYX, for the treatment of adult patients with advanced prostate cancer, physicians may prescribe ORGOVYX for indications or uses that are inconsistent with the approved label while we may not market or promote such off-label uses. If we or our collaboration partner, Pfizer, are found to have promoted such unapproved uses, we may, among other consequences, receive untitled or warning letters and become subject to significant liability, which would materially harm our business. Furthermore, the use of our products for indications other than those approved by the FDA or regulatory authorities outside the U.S. may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients. Both the U.S. federal government and foreign regulatory authorities have levied significant civil and criminal fines against companies and individuals for alleged improper promotion and have entered into settlement agreements with pharmaceutical companies to limit inappropriate promotional activities. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management’s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians’ prescribing our products for unapproved uses may also subject us to product liability claims, to the extent such uses lead to adverse events, side effects, or injuries. Product liability claims could divert management’s attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. Any of these events could harm our business and results of operations and cause our common share price to decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, fines, sanctions and exposure under other laws which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate Program, as administered by the Centers for Medicare and Medicaid Services (“CMS”) and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future. These programs generally require us to pay rebates or otherwise provide discounts to government payers in connection with drugs that are dispensed to beneficiaries/recipients of these programs. Pricing requirements and rebate/discount calculations are complex, vary among products and programs, and are often subject to interpretation by governmental or regulatory agencies and the courts. Thus, there can be no assurance that we will be able to identify all factors that may cause our discount and rebate payment obligations to vary from period to period, and our actual results may differ significantly from our estimated allowances for discounts and rebates. Changes in estimates and assumptions may have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Office of Inspector General of the Department of Health and Human Services and other Congressional enforcement and administrative bodies have increased their focus on pricing requirements for products, including, but not limited to the methodologies used by manufacturers to calculate average manufacturer price (“AMP”), and best price (“BP”), for compliance with reporting requirements under the Medicaid Drug Rebate Program. We are liable for errors associated with our submission of pricing data and for any overcharging of government payers. For example, failure to submit monthly/quarterly AMP and BP data on a timely basis could result in significant civil monetary penalties for each day the submission is late beyond the due date. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the Federal False Claims Act and other laws and regulations. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. In addition, in the event that CMS were to terminate our rebate agreement, no federal payments would be available under Medicaid or Medicare for our covered outpatient drugs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ORGOVYX is complex to manufacture, and manufacturing disruptions may occur that could cause us to experience disruptions in the supply of ORGOVYX.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX is complex to manufacture. Notwithstanding the fact that our third-party manufacturers have validated our process, manufacturing disruptions may occur. Such problems may prevent the production of lots that meet the specifications required for sale of the product and may be difficult and expensive to resolve. If any such issues were to arise with respect to ORGOVYX or our future product candidates, our business, financial results, or common share price could be adversely affected. Also, see the Risk Factor titled, “We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of drug substance and drug product. If these third parties do not perform as we expect, do not maintain their regulatory approvals, or become subject to other negative circumstances, it may result in delay in our ability to develop and commercialize our products.”</span></div><div id="iad55818e5d094e70a171c29f2aae2512_103"></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Relugolix Combination Tablet and for MVT-602</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success also depends on successful development and commercialization of relugolix combination tablet for our women’s health indications of uterine fibroids and endometriosis and MVT-602, and if we are successful in obtaining regulatory approval for these products, we will be subject to the same commercialization risks as described above for ORGOVYX.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although relugolix monotherapy has been approved in the U.S. as ORGOVYX for the treatment of adult patients with advanced prostate cancer, relugolix combination tablet has not yet been approved for our women’s health indications of uterine fibroids and endometriosis, nor has MVT-602 received any regulatory approvals. If relugolix combination tablet for either of our women’s health indications, or MVT-602 for the treatment of female infertility or other potential indications, receives regulatory approval in any indication, our commercialization of those products will be subject to the same or similar risks we currently face with the commercialization of ORGOVYX, as described under “Risks Related to Commercialization of ORGOVYX</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (relugolix) for the treatment of adult patients with advanced prostate cancer” above.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_106"></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Capital Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">not have adequate funds to cover our development and commercialization activities, we may have to</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">raise additional capital or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">curtail or cease operations. We may not be able to obtain funding through public or private offerings of our capital shares, debt financings, collaboration or licensing arrangements, or other sources.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began to commercialize ORGOVYX in the U.S. for the treatment of adult patients with advanced prostate cancer in January 2021, and plan to commercialize relugolix combination tablet, if approved, for women with uterine fibroids later this year. We also seek to advance additional product candidates through research and clinical development to regulatory approval and commercialization. These activities will require substantial financial resources.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, we had cash, cash equivalents and marketable securities of $684.9 million. Based on our current operating plan, we believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Annual Report on Form 10-K. This estimate is based on our current assumptions, including assumptions relating to our ability to manage our spend, that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. In future periods, if our cash, cash equivalents, marketable securities, and amounts that we expect to generate from product sales and/or third-party collaboration payments are not sufficient to enable us to fund our operations, we may need to raise additional funds in the form of equity, debt, or from other sources. In addition, we may choose to raise additional funds in the form of equity, debt, or from other sources due to market conditions or strategic considerations even if we believe we have sufficient funds for our current and future operating plans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating expenses, net of costs that are expected to be shared with Pfizer pursuant to the Pfizer Collaboration and License Agreement, to increase and our future capital requirements are expected to be significant. Our operating expenses and operating cash flows may fluctuate significantly from quarter-to-quarter and year-to-year and our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price, level of demand and net revenues generated from commercial sales of ORGOVYX and for any other product candidates that may receive marketing approval;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of regulatory milestones, sales milestones, and royalties that we are eligible to earn pursuant to the Richter Development and Commercialization Agreement and the Pfizer Collaboration and License Agreement;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, shared costs, and level of investment in our and our collaboration partners’ activities related to sales, marketing, market access, manufacturing, and distribution for ORGOVYX and for any other product candidates that may receive marketing approval;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, shared costs, and level of investment in our and our collaboration partners’ research and development activities involving ORGOVYX, relugolix combination tablet, and any other product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of our planned and ongoing clinical studies for our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of meeting regulatory requirements established by the FDA and comparable foreign regulatory authorities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost to maintain, expand, and protect our patent claims and other intellectual property rights;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of completion of commercial-scale manufacturing activities, including securing regulatory approval for commercial production;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to hire additional commercial operations, sales, scientific, clinical, regulatory, quality, and other personnel to support our commercialization, regulatory, and clinical development efforts; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs to implement or enhance operational, accounting, finance, quality, commercial, and management information systems.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Sumitomo Dainippon Pharma Loan Agreement, we may not raise additional capital without obtaining the consent of Sumitomo Dainippon Pharma. If we do not have sufficient funds to complete the development of, seek regulatory approvals for our product candidates and commercialize ORGOVYX and, if approved, our other product candidates, we may be required to delay, limit, reduce, or terminate our drug development programs, commercialization efforts, and/or limit or cease our operations if we are unable to obtain additional capital to support our current operating plan. In addition, attempting to secure additional capital may divert the time and attention of our management from day-to-day activities and harm our product candidate development and commercialization efforts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are required to meet certain terms and conditions to draw down funds under the Sumitomo Dainippon Pharma Loan Agreement. If we are unable to meet such terms and conditions, we may not be able to access funding from the Sumitomo Dainippon Pharma Loan Agreement. Further, we may be obligated to repay the loans prior to their scheduled maturity date under certain circumstances.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, we, one of our subsidiaries and Sumitomo Dainippon Pharma entered into the Sumitomo Dainippon Pharma Loan Agreement, pursuant to which Sumitomo Dainippon Pharma agreed to make revolving loans to us in an aggregate principal amount up to $400.0 million. As of March 31, 2021, approximately $41.3 million of borrowing capacity remained available to us under the Sumitomo Dainippon Pharma Loan Agreement. We may draw down additional funds under the Sumitomo Dainippon Pharma Loan Agreement once per calendar quarter, subject to certain terms and conditions, including the consent of our board of directors and no change of control having occurred with respect to us. We may not be able to meet such terms and conditions in the future and may not be able to secure additional funds. In addition, if Sumitomo Dainippon Pharma fails to own at least a majority of the outstanding common shares of Myovant, it may become unlawful under Japanese law for Sumitomo Dainippon Pharma to fund loans to us, and in which case we would not be able to continue to borrow under the Sumitomo Dainippon Pharma Loan Agreement. Furthermore, within 30 days of a change of control having occurred with respect to us, we will be obligated to repay the outstanding amount of loans and accrued interest under the Sumitomo Dainippon Pharma Loan Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never achieve or maintain profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in pharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate may fail to gain regulatory approval or fail to become commercially viable. Since inception, we have incurred significant operating losses and negative operating cash flows. We expect to continue to incur significant operating expenses as we commercially launch ORGOVYX in the U.S., continue to develop our product candidates and prepare for potential regulatory approvals and commercialization of relugolix combination tablet. The timing and magnitude of our net income (loss) will depend on the commercial success of ORGOVYX, as well as the timing and commercial success of any other product launches, as well as other potential business and operational activities. Likewise, any potential future milestone or royalty payments that we are eligible to earn under the Pfizer Collaboration and License Agreement and the Richter Development and Commercialization Agreement will depend on the regulatory and commercial success of ORGOVYX, relugolix monotherapy tablet, and relugolix combination tablet. As a result, we may never achieve or maintain profitability.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_109"></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of the Sumitomo Dainippon Pharma Loan Agreement place restrictions on our operating and financial flexibility.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Sumitomo Dainippon Pharma Loan Agreement are senior unsecured obligations including customary representations and warranties as well as affirmative and negative covenants, that are guaranteed on a full and unconditional basis by all our subsidiaries.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative covenants include limitations on additional indebtedness, liens, certain corporate changes, certain restricted payments, investment transactions with affiliates, entry into certain restrictive agreements, change in the nature of business, and use of proceeds. Compliance with these covenants may limit our flexibility in operating our business and our ability to take actions that might be advantageous to us and our shareholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Sumitomo Dainippon Pharma Loan Agreement also includes customary events of default, including payment defaults, breaches of representations and warranties and certain covenants following any applicable cure period, cross acceleration to certain debt, other failure to pay certain final judgments, certain events relating to bankruptcy or insolvency, certain breaches by us under our Investor Rights Agreement with Sumitovant and Sumitomo Dainippon Pharma, dated December 27, 2019, and failure of material provisions of the loan documents to remain in full force and effect or any contest thereto by us or any of our subsidiaries. Upon the occurrence of an event of default, a default interest rate of an additional 5.0% will apply to the outstanding principal amount of the loans, Sumitomo Dainippon Pharma may terminate its obligations to make loans to us and declare the principal amount of all outstanding loans and other obligations under the Sumitomo Dainippon Pharma Loan Agreement to become immediately due and payable, and Sumitomo Dainippon Pharma may take such other actions as set forth in the Sumitomo Dainippon Pharma Loan Agreement. Upon the occurrence of certain bankruptcy and insolvency events, the obligations of Sumitomo Dainippon Pharma to make loans to us would automatically terminate and the principal amount of all outstanding loans and other obligations due under the Sumitomo Dainippon Pharma Loan Agreement would automatically become due and payable. In addition, if it becomes unlawful for Sumitomo Dainippon Pharma to maintain the loans under the Sumitomo Dainippon Pharma Loan Agreement, we would be required to repay the outstanding principal amount of the loans and if a change of control occurs with respect to us, we would be required to repay the outstanding principal amount of the loans within 30 days of such change of control. We may not have enough available funds or be able to raise additional funds through equity or debt financings to repay these outstanding obligations at the time any event of default occurs. In that case, we may be required to delay, limit, reduce or terminate our clinical development efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our business, financial condition and results of operations could be substantially harmed as a result of any of these events.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify and acquire or in-license additional product candidates, which may limit our growth potential.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part of our strategy involves diversifying our product development risk by identifying and acquiring or in-licensing novel product candidates. We may fail to identify and acquire or in-license product candidates, including for reasons discussed in these risk factors and also:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the process by which we identify and decide to acquire product candidates may not be successful;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the competition to acquire or in-license promising product candidates is fierce and many of our competitors are large, multinational pharmaceutical, biotechnology and medical device companies with considerably more financial, development and commercialization resources and experience than we have; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, upon further study during the acquisition process, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential novel product candidates may prove to be unsuccessful and may not be effective in treating their targeted diseases.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, time and resources spent searching for, identifying, acquiring, and developing potential product candidates may distract management’s attention from our primary business. If we are unable to identify and acquire or in-license suitable product candidates, we will be unable to diversify our product risk. We believe that any such failure could have a significant negative impact on our prospects for future growth.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of drug substance and drug product. If these third parties do not perform as we expect, do not maintain their regulatory approvals, or become subject to other negative circumstances, it may result in delay in our ability to develop and commercialize our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and we do not expect to own or operate, facilities for drug substance and drug product manufacturing, storage and distribution, or testing and are subject to the risk that our contract manufacturers become subject to negative circumstances. For example, in June 2016, we and one of Takeda’s affiliates, Takeda Pharmaceutical Company Limited (“Takeda Limited”) entered into an agreement for the manufacture and clinical supply of relugolix pursuant to which Takeda Limited supplied us with, and we obtained from Takeda, all of our requirements for relugolix drug substance and drug product that were used under our development plans. In May 2018, we entered into a Commercial Manufacturing and Supply Agreement with Takeda pursuant to which Takeda agreed to manufacture and supply us with certain commercial relugolix drug substance quantities. In addition, in April 2019, we entered into a Commercial Manufacturing and Supply Agreement with Excella GmbH &amp; Co. KG (“Excella”) pursuant to which Excella agreed to manufacture and supply us with certain commercial relugolix drug substance quantities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda is no longer developing MVT-602. Additional process development and manufacturing would be required for us to complete further Phase 2 and Phase 3 clinical studies for MVT-602. Third-party vendors may be difficult to identify for MVT-602 process and formulation development and manufacturing due to special capabilities required and they may not be able to meet our quality standards.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we need to replace a third-party manufacturer, or if any of our third-party manufacturers experience adverse developments, including with respect to adverse findings during regulatory inspections, delays in regulatory approvals and/or the COVID-19 pandemic, we could experience a significant delay in the supply of a product candidate, which could result in a considerable delay in completing our clinical studies, product testing, and potential regulatory approval of our product candidates. In addition, the commercial launch of our product candidates could be delayed and there could be a shortage in supply, which would impair our ability to generate revenue from the sale of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the regulatory authorities pursuant to inspections that may be conducted after we submit our regulatory applications to such regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMP requirements and other regulations and laws for the manufacture of relugolix drug substance and drug product. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable foreign regulatory authorities, they may not be able to secure or maintain regulatory approvals for their manufacturing facilities and any applications that we submit to the FDA or other regulatory authorities that list those manufacturing facilities may be negatively affected. Our third-party contract manufacturing facilities must also be in an acceptable state of cGMP compliance and not be subject to a cGMP related regulatory or enforcement action that limits their ability to manufacture drug substance or drug product. For example, if any of the drug substance supplied by a contract manufacturing partner cannot be utilized due to quality or cGMP concerns, adverse findings during regulatory inspections or other reasons, our development plans and commercialization of relugolix, if approved, could be significantly delayed or otherwise adversely affected. The FDA or other regulatory authority may withhold approval of any pending regulatory applications or supplements in which non-complaint manufacturing facilities are listed. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Takeda received a warning letter from the FDA which indicated that the FDA was not satisfied with Takeda’s response to an FDA Form 483 issued to Takeda following its routine inspection of aseptic finished pharmaceuticals manufacturing at Takeda’s manufacturing facility located at Takeda 4720, Mitsui, Hikari, Yamaguchi (“Hikari Facility”). We initially listed both Takeda and Excella as contract manufacturing organizations (“CMOs”) in our regulatory filings for the manufacture of relugolix drug substance. We are now procuring the commercial relugolix drug substance for U.S. ORGOVYX solely from Excella. We have removed the Hikari Facility as a manufacturing site from our NDA submissions and may remove </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it from other regulatory filings if required until Takeda corrects the violations noted in the warning letter to the satisfaction of the regulatory authorities. We cannot predict if or when Takeda will correct the violations and deviations to the satisfaction of the FDA or any other regulatory agency or whether the regulatory agencies will be satisfied with Takeda’s responses. The COVID-19 pandemic may also cause delays in the remediation and re-inspection process. We also face the risk that Excella or our other CMOs may face adverse developments, including with respect to adverse findings during regulatory inspections, delays in regulatory approval and/or the COVID-19 pandemic. If Excella or our other CMOs fail to fulfill their obligations to manufacture and supply relugolix drug substance and drug product needed for ORGOVYX and our other anticipated launches, or if any of the materials cannot be utilized due to quality or cGMP concerns, adverse findings during regulatory inspections, process validation delays, or other reasons, our development plans and commercialization of ORGOVYX and any of our other product candidates could be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates contain highly potent compounds and therefore require specialized manufacturing facilities. Depending on actual commercial demand, additional third-party manufacturing facilities will have to be established to meet the demand through technology transfer, process validation and regulatory approval before product manufactured at the new facilities can be marketed. Any delay in the technology transfer and process validation could limit adequate supply to meet our commercial demand.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our reliance on third-party manufacturers entails various risks, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or inability to manufacture ORGOVYX or relugolix combination tablet;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of the drug substance transferred from a CMO to meet our product specifications and quality requirements;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or inability to procure or expand sufficient manufacturing capacity;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing and product quality issues related to scale-up of manufacturing;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs and validation of new equipment and facilities required for scale-up;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with applicable laws, regulations, and standards, including cGMP and similar foreign standards;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficient or improper record-keeping;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to negotiate manufacturing and quality agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell ORGOVYX, relugolix combination tablet or MVT-602, if approved, or any future product candidate in a timely fashion, in sufficient quantities or under acceptable terms;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse inspection findings by the FDA or other regulatory authorities at third-party manufacturing facilities and/or failure to remediate such findings;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cGMP regulatory or enforcement action at our third-party manufacturing facilities that limit their ability to manufacture drug substance or drug product for commercial use;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or other regulatory sanctions related to the manufacture of another company’s products;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">carrier disruptions or increased costs that are beyond our control; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to deliver our products under specified storage conditions and in a timely manner.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could also lead to clinical study delays, cost overruns, delay or failure to obtain regulatory approval or impact our ability to successfully commercialize our products, as well as potential product liability litigation, product recalls or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product withdrawals. Some of these events could be the basis for the FDA or other regulatory authority action, including injunction, recall, seizure, or total or partial suspension of production.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our or our affiliates’ employees, independent contractors, third-party manufacturers, principal investigators, consultants, commercial collaboration partners, service providers, and other vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory or legal standards and requirements, which could have an adverse effect on our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, advisers, including third-party manufacturers, principal investigators, consultants, commercial collaboration partners, service providers, and other vendors, or those of our affiliates, may engage in fraudulent, illegal activity, or other misconduct. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA or other regulatory bodies, including: those laws that require the reporting of true, complete, and accurate information to such regulatory bodies; laws that require manufacturing by cGMP standards; federal, state and foreign healthcare fraud and abuse laws and data privacy laws; or laws and regulations that require the true, complete, and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive regulations intended to prevent fraud, kickbacks, self-dealing, bribery, corruption, antitrust violations, and other abusive practices. See the Risk Factors titled “Our current and future relationships with investigators, healthcare professionals, consultants, third-party payers, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties,” and “International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, economic, and other risks associated with conducting business outside of the U.S., which could interrupt our business operations and harm our future international expansion and, consequently, negatively impact our financial condition, results of operations, and cash flows.” These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical studies, creating fraudulent data in our nonclinical or clinical studies or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. We have a Code of Business Conduct and Ethics and other corporate compliance policies, but it is not always possible to identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business interruptions resulting from effects of pandemics or epidemics, such as the COVID-19 pandemic, may materially and adversely affect our business and financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may materially and adversely affect our business and financial condition. For example, the majority of our employees continue to work from home as a result of the COVID-19 pandemic. Employees may be less efficient given competing priorities with home-schooling or caring for sick family members, and employee engagement and productivity may decrease from the stress of the COVID-19 pandemic resulting in delays in the progress of our business. In addition, we rely on third parties in the U.S. and in various parts of the world to assist in the conduct of our clinical studies and to supply us with sufficient drug supplies. Our ability to ensure continuous clinical drug supply to patients and our ability to ensure continuous patient follow up and data monitoring for our ongoing clinical studies may be adversely impacted. Likewise, while we currently expect that the drug supply we have on hand or expect to procure will be sufficient to support our ongoing clinical studies, our ORGOVYX commercial launch, and anticipated commercial launches of relugolix combination tablet, our supply chain for raw materials, drug substance and drug product is worldwide, and the duration of the COVID-19 pandemic and its impact on the ability of our suppliers to operate could negatively impact our manufacturing supply chain for ORGOVYX, for any other product candidates that may receive regulatory approval, or for clinical study materials. If disruptions to our supply chain persist for an extended period of time, our clinical study timelines, our financial condition and our results of operations may be negatively impacted. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has made it more difficult for our medical affairs team to present scientific data and for our regional medical advisors to engage potential prescribers in scientific exchange. Multiple medical conferences have been canceled, postponed or moved to virtual formats, resulting in fewer opportunities to present our scientific data and our medical affairs team members can only communicate virtually in many instances making it more difficult to educate and engage in scientific exchange.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic may impact the FDA’s review process and timing of potential approval of our product candidates. Regulatory agency pre-approval inspections are now limited, and it is not clear if virtual inspections will be required and acceptable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may negatively impact our ability to rapidly and effectively educate potential prescribers and payers and, successfully commercialize ORGOVYX and our other product candidates, if approved. We launched ORGOVYX in January 2021, and may launch other approved products in the COVID-19 environment. In response to the COVID-19 pandemic, health professionals may reduce staffing and reduce or postpone appointments with patients, or patients may cancel or miss appointments, resulting in potential delays in diagnosis and treatment, and therefore fewer prescriptions. In addition, our sales teams have been and would likely have to continue to make presentations to physicians and the medical community in many cases by virtual means instead of in-person, which could reduce the number of medical professionals we are able to present to, and these virtual meetings may not be as successful as in-person meetings. Reduced access to healthcare providers as a result of social distancing protocols may impact or require adjustment to our planned commercialization activities, including the way our field teams engage with healthcare providers and facilities. Travel restrictions may make it more difficult for us to maximize the potential of our third-party market access, marketing and distribution capabilities, such as our relationships with Sunovion, Pfizer, and Richter and provide adequate collaboration and oversight.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may negatively impact our ability to attract and retain the human resources required to maintain and build out our commercial capabilities. Conducting interviews remotely makes it more difficult to ensure we are recruiting and hiring high-quality employees, and the uncertainty created by the COVID-19 pandemic makes it less likely potential candidates will be willing to leave a stable job to explore a new opportunity.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic and global efforts to address the COVID-19 pandemic will impact our operations will depend on future developments, which are highly uncertain and cannot be predicted at this time, and include the duration, severity and scope of the outbreak and the actions taken to contain or treat the coronavirus outbreak. In addition, the COVID-19 pandemic may also have the effect of heightening many of the other risks described in this “Risk Factors” section.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, economic, and other risks associated with conducting business outside of the U.S., which could interrupt our business operations and harm our future international expansion and, consequently, negatively impact our financial condition, results of operations, and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Part of our business strategy involves international expansion, including establishing and maintaining operations outside of the U.S., and establishing and maintaining relationships with healthcare providers, payers, government officials, distributors, manufacturers and other third parties globally in case any of our product candidates is approved for marketing outside of the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting business internationally involves a number of risks, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">multiple conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment, immigration and labor laws, privacy and cybersecurity laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals and rules governing drug commercialization in foreign countries;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible failure by us or our distributors to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidates, if approved, in various countries;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in managing foreign operations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">complexities associated with managing multiple payer-reimbursement, pricing and insurance regimes or self-pay systems;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable, and exposure to foreign currency exchange rate fluctuations;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced or no protection over intellectual property rights;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, economic instability, or natural disasters, including, but not limited to, wars and terrorism, economic weakness, inflation, political instability in particular foreign economies and markets, boycotts, curtailment of trade, labor disputes, unexpected changes in tariffs, and other business restrictions, outbreak of disease (such as the COVID-19 pandemic), fires, earthquakes, hurricane, tornado, severe storm, power outage, system failure, typhoons or floods;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with foreign laws, regulations, standards and regulatory guidance governing the collection, use, disclosure, retention, security and transfer of personal data, including the European Union General Data Protection </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation (the “GDPR”) which introduced strict requirements for processing personal data of individuals within the EU; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to comply with the Foreign Corrupt Practices Act, including its books and records provisions and its anti-bribery provisions, the United Kingdom Bribery Act 2010, and similar antibribery and anticorruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors’ activities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these risks, if encountered, could interrupt our business operations and harm our future international expansion and, consequently, negatively impact our financial condition, results of operations, and cash flows. We have no prior experience in certain countries, and many biopharmaceutical companies have found the process of marketing their products in foreign countries to be very challenging.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The withdrawal of the United Kingdom (the “U.K.”) from the European Union (the “EU”), commonly referred to as “Brexit,” may adversely impact our ability to obtain regulatory approvals of our product candidates in the EU, result in restrictions or imposition of taxes and duties for importing our product candidates into the EU, and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the EU.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the result of a referendum in 2016, the U.K. left the EU on January 31, 2020, commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements between the U.K. and the EU, the U.K. was subject to a transition period until December 31, 2020 (the “Transition Period”) during which EU rules continued to apply. A trade and cooperation agreement (the “Trade and Cooperation Agreement”) that outlines the future trading relationship between the U.K. and the EU was agreed to in December 2020. Since a significant proportion of the regulatory framework in the U.K. applicable to our business and certain of our product candidates are derived from EU directives and regulations, Brexit has had, and may continue to have, a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. or the EU. For example, the U.K is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be required to market our product candidates in the U.K. It is currently unclear whether the Medicines &amp; Healthcare products Regulatory Agency (“MHRA”) in the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the U.K. or the EU and restrict our ability to generate revenue and achieve and sustain profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Trade and Cooperation Agreement provides for the tariff-free trade of medicinal products between the U.K. and the EU there may be additional non-tariff costs to such trade which did not exist prior to the end of the Transition Period. Further, should the U.K. diverge from the EU from a regulatory perspective in relation to medicinal products, tariffs could be put into place in the future. We could therefore, both now and in the future, face significant additional expenses (when compared to the position prior to the end of the Transition Period) to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or other non-tariff barriers on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the U.K. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the EU.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, and those of our third-party collaborators, consultants or contractors, may fail or suffer cybersecurity breaches and data leakage, which could result in a material disruption of our business and operations or liabilities that adversely affect our financial performance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our computer systems, as well as those of our contract research organizations (“CROs”), CMOs, third-party logistics providers, third-party collaboration partners, and other contractors, consultants, and law and accounting firms, may sustain damage or data leakage from computer viruses, unauthorized access or disclosure, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war, and telecommunication and electrical failures. We rely on our third-party providers to implement effective security and data recovery measures and identify and correct for any such failures, deficiencies or breaches. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of the commercialization of ORGOVYX and our drug development programs. For example, the loss of commercialization information, nonclinical or clinical study data from </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completed, ongoing or planned clinical studies could result in delays in our commercialization, regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data, access or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, suffer reputational damage, and the further development of any current or future product candidate could be delayed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable U.S. and foreign privacy and data protection laws and regulations, we may be subject to liabilities that adversely affect our business, operations and financial performance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state laws and regulations requiring that we take measures to protect the privacy and security of certain information we gather and use in our business. For example, federal and state security breach notification laws, state health information privacy laws and federal and state consumer protection laws impose requirements regarding the collection, use, disclosure and storage of personal information. In addition, California enacted the California Consumer Privacy Act (“CCPA”), which became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may increase data breach litigation. Although the CCPA includes exemptions for certain clinical study data, and Health Insurance Portability and Accountability Act (“HIPAA”) protected health information, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents. The CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to or affected by foreign laws and regulations, including regulatory guidance, governing the collection, use, disclosure, security, transfer and storage of personal data, such as information that we collect about patients and healthcare providers in connection with clinical studies and our other operations in the U.S. and abroad. The global legislative and regulatory landscape for privacy and data protection continues to evolve, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. For example, the EU has adopted the GDPR, which has strict requirements for processing personal data. The GDPR increases our compliance burden with respect to data protection, including by mandating potentially burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and leverage information about them. The processing of sensitive personal data, such as information about health conditions, entails heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for breach reporting requirements, more robust regulatory enforcement and fines of up to the greater of 20 million euros or 4% of annual global revenue. While companies are afforded some flexibility in determining how to comply with the GDPR’s various requirements, significant effort and expense are required to ensure continuing compliance with the GDPR. Moreover, the requirements under the GDPR and guidance issued by different EU member states may change periodically or may be modified, and such changes or modifications could have an adverse effect on our business operations if compliance becomes substantially costlier than under current requirements. It is also possible that each of these privacy laws may be interpreted and applied in a manner that is inconsistent with our practices. Further, Brexit has created uncertainty with regard to data protection regulation in the U.K. In particular, it is unclear whether, post Brexit, the U.K. will enact data protection legislation equivalent to the GDPR and how data transfers to and from the U.K. will be regulated. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The failure to successfully expand and maintain our enterprise resource planning (“ERP”) system and other information technology systems could adversely affect our business and results of operations or the effectiveness of internal control over financial reporting.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During our fiscal year 2019, we began the implementation of a company-wide ERP system pertaining to certain business, operational, and finance processes. We have continued to optimize this ERP system and have implemented and continue to optimize other systems as a part of our ongoing technology and process improvement initiatives. ERP and other information technology system implementations are complex and time-consuming projects that require transformations of business, operational, and finance processes. Any such transformation involves risk inherent in the conversion to a new system, including loss of information and potential disruption to normal operations. The implementation and optimization of the ERP system and other information technology systems has required, and will continue to require, the investment of significant financial and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">human resources. These systems are critical to our ability to accurately maintain books and records and prepare our financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruptions, delays, or deficiencies in the design or the ongoing maintenance and optimization of the ERP system and other information technology systems could adversely affect our ability to accurately maintain our books and records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business. Additionally, if the ERP system and other information technology systems do not operate as intended, the effectiveness of our internal control over financial reporting could be adversely affected and could cause us to fail to comply with SEC obligations related to our internal control over financial reporting. In addition, if we experience interruptions in service or operational difficulties and are unable to effectively manage our business following the implementation or optimization of the ERP system or other information technology systems, our business and results of operations could be harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The phase-out of the London Interbank Offered Rate (“LIBOR”), or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our outstanding variable rate indebtedness with Sumitomo Dainippon Pharma.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2017, the United Kingdom’s Financial Conduct Authority (the authority that regulates LIBOR) announced that after 2021, it would no longer compel banks to submit the rates required to calculate LIBOR. This announcement indicates that the continuation of LIBOR on its current basis cannot and will not be guaranteed after 2021. It is unclear whether new methods of calculating LIBOR will be established such that it continues to exist after 2021, or if alternative rates or benchmarks will be adopted. The interest rate under the Sumitomo Dainippon Pharma Loan Agreement is calculated based on LIBOR and, when LIBOR is phased out, we will need to agree with Sumitomo Dainippon Pharma to a new method of calculating the interest rate under the Sumitomo Dainippon Pharma Loan Agreement. Changes in the method of calculating LIBOR, or the replacement of LIBOR with an alternative rate or benchmark, may adversely affect interest rates and result in higher borrowing costs. This could materially and adversely affect our results of operations, cash flows and liquidity. We cannot predict the effect of the potential changes to LIBOR or the establishment and use of alternative rates or benchmarks.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_112"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Regulatory Approval</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical studies are very expensive, time-consuming, difficult to design and implement, and involve uncertain outcomes. Clinical study failures can occur at any stage of clinical studies, and we could encounter problems that cause us to suspend, abandon or repeat clinical studies. We cannot predict with any certainty the timing for commencement or completion of current or future clinical studies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate will require extensive clinical testing resulting in sufficiently positive outcomes before we are prepared to submit an NDA or other similar application for regulatory approval. Human clinical studies are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For example, the FDA or other regulatory authorities may not agree with our proposed plans for any clinical studies of relugolix combination tablet, relugolix monotherapy tablet, MVT-602, or any other potential future product candidates, which may delay the approval of an NDA or similar application. The clinical study process is also very time-consuming. The commencement and completion of clinical studies may be delayed by several factors, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to obtain regulatory approval to commence a study or regulatory actions requiring a hold on any of our clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of effectiveness during clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identification of dosing issues;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to reach agreement on acceptable terms with prospective CROs and/or clinical study sites, the terms of which can be subject to extensive negotiations and may vary significantly among different CROs and clinical study sites;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">slower than expected rates of patient recruitment and enrollment or failure to recruit suitable patients to participate in a study;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to open a sufficient number of clinical study sites;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated impact from changes in or modifications to clinical study design;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability or unwillingness of clinical investigators or study participants to follow our clinical and other applicable protocols, including missed assessments or impeded access to study sites due to government or institutional stay-at-home or shelter-in-place measures during the COVID-19 pandemic;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">premature discontinuation of study participants from clinical studies or missing data, including from patients unable to come to study visits during the COVID-19 pandemic;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to manufacture or release sufficient quantities of relugolix, MVT-602, estradiol, progestin or placebo or failure to obtain sufficient quantities of concomitant medication, that in each case meet our quality standards, for use in clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to monitor patients adequately during or after treatment; or</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inappropriate unblinding of study patients or study results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical study failures can occur at any stage of clinical studies, and we could encounter problems that cause us to suspend, abandon or repeat clinical studies. We, the FDA or an institutional review board or other regulatory authority may suspend our clinical studies at any time if it appears that we or our collaborators are failing to conduct a clinical study in accordance with regulatory requirements, including, the FDA’s current Good Clinical Practices (“cGCP”) or cGMP regulations, that we are exposing participants to unacceptable health risks, or if the FDA or other regulatory authority, as the case may be, finds deficiencies in our Investigational New Drug application or other submissions or the manner in which the clinical studies are conducted. In addition, product candidates in later stages of clinical development may fail to show the desired safety and efficacy outcomes despite having progressed successfully through prior stages of preclinical and clinical testing. Results from clinical studies may require further evaluation, delaying the next stage of clinical development or submission of an NDA or other similar application for regulatory approval. Therefore, we cannot predict with any certainty the timing for commencement or completion of current or future clinical studies. If we experience delays in the commencement or completion of our clinical studies, or if we terminate a clinical study prior to completion, the commercial prospects of any product candidates could be harmed, and our ability to generate net product revenue from any product candidates may be delayed. In addition, any delays in our clinical studies could increase our costs, cause a decline in our common share price, slow down the regulatory approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial condition, and results of operations. In addition, many of the factors that cause or lead to a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical studies may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical study site and the utility of the clinical study itself may be jeopardized. Clinical study sites, CROs and manufacturing sites may be inspected for compliance with cGCP or cGMP. Any questions about data integrity or significant quality issues could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the research and development of relugolix and MVT-602 previously conducted by Takeda. If Takeda did not conduct this research and development in compliance with applicable requirements, it could result in increased costs and delays in our development of these product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our acquisition of worldwide rights (excluding Japan and certain other Asian countries) to relugolix and worldwide rights to MVT-602, we had no involvement with or control over the nonclinical or clinical development of relugolix or MVT-602. We are dependent on Takeda having conducted such research and development in accordance with the applicable protocols, legal, regulatory, and scientific standards, having accurately reported the results of all clinical studies and other research conducted prior to our acquisition of the rights to relugolix and MVT-602, having correctly collected and interpreted the data from these studies and other research, and having supplied us with complete information, data sets, and reports required to adequately demonstrate the results reported through the date of our acquisition of these assets. Problems related to any of such nonclinical or clinical work could result in increased costs and delays in the development of our product candidates, which could adversely affect our ability to generate any future revenue from these product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recruitment, enrollment and retention of patients in clinical studies is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical studies on our current timelines, or at all, and even once enrolled we may be unable to retain a sufficient number of patients to satisfactorily complete any of our clinical studies. Enrollment in our clinical studies may be slower than we anticipated, leading to delays in our development timelines. Patient enrollment and retention in clinical studies depends on many factors, including the size of the patient population, the nature</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the study protocol, our ability to recruit clinical study investigators with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical studies of competing drugs for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the study and the proportion of patients screened that meets those criteria, our ability to obtain and maintain patient consents, and the risk that patients enrolled in clinical studies will not comply with the protocol or will drop out of the studies before completion. In addition, unforeseen global instability, including political instability or instability from an outbreak of pandemic or contagious disease, su</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ch as the COVID-19 pandemic, in or around the countries in which we conduct our clinical studies, could delay the commencement or rate of completion of our clinical studies.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Furthermore, any negative results we or certain collaboration partners may report in clinical studies of our product candidates may make it difficult or impossible to recruit, enroll, and retain patients in other clinical studies of that same product candidate. Simil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arly, negative or positive results reported by our competitors about their products or product candidates may negatively affect patient recruitment, enrollment, or retention in our clinical studies. Also, marketing authorization of competitors in the same class of product candidates may impair our ability to recruit, enroll, or retain patients into our clinical studies, delaying or potentially preventing us from completing clinical studies. Delays or failures in planned patient recruitment, enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of our clinical studies may not support our proposed claims for our product candidates. The results of previous clinical studies may not be predictive of future results, and interim or top-line data may be subject to change or qualification based on the complete analysis of data.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our clinical studies are completed as planned, we cannot be certain that their results will support the efficacy or safety of our product candidates. For example, product candidates may not meet the criteria for success for their primary endpoint specified in the statistical analysis plan, highlighting the importance of appropriate selection of the primary endpoint, statistical powering of a clinical study, and diligent oversight of the treatment compliance of those patients enrolled into the study. Success in nonclinical testing and early clinical studies does not ensure that later clinical studies will be successful, and we cannot be sure that the results of later clinical studies will replicate the results of prior clinical studies and nonclinical testing. Likewise, promising results in interim analyses or other preliminary analyses do not ensure that the clinical study as a whole will be successful. In addition, the FDA may not agree that clinical study results are sufficient for approval for any product candidate, or even if approved, may not support a label that is capable of competing with existing treatments. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in clinical studies, even after having achieved promising results in earlier nonclinical or clinical studies. These setbacks have been caused by, among other things, nonclinical findings made while clinical studies were underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Positive results from any of our clinical studies may not be predictive of the results of any of our other ongoing and potential future clinical studies, and there can be no assurance that the results of studies conducted by third parties will be viewed favorably or are indicative of our own future study results. We may publicly disclose top-line or interim data from time to time, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review, audit and verification of the data related to the particular study. We make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results once additional data have been received and fully evaluated.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A future failure of a clinical study to meet its primary endpoints would likely cause us to abandon a product candidate and may delay development of any other product candidates. Any delay in, or termination of, our clinical studies will delay the submission of our NDAs to the FDA or other similar applications to other foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates and generate net product revenue.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reported data or other clinical development announcements by Takeda, its partners or sublicensees, or by our collaboration partners, including Pfizer and Richter may adversely affect our commercialization of ORGOVYX and our clinical development plans.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Takeda, its partners and sublicensees and our collaboration partners, Pfizer and Richter, may be involved in the further clinical development of relugolix. Favorable announcements by Takeda, Pfizer or Richter do not guarantee that the results of our clinical studies will also be favorable as the designs of our clinical studies may differ from those of Takeda, Pfizer or Richter. Further, if clinical study or post-marketing adverse events regarding relugolix are reported, or subsequent announcements by our partners regarding relugolix are unfavorable, it could negatively impact our commercialization of ORGOVYX and our clinical development plans for or opinions of the FDA or other regulatory authorities with respect to relugolix. For example, Takeda has developed relugolix for the treatment of women with uterine fibroid-associated pain and heavy menstrual bleeding in Japan. Takeda reported positive top-line results from its two Phase 3 clinical studies in Japan in women with uterine fibroids and has obtained market authorization in Japan from the Ministry of Health, Labor and Welfare for Relumina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablets 40 mg (generic name: relugolix) for the improvement of symptoms of uterine fibroids, including heavy menstrual bleeding, lower abdominal pain, lower back pain, and anemia. We cannot provide assurance that the FDA or other health authorities will allow us to use the data from Takeda’s clinical studies in support of any NDA or marketing authorization application that we may submit, and such data may be interpreted differently by the regulatory authorities and provide contradictory evidence in support of FDA’s (or other regulatory authority) evaluation. If the FDA or other regulatory authorities do not allow us to use the data from Takeda’s clinical studies, we may be required to perform additional clinical studies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming, and inherently unpredictable. If we are not able to obtain required regulatory approvals, we will not be able to commercialize relugolix combination tablet, relugolix monotherapy tablet, or MVT-602, and our ability to generate net product revenue will be materially impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested and expect to continue to invest a substantial portion of our efforts and expenditures in the development and advancement of our product candidates. The research, testing, manufacturing, labeling, approval, sale, marketing and distribution of products are and will remain subject to extensive regulation by the FDA and other regulatory authorities in the U.S. and other countries. We are not permitted to market our product candidates in the U.S. until we receive approval of NDAs or in any foreign country until we receive the requisite approvals from the appropriate regulatory authorities in such countries. Obtaining approval of an NDA or similar foreign regulatory approval is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or other foreign regulatory authority may delay, limit or deny approval of our product candidates. The time required to obtain approval of an NDA by the FDA or similar regulatory authorities outside of the U.S. is unpredictable but typically takes many years following the commencement of clinical studies and depends upon numerous factors, including the substantial discretion of the regulatory authority. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approvals may change during the course of a product candidate’s clinical development and may vary among jurisdictions. Obtaining approval of an NDA from the FDA or a regulatory approval from a regulatory authority outside the U.S. is an expensive process. The submission of NDAs is subject to a substantial application user fee, and the manufacturer and/or sponsor under an approved NDA are also subject to annual program user fees.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We may incur additional costs in the future for our anticipated regulatory submissions, including the fees associated with NDA and foreign equivalent submissions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing marketing approvals requires the submission of extensive nonclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the safety and efficacy of our product candidates for the specified indication. The process of responding to the FDA or other regulatory authorities’ information requests in the review process, potentially preparing for and appearing at a public advisory committee or oral hearing and preparing our manufacturers and investigators to successfully complete inspections by the FDA or other regulatory authorities during the approval process requires significant human and financial resources. If the information from our completed clinical studies is insufficient to support regulatory approvals, we may have to complete ongoing or additional clinical studies. For example, GnRH receptor antagonists, like relugolix, when taken alone, may cause loss of bone mineral density due to the induced hypoestrogenic state that may limit duration of use. This risk, and a related risk of hot flash or vasomotor symptoms, may be mitigated by the co-administration of relugolix in combination with low-dose estradiol and a progestin. A key part of our relugolix clinical development strategy has been to formulate a single-tablet fixed-dose combination of relugolix with low-dose estradiol and a progestin (relugolix combination tablet) to maintain bone health and mitigate side effects of a low-estrogen state such as vasomotor symptoms, and to facilitate patient convenience and compliance. If the FDA or another regulatory authority concludes that the data from these studies are insufficient to support regulatory approvals, we may be required to conduct further studies and we could face delays and increased expenses associated with our development programs and our commercial opportunity could be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party CROs and consultants to assist us in submitting and supporting the applications necessary to gain marketing approvals. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Delays or errors in the submission of applications for marketing approvals or issues, including those related to gathering the appropriate data and the inspection process, may ultimately delay or affect our ability to obtain regulatory approvals, commercialize our product candidates, and generate net product revenue. Despite efforts at compliance, from time to ti</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">me, we or our partners may receive notices of manufacturing, quality-related, or other observations following inspections by regulatory authorities, as well as official agency correspondence regarding compliance. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in June 2020, the FDA issued a warning letter to Takeda following a routine inspection of aseptic finished pharmaceuticals (drug product) manufacturing at the Hikari Facility. The Hikari Facility is one of two CMOs included in our initial regulatory filings for the manufacture of relugolix drug substance (“API”). The warning letter indicated that the FDA was not satisfied with Takeda’s response to an FDA Form 483 issued to Takeda following the inspection and cited significant violations of cGMP for finished pharmaceuticals. Although API manufacturing was not included in the scope of the FDA’s inspection that led to the warning letter, the Hikari Facility is classified under one FDA Establishment Identifier and the facility has a common quality system. We are now procuring the commercial relugolix drug substance for U.S. ORGOVYX solely from Excella, pursuant to the Commercial Manufacturing and Supply Agreement we have with Excella. Due to the warning letter, we have removed the Hikari Facility as a manufacturing site from our NDA submissions and may remove it from other regulatory filings if required until Takeda corrects the violations noted in the warning letter to the satisfaction of the regulatory authorities. We cannot predict if or when Takeda will correct the violations and deviations to the satisfaction of the FDA or any other regulatory agency or whether the regulatory agencies will be satisfied with Takeda’s responses. The COVID-19 pandemic may also cause delays in the remediation and re-inspection process. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face the risk that Excella or our other CMOs may face adverse developments, including with respect to adverse findings during regulatory inspections, delays in regulatory approval and/or the COVID-19 pandemic. If Excella or our other CMOs fail to fulfill their obligations to manufacture and supply relugolix drug substance and drug product needed for our commercialization, or if any of the materials cannot be utilized due to quality or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMP concerns, adverse findings during regulatory inspections, process validation, or other reasons, our development plans and commercialization of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our product candidates could be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain approval for a product candidate in one country or jurisdiction, we may never obtain approval for or commercialize it in any other jurisdiction which would limit our ability to realize our product candidates’ full market potential.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the U.S. does not ensure approval by regulatory authorities in any other country or jurisdiction. In addition, clinical studies conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approval could result in difficulties and costs for us and require additional nonclinical studies or clinical studies which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval. We are reliant, in part, upon the regulatory expertise of Richter to gain approval for relugolix combination tablet in the licensed territories to Richter and are completely reliant on Richter to generate revenue in the licensed territories to Richter. If we or Richter fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Relugolix combination therapy, relugolix monotherapy and MVT-602 may cause adverse effects or have other properties that could halt, delay or prevent their commercialization, regulatory approval or limit the scope of any approved label or market acceptance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events associated with relugolix combination therapy, relugolix monotherapy, or MVT-602 could cause us, regulatory authorities, other reviewing entities or clinical study sites to interrupt, delay, request modification of, or halt clinical studies and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events are reported in our clinical studies for relugolix combination therapy, relugolix monotherapy or MVT-602 or any future product candidates, our ability to obtain regulatory approval or a desirable label for such product candidates may be negatively impacted. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the study or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. Any of these occurrences may harm our business, financial condition and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if post-marketing adverse events related to Relumina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are reported, it could negatively impact our clinical development and commercialization plans for relugolix.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ORGOVYX causes, or any of our product candidates are approved and then cause, serious or unexpected side effects, a number of potentially significant negative consequences could result, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or require a Risk Evaluation and Mitigation Strategy (a “REMS”) (or equivalent outside the U.S.) to impose restrictions on its distribution or other risk management measures;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to recall a product;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to conduct post-marketing studies or clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications or limit the duration of use;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to change the way the product is administered or to conduct additional clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to repeat a nonclinical or clinical study or terminate a program, even if other studies or studies related to the program are ongoing or have been successfully completed;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could elect to discontinue the sale of our product;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing ORGOVYX and our other product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even though we have obtained regulatory approval for ORGOVYX in the U.S., or even if we obtain regulatory approval for our other product candidates, we face or will still face extensive regulatory requirements and our products may face future development risks and regulatory difficulties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ORGOVYX, and any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising, and promotional activities for such product, among other things, are and will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment of registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of drug product samples to physicians, recordkeeping, and cGCP requirements for any clinical studies that we conduct post-approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or the FDA or other regulatory authorities may require that contraindications, warnings or precautions-including in some cases, a boxed warning, be included in the product labeling. Even if any product candidate receives marketing approval, if the indication approved by regulatory authorities is narrower than we expect or the accompanying label limits the approved use of our product, our sales of products could be limited and we may not generate significant revenue from sales of our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities closely regulate the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA does not regulate the behavior of physicians in their choice of treatments and physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. However, regulatory authorities, including the FDA, impose stringent restrictions on manufacturers’ communications regarding off-label use of their products, and if regulatory authorities believe that we are in violation of these restrictions, we may be subject to enforcement action for off-label marketing. Violations of the Federal Food, Drug, and Cosmetic Act in the U.S., and other comparable regulations in foreign jurisdictions, relating to the promotion of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drugs may lead to enforcement actions and investigations by the FDA, Department of Justice, State Attorney Generals and other foreign regulatory agencies alleging violations of U.S. federal and state health care fraud and abuse laws, as well as state consumer protection laws and comparable laws in foreign jurisdictions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements may yield various results, including those discussed in the Risk Factor titled, “Relugolix combination therapy, relugolix monotherapy and MVT-602 may cause adverse effects or have other properties that could halt, delay or prevent their commercialization, regulatory approval or limit the scope of any approved label or market acceptance.”</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future relationships with investigators, healthcare professionals, consultants, third-party payers, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payers, patient support channels, charitable organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws regulate the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our products for which we obtain marketing approval. Such laws include, among others, the federal Anti-Kickback Statute, the federal false claims laws, HIPAA, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the federal Physician Payments Sunshine Act and analogous state fraud and abuse, data privacy, and transparency laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal, and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare Part D, Medicaid, and other federal healthcare programs or similar programs in other countries or jurisdictions, contractual damages, reputational harm, diminished profits, and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even the mere issuance of a subpoena or the fact of an investigation alone, regardless of the merit, may result in negative publicity, a drop in our share price, and other harm to our business, financial condition, and results of operations. Defending against any such actions can be costly, time- consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in legislation may increase the difficulty and cost for us to obtain marketing approval for and commercialize relugolix combination tablet, relugolix monotherapy tablet or MVT-602 and affect the prices we may obtain.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of relugolix combination tablet, relugolix monotherapy tablet or MVT-602, restrict or regulate post-approval activities, and affect our ability to profitably sell any products for which we obtain marketing approval.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Such scrutiny has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states in the U.S. have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have also been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance, or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">post-marketing testing and other requirements. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_115"></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent upon our relationships with collaboration partners to further develop, fund, manufacture and commercialize ORGOVYX, relugolix combination tablet and our other product candidates. If such relationships are unsuccessful, or if a collaboration partner terminates its collaboration agreement with us, it could negatively impact our ability to conduct our business and generate net product revenue. Failure by a collaboration partner to perform its duties under its collaboration agreement with us (e.g. financial reporting or internal control compliance) may negatively affect us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 26, 2020, we entered into the Pfizer Collaboration and License Agreement, pursuant to which we and Pfizer will collaborate to jointly develop and commercialize relugolix in oncology and women’s health in the Co-Promotion Territory. In addition to the Pfizer Collaboration and License Agreement, we have entered into collaboration arrangements with other collaboration partners. On August 1, 2020, we entered into a Market Access Services Agreement, as amended, with Sunovion pursuant to which, among other things, Sunovion has agreed to provide to us certain market access services with respect to the distribution and sale of ORGOVYX for prostate cancer and relugolix combination tablet for uterine fibroids and endometriosis. On March 30, 2020, we entered into the Richter Development and Commercialization Agreement pursuant to which, among other things, Richter will be responsible for all commercialization activities for relugolix combination tablet for uterine fibroids and endometriosis in certain territories outside of the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of risks associated with our dependence on our relationships with our collaboration partners, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our collaboration partners may terminate their collaboration agreements with us for reasons specified in the collaboration agreements, including our breach;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for us to identify and secure on commercially reasonable terms the services of third parties to perform key activities, including development and commercialization activities, currently performed by our collaboration partners in the event that a collaboration partner was to terminate its collaboration with us;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse decisions by a collaboration partner regarding the amount and timing of resource expenditures for the commercialization, distribution and sale of ORGOVYX or relugolix combination tablet;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by a collaboration partner to perform its duties under its collaboration agreement with us (e.g., its failure to comply with regulatory requirements which may disrupt its performance of its obligations under the collaboration agreement with us);</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by a collaboration partner to timely deliver accurate and complete financial information to us or to maintain adequate and effective internal control over its financial reporting may negatively affect our ability to meet our financial reporting obligations as required by the SEC;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decisions by a collaboration partner to prioritize other of its present or future products more highly than ORGOVYX or our other product candidates when it performs its duties;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible disagreements with a collaboration partner as to the timing, nature and extent of our development plans or distribution and sales and marketing plans; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the financial returns to us, if any, under our collaboration agreements with Pfizer and Richter, depend in large part on the achievement of milestones and generation of product sales, and if Pfizer or Richter fail to perform or satisfy their obligations under the collaboration agreements, the development and commercialization of ORGOVYX and relugolix combination tablet could be delayed, hindered or may not occur and our business and prospects could be materially and adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to these factors and other possible disagreements with our collaboration partners, we may be delayed or prevented from further developing, manufacturing or commercializing ORGOVYX, relugolix combination tablet or our other product candidates or we may become involved in litigation or arbitration, which would be time consuming and expensive. </span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any collaboration partner were to terminate our collaborative relationship with it unilaterally, we would need to undertake development, commercialization or distribution or sale activities for ORGOVYX, relugolix combination tablet and other product candidates solely at our own expense and/or seek one or more other partners for some or all of these activities in the U.S. or worldwide. If we pursued these activities on our own, it would significantly increase our capital and infrastructure </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, might limit the indications we are able to pursue for ORGOVYX, relugolix combination tablet and our product candidates and could prevent us from effectively commercializing ORGOVYX, relugolix combination tablet and our other product candidates. If we sought to find one or more other pharmaceutical company partners for some or all of these activities, we may not be successful in such efforts, or they may result in collaborations that have us expending greater funds and efforts than our relationships with our current collaboration partners.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory requirements or manufacturing disruptions may make it difficult for us to be able to obtain materials or supplies necessary to conduct clinical studies or to manufacture and sell any of our product candidates, if approved.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To sustain our business, we need access to sufficient quantities of our product candidates to satisfy our clinical study needs and, if approved, to maintain sufficient commercial inventories of our products. If we are unable to purchase sufficient quantities of these materials or find suitable alternate materials in a timely manner, our development efforts for our product candidates may be delayed or our ability to manufacture commercial products would be limited.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suppliers of key components and materials must be named in the NDA or marketing authorization application filed with the FDA, the EMA, or other regulatory authority for any product candidate for which we are seeking marketing approval, and significant delays can occur if those suppliers are not approved or the qualification of a new supplier is required. For example, the receipt by Takeda of the warning letter described in the risk factor titled “We do not have our own manufacturing capabilities and rely on third parties to produce clinical and commercial supplies of drug substance and drug product. If these third parties do not perform as we expect, do not maintain their regulatory approvals, or become subject to other negative circumstances, it may result in delay in our ability to develop and commercialize our products” has caused us to rely on our Commercial Manufacturing and Supply Agreement with Excella to a greater extent than we had intended, and may require us to remove the Hikari Facility from our regulatory filings until Takeda corrects the violations noted in the warning letter to the satisfaction of the regulatory authorities. We cannot predict if or when Takeda will correct the violations and deviations to the satisfaction of the FDA or any other regulatory agency or whether the regulatory agencies will be satisfied with Takeda’s responses. The COVID-19 pandemic may also cause delays in the remediation and re-inspection process. Even after a manufacturer is qualified by the regulatory authority, the manufacturer must continue to expend time, money, and effort in the area of production and quality control to ensure full compliance with cGMP. Manufacturers are subject to regular, periodic inspections by the regulatory authorities both prior to and following initial approval. If, as a result of these inspections, a regulatory authority determines that the equipment, facilities, laboratories or processes do not comply with applicable regulations and conditions of product approval, the regulatory authority may suspend the manufacturing operations, issue import restrictions or other cGMP or regulatory action that could affect our ability to obtain materials from such supplier. If the manufacturing operations of any single suppliers for any of our products are adversely affected or suspended, we may be unable to generate sufficient quantities of commercial or clinical supplies of product to meet demand, which could harm our business. In addition, if delivery of materials from our suppliers was interrupted for any reason, we may be unable to ship commercial products that may be approved for marketing or supply our products in development for clinical studies. In addition, some of our products and the materials that we utilize in our operations are made only at one facility, which we may not be able to replace in a timely manner and on commercially reasonable terms, or at all. Problems with any of the single suppliers we depend on, including in the event of a disaster, including an earthquake or a pandemic, equipment failure, or other difficulty, may negatively impact our development and commercialization efforts. If we were to encounter any of these difficulties, our ability to provide our products, if approved, and product candidates to patients would be jeopardized.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are reliant on third parties to conduct, manage, and monitor our clinical studies, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not have the ability to independently conduct nonclinical studies that comply with Good Laboratory Practice (“GLP”) requirements. We rely substantially on CROs and clinical study sites to ensure the proper and timely conduct of our clinical studies, and we have limited influence over their actual performance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon CROs to monitor and manage data for our clinical programs, as well as for the execution of nonclinical studies. We control only certain aspects of our CROs’ activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CROs are required to comply with current GLP and GCP regulations and guidelines enforced by the FDA and are also required by the competent authorities of the member states of the European Economic Area and comparable foreign regulatory authorities to comply with the International Council for Harmonization guidelines for any of our product candidates that are in nonclinical and clinical development, respectively. The regulatory authorities enforce GCP regulations through periodic inspections of clinical study sponsors, principal investigators, and clinical study sites. Although we rely on CROs to conduct our GLP-compliant nonclinical studies and GCP-compliant clinical studies, we remain responsible for ensuring that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">each of our GLP nonclinical studies and GCP clinical studies is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with current GCP requirements, the clinical data generated in our clinical studies may be deemed unreliable and the FDA or comparable foreign regulatory authorities may reject our marketing applications or require us to perform additional clinical studies before approving our marketing applications. Accordingly, if we or our CROs fail to comply with these regulations or other applicable laws, regulations or standards, or fail to recruit a sufficient number of subjects, we may be required to repeat clinical studies, which would delay the relevant regulatory approval process. Failure by our CROs to properly execute study protocols in accordance with applicable law could also create product liability and healthcare regulatory risks for us as the sponsor of those studies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have agreements governing their activities, our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our (or their own) clinical protocols or regulatory requirements or for any other reasons, our clinical studies may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop could be harmed, our costs could increase, and our ability to generate revenue could be delayed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and our CROs are subject to various data privacy laws in the U.S., Europe, and elsewhere that are often uncertain, contradictory, and evolving. It is possible that these data privacy laws may be interpreted and applied inconsistent with our or our CROs practices. If so, this could result in government-imposed fines or orders requiring that we or our CROs change our practices, which could adversely affect our business. Also, see the Risk Factor titled, “If we fail to comply with applicable U.S. and foreign privacy and data protection laws and regulations, we may be subject to liabilities that adversely affect our business, operations and financial performance.”</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms or in a timely manner. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, and prospects.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_118"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to our drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the U.S. and other countries with respect to relugolix, MVT-602, and any future product candidates. We seek to protect our proprietary position by filing patent applications in the U.S. and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patents and patent applications that we own or have in-licensed may fail to result in issued patents with claims that protect relugolix, MVT-602 or any future product candidate in the U.S. or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover relugolix, MVT-602 or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates or companion diagnostic that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for relugolix, MVT-602 or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future drugs. Any such outcome could have a materially adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the U.S. For example, many countries restrict the patentability of methods of treatment of the human body. Publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office (the “USPTO”) or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the U.S. and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension), or both. The scope of patent protection may also be limited. Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed certain intellectual property rights covering our current product candidates from Takeda. If, for any reason, the Takeda License Agreement is terminated or we otherwise lose those rights, it could adversely affect our business. The Takeda License Agreement imposes, and any future collaboration agreements or license agreements we enter into are likely to impose various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering relugolix, MVT-602 or any future product candidate, our competitors might be able to enter the market, which would have an adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development of relugolix combination therapy, relugolix monotherapy, MVT-602, and commercialization of ORGOVYX and any future product candidate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the U.S., involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation, and administrative law proceedings, inter partes review, and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurances that third-party patents do not exist which might be enforced against our drugs or product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming, and unsuccessful.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the U.S., in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the U.S. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could impair our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, and defending patents covering relugolix, MVT-602, and any future product candidate throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection, but where patent enforcement is not as strong as that in the U.S. These products may compete </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with our products in jurisdictions where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we expect to rely on third parties to manufacture ORGOVYX and other clinical study materials, and any future product candidates, and we expect to collaborate with third parties on the development of relugolix, MVT-602, and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint R&amp;D programs that may require us to share trade secrets under the terms of our R&amp;D partnerships, market access, distribution or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors, and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_121"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Being a Controlled Company</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with Sumitovant, our majority shareholder, and with Sumitovant’s parent, Sumitomo Dainippon Pharma, and their affiliates, including Sunovion, that may be perceived to create conflicts of interest which, if other investors perceive that Sumitovant or Sumitomo Dainippon Pharma will not act in the best interests of all of our shareholders, may affect the price of our common shares and have other effects on our company. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of relationships that may give rise to certain conflicts of interest between Sumitovant and Sumitomo Dainippon Pharma, and their affiliates, on the one hand, and the other investors of our common shares and us, on the other hand. We are party to a loan agreement with Sumitomo Dainippon Pharma that creates restrictions, including limiting or restricting our ability to take spe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cific actions, such as raising additional capital, incurring additional debt, making capital expenditures, or declaring dividends. In addit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion, we are party to an Investor Rights Agreement with Sumitovant and Sumitomo Dainippon Pharma that, although designed in part to provide protections for our minority shareholders, also provides rights to Sumitovant and Sumitomo Dainippon Pharma, such as the ability of Sumitomo Dainippon Pharma to appoint directors on our board, to maintain their share ownership percentage in our company, and provide Sumitomo Dainippon Pharma with certain information and give them access to certain of our records. Further, we are a party to a Market Access Services Agreement with Sunovion, a subsidiary of Sumitomo Dainippon Pharma, pursuant to which Sunovion provides certain market access services with respect to the distribution and sale of our product candidates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may enter </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">into additional agreements with Sumitovant or Sumitomo Dainippon Pharma or their affiliates in the future. Sumitovant and Sumitomo Dainippon Pharma and its affiliates may have interests which differ from our interests or those of the minority holders of our common shares. Any material transaction between us and Sumitomo Dainippon Pharma and its affiliates is subject to our related party transaction policy and the Investor Rights Agreement, which requires prior approval of such transaction by our Audit Committee composed of three independent directors. To the extent we fail to appropriately deal with any such conflicts of interests, it could negatively impact our reputation and ability to raise additional funds and the willingness of counterparties to conduct business with us, all of which could have an adverse effect on our business, financial condition, results of operations, and cash flows, and on the market price of our common shares. Further, our agreements with Sumitovant, Sumitomo Dainippon Pharma and Sunovion may result in unanticipated risks or other unintended consequences on our business and on investor perception that could have a significant impact on the market price of our common shares. Further, we are a party to a Market Access Services Agreement with Sunovion, a subsidiary of Sumitomo Dainippon Pharma, pursuant to which Sunovion provides certain market access services with respect to the distribution and sale of our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a “controlled company” within the meaning of the applicable rules of the NYSE and, as a result, qualify for exemptions from certain corporate governance requirements. If we rely on these exemptions, our shareholders will not have the same protections afforded to shareholders of companies that are subject to such requirements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a “controlled company” within the meaning of the NYSE corporate governance requirements. Under these rules, a “controlled company” may elect not to comply with certain corporate governance requirements. We have elected to use certain of these exemptions and we may continue to use all or some of these exemptions in the future. As a result, you may not have the same protections afforded to shareholders of companies that are subject to all of the NYSE corporate governance requirements.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_124"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Us and Our Shareholders Related to Our Being a Foreign Corporation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an exempted company limited by shares incorporated under the laws of Bermuda and it may be difficult for our shareholders to enforce judgments against us or our directors and executive officers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an exempted company limited by shares incorporated under the laws of Bermuda. As a result, the rights of our shareholders are governed by Bermuda law and our memorandum of association and bye-laws. The rights of shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in another jurisdiction. It may be difficult for investors to enforce in the U.S. judgments obtained in U.S. courts against us based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce judgments obtained in other jurisdictions, including the U.S., against us or our directors or officers under the securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws of other jurisdictions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bermuda law differs from the laws in effect in the U.S. and may afford less protection to our shareholders.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated under the laws of Bermuda. As a result, our corporate affairs are governed by the Bermuda Companies Act 1981, as amended, (the “Companies Act”) which differs in some material respects from laws typically applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, amalgamations, mergers and acquisitions, takeovers, shareholder lawsuits, and indemnification of directors. Generally, the duties of directors and officers of a Bermuda company are owed to the company only. Shareholders of Bermuda companies typically do not have rights to take action against directors or officers of the company and may only do so in limited circumstances. Shareholder class actions are not available under Bermuda law. The circumstances in which shareholder derivative actions may be available under Bermuda law are substantially more proscribed and less clear than they would be to shareholders of U.S. corporations. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company in which the act complained of is alleged to be beyond the corporate power of the company or illegal, or would result in the violation of the company’s memorandum of association or bye-laws. Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, in which an act requires the approval of a greater percentage of the company’s shareholders than those who actually approved it.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company’s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company. Additionally, under our bye-laws and as permitted by Bermuda law, each shareholder has waived any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of their duties, except for actions involving fraud or dishonesty. In addition, the rights of our shareholders and the fiduciary responsibilities of our directors under Bermuda law are not as clearly established as under statutes or judicial precedent in existence in jurisdictions in the U.S., particularly the State of Delaware. Therefore, our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction within the U.S.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are regulatory limitations on the ownership and transfer of our common shares.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares may be offered or sold in Bermuda only in compliance with the provisions of the Companies Act and the Bermuda Investment Business Act 2003, which regulates the sale of securities in Bermuda. In addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted company. However, the Bermuda Monetary Authority has, pursuant to its statement of June 1, 2005, given its general permission under the Exchange Control Act 1972 and related regulations for the issue and free transfer of our common shares to and among persons who are non-residents of Bermuda for exchange control purposes as long as the shares are listed on an appointed stock exchange, which includes the NYSE. Additionally, we have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of our common shares up to the amount of our authorized capital from time to time, and options, warrants, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depository receipts, rights, loan notes, debt instruments, and our other securities to persons resident and non-resident for exchange control purposes with the need for prior approval of such issue or transfer. The general permission or the specific permission would cease to apply if we were to cease to be listed on the NYSE or another appointed stock exchange.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation enacted in Bermuda as to economic substance may affect our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Economic Substance Act 2018 of Bermuda, as amended (the “Economic Substance Act”) that came into force on January 1, 2019, a registered entity other than an entity which is resident for tax purposes in certain jurisdictions outside Bermuda (a “non-resident entity”) that carries on as a business any one or more of the “relevant activities” referred to in the Economic Substance Act must comply with economic substance requirements. The Economic Substance Act may require in-scope Bermuda entities which are engaged in such “relevant activities” to be directed and managed in Bermuda, have an adequate level of qualified employees in Bermuda, incur an adequate level of annual expenditure in Bermuda, maintain physical offices and premises in Bermuda or perform core income-generating activities in Bermuda. The list of “relevant activities” includes carrying on any one or more of: banking, insurance, fund management, financing, leasing, headquarters, shipping, distribution and service centre, intellectual property and holding entities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Economic Substance Act currently, for so long as we are a non-resident entity, we are not required to satisfy any such economic substance requirements other than providing the Bermuda Registrar of Companies annually information on the jurisdiction in which it claims to be resident for tax purposes together with sufficient evidence to support that tax residence. We currently do not anticipate material impact on our business or operations from the Economic Substance Act. However, since such legislation is new and remains subject to further clarification and interpretation, it is not currently possible to ascertain the precise impact of the Economic Substance Act on us. If we ceased to be a non-resident entity, we may be unable to comply with the Economic Substance Act or may have to restructure our business to comply with the Economic Substance Act, either of which may have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to unanticipated tax liabilities and higher effective tax rates. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated under the laws of Bermuda, where we are not subject to any income or withholding taxes. We are centrally managed and controlled in the U.K., and under current U.K. tax law, a company which is centrally managed and controlled in the U.K. is regarded as resident in the U.K. for taxation purposes. Accordingly, we expect to be subject to U.K. taxation on our income and gains, and subject to U.K.’s controlled foreign company rules, except when an exemption applies. We may be treated as a dual resident company for U.K. tax purposes. As a result, our right to claim certain reliefs from U.K. tax may be restricted, and changes in law or practice in the U.K. could result in the imposition of further restrictions on our right to claim U.K. tax reliefs. We may also become subject to income, withholding or other taxes in certain jurisdictions by reason of our activities and operations, and it is also possible that taxing authorities in any such jurisdictions could assert that we are subject to greater taxation than we currently anticipate. Any such additional tax liability could adversely affect our results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions and on how we operate our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are incorporated under the laws of Bermuda. We currently have subsidiaries in the U.K., Switzerland, Ireland, and the U.S. If we succeed in growing our business, we expect to conduct increased operations through our subsidiaries in various countries and tax jurisdictions, in part through intercompany service agreements between our subsidiaries and us. In that case, our corporate structure and intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a tax-efficient manner and in compliance with applicable transfer pricing rules and regulations. If two or more affiliated companies are located in different countries or tax jurisdictions, the tax laws and regulations of each country generally will require that transfer prices be the same as those between unrelated companies dealing at arm’s length and that appropriate documentation be maintained to support the transfer prices. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable tax authorities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. For example, our effective tax rates could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant tax, accounting, and other laws, regulations, principles, and interpretations. In addition, our effective tax rate could be adversely affected if we do not obtain favorable tax rulings from certain taxing authorities. As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm’s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. If tax authorities in any of these countries were to successfully challenge our transfer prices as not reflecting arm’s length transactions, they could require us to adjust our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfer prices and thereby reallocate our income to reflect these revised transfer prices, which could result in a higher tax liability to us. In addition, if the country from which the income is reallocated does not agree with the reallocation, both countries could tax the same income, potentially resulting in double taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our financial condition, results of operations, and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. We continue to assess the impact of such changes in tax laws on our business and may determine that changes to our structure, practice, tax positions or the manner in which we conduct our business are necessary in light of such changes and developments in the tax laws of other jurisdictions in which we operate. Such changes may nevertheless be ineffective in avoiding an increase in our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in our effective tax rate may reduce our net income in future periods.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in Europe (including the U.K. and Switzerland), the U.S., Bermuda, and other jurisdictions, as well as being affected by certain changes resulting from the Organization for Economic Co-operation and Development and their action plan on Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends continue. If such a situation was to arise, it could adversely impact our tax position and our effective tax rate. Failure to manage the risks associated with such changes, or misinterpretation of the laws providing such changes, could result in costly audits, interest, penalties, and reputational damage, which could adversely affect our business, results of our operations, and our financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including: (1) the jurisdictions in which profits are determined to be earned and taxed; (2) the resolution of issues arising from any future tax audits with various tax authorities; (3) changes in the valuation of our deferred tax assets and liabilities; (4) increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5) changes in the taxation of share-based compensation; (6) changes in tax laws or the interpretation of such tax laws, and changes in U.S. generally accepted accounting principles; and (7) challenges to the transfer pricing policies related to our structure.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. holders that own 10 percent or more of the vote or value of our common shares may suffer adverse tax consequences because we and our non-U.S. subsidiaries are expected to be characterized as “controlled foreign corporations” (“CFCs”), under Section 957(a) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-U.S. corporation is considered a CFC if more than 50 percent of (1) the total combined voting power of all classes of stock of such corporation entitled to vote, or (2) the total value of the stock of such corporation, is owned, or is considered as owned by applying certain constructive ownership rules, by U.S. shareholders (U.S. persons who own stock representing 10% or more of the vote or value of all outstanding stock of such non-U.S. corporation) on any day during the taxable year of such non-U.S. corporation. Certain U.S. shareholders of a CFC generally are required to include currently in gross income such shareholders’ share of the CFC’s “Subpart F income”, a portion of the CFC’s earnings to the extent the CFC holds certain U.S. property, and a portion of the CFC’s “global intangible low-taxed income” (as defined under Section 951A of the Code). Such U.S. shareholders are subject to current U.S. federal income tax with respect to such items, even if the CFC has not made an actual distribution to such shareholders. “Subpart F income” includes, among other things, certain passive income (such as income from dividends, interests, royalties, rents and annuities or gain from the sale of property that produces such types of income) and certain sales and services income arising in connection with transactions between the CFC and a person related to the CFC. “Global intangible low-taxed income” may include most of the remainder of a CFC’s income over a deemed return on its tangible assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we and our non-U.S. subsidiaries will be classified as CFCs in the current taxable year as a result of certain constructive ownership rules. For any U.S. holders who hold 10% or more of the vote or value of our common shares directly or indirectly, this may result in adverse U.S. federal income tax consequences, such as current U.S. taxation of Subpart F income and of any such shareholder’s share of our accumulated non-U.S. earnings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and profits (regardless of whether we make any distributions), taxation of amounts treated as global intangible low-taxed income under Section 951A of the Code with respect to such shareholder, and being subject to certain reporting requirements with the U.S. Internal Revenue Service. Any such U.S. holder who is an individual generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation. If you are a U.S. holder who holds 10% or more of the vote or value of our common shares, you should consult your own tax advisors regarding the U.S. tax consequences of acquiring, owning, or disposing our common shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. holders of our common shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest, and gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Additionally, a look-through rule generally applies with respect to 25% or more owned subsidiaries. If we are characterized as a PFIC, U.S. holders of our common shares may suffer adverse tax consequences, including having gains realized on the sale of our common shares treated as ordinary income rather than capital gain, the loss of the preferential tax rate applicable to dividends received on our common shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and the proceeds of sales of our common shares. In addition, special information reporting may be required.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets from time to time. The 50% passive asset test described above is generally based on the fair market value of each asset, with the value of goodwill and going concern value determined in large part by reference to the market value of our common shares, which may be volatile. With respect to the taxable year that ended on March 31, 2021, we believe that we were not a PFIC. Howe</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ver, we cannot predict whether we will or will not be classified as a PFIC in future taxable years because the PFIC tests are based upon the value of our assets, including any goodwill and going concern value, and the nature and composition of our income and assets, which cannot be known at this time. Because the determination of whether we are a PFIC for any taxable year is a fact-intensive determination made annually a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fter the end of each taxable year, and because certain aspects of the PFIC rules are uncertain, we cannot provide any assurances regarding our PFIC status for the current or future taxable years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented structures and arrangements intended to mitigate the possibility that we will be classified as a PFIC. There can be no assurance that the IRS will not successfully challenge these structures and arrangements, which may result in an adverse impact on the determination of whether we are classified as a PFIC. </span></div><div id="iad55818e5d094e70a171c29f2aae2512_127"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds may cause dilution to existing shareholders and/or may restrict our operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional funds by issuing equity or convertible debt securities, our existing shareholders’ ownership interest may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of a common shareholder. Any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as raising </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional capital, incurring additional debt, making capital expenditures, or declaring dividends.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to attract and retain key personnel.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to hire additional employees, including in our commercial department. The market for talent in our industry is very competitive. Many of the other pharmaceutical companies we compete against for qualified personnel have greater financial and other resources, more favorable risk profiles and a longer operating history in the biopharmaceutical industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates than what we have to offer. It is particularly difficult to recruit and hire new employees during the COVID-19 pandemic as conducting interviews remotely makes it more difficult to ensure we are recruiting and hiring high-quality employees, and the uncertainty created by the COVID-19 pandemic makes it less likely potential candidates will be willing to leave a stable job to explore a new opportunity.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our industry has experienced a high rate of turnover of management personnel in recent years. We are highly dependent on the skills and leadership of our management team and key employees. Our senior management and key employees may terminate their positions with us at any time. If we lose one or more members of our senior management team or key employees or unable to attract and retain other personnel to accomplish our business objectives, our ability to successfully implement our business strategies could be seriously harmed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to expand our organization and hire additional employees. Our management is expected to have increasing responsibilities to identify, recruit, maintain, motivate, and integrate additional employees, consultants and contractors which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may divert a disproportionate amount of its time and attention away from our day-to-day activities. The expected growth may also require significant capital expenditures and divert financial resources from other projects. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate or grow revenue could be adversely affected, and we may not be able to implement our business strategies. As a result, our future financial performance and our ability to complete clinical development, obtain regulatory approval, and commercialize our product candidates or any potential future product candidate may be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential product liability lawsuits against us could cause us to incur substantial liabilities and could impact ongoing and planned clinical studies as well as limit commercialization of any products that we may develop.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our product candidates in clinical studies and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by regulatory or governmental agencies, consumers, healthcare providers, other pharmaceutical companies or others taking or otherwise coming into contact with our products or product candidates. On occasion, large monetary judgments have been awarded in class action lawsuits in which drugs have had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liabilities and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products or any future product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation and significant negative media attention;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of participants from our clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend related litigation;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management’s attention from our primary business;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products or any future product candidate, if approved for commercial sale; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product liability and clinical study insurance we currently carry, and any additional product liability and clinical study insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future, we may not be able to maintain insurance coverage at commercially reasonable terms or in adequate amounts to protect us against losses due to liability. A successful product liability claim or series of claims brought against us could cause our common share price to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates we develop.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of social media platforms presents risks of inappropriate or harmful disclosures which could harm our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our potential patient population is active on social media. Social media practices in the pharmaceutical and biotechnology industries are evolving, which creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us, our products, or our product candidates on any social media platform. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators, and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly and our future operating results could fall below expectations. The market price of our common shares has been and is likely to continue to be highly volatile, and you may lose some or all of your investment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common shares has been and is likely to continue to be highly volatile and may be subject to significant fluctuations in response to a variety of factors. Our quarterly and annual operating results may fluctuate significantly in the future. Any future net product revenue will depend on the successful commercialization and sales of ORGOVYX and any other product candidates that receive marketing approval. Any future regulatory milestones, sales milestones and royalty payments we are eligible to earn from Pfizer under terms of the Pfizer Collaboration and License Agreement and from Richter under the terms of the Richter Development and Commercialization Agreement, or any potential future collaboration and license agreements, if any, will depend on the achievement of the underlying milestone event or level of sales activity. Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price, level of demand, and net revenues for our products, which may vary significantly as they are launched and compete for position in the marketplace;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which coverage and adequate reimbursement is available from government and private payers such as Medicare Part D, Medicaid, pharmacy benefit managers, health plans, self-insured organizations, insurance companies and other plan administrators with respect to ORGOVYX and our other product candidates, if approved, and the competitive response from existing and potential future therapeutic approaches that compete with our product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain addi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tional funding, or investor perception that we may be unable to obtain additional funding, if needed, or funding on desirable terms</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in the commencement, enrollment, and ultimate completion of our clinical studies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated results of clinical studies of any of our product candidates or those of our competitors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delay in submitting an NDA or similar application for any of our product candidates and any adverse development or perceived adverse development with respect to the FDA or other regulatory authority’s review of that NDA or similar application, as the case may be;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully develop and commercialize any of our current or future product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the U.S. or other countries or jurisdictions applicable to any of our current or future product candidates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse regulatory decisions or findings;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain adequate product supply for any of our current or future product candidates, or the inability to do so at acceptable prices;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to maintain or hire a qualified sales force;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to establish and maintain commercial capabilities and expertise including product marketing, sales, trade and distribution, pricing, market access, data analytics and insights, and other commercial operations functions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments or perceived adverse developments with respect to vendors on which we rely, including CMOs, CROs and third-party logistics providers;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products, services or technologies by our competitors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed financial projections we may provide to the public;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain effective internal control over financial reporting;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet or exceed the estimates and projections of the investor community;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts’ reports or recommendations on us or our competitors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments or perceived adverse developments with respect to our manufacturing, collaboration and alliance partners and affiliates, including Takeda, Excella, Sumitovant, Sumitomo Dainippon Pharma, Sunovion, Pfizer, and/or Richter;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in estimates of financial results or investment recommendations by securities analysts;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of management or other key personnel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short sales of our common shares;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or purchases of a substantial number of our common shares in the public market, by any of our significant shareholders, or the perception in the market that the holders of a large number of our common shares intend to sell or purchase common shares;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or purchases of our common shares by our executive officers or members of our Board of Directors;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of additional shares of our common shares, or the perception that such issuances may occur;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative coverage in the media or securities analyst reports, whether accurate or not;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes in our relationships with Sumitomo Dainippon Pharma, Sumitovant, Sunovion and/or their respective affiliates, or actions taken or omission of actions with respect to the Sumitomo Dainippon Pharma Loan Agreement, the Investor Rights Agreement, the Market Access Services Agreement or under the other agreements we entered with Sumitomo Dainippon Pharma, Sumitovant, Sunovion and their respective affiliates;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issuance of subpoenas or investigative demands, or the public fact of an investigation by a government agency, whether meritorious or not;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading liquidity of our common shares;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investors’ general perception of our company, our business, and our majority shareholder;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general political, economic, industry, and market conditions;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effects of natural or man-made catastrophic events, including the COVID-19 pandemic; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this “Risk Factors” section.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or securities analysts or investors for any period. If our operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the public, or if the forecasts we provide to the public are below the expectations of securities analysts or investors, the price of our common shares could decline substantially. Such a share price decline could occur even when we have met any previously publicly stated operating results and/or earnings guidance that we may provide.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility in our share price could subject us to securities class action litigation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory, and market conditions, may negatively affect the market price of our common shares, regardless of our actual operating performance. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant share price volatility in recent years. Such litigation, if instituted against us, could result in substantial costs and diversion of management’s attention and resources, which could materially and adversely affect our business, financial condition, results of operations, and growth prospects.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not anticipate paying any cash dividends on our common shares in the foreseeable future, capital appreciation, if any, would be your sole source of gain.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common shares. We currently anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. We are also subject to Bermuda legal constraints that may affect our ability to pay dividends on our common shares and make other payments. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our ability to pay dividends is currently restricted by the terms of the Sumitomo Dainippon Pharma Loan Agreement. As a result, capital appreciation, if any, of our common shares would be your sole source of gain on an investment in our c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommon shares for the foreseeable future.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1064"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.  Unresolved Staff Comments</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1070"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Properties</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at Suite 1, 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Floor, 11-12 St. James’s Square, London, United Kingdom SW1Y 4LB. Our registered office is located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. We also have business operations in Brisbane, California and Basel, Switzerland. We do not own any properties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease 40,232 square feet of office space located in Brisbane, California, pursuant to a lease agreement that expires in May of 2026, for which we have the option to extend the lease term for an additional seven years. We also sublease 20,116 square feet of office space pursuant to a sublease agreement that expires in February of 2024. We believe that our leased facilities are in good condition and are well maintained and that our current arrangements will be sufficient to meet our needs for the foreseeable future and that any required additional space will be available on commercially reasonable terms to meet space requirements if they arise.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_91"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Legal Proceedings</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings related to claims arising from the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results, or financial condition. </span></div><div id="iad55818e5d094e70a171c29f2aae2512_1077"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_88"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_130"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information for Common Shares</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares trade on the New York Stock Exchange (“NYSE”) under the symbol “MYOV.”  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Stock Transfer &amp; Trust Company is the transfer agent and registrar for our common shares. As of May&nbsp;6, 2021, we had six shareholders of record of our common shares. The number of beneficial owners of our common shares at that date was substantially greater. The number of holders of record is based upon the actual number of holders registered in our records at such date and excludes holders in “street name” or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common shares. We anticipate that we will retain all of our future earnings, if any, for use in the expansion and operation of our business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on a number of factors, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our board of directors may deem relevant. In addition, pursuant to Bermuda law, a company may not declare or pay dividends if there are reasonable grounds for believing that (1) the company is, or would after the payment be, unable to pay its liabilities as they become due or (2) that the realizable value of its assets would thereby be less than its liabilities. Furthermore, our ability to pay cash dividends is currently restricted by the terms of the Sumitomo Dainippon Pharma Loan Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&nbsp;11, 2021, we acquired 323,945 of our common shares directly from our former Principal Executive Officer to satisfy her tax withholding obligations resulting from the release of restricted stock awards. The number of shares acquired was based on the closing market price of $22.28 per common share and the total value approximated $7.2 million. These shares were retired and returned to our authorized and unissued common shares in March 2021. We do not currently have in place a repurchase program with respect to our common shares.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.527%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><br></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)<br>Total number of shares or units purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)<br>Average price paid per share or unit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)<br>Total number of shares (or units) purchased as part of publicly announced plans or programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(d)<br>Maximum number (or approximate dollar value) of shares (or units) that may yet be purchased under the plans or programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1-31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,945&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.28&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1-28, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1-31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,945&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div id="iad55818e5d094e70a171c29f2aae2512_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Selected Financial Data</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, because we may continue to report as a “smaller reporting company” for this Annual Report on Form 10-K, we are not required to provide the information required by this item in this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_76"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.  Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition, results of operations, and cash flows should be read in conjunction with the audited consolidated financial statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. This section generally discusses the fiscal years ended March 31, 2021 and 2020 items and comparisons between these fiscal years. Discussions of the fiscal year ended March&nbsp;31, 2019 items and comparisons between the fiscal years ended March&nbsp;31, 2020 and 2019 that are not included in this Annual Report on Form 10-K can be found in Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” of our Annual Report on Form 10-K for the fiscal year ended March&nbsp;31, 2020 filed with the United States Securities and Exchange Commission on May&nbsp;18, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. ORGOVYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (relugolix) was approved by the U.S. Food and Drug Administration (“FDA”) in 2020 as the first and only oral gonadotropin-releasing hormone (“GnRH”) receptor antagonist for the treatment of adult patients with advanced prostate cancer. Relugolix is also under regulatory review in Europe for men with advanced prostate cancer. In addition, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in the U.S. and Europe for women with uterine fibroids, has completed Phase 3 registration-enabling studies for women with endometriosis, and is being assessed for contraceptive efficacy in healthy women ages 18-35 years who are at risk for pregnancy. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for the treatment of female infertility as a part of assisted reproduction. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our efforts to identifying and in-licensing our product candidates, organizing and staffing our company, raising capital, preparing for and advancing the clinical development of our product candidates, preparing for and achieving regulatory approvals, and preparing for and executing on commercialization of our product candidates. Since our inception, we have funded our operations primarily from the issuance and sale of our common shares, from debt financing arrangements, and more recently from the upfront and milestone payments we received from Pfizer Inc. (“Pfizer”) and Gedeon Richter Plc. (“Richter”). We launched our first product, ORGOVYX, in the U.S. in January 2021 and began generating product revenue, net from sales of ORGOVYX in the U.S. in January 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our majority shareholder is Sumitovant Biopharma Ltd. (“Sumitovant”), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo Dainippon Pharma”). As of March 31, 2021, Sumitovant directly, and Sumitomo Dainippon Pharma indirectly, own 48,641,181, or approximately 53.5%, of our outstanding common shares.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Ended March 31, 2021 and Recent Business Updates </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this section, we summarize certain of our fiscal year ended March 31, 2021 and recent clinical, regulatory, and corporate updates. Additional information about our business, our approved product, and our product candidates is included in Part I. Item 1., “Business,” of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product and Product Candidates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Advanced Prostate Cancer (HERO Program)</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On December 18, 2020, the FDA approved ORGOVYX for the treatment of adult patients with advanced prostate cancer. ORGOVYX, which was granted Priority Review by the FDA, is the first and only oral GnRH receptor antagonist for men with advanced prostate cancer. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORGOVYX became commercially available through authorized specialty distributors in the U.S. in early January 2021. Our oncology sales force began promoting ORGOVYX to target prescribers in early January 2021 and the uro-oncology sales force of our collaboration partner, Pfizer, began actively promoting ORGOVYX to target prescribers in early February 2021.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 29, 2021, we announced that the European Medicines Agency (“EMA”) validated our previously submitted Marketing Authorization Application (“MAA”) for relugolix for the treatment of men with advanced prostate cancer. The validation of the application confirmed that the submission is sufficiently complete for the EMA to begin the formal review process. If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in Europe.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, efficacy and safety data from the Phase 3 HERO study were simultaneously published online in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and presented at the American Society of Clinical Oncology (“ASCO”)’s ASCO20 Virtual Scientific Program.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Uterine Fibroids (LIBERTY Program)</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In May 2020, we submitted a New Drug Application (“NDA”) to the FDA for relugolix combination tablet for the treatment of women with heavy menstrual bleeding associated with uterine fibroids, which has been accepted by the FDA with a target action date of June 1, 2021. If approved, we and Pfizer expect to launch relugolix combination tablet for the treatment of uterine fibroids in the U.S. in June 2021.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On September 14, 2020, we announced one-year data on bone mineral density from the Phase 3 LIBERTY program and from a prospective observational study of women with uterine fibroids.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On October 21, 2020, we presented one-year efficacy and safety data from the LIBERTY long-term extension study at the American Society for Reproductive Medicine (“ASRM”) 2020 Virtual Congress. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2021, we and our collaboration partner, Pfizer, announced publication in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New England Journal of Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Phase 3 LIBERTY 1 and LIBERTY 2 studies of investigational once-daily relugolix combination therapy in women with uterine fibroids.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 24, 2021, we and Pfizer announced positive safety and efficacy data from the LIBERTY randomized withdrawal study.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Endometriosis (SPIRIT Program)</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 22, 2020 and June 23, 2020, we announced positive top-line results from the SPIRIT 2 and SPIRIT 1 studies, respectively. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On October 20, 2020, data from the Phase 3 SPIRIT studies were presented at the ASRM 2020 Virtual Congress and the presentation was named the Prize Paper by the Endometriosis Special Interest Group.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 26, 2021, we and Pfizer announced positive one-year safety and efficacy data from the Phase 3 SPIRIT long-term extension study.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Prevention of Pregnancy (SERENE Program)</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 12, 2021, we and Pfizer announced that the first patient has been dosed in the Phase 3 single-arm, open-label SERENE study evaluating the contraceptive efficacy of relugolix combination tablet in healthy women ages 18-35 years who are at risk for pregnancy.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Partnerships</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2020, we entered into a collaboration agreement with Pfizer under which we and Pfizer will jointly develop and commercialize relugolix in oncology and women’s health and equally share profits and certain expenses, in the U.S. and Canada (the “Co-Promotion Territory”). In December 2020, we received a $650.0 million upfront payment and we are eligible to receive up to $3.7 billion of additional milestone payments, including two regulatory milestones of $100.0 million upon each FDA approval for relugolix combination tablet in uterine fibroids and endometriosis ($200.0 million in the aggregate), and tiered sales milestones of up to $3.5 billion upon reaching certain thresholds of annual net sales for oncology and the combined women’s health indications in the Co-Promotion Territory. We granted Pfizer an exclusive option to acquire development and commercialization rights to relugolix in oncology outside of the Co-Promotion Territory (excluding certain Asian markets). If Pfizer exercises this option, we will receive an additional $50.0 million payment and will be eligible to receive double-digit royalties on net sales. Pfizer’s decision is expected in mid-calendar year 2021. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August 2020, we entered into a three-year commercial collaboration agreement with Sunovion Pharmaceuticals Inc. (“Sunovion”). Under the agreement, Sunovion will provide certain third-party logistics, trade and retail distribution, contract operations, and market access account management services, and other services to us and, Sunovion will become a non-exclusive distributor of relugolix for prostate cancer and the exclusive distributor of relugolix combination tablet for uterine fibroids and endometriosis in the U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 4, 2021, we announced the appointment of David Marek as Chief Executive Officer of Myovant Sciences, Inc. Concurrent with this appointment, Mr. Marek was also appointed as Principal Executive Officer of Myovant Sciences Ltd. and as a member of our board of directors. Mr. Marek succeeds Dr. Lynn Seely, who previously held these positions. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 5, 2021, we announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">As of March 31, 2021, we had cash, cash equivalents and marketable securities of approximately $684.9 million. We currently believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our anticipated operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Annual Report on Form 10-K. See Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expected Upcoming Clinical and Regulatory Milestones</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this section, we summarize certain of our expected upcoming clinical and regulatory milestones.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA decision for relugolix combination tablet for the treatment of uterine fibroids expected by the June 1, 2021 target action date. If approved, we and Pfizer expect to launch relugolix combination tablet for the treatment of uterine fibroids in the U.S. in June 2021. Upon approval, we will receive a $100.0 million regulatory milestone payment from Pfizer pursuant to the Pfizer Collaboration and License Agreement.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory submission to the FDA for relugolix combination tablet for the treatment of women with endometriosis-associated pain expected in the second quarter of calendar year 2021.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">European Commission decision on the uterine fibroids MAA expected in mid-calendar year 2021. If approved, this launch will be executed by Richter, our commercialization partner for relugolix combination tablet for the uterine fibroids and endometriosis indications in Europe and certain other international markets.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MAA submission to the EMA for relugolix combination tablet for the treatment of women with endometriosis-associated pain expected in calendar year 2021. Richter will be the MAA sponsor.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">European Commission decision on the advanced prostate cancer MAA expected in calendar year 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19 on our Business</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared a pandemic resulting from the disease known as COVID-19 caused by a novel strain of coronavirus, SARS-Co V-2. In an effort to contain COVID-19 or slow its spread, governments around the world have enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. In certain countries, and in certain states within the U.S., such orders have been lifted, although recent trends in COVID-19 infections have led to the reinstatement of such orders in various jurisdictions. It remains unclear how long these measures will remain in place and whether these measures will be effective. Further, recently it has been reported that the rate of the reported number of COVID-19 cases in the U.S. is increasing, and new more virulent variants of the coronavirus have been identified, which may further impact the effects that the COVID-19 pandemic may have on us.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to protect the safety of our employees and our patients, we adopted safety measures in response to the COVID-19 pandemic that meet or exceed the guidelines established by government and public health officials. These measures include adopting policies applicable to office-based employees such as working from home, limiting the number of employees on site, and limiting business travel. At this time, we have not identified a material change to our productivity as a result of these measures, but this could change, particularly if restricted travel, closed schools, and shelter-in-place orders are not removed or significantly eased.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the impact of the COVID-19 pandemic on our ability to advance our clinical studies, our regulatory activities, our U.S. commercial launch activities for ORGOVYX, and our preparations for the potential commercialization of relugolix combination tablet has been limited and all of our publicly announced milestones remain on track. The FDA approved ORGOVYX for the treatment of adult patients with advanced prostate cancer on December&nbsp;18, 2020. In May 2020, we submitted our NDA to the FDA for relugolix combination tablet for the treatment of women with heavy menstrual bleeding </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associated with uterine fibroids, which has been accepted by the FDA with a target action date of June 1, 2021. We launched ORGOVYX in the U.S. in early January 2021, and may launch other approved products in the COVID-19 environment. In response to the COVID-19 pandemic, health professionals may reduce staffing and reduce or postpone appointments with patients, or patients may cancel or miss appointments, resulting in potential delays in diagnosis and treatment, and therefore fewer prescriptions. In addition, multiple medical conferences have been cancelled, postponed or moved to virtual formats, resulting in fewer opportunities to present our scientific data. In addition, our sales teams have been and would likely have to continue to make presentations to physicians and the medical community in many cases by virtual means instead of in-person, which could reduce the number of medical professionals we are able to present to, and these virtual meetings may not be as successful as in-person meetings. Reduced access to healthcare providers as a result of social distancing protocols may impact or require adjustments to our planned commercialization activities, including the manner in which our field teams engage with healthcare providers and facilities. At this time, we do not believe that the COVID-19 pandemic has disproportionately impacted us relative to other companies in our industry and the medical community appears to be highly engaged with our field team. To date, we have not experienced supply constraints, and we believe we have procured sufficient quantities of relugolix drug substance to meet our U.S. ORGOVYX launch plans and U.S. launch plans for relugolix combination tablet, if approved.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken numerous steps, and will continue to take further actions, in our approach to addressing the COVID-19 pandemic. We continue to monitor the rapidly evolving situation and guidance from international and domestic authorities, including federal, state, and local public health authorities and may take additional action based on their recommendations. The ultimate impact of the COVID-19 pandemic is highly uncertain and we do not yet know the full extent of potential delays or impacts on our business, our financial results, our clinical studies, our supply chains, our commercial launch for ORGOVYX, and pre-launch commercial readiness activities for relugolix combination tablet, end user demand for our products, if approved, healthcare systems or the global economy as a whole. As such, given the dynamic nature of this situation, we cannot estimate the ultimate impact of COVID-19 on our business, financial condition, or results of operations. Refer to the risk factor titled “Business interruptions resulting from effects of pandemics or epidemics, such as the COVID-19 pandemic, may materially and adversely affect our business and financial condition,” as well as other risk factors included in the section titled “Risk Factors” set forth in Part I. Item 1A.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of our Results of Operations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 18, 2020, the FDA approved ORGOVYX for the treatment of adult patients with advanced prostate cancer. In January 2021, we began to generate product revenue from sales of ORGOVYX in the U.S. We record product revenue net of estimated discounts, chargebacks, rebates, product returns, and other gross-to-net revenue deductions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration revenue represents the partial amortization of the upfront payment we received from Pfizer pursuant to the terms of the Pfizer Collaboration and License Agreement (see Note 13(B) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license and milestone revenue represents the partial recognition of previously deferred revenue associated with upfront and regulatory milestone payments we received from Richter pursuant to the terms of the Richter Development and Commercialization Agreement (see Note 13(A) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K). We recognize revenue as we satisfy our combined performance obligation to Richter. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of product revenue is composed of the cost of goods sold and royalty expense. Our cost of goods sold consists of raw materials, third-party manufacturing costs to manufacture the raw materials into finished product, freight, and indirect overhead costs associated with sales of ORGOVYX in the U.S. Our royalty expense consists of a fixed, high single-digit royalty on net sales of ORGOVYX payable to Takeda pursuant to the terms of the Takeda License Agreement (see Note 14(D) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA approval of ORGOVYX on December 18, 2020, we subsequently began capitalizing inventory manufactured or purchased after this date. As a result, we expensed certain manufacturing costs of ORGOVYX as R&amp;D expenses prior to FDA approval and, therefore, these costs are not included in cost of goods sold. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Expense to Pfizer</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration expense to Pfizer consists of Pfizer’s 50% share of net profits from sales of ORGOVYX in the U.S. (see Note 13(B) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&amp;D expenses to date have been primarily attributable to the clinical development of our product candidates including the conduct of multiple Phase 3 and earlier clinical studies, the expansion of our team, and the initiation of activities in preparation for our anticipated commercial launches such as the establishment of our medical affairs function, as well as regulatory and certain manufacturing activities. Our R&amp;D expenses include program-specific costs, as well as costs that are not allocated to a specific program.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our program-specific costs primarily include third-party costs, which include expenses incurred under agreements with CROs and CMOs, the cost of consultants who assist with the development of our product candidates on a program-specific basis, investigator grants, sponsored research, manufacturing costs in connection with producing materials for use in conducting nonclinical and clinical studies, as well as costs related to pre-commercial manufacturing activities and regulatory submissions, and other third-party expenses directly attributable to the development of our product candidates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unallocated R&amp;D costs primarily include employee-related expenses, such as salaries, share-based compensation, fringe benefits and travel for employees engaged in R&amp;D activities including clinical operations, biostatistics, regulatory, and medical affairs, and the cost of contractors and consultants who assist with R&amp;D activities not specific to a program and costs associated with nonclinical studies. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D activities have been, and will continue to be, central to our business model. We currently expect R&amp;D expenses for the year ending March 31, 2022, to be modestly lower than the R&amp;D expenses incurred in the year ended March 31, 2021, largely due to our sharing of certain expenses with Pfizer pursuant to the Pfizer Collaboration and License Agreement (see Note 13(B) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K). Overall, we expect declining spend on our Phase 3 clinical programs that are winding down to be offset primarily by incremental spend on new relugolix development programs, such as the Phase 3 SERENE study, to potentially expand the commercial opportunity for the relugolix franchise.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical studies and development of our product candidates will depend on a variety of factors that include, but are not limited to: the number of studies required for approval; the per patient study costs; the number of patients who participate in the studies; the number of sites included in the studies; the countries in which the studies are conducted; the length of time required to recruit and enroll eligible patients; the number of patients who fail to meet the study’s inclusion and exclusion criteria; the number of study drug doses that patients receive; the drop-out or discontinuation rates of patients; the potential additional safety monitoring or other studies requested by regulatory agencies; the duration of patient follow-up; the timing and receipt of regulatory approvals; the costs of clinical study materials; and the efficacy and safety profile of the product candidate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the probability of commercial success for ORGOVYX, or for any of our current or potential future product candidates, if approved, will depend on numerous factors, including competition, manufacturing capability and commercial viability. As a result, we are unable to determine with certainty to what extent we will generate net product revenue from commercialization and sale of any of our product candidates that receive regulatory approval. Our R&amp;D activities may be subject to change from time to time as we evaluate our priorities and available resources.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that certain R&amp;D expenses will be shared equally with Pfizer pursuant to the Pfizer Collaboration and License Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SG&amp;A expenses consist primarily of personnel costs, including salaries, sales incentive compensation, bonuses, fringe benefits, and share-based compensation expenses for our executive, finance, human resources, legal, information technology, commercial operations, marketing, market access, sales, and other administrative functions. Our SG&amp;A expenses also include marketing programs, advertising, conferences, congresses, travel expenses, professional fees for legal, accounting, auditing and tax services, and costs related to rent and facilities, insurance, information technology, commercial operations, and general overhead. Our SG&amp;A expenses also include costs incurred under our Market Access Services Agreement with Sunovion and our former consulting agreement with Sumitovant, which expired on March 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect SG&amp;A expenses to increase in future periods as we continue to expand our sales and marketing infrastructure and capabilities as well as general administrative functions to support multiple product launches and commercialization activities. These increases will likely include expenses associated with our oncology sales force which began promoting ORGOVYX in the U.S. in January 2021, as well as expected costs associated with the further build out of our commercial operations functions and the hiring of our women’s health sales force in advance of the potential FDA approval of relugolix combination tablet. SG&amp;A expenses in future periods are also expected to include certain expenses related to our patient support programs such as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">free trial drug and patient assistance for qualified uninsured patients. The timing of these increased expenditures and their magnitude are primarily dependent on our commercial success and sales growth of ORGOVYX, as well as the timing of any new product launches and other potential business and operational activities. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that certain SG&amp;A expenses will be shared equally with Pfizer pursuant to the Pfizer Collaboration and License Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest expense through December 31, 2019 consists of interest expense related to our previously outstanding debt with Hercules Capital, Inc. (“Hercules”) and NovaQuest Capital Management (“NovaQuest”), which we repaid on December 31, 2019, as well as the associated non-cash amortization of related debt discounts and issuance costs. Subsequently, our interest expense consists of related party interest expense pursuant to the Sumitomo Dainippon Pharma Loan Agreement, which bears interest at a rate per annum equal to 3-month LIBOR plus a margin of 3% payable on the last day of each calendar quarter. For the year ended March 31, 2021, our interest expense also includes accretion of the financing component of the cost share advance from Pfizer. See Note 13 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information about the Pfizer Collaboration and License Agreement. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt represents the difference between the carrying amount of our previously outstanding debt with Hercules and NovaQuest and the amounts we paid to retire the outstanding debt obligations on December 31, 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest income consists primarily of interest earned and the accretion of discounts to maturity for cash equivalents and marketable securities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Gain</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign exchange gain consists of the impact of changes in foreign currency exchange rates on our foreign exchange denominated liabilities, relative to the U.S. dollar. The impact of foreign currency exchange rates on our results of operations fluctuates period over period based on our foreign currency exposures resulting from changes in applicable exchange rates associated with our foreign denominated liabilities. Our primary foreign currency exposure has historically been the exchange rate between the Swiss franc and the U.S. dollar. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we changed the functional currency of our wholly-owned subsidiary in Switzerland, MSG, from the Swiss franc to the U.S. dollar. This change in functional currency is accounted for prospectively. As a result of this change, we currently expect that future impacts of changes in foreign currency exchange rates on our results of operations will not be significant. See Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_79"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the years ended March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,630&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,354&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and milestone revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,333&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,317&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration expense to Pfizer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,713&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,560&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,423&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,327&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,101&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274,887&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260,784)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274,887)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,663&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,851&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,552)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange gain</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,621)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254,798)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,228)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">761&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255,134)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288,989)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues to date have been generated substantially from the Richter Development and Commercialization Agreement and the Pfizer Collaboration and License Agreement, which are further discussed in Note 13 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. We began commercializing ORGOVYX in the U.S. for adult patients with advanced prostate cancer in January 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue, net from sales of ORGOVYX was $3.6 million for the year ended March 31, 2021. There were no such amounts recognized for the year ended March 31, 2020. Product revenue is recorded net of estimated discounts, chargebacks, rebates, product returns, and other gross-to-net revenue deductions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue for the year ended March 31, 2021 represents the partial amortization of the upfront payment received from Pfizer pursuant to the terms of the Pfizer Collaboration and License Agreement. There were no such amounts recognized for the year ended March 31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License and milestone revenue for the year ended March 31, 2021 represents the partial recognition of previously deferred revenue associated with upfront and regulatory milestone payments we received from Richter pursuant to the terms of the Richter Development and Commercialization Agreement. There were no such amounts recognized for the year ended March 31, 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2021, our cost of product revenue was $0.3 million, which includes the cost of goods sold and royalty expense payable to Takeda pursuant to the Takeda License Agreement (see Note 14(D) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA approval of ORGOVYX on December&nbsp;18, 2020, we subsequently began capitalizing the cost of inventory manufactured or purchased after this date. Prior to December&nbsp;18, 2020, costs to manufacture ORGOVYX were expensed as incurred as R&amp;D expenses. As a result, minimal cost of goods sold has been recorded for quantities of ORGOVYX </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold during for the year ended March 31, 2021 as these costs were previously recorded as R&amp;D expenses. We expect our cost of goods sold to increase in future periods as quantities of zero-cost ORGOVYX inventory are depleted from our inventory stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Expense to Pfizer</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2021, our collaboration expense to Pfizer was $1.7 million and represents Pfizer’s 50% share of net profits from the sales of ORGOVYX in the U.S. pursuant to the terms of the Pfizer Collaboration and License Agreement (see Note 13(B) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended March 31, 2021 and 2020, our R&amp;D expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Program-specific costs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Relugolix</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,835&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,737&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,902)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MVT-602</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Unallocated costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,049&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,524&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,460&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,716&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,744&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,128&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,885&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total R&amp;D expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,713&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,560&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,847)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses decreased by $55.8 million, to $136.7 million, in the year ended March 31, 2021 compared to $192.6 million in the year ended March 31, 2020. The decrease reflects a reduction in clinical study costs as a result of the wind down of our Phase 3 LIBERTY, HERO, and SPIRIT studies and cost reimbursements from Pfizer for certain R&amp;D expenses (See Note 13(B) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K). This decrease was partially offset by an increase in personnel expenses mainly driven by the continued expansion of our medical affairs organization in preparation for the U.S. commercial launch of ORGOVYX and the potential U.S. commercial launches of relugolix combination tablet, if approved, as well as regulatory expenses and submission fees.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the year ended March 31, 2021 consisted primarily of program-specific costs composed of CRO, drug supply and other study, regulatory, and manufacturing related costs of $60.1&nbsp;million, which includes fees related to our NDA submissions for ORGOVYX and relugolix combination tablet for uterine fibroids of $5.8 million, personnel expenses of $48.5 million, share-based compensation expense of $14.0 million, and other R&amp;D costs of $14.1 million, which primarily includes contractors, consultants, and information technology costs and other unallocated nonclinical research costs. R&amp;D expenses for the year ended March 31, 2021 are presented net of approximately $13.9&nbsp;million of cost share reimbursement from Pfizer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses for the year ended March&nbsp;31, 2020 consisted primarily of program-specific costs composed of CRO, drug supply, regulatory, and manufacturing related costs of $133.4 million, personnel expenses of $32.7 million, share-based compensation expense of $14.5 million, and other R&amp;D costs of $11.9 million, which primarily includes contractors, consultants, and information technology costs. The share-based compensation expense includes $1.8 million related to the accelerated vesting of certain equity awards as a result of a change in control of Myovant in connection with the closing of the Sumitomo-Roivant Transaction (see Note 6(A) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased by $99.1 million, to $181.4 million, in the year ended March 31, 2021 compared to $82.3 million in the year ended March&nbsp;31, 2020, primarily due to higher expenses related to commercial activities to support the ORGOVYX U.S. commercial launch and the potential U.S. commercial launches of relugolix combination tablet as well as higher personnel-related expenses primarily due to the hiring of our commercial operations, marketing, and market access teams, and our oncology sales force, higher share-based compensation expense primarily as a result of the acceleration, modification, and remeasurement of our former Principal Executive Officer’s equity awards (see Note 10(H) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K), and general overhead expenses to support our organizational growth.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the year ended March 31, 2021 consisted primarily of personnel expenses of $56.4 million, commercial operations expenses of $43.8 million, general overhead, administrative and information technology expenses of $24.6 million, shared-based compensation expense of $39.6 million (which includes approximately $25.7 million related to the acceleration, modification and remeasurement of our former Principal Executive Officer’s equity awards as discussed further in Note 10(H) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K), professional service fees of $9.0 million, and rent and other facilities-related costs of $3.5 million. For the year ended March 31, 2021, we also incurred related party expenses of $5.3 million pursuant to our agreements with Sunovion and Sumitovant. For additional information about these related party expenses, see Note 6 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. SG&amp;A expenses for the year ended March 31, 2021 are presented net of approximately $10.9 million of cost share reimbursement from Pfizer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses for the year ended March&nbsp;31, 2020 consisted primarily of share-based compensation expense of $25.7 million, personnel expenses of $19.1 million, commercial operations expenses of $12.7 million, general overhead, administrative and information technology expenses of $11.9 million, professional service fees of $6.0 million, a capital tax accrual of $3.6 million, and rent and other facilities-related costs of $2.8 million. The share-based compensation expense includes $10.2 million related to the accelerated vesting of certain equity awards as a result of a change in control of Myovant in connection with the closing of the Sumitomo-Roivant Transaction (see Note 6(A) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $10.4 million in the year ended March 31, 2021 and was primarily related to the Sumitomo Dainippon Pharma Loan Agreement, compared to $12.7&nbsp;million in the year ended March&nbsp;31, 2020 primarily related to our previously outstanding financing arrangements with NovaQuest and Hercules. The decrease in interest expense, despite higher outstanding loan balances, was primarily driven by the significantly lower interest rates associated with the Sumitomo Dainippon Pharma Loan Agreement as compared to the previously outstanding debt obligations to NovaQuest and Hercules, which were repaid in December 2019. Interest expense for the year ended March 31, 2021 also includes $0.6 million of accretion of the financing component of the cost share advance from Pfizer (see Note 13 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K). There was no such accretion for the year ended March&nbsp;31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no loss on extinguishment of debt for the year ended March 31, 2021. For the year ended March&nbsp;31, 2020, we incurred a $4.9&nbsp;million loss on extinguishment of debt associated with the write-off of unamortized debt issuance costs and debt discounts, prepayment penalties and early redemption fees in connection with the repayment of our outstanding obligations to NovaQuest and Hercules. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was approximately $0.2&nbsp;million and $2.6 million for the years ended March 31, 2021 and 2020, respectively. The decrease was primarily due to decreases in interest rates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange Gain</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange gain consists of the impact of changes in foreign currency exchange rates on our foreign exchange denominated liabilities. The impact of foreign exchange rates on our results of operations fluctuated period over period based on our foreign currency exposures resulting from changes in applicable exchange rates associated with our foreign denominated liabilities. For the years ended March 31, 2021 and 2020, we recorded a foreign exchange gain of $16.2 million and $1.6 million, respectively. The $14.6 million increase in foreign exchange gains in the year ended March 31, 2021 was primarily the result of the increase in our outstanding balance under the Sumitomo Dainippon Pharma Loan Agreement and the impact of fluctuations in the foreign currency exchange rate between the Swiss franc and the U.S. dollar.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax expense was $0.3 million and $0.8 million for the years ended March 31, 2021 and 2020, respectively. Our effective tax rate&nbsp;for the years ended March 31, 2021 and 2020 was&nbsp;(0.13)% and (0.26)%, respectively, and is driven by our jurisdictional earnings by location and a valuation allowance that eliminates our global net deferred tax assets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have funded our operations primarily from the issuance and sale of our common shares, from debt financing arrangements, and more recently from upfront and milestone payments we received from Richter and Pfizer. We began generating product revenue, net from the sales of ORGOVYX in the U.S. in January 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, we had cash, cash equivalents, marketable securities, and amounts available to us under the Sumitomo Dainippon Pharma Loan Agreement of $726.2 million, consisting of $684.9 million of cash, cash equivalents, and marketable securities and $41.3 million of borrowing capacity available to us under the Sumitomo Dainippon Pharma Loan Agreement, as compared to cash, cash equivalents, marketable securities, and amounts available to us under the Sumitomo Dainippon Pharma Loan Agreement of $365.9 million, consisting of $79.6 million of cash, cash equivalents, and marketable securities and $286.3 million of borrowing capacity available to us under the Sumitomo Dainippon Pharma Loan Agreement, as of March&nbsp;31, 2020. Additional funds under the Sumitomo Dainippon Pharma Loan Agreement may be drawn down by us no more than once per calendar quarter, subject to certain terms and conditions, including consent of our board of directors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Pfizer Collaboration and License Agreement, we are eligible to receive up to $3.7 billion of additional milestone payments, including two regulatory milestones of $100.0 million upon each FDA approval for relugolix combination tablet in uterine fibroids and endometriosis ($200.0 million in the aggregate), and tiered sales milestones of up to $3.5 billion upon reaching certain thresholds of annual net sales for oncology and the combined women’s health indications in the Co-Promotion Territory. We and Pfizer will equally share profits and certain expenses in the Co-Promotion Territory. In addition, if Pfizer exercises its option to acquire exclusive commercialization and development rights to relugolix in oncology in the Pfizer Territory, we will receive an option exercise fee of $50.0 million and will also be eligible to receive double-digit royalties on net sales of relugolix in the Pfizer Territory.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Richter Development and Commercialization Agreement, we are eligible to receive up to $137.5 million of additional milestone payments, including regulatory milestones of up to $30.0 million and tiered sales milestones of up to $107.5 million upon reaching certain thresholds of annual net sales for relugolix combination tablet in Richter’s territory, and tiered royalties on net sales following regulatory approval for relugolix combination tablet in Richter’s territory.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended March 31, 2020, we issued and sold common shares under our sales agreement with Cowen and Company, LLC (“Cowen”) to sell common shares having an aggregate offering price of up to $100.0 million from time to time through an “at-the-market” equity offering program under which Cowen was our agent. During the year ended March 31, 2020, we sold common shares under this agreement for aggregate net proceeds to us of approximately $2.5 million after deducting underwriting commissions and offering costs paid by us. No common shares were sold under the sales agreement during the year ended March 31, 2021. The “at-the-market” equity offering program expired in March 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Requirements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended March 31, 2021 and 2020, we had net losses of $255.1 million and $289.0 million, respectively. As of March 31, 2021, we had an accumulated deficit of approximately $1.0 billion. As of March 31, 2021, we had approximately $684.9 million in cash, cash equivalents, and marketable securities. We currently believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our anticipated operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Annual Report on Form 10-K. This estimate is based on our current assumptions, including assumptions related to our ability to manage our spend, that might prove to be wrong, and we could use our available capital resources sooner than we currently expect. In future periods, if our cash, cash equivalents, marketable securities, and amounts that we expect to generate from product sales and/or third-party collaboration payments, are not sufficient to enable us to fund our operations, we may need to raise additional funds in the form of equity, debt, or from other sources. In addition, we may choose to raise additional funds in the form of equity, debt, or from other sources due to market conditions or strategic considerations even if we believe we have sufficient funds for our current and future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our common shareholders’ ownership interest may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that adversely affect our common shareholders’ rights. The Sumitomo Dainippon Pharma Loan Agreement involves, and any agreements for future debt or preferred equity financings, if available, may involve, covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, raising capital through equity offerings, making capital expenditures or declaring dividends.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating expenses, net of costs that are expected to be shared with Pfizer pursuant to the Pfizer Collaboration and License Agreement, to increase as we commercialize ORGOVYX in the U.S., prepare for the potential  regulatory approvals and commercialization of relugolix combination tablet, initiate life cycle management activities for our relugolix </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">franchise, and potentially further develop our other product candidates and expand our pipeline. We expect our net cash burn to gradually decrease as our net revenues increase but our future capital requirements and operating expenses are expected to continue to be significant. Our operating expenses and operating cash flows may fluctuate significantly from quarter-to-quarter and year-to-year and our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the price, level of demand and net revenues generated from commercial sales of ORGOVYX and from any other product candidates that may receive marketing approval;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the achievement of regulatory milestones, sales milestones, and royalties that we are eligible to earn pursuant to the Richter Development and Commercialization Agreement and the Pfizer Collaboration and License Agreement;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, shared costs, and level of investment in our and our collaboration partners’ activities related to sales, marketing, market access, manufacturing, and distribution for ORGOVYX and for any other product candidates that may receive marketing approval; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, shared costs, and level of investment in our and our collaboration partners’ research and development activities involving ORGOVYX, relugolix monotherapy tablet, relugolix combination tablet, and any other product candidates; </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs, timing, and outcomes of regulatory submissions and regulatory reviews of our product candidates; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to expand our chemistry, manufacturing, and control and other manufacturing related activities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to identify, acquire, develop, and commercialize additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to integrate acquired technologies into a comprehensive regulatory and product development strategy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to maintain, expand, and protect our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to hire additional commercial operations, sales, scientific, clinical, regulatory, quality, and other personnel to support our commercialization, regulatory, and clinical development efforts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to implement or enhance operational, accounting, finance, quality, commercial, and management information systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to service our debt obligations and associated interest payments; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to operate as a public company.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial net product revenue from sales of ORGOVYX, relugolix combination tablet, MVT-602, or any future product candidate, we expect to fund our operations through a combination of cash, cash equivalents, and marketable securities currently on hand and amounts available to us under the Sumitomo Dainippon Pharma Loan Agreement, subject to the consent of our board of directors, as well as potential payments we are eligible to receive from Pfizer and Richter pursuant to the terms of our agreements with them.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the years ended March 31, 2021 and 2020 (in thousands): </span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,628&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,172)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,211)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,045&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,926&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Operating Activities </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2021, $370.6 million of cash was provided by operating activities, which was primarily driven by a net increase in deferred revenue of $457.9 million and a net increase in cost share advance from collaboration partner of $121.2 million, both of which were largely driven by the upfront payment received from Pfizer in December 2020 discussed previously. For the year ended March 31, 2021, net cash provided by operating activities also included an increase in accrued expenses and other current liabilities of $15.6 million (primarily due to an increase in accrued commercial and compensation-related expenses partially offset by a decrease in accrued R&amp;D expenses), as well as $53.7 million of non-cash share-based </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation expense (which includes approximately $25.7 million related to the acceleration, modification and remeasurement of our former Principal Executive Officer’s equity awards). These items were partially offset by a net loss for the period of $255.1 million primarily due to our ongoing development and clinical studies, and activities related to our preparation for potential regulatory approvals and commercialization of our product candidates, and the expansion of our company, and a non-cash foreign currency transaction gain of $16.2 million primarily related to amounts outstanding under the Sumitomo Dainippon Pharma Agreement. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2020, we used $221.2 million of cash in operating activities primarily due to our ongoing clinical studies, activities related to our preparation for potential regulatory approvals and commercialization of our product candidates, and the expansion of our company. This was primarily attributable to a net loss for the period of $289.0 million and a decrease of $24.7 million in accrued expenses and other current liabilities resulting primarily from a decrease in accrued R&amp;D expenses and decreases of $1.1 million in interest payable and $2.3 million in deferred interest payable related to our previously outstanding debt which was repaid in full on December 31, 2019. These amounts were partially offset by an increase of $40.0 million in deferred revenue related to the upfront payment we received from Richter on March 31, 2020, an increase in accounts payable of $4.3 million, due to timing of invoice payments, and an increase in other liabilities of $3.6 million, due to a capital tax accrual as a result of the change in control in Myovant, along with non-cash items including $40.3 million of share-based compensation expense as a result of an increase in headcount (which also includes $12.0 million related to the accelerated vesting of certain equity awards as a result of the change in control in Myovant in connection with the closing of the transaction between Roivant and Sumitomo Dainippon Pharma), $3.3 million of total depreciation, amortization and non-cash interest expense, and a $4.9 million loss on extinguishment of debt associated with the write-off of unamortized debt issuance costs and debt discounts, prepayment penalties and early redemption fees in connection with the repayment of outstanding obligations to NovaQuest and Hercules on December&nbsp;31, 2019.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Investing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2021, we used $9.2 million of cash in investing activities, of which $7.4 million was for the purchase of marketable securities, net of maturities and sales, and $1.8 million was for the purchase of property and equipment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2020, we used $3.9 million of cash in investing activities, of which $2.8 million was for the purchase of marketable securities, net of maturities, and $1.1 million was for the purchase of property and equipment.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended March 31, 2021, $238.0 million of cash was provided by financing activities. This was primarily due to proceeds of $245.0 million borrowed under the Sumitomo Dainippon Pharma Loan Agreement and proceeds of $6.7 million from the exercise of stock options under our 2016 Equity Incentive Plan, partially offset by payment of tax withholdings on net settlement of share awards of $13.7 million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&nbsp;year ended March 31, 2020, $145.9 million of cash was provided by financing activities. This was primarily due to the net proceeds of $137.0 million we received from issuances of our common shares, which included $134.5 million from the issuance and sale of 17,424,243 common shares in our underwritten public equity offering and $2.5 million from the sale of 106,494 common shares through our “at-the-market” equity offering program, and proceeds of $113.7 million borrowed under the Sumitomo Dainippon Pharma Loan Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we received proceeds of $0.9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the exercise of stock options under our 2016 Equity Incentive Plan. These amounts were partially offset by the repayment of our financing obligations and redemption fees to NovaQuest and Hercules, including payments to NovaQuest of $60.0 million for repayment of principal, early redemption fee of $2.4 million, and an annual debt administration fee of $0.3 million, and payments to Hercules of $40.0 million for repayment of principal, a prepayment penalty of $0.4 million, and an end-of-term charge of $2.6 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to our contractual obligations as of March&nbsp;31, 2021 and the effect such obligations are expected to have on our liquidity and cash flows in future years (in thousands): </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tbody><tr><td style="width:1.0%"></td><td style="width:43.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.387%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due by period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than 1 year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3-5 years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More than 5 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Related party debt obligations, including interest charge </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,468&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,672&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,343&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,453&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,515&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,028&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,180&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,891&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,983&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,523&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,344&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Related party debt obligations, including interest charge consists of principal and future interest payments due to Sumitomo Dainippon Pharma pursuant to the terms of the Sumitomo Dainippon Pharma Loan Agreement based on the amounts outstanding at March 31, 2021 and the interest rate in effect at March 31, 2021. See Note 6(A) to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Operating lease obligations consist of future rent payments under lease and sublease agreements for office space located in Brisbane, California. See Note 12 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Takeda</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Takeda License Agreement, we are required to pay Takeda a fixed, high single-digit royalty on net sales of relugolix and MVT-602 products in our territory. We cannot, at this time, determine when or if royalty payments will be required or what the total amount of such payments may be. Therefore, such payments are not included in the table above. See Note 14(D)  to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Service Providers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with certain vendors for the provision of goods and services, which includes manufacturing services with CMOs and development services with respect to CROs. These agreements may include certain provisions for purchase obligations and termination obligations that could require payment for the cancellation of committed purchase obligations or for early termination of the agreements. The amounts of the cancellation or termination payments vary and are based on the timing of the cancellation or termination and the specific terms of the agreements and are considered cancellable contracts. These cancellable contracts are not included in the table above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management’s discussion and analysis of our financial condition and results of operations is based on our audited consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The preparation of these audited consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingencies as of the dates of the audited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, or experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the estimates derived from the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates. We define our critical accounting policies as those under U.S. GAAP that require us to make subjective estimates and judgments about matters that are inherently uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. We have discussed our accounting policies with the audit committee of our board of directors, and we believe that our estimates and judgments relating to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration arrangements, revenue recognition, and R&amp;D expenses and accruals have the greatest potential impact on our consolidated financial statements. In addition, refer to Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information regarding our accounting policies.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We analyze our collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple units of account, we first determine which units of account of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While ASC 808 defines collaborative arrangements and provides guidance on the income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1) determining the appropriate unit of account or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature, such as ASC 606, or an accounting policy election by management. For units of account within the collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate revenue recognition method is determined and applied consistently. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts we receive prior to satisfying the revenue recognition criteria are recorded as deferred revenue on the audited consolidated balance sheets. If the related efforts underlying the deferred revenue are expected to be satisfied within the next twelve months, the deferred revenue is classified in current liabilities, otherwise it is classified as a non-current liability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that are within the scope of ASC 808, the recognition of collaboration revenue (expense) requires management judgement due to the fact that the terms of collaboration arrangements may be complicated, and the nature of the collaborative activities may change over time. Management judgement is exercised in determining the units of account within a collaboration arrangement and in allocating consideration to those units, estimating the collaboration revenue to be recognized, including estimating an appropriate term over which the collaboration revenue is expected to be recognized, as well as in determining the amortization method. For example, judgement is required in identifying material rights and performance obligations, and in estimating the stand-alone selling price of identified performance obligations and material rights, the estimates of which may include forecasted revenue, development timelines, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also judgement involved in the identification of costs that we incur related to the collaboration activities, evaluating the nature of these costs (for example, whether the costs relate to a particular geography or territory or whether the costs relate to clinical or commercial activities), and applying the terms of the respective collaborative arrangement to determine the portion of such costs that are the responsibility of the collaboration partner, which in certain circumstances requires significant judgement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are dependent on collaborative partners to provide us with information in a timely and accurate manner for use in preparing our consolidated financial statements and related disclosures. Certain of this information may also be subject to estimates. Should our collaborative partners fail to provide us with any such information in a timely manner, or should any estimates upon which such financial information was based, prove to be inaccurate, we could be required to record such adjustments in future periods.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Product Revenue, Net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recognized when physical control of our product is transferred to our customers, who are specialty distributors and pharmacies. Product sales are recorded net of various forms of variable consideration, including estimated (a) invoice discounts for prompt payment and specialty distributor and specialty pharmacy service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) group purchasing organization (GPO) discounts, performance rebates and administrative fees, (d) product returns and (e) costs of co-pay assistance programs for patients (collectively, “sales deductions”).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variability in the net transaction price for our product arises primarily from the aforementioned sales deductions. Significant judgment is required in estimating certain sales deductions. In making these estimates, we consider our historical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience, product price increases or decreases, current contractual and statutory requirements, unbilled claims, processing time lags for claims, inventory levels in the distribution channel, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary from our estimates, we adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">License, Milestone, and Other Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For units of account under ASC 606, we apply significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgements are discussed in more detail below:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Licenses of intellectual property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If the license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, we apply judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. We evaluate the measure of progress each reporting period and, if necessary, adjust the related revenue recognition accordingly.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes research, development or regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price on a cumulative catch-up basis in earnings in the period of the adjustment.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalties and commercial milestone payments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses and Accruals</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses primarily include personnel-related costs for employees engaged in R&amp;D activities and costs of third-parties who conduct clinical study and clinical manufacturing activities on our behalf, and are expensed as incurred unless there is an alternative future use in other R&amp;D projects. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider regulatory approval of product candidates to be uncertain and products manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory, but rather expensed as R&amp;D expenses when incurred.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accruals for clinical studies and other R&amp;D activities are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical study sites, CROs, and CMOs. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price, upon achievement of a milestone event, or on a time and materials basis. Payments under these agreements depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical study or similar conditions. The objective of our accrual policy is to match the recording of expenses in our audited consolidated financial statements to the actual services received and efforts </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expended. As such, expense accruals related to clinical studies and other R&amp;D activities are recognized based on our estimate of the degree of completion of the event or events specified in the agreements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accrual estimates are dependent upon the timeliness and accuracy of data provided by third parties regarding the status and cost of studies, and may not match the actual services performed by these organizations. During the course of a clinical study, we adjust our rate of clinical study expense recognition if actual results differ from our estimates. We make estimates of our clinical study expense as of each balance sheet date based on facts and circumstances known at that time. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and result in us reporting amounts that are too high or too low for any particular period. This could result in adjustment to our R&amp;D expense in future periods.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding the impact of recently adopted accounting pronouncements and the expected impact of recently issued accounting pronouncements not yet adopted on our consolidated financial statements, see Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1199"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, because we may continue to report as a “smaller reporting company” for this Annual Report on Form 10-K, we are not required to provide the information required by this item in this Annual Report on Form 10-K.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_13"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.  Financial Statements and Supplementary Data</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS OF MYOVANT SCIENCES LTD.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1138" tabindex="18">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1138" tabindex="18">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">Consolidated Balance Sheets as of March 31, 2021 and 2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">Consolidated Statements of Operations for the Fiscal Years Ended March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">0 and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">019</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">Consolidated Statements of Comprehensive Loss for the Fiscal Years Ended March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">, 2020 </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1099511629026" tabindex="18">Consolidated Statements of Shareholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_76" tabindex="18">’</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">Equity (De</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">ficit)</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> for the Fiscal Years Ended March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1099511629026" tabindex="18">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">Consolidated Statements of Cash Flows for the Fiscal Years Ended March 31, 2021</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_31" tabindex="18">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_31" tabindex="18">95</a></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_1138"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Myovant Sciences Ltd. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Myovant Sciences Ltd. (the Company) as of March&nbsp;31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, shareholders’ equity (deficit) and cash flows for each of the three years in the period ended March&nbsp;31, 2021, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at March&nbsp;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended March&nbsp;31, 2021, in conformity with U.S. generally accepted accounting principles. </span></div><div style="margin-top:15pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Application of collaborative arrangements guidance to the collaboration and license agreement with Pfizer, Inc. </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended March 31, 2021, the Company recorded collaboration revenue of $22.4 million under its collaboration and license agreement with Pfizer, Inc. (“Pfizer”). As described in Note 13 to the consolidated financial statements, the Company entered into a collaboration and license agreement with Pfizer under which the parties collaborate to jointly develop and commercialize relugolix in oncology and women’s health indications in the U.S. and Canada. In connection with the agreement, the Company received a $650 million upfront payment from Pfizer, of which $150 million represents Pfizer’s advanced payment for its share of expenses for the first two years of the agreement. The Company analyzed the units of account in the collaboration agreement to determine whether units of account were subject to ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the accounting for the collaboration and license agreement was especially challenging and subject to auditor judgment because of the subjectivity required to identify the units of account and determine whether the units of account are more indicative of collaborative activities or a customer-vendor relationship. Management also applied judgment to allocate arrangement consideration, including the $650 million upfront payment, to the units of account, and to determine the revenue recognition method and corresponding term over which revenue is expected to be recognized.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company’s accounting for the collaboration and license agreement with Pfizer, our audit procedures included, among others, reading and understanding the terms of the agreement and evaluating the Company’s identification of the units of account. We tested management’s application of U.S. generally accepted accounting principles to the cost sharing provisions of the agreement, the units of account, the revenue recognition method applied, and the expected term of the agreement, including consideration of termination provisions. Further, we recalculated revenue recognized and ending current and non-current deferred revenue as of March&nbsp;31, 2021.</span></div></td></tr></tbody></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company’s auditor since 2016.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&nbsp;11, 2021</span></div><div><span><br></span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="fact-identifier-40" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMy0xLTEtMS0w_5c44f27e-a37a-4467-94c3-1a4541602b06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">674,493</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="fact-identifier-41" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMy0zLTEtMS0w_56be6cd5-6342-46a2-a461-c98b4a2d760d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76,644</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="fact-identifier-42" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNS0xLTEtMS0yOTU2_fdd8e7ab-ca21-498b-8f11-84c65a2bd790" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,570</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="fact-identifier-43" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNS0zLTEtMS0yOTU2_d7a98a9b-adda-464a-8051-e8d33859779b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="fact-identifier-44" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNC0xLTEtMS0w_6a355c6c-b41d-474b-b85c-23ffee3abde6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,435</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="fact-identifier-45" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNC0zLTEtMS0w_52a11113-08bd-4d23-810e-a15b342bb644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,997</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="fact-identifier-46" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNi0xLTEtMS0yOTQ2_fdbb21b6-364b-47f2-bf80-2b6dbc99d3d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,611</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:InventoryNet" scale="3" id="fact-identifier-47" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNi0zLTEtMS0yOTQ2_d9608e5d-14e9-4160-97d8-bf9871c83808" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="fact-identifier-48" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNS0xLTEtMS0w_3922ed95-6b3b-4592-b9d9-a4773474e14d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,536</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="fact-identifier-49" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNS0zLTEtMS0w_40717e52-f722-4b2c-8bbb-a55775cd2176" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,269</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="fact-identifier-50" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNy0xLTEtMS0w_f1730408-7a98-4ce8-8052-9a1df1056c41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">704,645</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="fact-identifier-51" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNy0zLTEtMS0w_c09ef427-cd96-46fc-851f-9f4497344d52" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">87,910</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-52" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfOS0xLTEtMS0w_7c3c1aa5-8fdf-4b7d-bffb-ba496139d3f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,300</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="fact-identifier-53" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfOS0zLTEtMS0w_b05c5525-62c1-497c-8c90-13034a08d41c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,497</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="fact-identifier-54" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTAtMS0xLTEtMA_6dc94cdb-5907-4aea-96a1-30bb5dca0f94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,655</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="fact-identifier-55" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTAtMy0xLTEtMA_82887892-d6bc-4538-95db-19e54b0717a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,146</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="fact-identifier-56" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTEtMS0xLTEtMA_96e13898-4349-4287-b2a7-c417a249332d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,427</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="fact-identifier-57" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTEtMy0xLTEtMA_802d18c0-3fed-4183-a415-e1da7501dd2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,373</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="fact-identifier-58" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTItMS0xLTEtMA_27147eed-8664-42ac-990d-bb792d9a895b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">725,027</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="fact-identifier-59" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTItMy0xLTEtMA_a33973a8-2cf9-461a-befd-15946daabb8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,926</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and shareholders’ deficit</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="fact-identifier-60" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTUtMS0xLTEtMA_225e5801-8e4a-4e31-8346-e6bce55fc531" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,809</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="fact-identifier-61" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTUtMy0xLTEtMA_e2cfd38e-ab19-4cee-a191-4fb864281b49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,334</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedAndOtherLiabilitiesCurrent" scale="3" id="fact-identifier-62" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTktMS0xLTEtMA_181174e0-0388-47e2-bfd5-3445543bf980" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">44,612</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedAndOtherLiabilitiesCurrent" scale="3" id="fact-identifier-63" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMTktMy0xLTEtMA_8ebc3651-cfc5-459a-bd5e-1609c5d5a395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,060</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="fact-identifier-64" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjMtMS0xLTEtMzU1Ng_f46e77a0-c2b7-4123-ae36-def14ff2e5c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,636</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationShareBasedArrangementsLiabilityCurrent" scale="3" id="fact-identifier-65" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjMtMy0xLTEtMzU1Ng_935ff2da-d1d2-4bf4-b16a-88d694a0d237" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8f0779d6358d4c59af7d0b42d81c8e3e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="fact-identifier-66" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjAtMS0xLTEtMA_5ea26f90-0e7a-4fa4-8b7e-928e1ae8a144" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100,564</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ide85e32a24044ffc979f12f625b7267c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="3" id="fact-identifier-67" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjAtMy0xLTEtMA_783eebb9-910e-4e6b-a640-cd8b53e00760" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to collaboration partner</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedLiabilitiesCollaborationAgreementCurrent" scale="3" id="fact-identifier-68" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjUtMS0xLTEtNjU2MA_e0ed63f4-43ed-4cec-8396-a92615850ab4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,954</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="myov:AccruedLiabilitiesCollaborationAgreementCurrent" scale="3" id="fact-identifier-69" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjUtMy0xLTEtNjU2MA_85d2eabd-e2a4-40e4-8064-0d786eb644ad" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost share advance from collaboration partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiabilityCurrent" scale="3" id="fact-identifier-70" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjEtMS0xLTEtMA_7c5ddf29-fd95-40ad-87bd-15adc6a4ddb7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">92,415</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="myov:CollaborativeArrangementLiabilityCurrent" scale="3" id="fact-identifier-71" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjEtMy0xLTEtMA_79f357b1-bbc6-4e62-b09b-5e22f50df3a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-72" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjItMS0xLTEtMA_47997af7-74e2-46a8-a241-b7593785608a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,807</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-73" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjItMy0xLTEtMA_9a083200-1111-4e6e-abe1-7dcd77fb63e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,516</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="fact-identifier-74" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjMtMS0xLTEtMA_37877116-9413-41b8-9f78-c4c938df5fae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">543</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="fact-identifier-75" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjMtMy0xLTEtMA_74040968-7c2e-4476-ad89-8cb7768959ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="fact-identifier-76" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjYtMS0xLTEtMA_ee8826b2-d182-439c-aeb8-4c8db4039cdc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">281,340</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="fact-identifier-77" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjYtMy0xLTEtMA_a34a7008-8d10-4025-b839-8d77df4c698a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85,925</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="fact-identifier-78" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjgtMS0xLTEtMA_755b44de-6825-4d68-a4d5-354645447159" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">397,369</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRevenueNoncurrent" scale="3" id="fact-identifier-79" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjgtMy0xLTEtMA_e9db4bb5-cf97-47e2-a93e-d2695134a2fc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost share advance from collaboration partner, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiabilityNoncurrent" scale="3" id="fact-identifier-80" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjktMS0xLTEtMA_42eb8c8c-30ba-4ca8-aeb4-775b83333526" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,447</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="myov:CollaborativeArrangementLiabilityNoncurrent" scale="3" id="fact-identifier-81" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMjktMy0xLTEtMA_6b03d612-f523-4925-9299-a5edc382b3d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="fact-identifier-82" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzAtMS0xLTEtMA_48a2f031-01c1-4baf-8b47-51dcd9208941" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,189</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="fact-identifier-83" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzAtMy0xLTEtMA_2bd75df5-0b09-4410-b4a5-aea98c9382f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,996</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, less current maturities (related party)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="3" id="fact-identifier-84" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzItMS0xLTEtMA_22eba15a-b1fa-4785-b06b-e782304e2e68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">358,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesNoncurrent" scale="3" id="fact-identifier-85" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzItMy0xLTEtMA_5661fb4d-9986-4025-af02-6a3015ab8e29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="fact-identifier-86" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzMtMS0xLTEtMA_5cca01ec-5efd-4c97-a6ac-a24a3ff52798" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,947</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="fact-identifier-87" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzMtMy0xLTEtMA_5063df60-9589-4301-a0fc-6ae12e25f495" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,582</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="fact-identifier-88" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzQtMS0xLTEtMA_92f6eacd-2f14-451a-a56a-3cd303bb7093" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,078,992</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="fact-identifier-89" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzQtMy0xLTEtMA_d73fa13a-1528-44d2-842a-8f8db6d16955" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">214,203</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-90" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzUtMS0xLTEtMA_6200bc7b-8c30-4940-b5c7-f69f4a71c8d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="fact-identifier-91" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzUtMy0xLTEtMA_cf989be5-d634-4307-af1e-8566d330beda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders’ deficit:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, par value $<span><ix:nonfraction unitref="usdPerShare" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="9" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-92" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzI5_5afe9ed8-ab5c-4eef-818f-35c7ee098efc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usdPerShare" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="9" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-93" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzI5_68c39459-1442-49ae-9faf-ac513c957493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.000017727</ix:nonfraction></span></ix:nonfraction></span> per share, <span><ix:nonfraction unitref="shares" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="fact-identifier-94" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzQz_5df8103b-c48e-4563-93a9-9a28f45918d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="fact-identifier-95" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzQz_b9eb8bc2-4739-4918-a721-ad306a85fabd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">564,111,242</ix:nonfraction></span></ix:nonfraction></span> shares authorized, <span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="fact-identifier-96" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzY1_0bd49b7d-6978-4a5f-a6ec-a867fe217595" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="fact-identifier-97" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzY1_db26c7b3-fd36-4dde-90c0-76261676b734" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,000,869</ix:nonfraction></span></ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="fact-identifier-98" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzcy_31446a22-59b1-417f-98bf-99d7413f06a5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="shares" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="fact-identifier-99" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMC0xLTEtMC90ZXh0cmVnaW9uOmQzMDMwMDhiNjU0MTRiYjdiNTQzYTEwZTE1NzU0M2EwXzcy_baa3026a-1fcf-4d1a-8479-a34e68e2b7b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,833,998</ix:nonfraction></span></ix:nonfraction></span> issued and outstanding at March 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-100" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMS0xLTEtMA_9d6ac927-c755-4799-bc44-89710d9dc770" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="fact-identifier-101" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzctMy0xLTEtMA_9c920a6a-751f-44d9-b3d8-f2bab14972a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="fact-identifier-102" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzktMS0xLTEtMA_91e31ea5-6c81-431d-922f-0ee50d363331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">709,466</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="fact-identifier-103" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfMzktMy0xLTEtMA_920dd020-96a4-474e-9815-b76502a9bfeb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">684,381</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="fact-identifier-104" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDAtMS0xLTEtMA_451e0f10-4720-43b6-81a1-1187bcfcdc18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,285</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="fact-identifier-105" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDAtMy0xLTEtMA_36a4d1aa-104f-4ee2-a850-78bc54975106" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,646</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="fact-identifier-106" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDEtMS0xLTEtMA_7d823f55-521c-4c30-b425-1b8bcfdb6c19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,046,148</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="fact-identifier-107" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDEtMy0xLTEtMA_f0ac77f5-2980-428e-9d30-4ec7a1313a8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">791,014</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders’ deficit </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-108" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDItMS0xLTEtMA_ecd3d093-1cd6-431a-a310-99678790b2e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">353,965</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-109" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDItMy0xLTEtMA_b62cb296-cd9c-4078-ad7b-9cdce06241c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,277</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders’ deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="fact-identifier-110" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDMtMS0xLTEtMA_f8afa48c-9ecf-4b6e-bc0f-06457c0063da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">725,027</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="fact-identifier-111" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xNi9mcmFnOjcxMzBkMmI3NzJiYjRkYTY4NGU2MTNhMzkxMzdhMDk0L3RhYmxlOjEyMWEyYzcyNGJkMzRhODc4MTNmZThkMzU2NjU3OWM4L3RhYmxlcmFuZ2U6MTIxYTJjNzI0YmQzNGE4NzgxM2ZlOGQzNTY2NTc5YzhfNDMtMy0xLTEtMA_7fd489c0-0c08-44ff-90ed-9a658b9fbb29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,926</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_19"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except share and per share data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iffc37857417e4a9f8b585b4b4ca869dc_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-112" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMy01LTEtMS0yOTA0_3732a222-8394-43c6-b333-adb727e37e80" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,630</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if10a70d569d04a69ae8cd6c0fd2d95b3_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-113" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMy03LTEtMS0yOTA0_e57d5c8d-6009-4a01-b829-77ea18358870" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ieb70d87d00f54750a09b71cd219de7d5_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-114" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMy05LTEtMS0yOTA0_4c3c63c2-52e8-4949-be79-0bc6f4bb5632" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="fact-identifier-115" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNC01LTEtMS0xOTM2MQ_bc938e4c-c431-4472-b230-79cc0376a2aa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,354</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="fact-identifier-116" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNC03LTEtMS0xOTM2MQ_59e591f6-a8a2-45ed-988b-9a619db3351a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" xsi:nil="true" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="fact-identifier-117" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNC05LTEtMS0xOTg5Ng_451d3076-ed18-4cd5-8c0f-ac83cd8ba2b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"></ix:nonfraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and milestone revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic265aae726454c4089f67ca1ee78a7a7_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-118" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNC01LTEtMS0w_eb8c7568-632b-49ca-bf7f-9ca6e8027361" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,333</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i160c41394db246a5882746745393046e_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-119" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNC03LTEtMS0w_f9ea4801-29a9-4723-8d53-24c92ee281f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i476d00d6d1d74cb3bf79fd01cf60745a_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="fact-identifier-120" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNC05LTEtMS0yNTU4_ffb520f1-9468-4a3d-8a5f-fb6a41c2d490" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="fact-identifier-121" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNS01LTEtMS0w_b48b28a5-fac7-49cb-a67c-43639ea0e7e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">59,317</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="fact-identifier-122" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNS03LTEtMS0w_f2a06dcd-9c3d-4d1d-95b5-bdfb13874bdc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:Revenues" scale="3" id="fact-identifier-123" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNS05LTEtMS0yNTU4_b48602a7-d84d-414a-a2c8-eba38adc4b18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8cf1a2d33619471aa16d38eb9243e185_D20200401-20210331" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="fact-identifier-124" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy01LTEtMS02NTg1_c0459cbd-3e28-4975-ae8e-977ff80a1064" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">301</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i8b4a4133e70b4c39a775c1259ddb1bcd_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="fact-identifier-125" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy03LTEtMS02NTg1_73090266-96ab-4635-9534-56a3f8f22379" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i34570be86f5c4d238bc3375d7a2642fa_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="fact-identifier-126" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy05LTEtMS02NTg1_86c14d10-f4ff-46f9-9bf0-4b610effa8a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration expense to Pfizer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fca78b28e13473bbba9cab0265c782f_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="fact-identifier-127" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC01LTEtMS02NTg1_114f7d9e-d4cf-4f71-bd27-42f2eea1380d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,664</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i054c7fc8b51e4b05a98a285ed6f44dce_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="fact-identifier-128" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC03LTEtMS02NTg1_094b5722-184f-40dd-8f85-9a6fa1173804" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9641067803a1427698e5ea7056683ff2_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="fact-identifier-129" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC05LTEtMS02NTg1_2693a1db-5686-4c17-8edc-e6a35669ce11" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="fact-identifier-130" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy01LTEtMS0w_bfa657ec-8b27-4d75-8ed3-01c621126e81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">136,713</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="fact-identifier-131" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy03LTEtMS0w_bc3f3fb9-6923-438a-9201-3664bcd15781" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">192,560</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="fact-identifier-132" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfNy05LTEtMS0yNTYx_c58ca93d-8a7a-46f4-b531-0db490a1dbc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">222,607</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="fact-identifier-133" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC01LTEtMS0w_f18b3b75-a3be-45e9-888d-f145380909b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">181,423</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="fact-identifier-134" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC03LTEtMS0w_957b1efc-e204-4659-94bd-1935601fdfb4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">82,327</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="fact-identifier-135" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOC05LTEtMS0yNTYx_11bfd018-24fe-455f-9780-bcbdf9fb54bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">42,219</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:CostOfGoodsAndServicesSoldAndOperatingExpenses" scale="3" id="fact-identifier-136" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOS01LTEtMS0w_310061d5-228e-4b96-bdeb-6f9511784987" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">320,101</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:CostOfGoodsAndServicesSoldAndOperatingExpenses" scale="3" id="fact-identifier-137" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOS03LTEtMS0w_b25a4201-6d51-4655-847c-95b9476de835" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">274,887</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="myov:CostOfGoodsAndServicesSoldAndOperatingExpenses" scale="3" id="fact-identifier-138" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfOS05LTEtMS0yNTYx_b820cd40-1ff6-44ba-81ad-c65bb8f5b0a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">264,826</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="fact-identifier-139" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTAtNS0xLTEtMA_119e7fad-3435-44b4-bf77-c4621101cb07" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">260,784</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="fact-identifier-140" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTAtNy0xLTEtMA_6f68e4f4-ae7b-47e3-8124-3091584941c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">274,887</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="fact-identifier-141" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTAtOS0xLTEtMjU2MQ_3dce8b10-67e4-4535-813c-952b661e008c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">264,826</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-142" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTEtNS0xLTEtMA_929d3519-b4de-43b6-a251-e155438f33a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,401</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-143" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTEtNy0xLTEtMA_992cac55-5caa-47ac-8f7d-57eefc826d5f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,663</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-144" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTEtOS0xLTEtMjU2NA_b84b8186-4408-466a-a00b-0d5a9b15ff58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,821</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-145" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTItNS0xLTEtMA_7f996871-cfcc-4dc1-bc8e-7ef38d6a8fd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-146" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTItNy0xLTEtMA_96a59092-fcfc-4e30-98f4-a62263c9cce7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,851</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-147" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTItOS0xLTEtMjU2NA_4a3d51ae-713b-496c-b31d-779f27dd01e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="fact-identifier-148" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTMtNS0xLTEtMA_e84f3e0f-2ee8-4603-987c-0ba8b458d429" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">211</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="fact-identifier-149" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTMtNy0xLTEtMA_175c5d6a-bb2d-4f07-b340-9aa7723794c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,552</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="fact-identifier-150" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTMtOS0xLTEtMjU2NA_1d114254-8431-4784-84de-3e6da28151f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">881</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange (gain) loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="fact-identifier-151" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTQtNS0xLTEtMA_edec9ad1-8911-487d-93c7-aa16b723bef3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,176</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="fact-identifier-152" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTQtNy0xLTEtMA_8ceece11-dbd9-4491-bdee-f61845c72725" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,621</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="fact-identifier-153" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTQtOS0xLTEtMjU2NA_76caea09-fb4f-4ac1-9732-1d80a47bc70b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">309</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="fact-identifier-154" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTUtNS0xLTEtMA_c66cc57e-d5ce-4b05-b79f-0bb3041063c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">254,798</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="fact-identifier-155" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTUtNy0xLTEtMA_548240d0-057f-4241-8ed4-ffab8ab5d17d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,228</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="fact-identifier-156" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTUtOS0xLTEtMjU2NA_4a32f610-7510-475d-ac7c-14969f5e6c1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,075</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-157" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTYtNS0xLTEtMA_413c18a7-059a-4d2a-a846-dc77475ace3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-158" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTYtNy0xLTEtMA_27d1d674-0098-4f05-9489-f5fc5b98d9f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">761</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-159" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTYtOS0xLTEtMjU2Nw_80e5f90e-20af-4e87-9c91-b5f1b2bbd141" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-160" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTctNS0xLTEtMA_f1a87f16-2b39-4528-bd15-41713b0e819e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,134</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-161" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTctNy0xLTEtMA_3a4a5616-ed5b-4988-bc93-9f0000e64300" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,989</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-162" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTctOS0xLTEtMjU2Nw_973a5e96-50ba-4bdf-963f-224d29917838" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,551</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share — basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="fact-identifier-163" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTgtNS0xLTEtMA_79e459f6-7df0-4397-b320-a0e8cfe7ad61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.83</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="fact-identifier-164" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTgtNy0xLTEtMA_6e5c2069-5d9c-495d-a629-680b9baba97c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.37</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usdPerShare" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="fact-identifier-165" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTgtOS0xLTEtMjU3MA_76bd5fb1-59b8-4652-a500-27ca01d5b2da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.09</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding — basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="fact-identifier-166" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTktNS0xLTEtMA_3363020c-3abe-43e3-adb8-1fc78333e15a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,036,459</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="fact-identifier-167" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTktNy0xLTEtMA_3f449ba4-80af-4ad2-be78-e7e2ddaefa3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">85,839,303</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="fact-identifier-168" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RhYmxlOjY1NTNkMDhiZWE0NTQwYzhhNmEwNDgyNzcxOTkwYzI5L3RhYmxlcmFuZ2U6NjU1M2QwOGJlYTQ1NDBjOGE2YTA0ODI3NzE5OTBjMjlfMTktOS0xLTEtMjU3MA_40ccb4e6-4134-4297-abec-0f493434cebf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">66,910,060</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:footnote id="fact-identifier-169" continuedat="iefdbf1d4d0c84642af2468ac5e53edce" footnoterole="http://www.xbrl.org/2003/role/footnote" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNTQ5NzU1ODE0MTE4NA_fe39f7c2-85a4-4f1c-9b5b-85baf19f27ec" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"> </ix:footnote></span></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><span><ix:continuation id="iefdbf1d4d0c84642af2468ac5e53edce" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">Includes $<span><ix:nonfraction unitref="usd" contextref="i3c23f8eed98b444c9c9270d7a5adc3e3_D20200401-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="fact-identifier-171" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfMTA5OTUxMTYzMDAzOQ_ae642995-9338-417b-a576-ccd47a667688" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58</ix:nonfraction></span> of expense (inclusive of third-party pass-through costs) for the year ended March 31, 2021 to related parties (see Note 6).</ix:continuation></span></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNzU3_42e42f1e-cd52-4ac4-8835-0f71a5002afb" footnoterole="http://www.xbrl.org/2003/role/footnote">Includes $<span><ix:nonfraction unitref="usd" contextref="i3c23f8eed98b444c9c9270d7a5adc3e3_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="fact-identifier-172" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfMTU4_cde7bcb2-7a49-45ce-83ca-e7f275ab464b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,330</ix:nonfraction></span> of expense (inclusive of third-party pass-through costs) for the year ended March 31, 2021 to related parties (see Note 6).</ix:footnote></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNzU4_35e53685-1e4c-44d0-a67e-84fabb7b160d" footnoterole="http://www.xbrl.org/2003/role/footnote">Includes $<span><ix:nonfraction unitref="usd" contextref="if349c6471a15451d8608a9388e4a832b_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-173" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfNDA5_8f7fc45f-07b9-4f7b-b776-5ab54d56aad3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,766</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usd" contextref="i2321815be65048179f59af7408ba61d4_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="fact-identifier-174" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xOS9mcmFnOmFhM2U4ZTE2MGQ4ZjRlOGE5ZjQ4MjFhYjliZWU3MTEyL3RleHRyZWdpb246YWEzZThlMTYwZDhmNGU4YTlmNDgyMWFiOWJlZTcxMTJfMTA5OTUxMTYyOTc3Mg_ba4f9d0e-7868-4121-a4ef-805a75cba7ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,441</ix:nonfraction></span> of interest expense under the Sumitomo Dainippon Pharma Loan Agreement for the years ended March 31, 2021 and 2020. (see Note 6(A)).</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-175" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfMi01LTEtMS0w_e6d800ab-9750-48c4-9fc1-607ae4e0fef1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,134</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-176" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfMi03LTEtMS0w_7dce7bd7-9fc5-42ab-81df-de1ed4e9bcb9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,989</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-177" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfMi05LTEtMS00MzQy_973a5e96-50ba-4bdf-963f-224d29917838" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,551</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-178" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNC01LTEtMS0w_815305f9-50ed-4e60-955a-a904b993abe6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,639</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-179" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNC03LTEtMS0w_99dd61b7-4853-4319-a74e-8de618075c73" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,153</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-180" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNC05LTEtMS0xMDUwNg_e18111fe-7333-47f8-91c2-8af274cb0fa9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">483</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-181" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNS01LTEtMS0w_3bd53a8a-ffe3-4d08-9652-93e0eeebe842" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,639</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-182" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNS03LTEtMS0w_4d539a2a-9426-40fc-ad28-1d23629bccf9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,153</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-183" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNS05LTEtMS0xMDUwNg_adab73a9-9692-4949-9519-d02104bec52b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">483</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="fact-identifier-184" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNi01LTEtMS0w_acf5f039-db3f-499a-b5b5-3c8cb73e5590" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">270,773</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="fact-identifier-185" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNi03LTEtMS0w_3a4dfb69-755d-43d6-8506-d3279dd0aa05" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">291,142</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="fact-identifier-186" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yMi9mcmFnOjhkMDZkZmY3ZDNhZDQzNWM4Y2YyMjg5MjAzZWUzOWI2L3RhYmxlOjc4ZjBmNzJiNTY4ZTQxMTI5MTgwOGQ3NzhmOWIwODg1L3RhYmxlcmFuZ2U6NzhmMGY3MmI1NjhlNDExMjkxODA4ZDc3OGY5YjA4ODVfNi05LTEtMS0xMDUwNg_a7ad1ff7-1408-49e0-af24-4953c0b9a157" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,068</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_1099511629026"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Shareholders’ Equity (Deficit) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span><br></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.891%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.334%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated <br>Other Comprehensive <br>(Income) Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders’ <br>&nbsp;Equity (Deficit)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i61d0175b2e42410da8d8b92684250864_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="fact-identifier-187" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yLTEtMS0xLTQzNjM_731b879d-e015-423c-829e-635fe193e4a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60,997,856</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i61d0175b2e42410da8d8b92684250864_I20180331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-188" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yLTMtMS0xLTQzNjM_117e89af-e1b8-4185-a4ee-8d70f7f3a26e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i68945742841b40e68e0478668b632941_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-189" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yLTUtMS0xLTQzNjM_69cd2624-a5f1-42e5-8689-22f318c14b51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">266,178</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie9dcc325cc19453e834f9bdedc5ff57e_I20180331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-190" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yLTctMS0xLTQzNjM_035a0b67-cf73-4ad1-acba-632c2f8b4222" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i956394f3bf6348cca5d26f889b906891_I20180331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-191" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yLTktMS0xLTQzNjM_36aa0fdd-59e1-4d97-aa67-f028ac9a7de9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">228,474</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaaaac77afb624e62b09f40c92b485ea0_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-192" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yLTExLTEtMS00MzYz_6c347932-8b05-4419-b3e3-c92c4844434e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,729</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with “at-the-market” equity offering, net of commissions and offering costs of $<span><ix:nonfraction unitref="usd" contextref="ic2976f6ca9974c84a27bd4800eb31e6a_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="fact-identifier-193" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8zLTAtMS0xLTExNjI2L3RleHRyZWdpb246MjgyZWUwYTM0N2RkNDI3OWE3YTY3NjQ1Mjc3NzhlMGZfMTA5OTUxMTYyNzkwNQ_a33a3ede-6cd6-4856-8704-c0733c0b1dae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,919</ix:nonfraction></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ie385a303d391492087df1a4e47452b8a_D20180401-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="fact-identifier-194" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8zLTEtMS0xLTQzNjM_c11e32c6-401f-416f-a87d-9f93f9550135" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,970,129</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1ada8c2f2f3b4d69b0a3fe2eb9295c9d_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-195" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8zLTUtMS0xLTQzNjM_5ad8d1a5-6e51-40ac-bc06-c4310e97e1f5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84,052</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic2976f6ca9974c84a27bd4800eb31e6a_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-196" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8zLTExLTEtMS00MzYz_97c619cf-c311-4788-b51d-8fa0fa1ceade" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84,052</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with Private Placement with former majority shareholder</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0137e39b3dca4703939d787a21b30d7b_D20180401-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="fact-identifier-197" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTEtMS0xLTQ0MTI_9baf4b18-a452-4165-826e-09f1c4c30a1e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,110,015</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i90226e0502534a7687a95bbda83d0759_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-198" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTUtMS0xLTQ0MTI_88c21aac-918d-469b-8b76-17ca4184ca90" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i5db119d101d64f3fa903075699a23d4b_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-199" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTExLTEtMS00NDEy_3d93585e-3faf-4b01-8538-cb77d6b5b339" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if307d320921b49eaa929b311c7c0587c_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="fact-identifier-200" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl81LTUtMS0xLTQ0MTI_cfd2d65d-c3e1-4dc9-99f0-6cb283b843c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,067</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="fact-identifier-201" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl81LTExLTEtMS00NDEy_36454783-8b91-4e41-968e-169d05dbf050" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,067</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contribution from former majority shareholder — share-based compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if307d320921b49eaa929b311c7c0587c_D20180401-20190331" decimals="-3" name="myov:AdjustmentsToAdditionalPaidInCapitalCapitalContributionFromSharebasedCompensation" scale="3" id="fact-identifier-202" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTUtMS0xLTQ0MTI_cb450de3-e15c-4fe4-b118-bde0645ed550" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">629</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="myov:AdjustmentsToAdditionalPaidInCapitalCapitalContributionFromSharebasedCompensation" scale="3" id="fact-identifier-203" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTExLTEtMS00NDEy_14b68304-89e5-4eab-9ba2-a72209e36064" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">629</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contribution from former majority shareholder</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if307d320921b49eaa929b311c7c0587c_D20180401-20190331" decimals="-3" name="myov:AdjustmentstoAdditionalPaidinCapitalRelatedPartyCapitalContribution" scale="3" id="fact-identifier-204" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl83LTUtMS0xLTQ0MTI_fe520b60-6675-428e-baf4-abac32a70423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">752</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="myov:AdjustmentstoAdditionalPaidinCapitalRelatedPartyCapitalContribution" scale="3" id="fact-identifier-205" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl83LTExLTEtMS00NDEy_41453576-ef54-48b6-927d-61d6e799c959" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">752</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idaeb13ab941f462f8dd689170cd64c01_D20180401-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-206" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl84LTctMS0xLTQ0MTI_da827caa-0d5d-46b1-99f8-80c350b3f0f9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">483</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-207" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl84LTExLTEtMS00NDEy_978464a5-08ea-477a-8265-d5f6aea780c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">483</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with public equity offering, net of commissions and offering costs of $<span><ix:nonfraction unitref="usd" contextref="i4e33c24894de473e812d75848df1f2b4_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="fact-identifier-208" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl85LTAtMS0xLTExNjMzL3RleHRyZWdpb246MTQ5YjQ4ZmM5NzFhNDM2NWFkNWU1OTVmY2E1ZDQ3ZDRfMTA5OTUxMTYyNzg5Ng_daac6d0f-f3b8-4eb4-9dfa-98bb109abde7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,110</ix:nonfraction></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i497ad0ffa4584983bacd47a8166fb918_D20180401-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="fact-identifier-209" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl85LTEtMS0xLTQ0MTI_9cf9fdad-6485-4b28-a2f2-b745833f28f3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,533,399</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i99ca3e98a7d04bb797aeb3113f6ce0db_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-210" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl85LTUtMS0xLTQ0MTI_22928aaf-f21b-45ce-9829-f6046c1d6f41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74,391</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4e33c24894de473e812d75848df1f2b4_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-211" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl85LTExLTEtMS00NDEy_d415d894-ef4a-4392-9414-bfd8dc84d6a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">74,391</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued to NovaQuest, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3db108d1008d4bf089c98bfaa7f9a1c7_D20180401-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="fact-identifier-212" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMC0xLTEtMS00NDEy_6a809743-69f2-4def-9165-8985ceae4391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,286,284</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i06cfff86bba34830a947e138a4da05a6_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-213" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMC01LTEtMS00NDEy_2cf782a1-3016-48d4-a490-9bee47607262" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,982</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie8ce49038ae1495195d828b434b81c44_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-214" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMC0xMS0xLTEtNDQxMg_e6330456-0dc3-4d75-aa6b-5e5bced1bdc4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,982</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options and vesting of RSUs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i28ca06d3712d432e89160d8b9d21b785_D20180401-20190331" decimals="INF" format="ixt:numdotdecimal" name="myov:StockIssuedDuringPeriodSharesRestrictedStockAwardsVestedandStockOptionsExercisedNetofForfeitures" scale="0" id="fact-identifier-215" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMS0xLTEtMS00NDEy_68991708-cfea-48e8-9b5d-a3143fa319a8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">159,807</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if307d320921b49eaa929b311c7c0587c_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="myov:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsExercisedNetofForfeitures" scale="3" id="fact-identifier-216" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMS01LTEtMS00NDEy_3940fec2-c75e-4aa2-b693-cefa97df91ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,300</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="myov:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsExercisedNetofForfeitures" scale="3" id="fact-identifier-217" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMS0xMS0xLTEtNDQxMg_7148a6c8-3fb7-4ed5-a0c0-faa8b183471a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,300</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0a218cb0267c4d579e747d655e88b3a1_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-218" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMi05LTEtMS00NDEy_6501cead-e154-4100-9433-beb54061b01b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,551</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-219" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xMi0xMS0xLTEtNDQxMg_fda6f9fb-6a2b-42cd-b1be-3ae61f1206c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,551</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i45f4aa5653414da7ae04aa838147d6cc_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="fact-identifier-220" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTEtMS0xLTQzNjM_79bc851c-eabd-453f-9132-e3f1ac7d63dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">72,057,490</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i45f4aa5653414da7ae04aa838147d6cc_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-221" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTMtMS0xLTQzNjM_1cdc0890-f573-42f6-99e1-c88b6cc88168" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i562afd9841c148ca9384190c6e0102cd_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-222" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTUtMS0xLTQzNjM_bbc293b6-45c2-4bef-8950-3f07bf0c4841" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">505,851</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i66ce50bb7a0c498d9ea0450a13c6e803_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-223" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTctMS0xLTQzNjM_8fc63973-0b48-409e-ac9e-7a658673cfa2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">507</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i6ac1aba889714a8984ad9d9a6bd42a72_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-224" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTktMS0xLTQzNjM_ca771400-f640-484e-bfa2-a0b8d1ed1a60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">502,025</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-225" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl80LTExLTEtMS00MzYz_5ebfad9b-ac4d-4fe5-b738-c1aa1047f9ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,334</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with “at-the-market” equity offering, net of commissions of $<span><ix:nonfraction unitref="usd" contextref="i9617fb45d9424787a8eafd2ba4e4de52_D20190401-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="fact-identifier-226" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNC0wLTEtMS0xMTY0MS90ZXh0cmVnaW9uOmNkNzAxMmQ3MDNlYTQyNWRhNzE5M2I1MmUyYzJkNjc1XzEwOTk1MTE2Mjc4ODA_f0d46e8e-ba93-4a24-94b2-1ac9949e4259" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79</ix:nonfraction></span></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i2273728e14114fa392000925352b6a83_D20190401-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="fact-identifier-227" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNC0xLTEtMS00NDM2_d9f65829-f46c-4579-94db-c7a0bad18561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">106,494</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4a859c7761234c979689270973d3badc_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-228" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNC01LTEtMS00NDQw_0fb18d44-c46e-43bd-8fd4-0a43ed56b20c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,546</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9617fb45d9424787a8eafd2ba4e4de52_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-229" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNC0xMS0xLTEtNDQ0MA_247c996d-d080-41d7-a887-c86369a91ee5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,546</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares in connection with public equity offering, net of commissions and offering costs of $<span><ix:nonfraction unitref="usd" contextref="i1b4f10066b2947649f8511819ee273e0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="fact-identifier-230" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS0wLTEtMS0xMTY0NS90ZXh0cmVnaW9uOjJiYmE3MmI1OTQzMjQ0YzZhZjQwOTA5Y2Q0NmM4MzYzXzEwOTk1MTE2Mjc4OTY_30b5bc40-213d-4ee7-8373-f1438a63da2f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,292</ix:nonfraction></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i0a287ab55ddc4ea8843a5299da4de0d2_D20190401-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="fact-identifier-231" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS0xLTEtMS00NDM2_47c0e373-82aa-4d02-9f4e-a4db88e917e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,424,243</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id670791c2abf4c7590246e9218224792_D20190401-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-232" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS0zLTEtMS00NDM2_6abe1d53-4e68-41e3-8373-63d03be334f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib6e12f6acf3147a5a74844e2373b7c41_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-233" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS01LTEtMS00NDQw_710f28f0-a80f-450f-9306-81089dcde423" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,457</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1b4f10066b2947649f8511819ee273e0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="fact-identifier-234" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS0xMS0xLTEtNDQ0MA_8cbecfe1-4d5f-4053-8ad4-384a036300ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134,458</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19fdc1f929614896983285ba13d2fe37_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="fact-identifier-235" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi01LTEtMS00NDQw_468266b7-beaf-499e-9beb-6e96903484cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,102</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="fact-identifier-236" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi0xMS0xLTEtNDQ0MA_51a61776-8856-4ce7-9f3d-221f2d40ec9b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,102</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contribution from former majority shareholder — share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19fdc1f929614896983285ba13d2fe37_D20190401-20200331" decimals="-3" name="myov:AdjustmentsToAdditionalPaidInCapitalCapitalContributionFromSharebasedCompensation" scale="3" id="fact-identifier-237" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNy01LTEtMS00NDQw_618c0557-e2e6-402b-9847-bb23944cbd01" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">149</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="myov:AdjustmentsToAdditionalPaidInCapitalCapitalContributionFromSharebasedCompensation" scale="3" id="fact-identifier-238" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNy0xMS0xLTEtNDQ0MA_9a83ea21-cbd6-4b11-9543-0d3f8c3ca248" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">149</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contribution from former majority shareholder</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19fdc1f929614896983285ba13d2fe37_D20190401-20200331" decimals="-3" name="myov:AdjustmentstoAdditionalPaidinCapitalRelatedPartyCapitalContribution" scale="3" id="fact-identifier-239" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xOC01LTEtMS00NDQw_0ba6a76d-d308-495c-8b05-3c5ad4eee1e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">334</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="myov:AdjustmentstoAdditionalPaidinCapitalRelatedPartyCapitalContribution" scale="3" id="fact-identifier-240" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xOC0xMS0xLTEtNDQ0MA_42fb77d5-cd39-42c2-970c-b59d6daaea59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">334</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i8fda2b40754b4565bba683c66721b63f_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-241" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xOS03LTEtMS00NDQw_2da93ad7-1564-4ba9-a0fd-1caf3fdd6839" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,153</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-242" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xOS0xMS0xLTEtNDQ0MA_9d99b582-575a-4dd5-9a24-98cba955c659" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,153</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options and vesting of PSUs and RSUs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id670791c2abf4c7590246e9218224792_D20190401-20200331" decimals="INF" format="ixt:numdotdecimal" name="myov:StockIssuedDuringPeriodSharesRestrictedStockAwardsVestedandStockOptionsExercisedNetofForfeitures" scale="0" id="fact-identifier-243" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yMC0xLTEtMS00NDM2_5759454e-4523-474f-999d-3ba156d6850c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">245,771</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i19fdc1f929614896983285ba13d2fe37_D20190401-20200331" decimals="-3" name="myov:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsExercisedNetofForfeitures" scale="3" id="fact-identifier-244" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yMC01LTEtMS00NDQw_3ff53c13-9959-4c42-b07d-6bbc4735e0c1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">942</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="myov:StockIssuedDuringPeriodValueRestrictedStockAwardsVestedandStockOptionsExercisedNetofForfeitures" scale="3" id="fact-identifier-245" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yMC0xMS0xLTEtNDQ0MA_e44b9e16-7b09-4659-8a56-7265b3bdcd41" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">942</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ib0c4217a5fc141e0bb845d65ef5ac4be_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-246" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl81LTktMS0xLTQzNjM_2dd9b0b8-18c4-48bf-b382-f12998238c3b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,989</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-247" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl81LTExLTEtMS00MzYz_606cb0ac-3c2e-47ee-aab0-1fc95378ab53" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,989</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i18069b355e1c466c9d9d58d5de4fd598_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="fact-identifier-248" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTEtMS0xLTQzNjM_45c3e487-2a99-485c-9ec4-fe158e3459d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">89,833,998</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i18069b355e1c466c9d9d58d5de4fd598_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-249" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTMtMS0xLTQzNjM_644649bd-971b-4316-bb17-08b83ef272ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia01aa3463454442781e4dcad06c1fd71_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-250" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTUtMS0xLTQzNjM_fb973eff-cc52-42bc-b1f8-d12c48083152" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">684,381</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ia0c80634e601403fa4e2efd8a7f3492f_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-251" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTctMS0xLTQzNjM_8013fbb0-e43f-4f82-bd0d-2c96b1f48001" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,646</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ibefe2a474ee14ff3975172141efdb176_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-252" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTktMS0xLTQzNjM_c7caaf3b-27c3-424c-a4d7-017198247377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">791,014</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-253" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl82LTExLTEtMS00MzYz_fe2d4c66-3296-4df7-af82-614de788b65d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,277</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.891%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.334%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="fact-identifier-254" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl83LTUtMS0xLTQzNjM_51e75598-704d-49cf-8059-2e1ace4e8f92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,676</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="fact-identifier-255" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl83LTExLTEtMS00MzYz_20368964-2362-402d-b3aa-7c42e6cb487b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,676</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation awards reclassified to current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationExpenseReclassifiedToLiabilities" scale="3" id="fact-identifier-256" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNC01LTEtMS0xNTQ1Nw_5e9f5646-94fa-45e5-9026-571d7157498d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,473</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationExpenseReclassifiedToLiabilities" scale="3" id="fact-identifier-257" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNC0xMS0xLTEtMTU0NTc_4ff562a0-b5e8-4158-b831-4f0d0cc3d639" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,473</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation liabilities reclassified to equity upon settlement of awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationLiabilitiesReclassifiedToEquity" scale="3" id="fact-identifier-258" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNS01LTEtMS0xNTQ1Nw_6020c478-8d1a-4956-aee4-5d1fe440e29a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,446</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationLiabilitiesReclassifiedToEquity" scale="3" id="fact-identifier-259" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNS0xMS0xLTEtMTU0NTc_f7e01346-1069-4b43-a7a3-f0758734c1ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,446</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense reclassified to current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AdjustmentsToAdditionalPaidInCapitalChangeInFairOfShareBasedCompensationExpenseRecordedToLiabilities" scale="3" id="fact-identifier-260" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNi01LTEtMS0xNTQ1Nw_8d3cd747-1a91-4512-8c93-15b9e7069b93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,609</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AdjustmentsToAdditionalPaidInCapitalChangeInFairOfShareBasedCompensationExpenseRecordedToLiabilities" scale="3" id="fact-identifier-261" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNi0xMS0xLTEtMTU0NTc_c5ab5ef4-90a3-4e49-b0ba-26008468adeb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,609</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of share awards, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i6e48627d4625437a8773e7da5c3ce588_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="fact-identifier-262" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNy0xLTEtMS0xNTQ1Mw_70c458d8-5967-435d-8dcf-14ff69cb9b4e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">261,095</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="fact-identifier-263" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNy01LTEtMS0xNTQ1Nw_e2095b6d-b68e-430c-b6de-bf2ce8cfaf38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,664</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="fact-identifier-264" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8yNy0xMS0xLTEtMTU0NTc_9936c7db-14e9-456f-b0db-f14cd79ede0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,664</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of shares upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i6e48627d4625437a8773e7da5c3ce588_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="fact-identifier-265" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl84LTEtMS0xLTQzNjM_54d694f0-f407-4390-a09c-a353d0c512c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">905,776</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i93660c2e5ff743729c163dfc1377ad3e_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-266" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl84LTUtMS0xLTQzNjM_b9815a8c-e813-494a-a857-eb1a678bb0f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,709</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="fact-identifier-267" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl84LTExLTEtMS00MzYz_364d5446-1ba7-4b5b-9356-6a01ef291e1b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,709</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ia6fe03c315034c978a108ee01765c807_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-268" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNC03LTEtMS00MzYz_8b98e3c2-0741-43b2-b772-e84bb6da6b13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,639</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="fact-identifier-269" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNC0xMS0xLTEtNDM2Mw_67cf7c0d-e9ee-4404-9488-d0035600cce1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,639</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i78be8e9dc90f48a78cf2ec4656e47a13_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-270" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS05LTEtMS00MzYz_33c1b65f-4c2a-4974-9190-0f953036b4b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,134</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-271" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNS0xMS0xLTEtNDM2Mw_6af013e6-b360-4eb4-8bf1-5c7535aecef2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,134</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i7e3a32c9a2a5400a8e24118bf404b14d_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="fact-identifier-272" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi0xLTEtMS00MzYz_3457fdc4-ad85-41c9-b154-63f8e976350b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">91,000,869</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i7e3a32c9a2a5400a8e24118bf404b14d_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-273" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi0zLTEtMS00MzYz_6eebb526-6ecc-4a9d-88d8-990ed17afa48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i41653fb53f874e489854f639ad2a842e_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-274" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi01LTEtMS00MzYz_0b7cb373-dffd-47e9-b421-2dfcac66ac26" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">709,466</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ie2f5a48a02db4820b68629ff4c7ef6f1_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-275" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi03LTEtMS00MzYz_2057b490-856b-4034-a9ba-c70d1c4df2c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,285</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i157c79b0fe854791ae5956a9797a6af4_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-276" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi05LTEtMS00MzYz_e2b5487d-6b3e-4dbe-bac8-6eed7775f5c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,046,148</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="fact-identifier-277" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMDk5NTExNjI5MDI2L2ZyYWc6MmU5MjI5ZjMyMjNkNDNlODliOTI5YThlM2E5YWI1ZjkvdGFibGU6OWI1MTBhNGZjYTkwNDgwOTg2YjM4MzE3NTE4YzA3YzIvdGFibGVyYW5nZTo5YjUxMGE0ZmNhOTA0ODA5ODZiMzgzMTc1MThjMDdjMl8xNi0xMS0xLTEtNDM2Mw_6c17f190-0222-4eaf-bd33-d94673a7d40b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">353,965</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-bottom:5pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-278" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMy0xLTEtMS0w_4d39a1a9-c519-4737-abb8-2b589a2a103c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">255,134</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-279" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMy0zLTEtMS0w_6c2dce8c-23b8-4b87-a34a-f1dc5faa6eff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,989</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="fact-identifier-280" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMy01LTEtMS04NzUw_aee6fd35-31bb-4719-aade-1f7672bb2208" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,551</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="fact-identifier-281" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNi0xLTEtMS0w_a9b36e9b-6d2d-49b5-b903-5ec08e0440a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,676</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="fact-identifier-282" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNi0zLTEtMS0w_7bf67934-d2e7-4fea-b0c7-dce67846d325" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,251</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="fact-identifier-283" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNS01LTEtMS04NzYz_caa05305-7551-4019-8820-7e4130cc610a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,696</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:DepreciationandAmortizationExcludingAmortizationofDebtIssuanceCostsandDiscounts" scale="3" id="fact-identifier-284" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNy0xLTEtMS0w_b12d24f9-f1f7-4f8a-ab59-1f6f569e84bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,479</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:DepreciationandAmortizationExcludingAmortizationofDebtIssuanceCostsandDiscounts" scale="3" id="fact-identifier-285" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNy0zLTEtMS0w_3c65709b-03e0-467c-9ca1-2f669a52ae2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,765</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="myov:DepreciationandAmortizationExcludingAmortizationofDebtIssuanceCostsandDiscounts" scale="3" id="fact-identifier-286" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNi01LTEtMS04NzYz_5c8ec08c-52b0-4f1d-8244-926c951a39bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">438</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="fact-identifier-287" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOC0xLTEtMS0w_badf4d3f-9a79-4f28-8b2e-9e0bdc502c07" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">635</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="fact-identifier-288" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOC0zLTEtMS0w_681525c6-da84-48ab-9691-ad9fc0495b17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,486</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="fact-identifier-289" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNy01LTEtMS04Nzcw_34827c18-f930-4feb-9d9c-3a29b6c2d7ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,084</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-290" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOS0xLTEtMS0w_0c0ec5ef-5192-4899-b38c-283ac9f6cd6a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-291" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOS0zLTEtMS0w_680e462a-edb9-4994-829d-6125a1216139" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,851</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="fact-identifier-292" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOC01LTEtMS04NzYz_90b2f716-cb71-4fdf-921c-b8dc296972cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency transaction (gain) loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="fact-identifier-293" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTAtMS0xLTEtMA_0a73ceb5-3b38-4d52-bf3e-040de4414bbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16,176</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="fact-identifier-294" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTAtMy0xLTEtMA_08b9db91-4db5-4c1e-8793-22e0e2e5aa99" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,621</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="fact-identifier-295" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfOS01LTEtMS04NzYz_834ce945-5211-4a00-b7b4-8f7e27d32ae8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">309</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="fact-identifier-296" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTEtMS0xLTEtMA_f0007378-8e26-479e-8235-053a0b8647d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">537</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="fact-identifier-297" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTEtMy0xLTEtMA_aa4af4b9-46eb-47b5-993c-604b24c87602" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">359</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="fact-identifier-298" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTAtNS0xLTEtODc2Mw_f56bf18e-bc3f-4b3d-90be-5d4efdb9b8f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">926</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="fact-identifier-299" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTItMS0xLTEtMTU2ODg_0adb96a0-0264-4b3d-bed0-4979bd489d4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,570</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="fact-identifier-300" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTItMy0xLTEtMTU2ODg_2608727e-9a2b-420d-8c0a-fafc5423676f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="fact-identifier-301" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTItNS0xLTEtMTU2ODg_0cc442df-acfd-498c-be9e-00926a8ebff9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="fact-identifier-302" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTMtMS0xLTEtMTU2ODg_40d6e237-f6ce-4c33-ae97-1ae4019ba5d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,611</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="fact-identifier-303" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTMtMy0xLTEtMTU2ODg_ef917f8c-b57f-47e7-94e7-2e60c05a9046" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="fact-identifier-304" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTMtNS0xLTEtMTU2ODg_648f1fc9-d7d2-4410-b2f4-26764129d199" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-305" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTMtMS0xLTEtMA_94add03a-3038-4dc7-bbcf-a3adf531e750" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,267</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-306" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTMtMy0xLTEtMA_f853e951-e497-442c-a10a-8fcc3250e55a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,925</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="fact-identifier-307" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTItNS0xLTEtODc3NQ_87bdfbed-e21c-4367-b1f8-44975aa8c607" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,055</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="3" id="fact-identifier-308" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTUtMS0xLTEtMA_2630c6da-f9c6-4c91-980a-e7657ce08493" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="3" id="fact-identifier-309" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTUtMy0xLTEtMA_f8aeba22-92a0-49c4-9b2c-70696dbf3933" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">524</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" scale="3" id="fact-identifier-310" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTQtNS0xLTEtODc3OA_2667eb18-7345-436c-b878-11ef724edf8b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="fact-identifier-311" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTYtMS0xLTEtMA_77d54c4f-fe80-4885-9263-8cc139f7a203" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,441</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="fact-identifier-312" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTYtMy0xLTEtMA_eb89c4a8-f864-4d89-aa4e-ec5a0b71dbd2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="fact-identifier-313" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTUtNS0xLTEtODc3OA_2cba0b0b-07e2-4bb6-a524-c349a822e112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="fact-identifier-314" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTctMS0xLTEtMA_54285054-db27-4565-962f-b47a9cd928fb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,457</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="fact-identifier-315" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTctMy0xLTEtMA_33e5cc68-ce63-4a6b-aa07-2eea2ac614de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,315</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="fact-identifier-316" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTYtNS0xLTEtODc3OA_4b356d44-7263-40ba-8801-6e5b3ea4e1e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,441</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseinInterestPayableNetCurrent" scale="3" id="fact-identifier-317" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTktMS0xLTEtMA_433db4de-d414-4773-98bf-838dca58c8c0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseinInterestPayableNetCurrent" scale="3" id="fact-identifier-318" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTktMy0xLTEtMA_87fbaf0e-5abd-408d-89e4-63e6e26f3771" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,077</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="myov:IncreaseDecreaseinInterestPayableNetCurrent" scale="3" id="fact-identifier-319" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTctNS0xLTEtODc4Nw_d9ab03c3-9cb5-417b-82e4-337848d91965" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">795</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="fact-identifier-320" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjEtMS0xLTEtMA_42b2a81a-d6a7-4779-bf22-bf63a72b7369" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15,552</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="fact-identifier-321" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjEtMy0xLTEtMA_f0ecac72-e9c1-4f9d-bf3e-0a21c888a3da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24,675</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="3" id="fact-identifier-322" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMTktNS0xLTEtODc5MQ_f573e428-8c92-495a-94d4-ac63c0edc075" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,510</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="fact-identifier-323" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjItMS0xLTEtMA_91bfcdb5-9dfa-428a-89d5-7d77d4b1b27d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">457,933</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="fact-identifier-324" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjItMy0xLTEtMA_a1175a6b-9263-463f-a210-c9e785952f06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" id="fact-identifier-325" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjAtNS0xLTEtODc5Ng_ea8f2958-e133-4ac3-a06a-3e282e16b116" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to collaboration partner</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseInAccruedLiabilitiesCollaborationAgreementCurrent" scale="3" id="fact-identifier-326" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjItMS0xLTEtMTU2OTU_245c36d8-25e5-4369-a616-313a764b7925" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,954</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseInAccruedLiabilitiesCollaborationAgreementCurrent" scale="3" id="fact-identifier-327" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjItMy0xLTEtMTU2OTU_6cef2b90-23f8-4a12-a82a-5272f4c55693" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseInAccruedLiabilitiesCollaborationAgreementCurrent" scale="3" id="fact-identifier-328" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjItNS0xLTEtMTU2OTU_b992eaca-d041-440a-9a9b-80325174c4e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost share advance from collaboration partner</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseInCollaborativeArrangementLiability" scale="3" id="fact-identifier-329" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjMtMS0xLTEtMA_2da8da2c-caba-49ca-b653-b4a22ba13b92" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">121,227</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseInCollaborativeArrangementLiability" scale="3" id="fact-identifier-330" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjMtMy0xLTEtMA_f88e56ff-a957-4363-8162-d2a15e06aeb6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseInCollaborativeArrangementLiability" scale="3" id="fact-identifier-331" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjEtNS0xLTEtODgxNA_f67b3fe9-38e0-4d84-b933-8de839249b1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseinOperatingLeaseLiability" scale="3" id="fact-identifier-332" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjQtMS0xLTEtMA_c2381777-5d39-4708-b48d-e5a5ec3488e6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,516</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" name="myov:IncreaseDecreaseinOperatingLeaseLiability" scale="3" id="fact-identifier-333" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjQtMy0xLTEtMA_d4e27d08-e50b-4a88-881c-d50575fcd36f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">882</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseinOperatingLeaseLiability" scale="3" id="fact-identifier-334" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjItNS0xLTEtODgxNA_e976a255-8989-4423-ab48-a4dfa6e2ed85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" id="fact-identifier-335" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjMtMS0xLTEtODgxMQ_52f37173-5f63-42ec-b987-c7c3cebd8814" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" id="fact-identifier-336" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjMtMy0xLTEtODgxMQ_4224c87c-ef81-4669-97d8-eef1c680e62e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredLiabilities" scale="3" id="fact-identifier-337" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjMtNS0xLTEtODgxMQ_d7da505e-92fe-410a-9732-568ef234477e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">749</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred interest payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="myov:IncreaseDecreaseinInterestPayableNetNoncurrent" scale="3" id="fact-identifier-338" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjUtMS0xLTEtMA_77457605-6fc9-4f81-9177-865dd2ca87a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseinInterestPayableNetNoncurrent" scale="3" id="fact-identifier-339" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjUtMy0xLTEtMA_5eac3660-10d9-45eb-aeff-b31e5586defb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,273</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseinInterestPayableNetNoncurrent" scale="3" id="fact-identifier-340" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjQtNS0xLTEtODgxNw_fbcdaae5-2ac9-48b8-b1aa-6c24fda16a58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,018</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due to related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="fact-identifier-341" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjYtMS0xLTEtMA_aee8e2eb-0a76-4ef7-b3bd-95ac1c26234c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">528</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="fact-identifier-342" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjYtMy0xLTEtMA_34319dfb-b9a9-442c-9b32-dcc3ad00cf1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" scale="3" id="fact-identifier-343" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjUtNS0xLTEtODgyMA_b1677ed4-7d1f-46a1-8d6e-de340a1fef10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="fact-identifier-344" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjctMS0xLTEtMA_92aab527-1fce-429a-8c2d-01b9bca12025" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">635</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="fact-identifier-345" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjctMy0xLTEtMA_ed96466c-8c0d-47e7-9114-58dac6f15822" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,582</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="fact-identifier-346" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjYtNS0xLTEtODgyNg_13b0fbde-6f77-4e7a-bcb1-162da4cf3a48" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="fact-identifier-347" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjgtMS0xLTEtMA_7bb8d31b-30b7-4067-b9fa-5cc399a8647b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">370,628</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="fact-identifier-348" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjgtMy0xLTEtMA_9a6a63f0-587e-4184-9a17-924369c6fb58" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">221,172</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="fact-identifier-349" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjctNS0xLTEtODgyMw_5eb7cae5-2b77-483a-a545-3da2f391a874" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">224,088</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="fact-identifier-350" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzAtMS0xLTEtMA_f1c4a207-6803-4228-acea-669d0e11db22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">63,824</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="fact-identifier-351" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzAtMy0xLTEtMA_971c5f03-7536-4d37-9683-f705e6315ffa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,076</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="fact-identifier-352" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMjktNS0xLTEtODgzMQ_7e055d57-8d15-4ef1-887f-6b36ab6adce5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:ProceedsFromMaturitiesPrepaymentsAndCallsOfMarketableSecurities" scale="3" id="fact-identifier-353" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzEtMS0xLTEtMA_76e6e9b7-73a7-4526-a7ba-379710469598" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">33,261</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:ProceedsFromMaturitiesPrepaymentsAndCallsOfMarketableSecurities" scale="3" id="fact-identifier-354" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzEtMy0xLTEtMA_3dda9a8d-fc5f-4fb2-a244-8c16f05f4521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,240</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:ProceedsFromMaturitiesPrepaymentsAndCallsOfMarketableSecurities" scale="3" id="fact-identifier-355" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzAtNS0xLTEtODgzMQ_0c89a240-7e75-4511-9b5d-9ed2dd464968" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:ProceedsFromSaleOfMarketableSecurities" scale="3" id="fact-identifier-356" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzMtMS0xLTEtMTU3MDE_4a5461a2-d69d-4336-b3e2-15bbb46d57dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">23,125</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:ProceedsFromSaleOfMarketableSecurities" scale="3" id="fact-identifier-357" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzMtMy0xLTEtMTU3MDE_af28f703-2e8b-4252-aabc-5caa033cf18f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:ProceedsFromSaleOfMarketableSecurities" scale="3" id="fact-identifier-358" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzMtNS0xLTEtMTU3MDE_8865d901-83aa-42e4-a9dc-915b49c7def1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-359" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzItMS0xLTEtMA_b9cda68a-e670-42ec-9543-e1a2719514f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,773</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-360" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzItMy0xLTEtMA_609c9b40-e734-4358-95b3-370617152035" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,099</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="fact-identifier-361" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzEtNS0xLTEtODgzMQ_4d576626-030d-46a0-b0fb-0826ac0614c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,236</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-362" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzMtMS0xLTEtMA_006471be-7d8c-43c5-ba89-742ad85ac961" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,211</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-363" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzMtMy0xLTEtMA_b6a3ea98-0c51-47f2-907f-ba86d201dbc6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,935</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="fact-identifier-364" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzItNS0xLTEtODgzNA_6cdfa83f-f738-4ff3-8b51-4ba6c2db9df1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,236</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common shares, net of issuance costs paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="fact-identifier-365" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzUtMS0xLTEtMA_64483a8b-e603-4e01-ad63-ee07a140a415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="fact-identifier-366" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzUtMy0xLTEtMA_faa0b20f-8f15-40a2-9743-e8d643a1d83a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">137,004</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="fact-identifier-367" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzUtNS0xLTEtNDUyMw_52a2a332-5e54-48ff-abe3-e06f5f27c980" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">218,925</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from related party debt financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" id="fact-identifier-368" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzctMS0xLTEtMA_b3556c58-173e-4349-a5ff-200ceb8c55e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">245,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" id="fact-identifier-369" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzctMy0xLTEtMA_67d1f841-f9b4-4e12-b278-0a55fbc8cd94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" id="fact-identifier-370" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzctNS0xLTEtNDUyMw_ab56fe99-3500-4b4d-a319-fe97284d8f60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-371" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzgtMS0xLTEtMA_e68cbded-1cd7-42f0-acb2-05a3a9717a89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,709</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-372" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzgtMy0xLTEtMA_a0f158d6-dec0-4a5b-8a72-f56f9969d363" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">942</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="fact-identifier-373" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzYtNS0xLTEtODg4Mw_45f3a4c5-833d-4731-8c00-56de12dea8ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,300</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from third-party debt financing, net of financing costs paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="3" id="fact-identifier-374" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDAtMS0xLTEtNDU1NA_cdc15028-d2c0-46eb-b93b-755ef7c98de1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="3" id="fact-identifier-375" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDAtMy0xLTEtNDU1NA_a517d9de-ed79-4e5a-b2e8-a666fc359488" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="3" id="fact-identifier-376" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDAtNS0xLTEtNDU1NA_74e4b003-0251-4ed3-8d9d-9e430452e2cc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,974</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of tax withholding on net settlement of share awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="fact-identifier-377" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDMtMS0xLTEtNDU3MQ_60f5591b-36fe-4802-89d9-3e8e7a933a06" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13,664</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="fact-identifier-378" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDMtMy0xLTEtNDU3MQ_39ea8395-0c90-4305-93dc-b43968fd4d51" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="fact-identifier-379" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDMtNS0xLTEtNDU3MQ_fa6a7aa1-6f9e-42fb-82f6-3a429784d9fe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of third-party debt financings and redemption and administration fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="fact-identifier-380" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzktMS0xLTEtMA_84cea6b4-2648-4fee-af00-cd7a2f4d09fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="fact-identifier-381" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfMzktMy0xLTEtMA_581dd760-8edf-4b8e-a23c-9aff9a100fe2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">105,720</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="fact-identifier-382" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDItNS0xLTEtNDU1Nw_1934c571-a00d-4b43-8426-88f11b1bd8eb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">300</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="fact-identifier-383" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDEtMS0xLTEtMA_b1398441-9e98-4a29-bafa-9bc1c98bfa45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">238,045</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="fact-identifier-384" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDEtMy0xLTEtMA_9a4f6a5d-6bd0-4873-9361-31663bf9c26f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">145,926</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="fact-identifier-385" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDEtNS0xLTEtNDUyMA_5ec5277d-737f-4abe-86de-a6e59ea25982" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,899</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="fact-identifier-386" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDItMS0xLTEtMA_3c1e84ed-4532-4d13-9609-a914282abef0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">599,462</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="fact-identifier-387" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDItMy0xLTEtMA_78d8c6ea-221e-4466-8460-d07c0028ef18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">79,181</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="fact-identifier-388" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDItNS0xLTEtNDUxNw_5d17e042-d130-4a7b-8d20-4445c3e67f25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">48,575</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-389" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDMtMS0xLTEtMA_52537781-6db4-4ca9-8158-64e85168ab81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,018</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-390" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDMtMy0xLTEtMA_3e1669e3-4542-4ccd-9024-0dd3dc0e1cdf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157,199</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaaaac77afb624e62b09f40c92b485ea0_I20180331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-391" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDMtNS0xLTEtNDUxNw_ea305285-fc47-4e0f-9d49-9a8913c0a13e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,624</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-392" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDQtMS0xLTEtMA_fb326215-089b-4a81-bc3d-93831536478c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">677,480</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-393" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDQtMy0xLTEtMA_9d17d631-88bc-4525-aacb-f8b1837329c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,018</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-394" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDQtNS0xLTEtNDUxNw_971cd2bb-7f2d-47e9-8a41-b40173ee0cde" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157,199</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of share-based compensation awards from additional paid-in capital to current liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:NoncashReclassificationOfShareBasedCompensationExpenseFromAdditionalPaidInCapitalToLiabilities" scale="3" id="fact-identifier-395" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTEtMS0xLTEtNDU5OQ_deca1125-16d2-44a6-a2b2-593ed2eef89f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,473</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:NoncashReclassificationOfShareBasedCompensationExpenseFromAdditionalPaidInCapitalToLiabilities" scale="3" id="fact-identifier-396" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTEtMy0xLTEtNDU5OQ_ecdedabb-d6c3-4ad8-9630-60a76b8942a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:NoncashReclassificationOfShareBasedCompensationExpenseFromAdditionalPaidInCapitalToLiabilities" scale="3" id="fact-identifier-397" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTEtNS0xLTEtNDU5OQ_499b6297-ae65-4a5e-ae0b-3101d495571f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of share-based awards recorded to additional paid-in capital</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:NoncashIncreaseDecareaseInDeferredCompensationShareBasedArrangementsLiability" scale="3" id="fact-identifier-398" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDktMS0xLTEtMTU4ODM_9a4cb1b7-241f-4204-9e7d-30bc42171886" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,609</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:NoncashIncreaseDecareaseInDeferredCompensationShareBasedArrangementsLiability" scale="3" id="fact-identifier-399" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDktMy0xLTEtMTU4ODM_3ddd352a-4a85-4534-86ee-6a7103cb74c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:NoncashIncreaseDecareaseInDeferredCompensationShareBasedArrangementsLiability" scale="3" id="fact-identifier-400" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDktNS0xLTEtMTU4ODM_ff340cb7-1716-4aba-8e6e-a8fb31c483bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of share-based compensation liabilities to additional paid-in capital upon settlement of awards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:NoncashReclassificationOfShareBasedCompensationExpenseFromLiabilitiesToAdditionalPaidInCapital" scale="3" id="fact-identifier-401" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTItMS0xLTEtNDU5OQ_7958af89-3a2b-42ad-acab-17a6c98455f7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,446</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:NoncashReclassificationOfShareBasedCompensationExpenseFromLiabilitiesToAdditionalPaidInCapital" scale="3" id="fact-identifier-402" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTItMy0xLTEtNDU5OQ_d40b8636-215f-435e-abae-78445ab94c97" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:NoncashReclassificationOfShareBasedCompensationExpenseFromLiabilitiesToAdditionalPaidInCapital" scale="3" id="fact-identifier-403" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTItNS0xLTEtNDU5OQ_0ea523a0-2943-446e-8b5e-5b225b9ef05a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment purchases included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="fact-identifier-404" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTAtMS0xLTEtMTU4Nzg_75514865-3ca9-42bb-a620-a2d10459f17a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="fact-identifier-405" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTAtMy0xLTEtMTU4Nzg_4d241448-ad63-466a-b846-b67fff27d43f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="fact-identifier-406" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNTAtNS0xLTEtMTU4Nzg_db5c7593-bd50-4d2c-8912-a1a91630038c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash paid:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="fact-identifier-407" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDYtMS0xLTEtMA_7a194a92-7aa8-4710-8c20-10e6f0df5996" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">513</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="fact-identifier-408" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDYtMy0xLTEtNDUxMA_4376bc46-6872-4701-addc-7b0d22334de4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">38</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="fact-identifier-409" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDYtNS0xLTEtNDUxMA_662f388c-a7d8-44b8-a9dd-cc05b6a51b10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="myov:InterestPaidExcludingCapitalizedInterestOperatingActivitiesExcludingRelatedParties" scale="3" id="fact-identifier-410" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDctMS0xLTEtMA_ae7d38a4-fc13-4744-92f7-b6c7cebf4dd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:InterestPaidExcludingCapitalizedInterestOperatingActivitiesExcludingRelatedParties" scale="3" id="fact-identifier-411" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDctMy0xLTEtNDUxMA_4661e9e4-7627-47c5-abb2-cbe55fbf931d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">13,030</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="myov:InterestPaidExcludingCapitalizedInterestOperatingActivitiesExcludingRelatedParties" scale="3" id="fact-identifier-412" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDctNS0xLTEtNDUxMA_46869db0-7f8b-4a54-9d63-629e3707dbc7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3,923</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (related party)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:InterestPaidExcludingCapitalizedInterestOperatingActivitiesRelatedParties" scale="3" id="fact-identifier-413" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDgtMS0xLTEtNDUxMA_443869dd-0c26-41d0-adf5-e3acd970c82f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9,819</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:InterestPaidExcludingCapitalizedInterestOperatingActivitiesRelatedParties" scale="3" id="fact-identifier-414" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDgtMy0xLTEtNDUxMA_04aefe64-48ed-4c0d-8ec5-77fafed8951f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,426</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:InterestPaidExcludingCapitalizedInterestOperatingActivitiesRelatedParties" scale="3" id="fact-identifier-415" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RhYmxlOjA2ZDgyZmUwOGNmODRmODdiZTE3ZWZkNTgzZWE4MTYwL3RhYmxlcmFuZ2U6MDZkODJmZTA4Y2Y4NGY4N2JlMTdlZmQ1ODNlYTgxNjBfNDgtNS0xLTEtNDUxMA_8c9b27dd-83c4-48bc-8e39-0b93032e6d0d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RleHRyZWdpb246YWEyNTUyNTYxYTIxNDdmZjkwN2Q2MWE0NDJmMzBiMTRfNDMy_eda06ed6-16ec-4c45-ac18-6ffec5e9e12c" footnoterole="http://www.xbrl.org/2003/role/footnote">Includes amortization of operating lease right-of-use assets.</ix:footnote></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8yOC9mcmFnOmFhMjU1MjU2MWEyMTQ3ZmY5MDdkNjFhNDQyZjMwYjE0L3RleHRyZWdpb246YWEyNTUyNTYxYTIxNDdmZjkwN2Q2MWE0NDJmMzBiMTRfNDMx_90314d1e-1b3d-47a2-bd5d-d5f50ab487f2" footnoterole="http://www.xbrl.org/2003/role/footnote"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes imputed interest on cost share advance from collaboration partner for the year ended March 31, 2021 and amortization of debt discount and issuance costs for the years ended March&nbsp;31, 2020 and 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:footnote></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_31"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MYOVANT SCIENCES LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="iad55818e5d094e70a171c29f2aae2512_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="fact-identifier-416" continuedat="i014a6d74b30548cc98e380ae161c1bf3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNC9mcmFnOjEzN2YwNDZiNWExMTRlOWM4ZTJhMmZkNDBmZDY3NWZiL3RleHRyZWdpb246MTM3ZjA0NmI1YTExNGU5YzhlMmEyZmQ0MGZkNjc1ZmJfMTY4MA_8019aca8-ca0c-4dd4-8850-69e1ae1a3297" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Description of Business</ix:nonnumeric></span></span></div><span><ix:continuation id="i014a6d74b30548cc98e380ae161c1bf3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myovant Sciences Ltd. (together with its wholly-owned subsidiaries, the “Company”) is a biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. ORGOVYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (relugolix) was approved by the U.S. Food and Drug Administration (“FDA”) in 2020 as the first and only oral gonadotropin-releasing hormone (“GnRH”) receptor antagonist for the treatment of adult patients with advanced prostate cancer. Relugolix is also under regulatory review in Europe for men with advanced prostate cancer. In addition, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) is under regulatory review in the U.S. and Europe for women with uterine fibroids, has completed Phase 3 registration-enabling studies for women with endometriosis, and is being assessed for contraceptive efficacy in healthy women ages 18-35 years who are at risk for pregnancy. The Company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for the treatment of female infertility as a part of assisted reproduction.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has devoted substantially all of its efforts to identifying and in-licensing its product candidates, organizing and staffing the Company, raising capital, preparing for and advancing the clinical development of its product candidates, preparing for and achieving regulatory approvals, and preparing for and executing on commercialization of its product candidates. Since its inception, the Company has funded its operations primarily from the issuance and sale of its common shares, from debt financing arrangements, and more recently from the upfront and milestone payments received from Pfizer Inc. (“Pfizer”) and Gedeon Richter Plc. (“Richter”). The Company launched its first product, ORGOVYX, in the U.S. in January 2021 and began generating product revenue, net from sales of ORGOVYX in the U.S. in January 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s majority shareholder is Sumitovant Biopharma Ltd. (“Sumitovant”), a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo Dainippon Pharma”). As of March 31, 2021, Sumitovant directly, and Sumitomo Dainippon Pharma indirectly, own <span><ix:nonfraction unitref="shares" contextref="i3bdf6a726fa9489bbf814c38dbe12bb1_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:RelatedPartyOwnershipInterestHeldByRelatedPartyShares" scale="0" id="fact-identifier-418" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNC9mcmFnOjEzN2YwNDZiNWExMTRlOWM4ZTJhMmZkNDBmZDY3NWZiL3RleHRyZWdpb246MTM3ZjA0NmI1YTExNGU5YzhlMmEyZmQ0MGZkNjc1ZmJfMTYxMQ_e8b8ea39-7088-4c03-a831-adb5debbbc31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,641,181</ix:nonfraction></span>, or approximately <span><ix:nonfraction unitref="number" contextref="i3bdf6a726fa9489bbf814c38dbe12bb1_I20210331" decimals="3" name="myov:RelatedPartyOwnershipInterestHeldByRelatedParty" scale="-2" id="fact-identifier-419" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNC9mcmFnOjEzN2YwNDZiNWExMTRlOWM4ZTJhMmZkNDBmZDY3NWZiL3RleHRyZWdpb246MTM3ZjA0NmI1YTExNGU5YzhlMmEyZmQ0MGZkNjc1ZmJfMTYzMg_52d496c2-d4ab-453a-9e96-1c0f3b0428c1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">53.5</ix:nonfraction></span>%, of the Company’s outstanding common shares.</span></div></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="fact-identifier-420" continuedat="ie6d9f1c3e6cc4989abb7d85c6f05461e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjc5OTc_a78604f0-8351-4af9-9c7a-10df47150742" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Summary of Significant Accounting Policies</ix:nonnumeric></span></span></div><span><ix:continuation id="ie6d9f1c3e6cc4989abb7d85c6f05461e" continuedat="i9a8003a1646d42fc9225f0f2a0585009" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="fact-identifier-422" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwNDg_608f8df1-7066-4393-8582-fd98ec998395" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fiscal year ends on March 31, and its first three fiscal quarters end on June 30, September 30 and December 31. The Company has determined that it has <span><ix:nonfraction unitref="segment" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="fact-identifier-423" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTY1ODU4MA_234cd08d-91a1-468d-8801-47786be42368" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="segment" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="fact-identifier-424" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTY1ODU4MA_9b071d86-464e-4c5c-87d3-27392df6b938" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">one</ix:nonfraction></span></ix:nonfraction></span> operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Update (“ASU”) issued by the Financial Accounting Standards Board (“FASB”). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. The Company has no unconsolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="myov:LiquidityAndCapitalResourcesPolicyPolicyTextBlock" id="fact-identifier-425" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwMDk_646a8dff-ebed-4cc8-a420-51cf7ae735a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, the Company had approximately $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" id="fact-identifier-426" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjg0OA_8d0ce035-0c93-407d-9d22-8f23e6feabec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">684.9</ix:nonfraction></span> million in cash, cash equivalents, and marketable securities. The Company currently believes that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its anticipated operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, if the Company’s cash, cash equivalents, marketable securities, and amounts that it expects to generate from product sales and/or third-party collaboration payments are not sufficient to enable the Company to fund its operations, the Company may need to raise additional funds in the form of equity, debt, or from other sources. There can be no assurances that such funding sources will be available at terms acceptable to the Company, or at all. If the Company has insufficient funding to meet its working capital needs, it could be required to delay, limit, reduce, or terminate its drug development programs, commercialization efforts, and/or limit or cease operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, the Company had approximately $<span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="fact-identifier-427" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMzkzMw_5b9150aa-f3e3-46ad-b90d-41528fab8f04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41.3</ix:nonfraction></span> million of borrowing capacity available to it under the Sumitomo Dainippon Pharma Loan Agreement (see Note 6(A)) and is also eligible to receive up to $<span><ix:nonfraction unitref="usd" contextref="i734cf075e84444f4acaa76dbe31c5fc1_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementMilestonesOutstandingValue" scale="9" id="fact-identifier-428" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNDA3OQ_9b8fc862-58a3-4530-b136-a73415ba2463" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.7</ix:nonfraction></span> billion and $<span><ix:nonfraction unitref="usd" contextref="id065c50329c0435a88678e4da94aabf5_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementMilestonesOutstandingValue" scale="6" id="fact-identifier-429" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNDA4Ng_0c680ed3-1d58-432a-8fbf-4969f70b48dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">137.5</ix:nonfraction></span> million of additional milestone payments from Pfizer and Richter pursuant to the Pfizer Collaboration and License Agreement (see Note 13(B)) and the Richter Development and Commercialization Agreement (see Note 13(A)), respectively, as well as potential royalty payments on net sales under each agreement.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i9a8003a1646d42fc9225f0f2a0585009" continuedat="ib2f80c07d3404dd88a3b6f7eec540a5b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:UseOfEstimates" id="fact-identifier-431" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwMzY_4dcf37f1-934c-48ed-a203-08b191deee66" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions in certain circumstances that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets and liabilities, and disclosures of contingencies at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Determinations in which management uses subjective judgments include, but are not limited to, collaboration arrangements, revenue recognition, share-based compensation expenses, research and development (“R&amp;D”) expenses and accruals, leases, and income taxes. In addition, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period, that are not readily apparent from other sources. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts, or experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.</span></div></ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="fact-identifier-432" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUxOQ_2af4f2e5-a41e-4df0-b7d1-b86a6ce5be10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the prior years’ consolidated statements of cash flows to place them on a comparable basis with the current year regarding the presentation of foreign currency transaction gains and losses and summarizing financing activities pertaining to sales of the Company’s common shares. Net loss and shareholders’ equity (deficit) previously reported were not affected by these reclassifications.</span></div></ix:nonnumeric></span><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to companies in the biotechnology and pharmaceutical industries, including, but not limited to, risks of failure or unsatisfactory results of nonclinical and clinical studies, the need for significant capital to fund the development of its product candidates and the commercialization of any product candidates that may obtain marketing approval, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of any of its product candidates that obtain regulatory approval, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, ability to transition from pilot-scale manufacturing to large-scale production of products, and dependence on third-party service providers such as contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and third-party logistics providers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. Through May&nbsp;11, 2021, the date of issuance of this Annual Report on Form 10-K, the Company’s results of operations and cash flows have not been significantly impacted by the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments, and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of May&nbsp;11, 2021.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ConcentrationRiskCreditRisk" id="fact-identifier-433" continuedat="ic8d5ecccaf70493b9755177897d19476" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUyMQ_e8807430-7c97-4184-a650-ca06c62aaaea" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk include cash, cash equivalents, and marketable securities. As of March&nbsp;31, 2021, cash, cash equivalents, and marketable security balances are diversified between four financial institutions. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and the issuers of its cash equivalents and marketable securities. The Company maintains its cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities of investments to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments.</span></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ic8d5ecccaf70493b9755177897d19476" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company is also subject to credit risk from accounts receivable related to its product sales. The Company monitors its exposure within accounts receivable and records a reserve against uncollectible accounts receivable as necessary. The Company has entered into distribution agreements with a limited number of specialty distributors and pharmacies, and all of the Company’s product sales are to these customers. Customer creditworthiness is monitored and collateral is not required.</ix:continuation></span> For the year ended March 31, 2021, the Company’s four largest customers represented <span><ix:nonfraction unitref="number" contextref="ia0b3e2c62d8349449f7511695df8a9c7_D20200401-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="fact-identifier-435" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTc1MTg5OQ_ad245d34-0829-4d11-873f-3112638f37dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span>% of the Company’s product revenue, net and <span><ix:nonfraction unitref="number" contextref="i6a4d7bea8057460ea21e7aed4564004b_D20200401-20210331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="fact-identifier-436" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTc1MTkwNg_440a0fa8-a448-4435-8179-b2d2a22027c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">95</ix:nonfraction></span>% of the Company’s accounts receivable at March&nbsp;31, 2021, and each of these customers represented 10% or greater of the </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="ib2f80c07d3404dd88a3b6f7eec540a5b" continuedat="i42ea408d448e423db7052487aa51aab9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company’s product revenue, net and accounts receivable. The Company began commercializing ORGOVYX in the U.S. in January 2021 and had no product revenue, net or accounts receivable prior to January 2021.</span></div><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="fact-identifier-438" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUyMg_9ea87317-23ae-4e70-bd19-ee0243099c0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments with a maturity of three months or less at the time of purchase to be cash equivalents. Interest income consists of interest earned and the accretion of discounts to maturity for cash equivalents and marketable securities. Restricted cash consists of funds held or designated to satisfy the requirements of certain agreements that are restricted in their use and are included in other assets on the consolidated balance sheets.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="myov:ScheduleofCashandCashEquivalentsRestrictedCashandCashEquivalentsTableTextBlock" id="fact-identifier-439" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjc5OTM_d62d1ef9-4706-4848-a558-2ab308ebdae3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash as reported on the consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash and consists of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="fact-identifier-440" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfMi0xLTEtMS0w_26e5422d-5bdd-4854-8ecf-cffa74189d32" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">674,493</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="fact-identifier-441" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfMi0zLTEtMS0w_3f08dc7a-808e-48f8-b06d-e24408988855" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">76,644</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="fact-identifier-442" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfMi01LTEtMS04ODk4_070da0f3-68a5-4050-b59f-2e7dff8fcf45" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">156,074</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="fact-identifier-443" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfMy0xLTEtMS0w_8c5f48c2-89c5-4fa8-9075-75c96da5630e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,987</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="fact-identifier-444" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfMy0zLTEtMS0w_134039fb-20b0-40f9-bad3-da48e15d8881" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,374</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="3" id="fact-identifier-445" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfMy01LTEtMS04ODk4_7700cc3e-de91-4122-81ad-5ff541f39d60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,125</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-446" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfNC0xLTEtMS0w_6b3db546-c335-4cfc-9426-f5ed5859e399" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">677,480</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-447" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfNC0zLTEtMS0w_987bef93-4647-4f84-9935-268537ceff19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">78,018</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="fact-identifier-448" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjEzYTJmMzJlOTk1NzQ0YWY4OTA3ZmQ2MGZjMDE3ZThjL3RhYmxlcmFuZ2U6MTNhMmYzMmU5OTU3NDRhZjg5MDdmZDYwZmMwMTdlOGNfNC01LTEtMS04ODk4_80709d16-ddaa-44db-8d79-0cb1eee867d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157,199</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="fact-identifier-449" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUyNA_430608cf-ce00-4300-b6e0-471b45b78937" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable, Net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable consists of amounts due from customers related to product sales and have standard payment terms. For certain customers, the accounts receivable for the customer is net of prompt pay discounts. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company reserves against accounts receivable for estimated losses that may arise from a customer’s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The Company began commercializing ORGOVYX in the U.S. in January 2021 and had no accounts receivable prior to January 2021. The Company has historically not experienced significant credit losses and no amounts were reserved for estimated losses as of March&nbsp;31, 2021.</span></div></ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:MarketableSecuritiesPolicy" id="fact-identifier-450" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwNDM_0a49a5d3-d023-46bd-9f52-672c1491764d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Debt Securities</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable debt securities are held in custodial accounts at a financial institution and managed by the Company’s investment advisor based on the Company’s investment guidelines. The Company considers all highly liquid investments in securities with a maturity of greater than three months at the time of purchase to be marketable securities. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies its marketable debt securities as available-for-sale at the time of purchase and reevaluates such designation at each balance sheet date. Unrealized gains and losses on available-for-sale securities are excluded from earnings and are recorded in accumulated other comprehensive (loss) income until realized. Any unrealized losses are evaluated for other-than-temporary impairment at each balance sheet date. Realized gains and losses are determined based on the specific identification method. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not intend to sell its marketable debt securities that are in an unrealized loss position, and it is unlikely that the Company will be required to sell its marketable debt securities before recovery of their amortized cost basis, which may be maturity. Factors considered in determining whether a loss is temporary include the length of time and extent to which the fair value has been less than the amortized cost basis and whether the Company intends to sell the security or whether it is more likely than not that the Company would be required to sell the marketable debt security before recovery of the amortized cost basis. See Note 3 for additional information.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="fact-identifier-451" continuedat="i9c84b1123fad4ec2ae4599398d766851" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwMzQ_bba8d4be-4411-4d5c-81d4-950163565826" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i42ea408d448e423db7052487aa51aab9" continuedat="i48a03d4f956744e8823b0c9f84cff485" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i9c84b1123fad4ec2ae4599398d766851" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1—Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2—Valuations are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3—Valuations are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recorded amounts of certain financial instruments, including cash, cash equivalents, accounts receivable, accounts payable, accrued liabilities, amounts due to collaboration partner, and amounts due to related parties, approximate fair value due to their relatively short maturities. Marketable debt securities that are classified as available-for-sale are recorded at estimated fair value and are include in Level 2 of the fair value hierarchy. The fair value of marketable debt securities is based on market prices from a variety of industry standard data providers and generally represents quoted prices for similar assets in active markets or have been derived from observable market data. Cost share advance from collaboration partner is recorded at its estimated fair value and is included in Level 2 of the fair value hierarchy. The carrying value of the Company’s debt obligations to Sumitomo Dainippon Pharma approximates fair value based on current interest rates for similar types of borrowings and is included in Level 2 of the fair value hierarchy. Share-based compensation liabilities related to stock options are remeasured at fair value on a recurring basis using the Black-Scholes option pricing model and are included in Level 2 of the fair value hierarchy. Share-based compensation liabilities related to common shares are remeasured at fair value on a recurring basis and are included in Level 1 of the fair value hierarchy.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:InventoryPolicyTextBlock" id="fact-identifier-454" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUyNg_b6ac7f55-15e7-4c80-8242-c1cd3c3c6a4c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company values its inventories at the lower-of-cost or net realizable value and determines the cost of inventories using the average-cost method. Inventories include the cost for raw materials, the cost to manufacture the raw materials into finished goods, and overhead. The Company performs an assessment of the recoverability of inventory during each reporting period, and writes down any excess and obsolete inventories to their net realizable value in the period in which the impairment is first identified. If they occur, such impairment charges are recorded as a component of cost of goods sold in the consolidated statements of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized, but rather expensed as R&amp;D expenses when incurred.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="fact-identifier-455" continuedat="i25ea71dee48e404d9c3860a9dcd5e249" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUyOA_0ffbeaa5-f452-4300-b80f-915e6fa1eb29" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisting of computers, equipment, furniture and fixtures, leasehold improvements, and software, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation is recorded for property and equipment using the straight-line method over the estimated useful lives of the assets, which range from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTY2MzQ0Ng_bf18bf41-873f-4c43-905e-ef781ff57372"><span><ix:nonnumeric contextref="i2e17d3c7464149bc9fdb25c557e46a14_D20200401-20210331" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="fact-identifier-456" isadditionalitemsonly="true" ishiddenelement="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTY2MzQ0Ng_bf18bf41-873f-4c43-905e-ef781ff57372" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isstandardonly="true" iscustomonly="false">three</ix:nonnumeric></span></span> to <span><ix:nonnumeric contextref="i131004c9c7534d6096944aef3ce9f4a7_D20200401-20210331" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="fact-identifier-457" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTU0Ng_a2df94ed-ad5f-42b6-95e7-6f57f65a838c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">seven years</ix:nonnumeric></span> once the asset is installed and placed into service. Leasehold improvements are amortized using the straight-line method over their estimated useful life or the remaining lease term, whichever is shorter.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the recoverability of its long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable, based on undiscounted cash flows. If such assets are considered to be impaired, an impairment loss is recognized and is measured as the amount by which </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i48a03d4f956744e8823b0c9f84cff485" continuedat="i480bba6776224c1f93448c77a8e49715" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i25ea71dee48e404d9c3860a9dcd5e249" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">the carrying amount of the assets exceed their estimated fair value, which is measured based on the projected discounted future net cash flows arising from the assets.</ix:continuation></span></span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="fact-identifier-460" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUyOQ_bea52a14-98c8-4e9c-9172-d4b3b51c9dbf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement includes a lease at the inception of the agreement. For each of the Company’s lease arrangements, the Company records a right-of-use asset representing the Company’s right to use an underlying asset for the lease term and a lease liability representing the Company’s obligation to make lease payments. Operating lease right-of-use assets and liabilities are recognized at the lease commencement date based on the net present value of the lease payments over the lease term. In determining the weighted-average discount rate used to calculate the net present value of lease payments, the Company uses its incremental borrowing rate based on information available at the lease commencement date. Lease expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company elected the practical expedient not to apply the recognition and measurement requirements to short-term leases, which is any lease with a term of one year or less as of the commencement date. If a lease includes options to extend the lease term, the Company does not assume the option will be exercised in its initial lease term assessment unless there is reasonable certainty that the Company will renew based on an assessment of economic factors present as of the lease commencement date.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="fact-identifier-461" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzMA_86c0b71e-759d-4699-b6de-ed54c502e546" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses litigation to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. In accordance with the guidance of the FASB on accounting for contingencies, the Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum amount in the range. In the cases where the Company believes that a material reasonably possible loss exists, the Company discloses the facts and circumstances of the contingency, including an estimable range, if possible.</span></div></ix:nonnumeric></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="fact-identifier-462" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzMg_8dc22e3a-b14c-4e1b-87e6-8a9e55f60cc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into collaboration arrangements with pharmaceutical and biotechnology partners. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine whether such arrangements involve joint operating activities performed by the parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in responsibilities of all parties in the arrangement. For collaboration arrangements within the scope of ASC 808 that contain multiple units of account, the Company first determines which units of account of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and, therefore, within the scope of ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While ASC 808 defines collaboration arrangements and provides guidance on income statement presentation, classification, and disclosures related to such arrangements, it does not address recognition and measurement matters, such as (1) determining the appropriate unit of account or (2) when the recognition criteria are met. Therefore, the accounting for these arrangements is either based on an analogy to other accounting literature, such as ASC 606, or an accounting policy election by management. For units of account within collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate revenue recognition method is determined and applied consistently.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="fact-identifier-463" continuedat="ie9c53abd22bd46e9993eae120f92d7f6" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwMTc_9901a316-9c2b-47ed-8d85-781624146290" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For units of account under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">License, Milestone and Other Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For units of account under ASC 606, the Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining when performance obligations have been met, assessing the recognition and future reversal of variable </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i480bba6776224c1f93448c77a8e49715" continuedat="i7c38204a25e74833954f94d0afd90fd6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="ie9c53abd22bd46e9993eae120f92d7f6" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Licenses of intellectual property</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Milestone payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company’s control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative catch-up basis in earnings in the period of the adjustment.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Royalties and sales-based milestone payments</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For arrangements that include sales-based royalties, including sales-based milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Product Revenue, net</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the net sales price, or “transaction price,” which includes estimates of variable consideration that result from (a) invoice discounts for prompt payment and specialty distributor and specialty pharmacy service fees, (b) government and private payer rebates, chargebacks, discounts and fees, (c) group purchasing organization (“GPO”) discounts, performance rebates and administrative fees, (d) product returns and (e) costs of co-pay assistance programs for patients. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales. The reserves are classified as reductions to accounts receivable, net or accrued expenses and other current liabilities if payable to a third-party. Where appropriate, the Company utilizes the expected value method to determine the appropriate amount for estimates of variable consideration based on factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The amount of variable consideration that is included in the transaction price may be constrained and is included in net product revenues only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes significant estimates and judgments that materially affect its recognition of product revenue, net. Claims by third-party payers for rebates, chargebacks and discounts frequently may be submitted to the Company significantly after the related sales, potentially resulting in adjustments in the period in which the new information becomes known. The Company will adjust its estimates based on new information, including information regarding actual rebates, chargebacks and discounts for its products, as it becomes available.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:CostOfSalesPolicyTextBlock" id="fact-identifier-466" continuedat="i55e469dc8ed74277b84e127be0ae8e9f" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzNA_f12bb11c-4739-4b6b-ada5-c8623583b711" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Product Revenue</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product revenue is composed of the cost of goods sold and royalty expense. Cost of goods sold consists of the cost of raw materials, third-party manufacturing costs to manufacture the raw materials into finished product, freight, and indirect overhead costs associated with sales of ORGOVYX in the U.S. Royalty expense consists of a fixed, high single-digit royalty on net sales of ORGOVYX payable to Takeda pursuant to the terms of the Takeda License Agreement (see Note 14(D)). </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i7c38204a25e74833954f94d0afd90fd6" continuedat="ib2de61b7984e4f9da2abf40b4224cc21" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i55e469dc8ed74277b84e127be0ae8e9f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the FDA approval of ORGOVYX on December 18, 2020, the Company subsequently began capitalizing inventory manufactured or purchased after this date. As a result, certain manufacturing costs of ORGOVYX were expensed as R&amp;D expenses prior to FDA approval and, therefore, these costs are not included in cost of goods sold. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Expense to Pfizer</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration expense to Pfizer consists of Pfizer’s 50% share of net profits from sales of ORGOVYX in the U.S. (see Note 13(B)).</span></div></ix:continuation></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="fact-identifier-469" escape="true" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzNQ_ad90ff9d-e50d-447e-8d23-4b45c00746da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D costs are expensed as incurred. Clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based on an ongoing review of the level of effort and costs actually incurred. R&amp;D expenses consist of employee-related expenses, such as salaries, share-based compensation, benefits and travel expenses for employees engaged in R&amp;D activities, expenses from third parties who conduct R&amp;D activities on behalf of the Company, investigator grants, sponsored research, and fees incurred for regulatory submissions. The Company expenses in-process R&amp;D projects acquired as asset acquisitions which have not reached technological feasibility and which have no alternative future use.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers regulatory approval of product candidates to be uncertain and products manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory, but rather expensed as R&amp;D expenses when incurred.</span></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="fact-identifier-470" continuedat="i7f03cb6632fa426e8ddda10d24c15ccc" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzNg_085e9965-ac11-4f27-b9e3-a4b09f153d4a" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">dvertising Expense</ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i7f03cb6632fa426e8ddda10d24c15ccc" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">In connection with the FDA approval and commercial launch of ORGOVYX in January 2021, the Company began to incur advertising costs. Advertising costs, which include promotional expenses, are expensed as incurred.</ix:continuation></span> The Company incurred approximately $<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="6" id="fact-identifier-472" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTc1MTQ2Nw_07fef88a-f25f-4e54-ae00-7b4d756b98f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.9</ix:nonfraction></span>&nbsp;million of advertising costs, net of cost share reimbursements from Pfizer pursuant to the terms of the Pfizer Collaboration and License Agreement (see Note 13(B)), during the year ended March 31, 2021. <span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AdvertisingExpense" scale="0" id="fact-identifier-473" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI2NDQ4Ng_3cb84c39-a6bc-44b8-a2f0-45e6496696ea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AdvertisingExpense" scale="0" id="fact-identifier-474" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI2NDQ4Ng_f73c0a36-0781-4b16-8e4d-db0a6965a800" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonfraction></span></ix:nonfraction></span> amounts were incurred during the years ended March&nbsp;31, 2020 and 2019. </span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="fact-identifier-475" continuedat="ia17a57b9f9874924b34f88f1145fa779" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzNw_75705809-fd8c-452f-b1ef-fd0a835d2a56" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company recognizes forfeitures in the period in which such forfeiture occurs and records share-based compensation expense as though all awards are expected to vest.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant date fair value of stock options, and the resulting share-based compensation expense, using the Black-Scholes option-pricing model, which requires the use of subjective assumptions. These assumptions include:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term represents the period that the Company’s share-based awards are expected to be outstanding and is determined using the simplified method in accordance with the Securities and Exchange Commission (“SEC”), Staff Accounting Bulletin (“SAB”) No. 107 and No. 110 (based on the mid-point between the vesting date and the end of the contractual term).</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected volatility considers the Company’s historical volatility and weighted average measures of volatility of a peer group of companies for a period equal to the expected term of the stock options. The Company’s peer group of publicly traded biopharmaceutical companies was chosen based on their similar size, stage in the life cycle or area of specialty.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free interest rate is based on the interest rates paid on securities issued by the U.S. Treasury with a term approximating the expected term of the stock options.</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividend.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has never paid, and does not anticipate paying, cash dividends on its common shares. Therefore, the expected dividend yield was assumed to be <span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="fact-identifier-476" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMTA5OTUxMTY2NjYyOQ_11924c73-e044-45ba-b16a-a75177c175e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">zero</ix:nonfraction></span>.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense associated with restricted stock units (“RSU”) and performance share units (“PSU”)  is based on the fair value of the Company’s common shares on the grant date, which equals the closing market price of the Company’s common shares on the grant date. The Company recognizes the share-based compensation expense related to RSUs on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. The Company recognizes the share-based compensation expense related to PSUs if the performance criteria are deemed probable of being met. Share-based compensation liabilities (a current liability) are remeasured at fair value each reporting period until the </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="ib2de61b7984e4f9da2abf40b4224cc21" continuedat="ifd756f30dca44259ab0a8a881bb690ce" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="ia17a57b9f9874924b34f88f1145fa779" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common share awards are settled or become mature, with the change in fair value recorded as share-based compensation expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No tax benefits for share-based compensation have been recognized in the consolidated statements of shareholders’ equity (deficit) or consolidated statements of cash flows. The Company has not recognized, and does not expect to recognize in the near future, any tax benefits related to share-based compensation as a result of its full valuation allowance on net deferred tax assets and net operating loss carryforwards.</span></div></ix:continuation></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:IncomeTaxPolicyTextBlock" id="fact-identifier-479" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzOA_0c162094-8c42-424b-ac7c-4bf249275dc2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense as incurred.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="fact-identifier-480" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTUzOQ_4c4fe39f-72f2-44a9-b62b-a299fcb9d06b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss per Common Share</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss applicable to common shareholders by the weighted-average number of common shares outstanding during the period, reduced, when applicable, for outstanding yet unvested shares of restricted common shares. The computation of diluted net loss per common share is based on the weighted-average number of common shares outstanding during the period plus, when their effect is dilutive, incremental shares consisting of shares subject to stock options, restricted stock units, restricted stock awards, performance stock units, and warrants. In periods in which the Company reports a net loss, all common share equivalents are deemed anti-dilutive such that basic net loss per common share and diluted net loss per common share are equal. Potentially dilutive common shares have been excluded from the diluted net loss per common share computations in all periods presented because such securities have an anti-dilutive effect on net loss per common share due to the Company’s net loss. There are no reconciling items used to calculate the weighted-average number of total common shares outstanding for basic and diluted net loss per common share.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="fact-identifier-481" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTU0Mw_ed899027-bfec-4a19-b828-79c6083359ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021, 2020 and 2019 potentially dilutive securities were as follows: &nbsp;&nbsp;&nbsp;&nbsp;</span></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i278b998c8dd24659b492f5d16d108ab9_D20200401-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-482" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfMi0xLTEtMS0yMTE5_65f9eaf0-a3b4-438f-91af-bce85aecf4b2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,293,331</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ib6e5a3d7a6124d999c6a0938694445bc_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-483" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfMi0zLTEtMS0yMTE5_f7ba2e1c-8fea-488a-9364-7206f09d2ff0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,723,302</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8a5c8a215cac437da65fb0d335451cdb_D20180401-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-484" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfMi01LTEtMS03MjI5_7a9ea27c-f13a-45b7-a277-c669a58391ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,396,465</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i627594ceb5664d49be7e2a6b91d8f7cc_D20200401-20210331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-485" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfMy0xLTEtMS0yMTE5_25f255ff-f429-45bd-a048-84b9f63f67e0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8ee355aa008e4b919ff1f014345b7efa_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-486" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfMy0zLTEtMS0yMTE5_57c05b84-edbb-4110-99c3-1a0529a45c50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">634,623</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i8bc94df2f5824d348f6acdeca26456cd_D20180401-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-487" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfMy01LTEtMS03MjI5_70e60ad2-6140-4a01-8266-e9512e345046" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">916,679</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (unvested)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i171aa1d8fad04b9b8343dd08b02f156d_D20200401-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-488" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNC0xLTEtMS0yMTE5_de45c9c7-22f1-407b-a6cb-1b3a7d420238" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,194,562</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ie4704b12df0247899d9b7694353be980_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-489" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNC0zLTEtMS0yMTE5_3a0cdc2a-14aa-4e00-aac0-9872a8af8f94" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">645,689</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i807d21c1ce3b49c4b1f962e6d45a953a_D20180401-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-490" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNC01LTEtMS03MjI5_ead4dcfa-57f8-46d9-86a1-43d9d73ed9c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,387</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units (unvested)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i50492cdba76f4a2c989a79fba0f76dd7_D20200401-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-491" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNS0xLTEtMS0yMTE5_eaf28cb3-16cc-4799-a392-88a448b6a3a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,673</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i2fca2879d16d43a79b79683f7c737832_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-492" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNS0zLTEtMS0yMTE5_b6eff571-71c9-496e-93d7-e8fcc20ae3b3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">299,870</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i3231f0283b4c4951a38d1fb1ad37ef99_D20180401-20190331" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-493" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNS01LTEtMS03MjI5_6216573f-a9e0-43b0-8f68-a2b770a57fd4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i57ae0204ce764ee4a4aa18b6e29aa73e_D20200401-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-494" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNi0xLTEtMS0yMTE5_5e16e84a-492f-4fcd-8da5-473d8663c51f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i11d3054f377c4832b8baae30c9d29217_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-495" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNi0zLTEtMS0yMTE5_821b474c-6e73-411d-be5a-240ac92a549b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ic2a1fcaa43dd4ba09f221ca93334cbd5_D20180401-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-496" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNi01LTEtMS03MjI5_a809f31b-d5b9-470d-bf88-209db405a860" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,710</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-497" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNy0xLTEtMS0yMTE5_0162208f-cfa4-4951-b368-429e6925a3dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,938,276</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-498" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNy0zLTEtMS0yMTE5_f88b6f75-9160-4ed3-8fd0-73a93d7615c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,377,194</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="fact-identifier-499" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RhYmxlOjJlOWQ0YzVjOTUxNzQ5ODliNjQwYmNkMDg2YzNmYjY5L3RhYmxlcmFuZ2U6MmU5ZDRjNWM5NTE3NDk4OWI2NDBiY2QwODZjM2ZiNjlfNy01LTEtMS03MjI5_a23d6681-277a-4ff6-bac9-7d58dd5e6cc3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,426,241</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="fact-identifier-500" continuedat="i568a07c9c18b41478073548368dd36a4" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwMjA_572ee457-5790-417e-bf69-00c891346351" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="fact-identifier-501" continuedat="i62580e1a5884425c993c5c36a440b6ec" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTU0MA_a39aa272-2d61-4b7b-be98-bb0f240198ff" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Functional Currency</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to December 1, 2020, the functional currency of the Company’s wholly-owned subsidiary in Switzerland, Myovant Sciences GmbH (“MSG”), was the local currency where the subsidiary is located, the Swiss franc. Transactions in foreign currencies were translated to the functional currency at the rate of exchange at the date of the transaction. Transaction gains and </span></div></ix:nonnumeric></span></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="ifd756f30dca44259ab0a8a881bb690ce" continuedat="i6a2eb2ce15d24bfeb83802cb1536e2d9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i568a07c9c18b41478073548368dd36a4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i62580e1a5884425c993c5c36a440b6ec" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses were recognized in foreign exchange (gain) loss in the consolidated statements of operations. The results of operations of MSG were translated to U.S. dollar, the Company’s reporting currency, at the average rates of exchange during the period. The cumulative effect of these exchange rate adjustments was included in a separate component of other comprehensive income (loss) on the consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective December 1, 2020, as a result of significant changes in economic facts and circumstances in the operations of MSG, the functional currency of MSG was changed from the Swiss franc to the U.S. dollar. The change in the functional currency is accounted for prospectively from December 1, 2020. Therefore, any gains or losses that were previously recorded in accumulated other comprehensive income (loss) remain unchanged.</span></div></ix:continuation></span></ix:continuation></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:PushdownAccountingPolicyTextBlock" id="fact-identifier-505" continuedat="i9b546b3891ba4b41b4477fadeb161e6a" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfNTQ5NzU1ODI1MTU0MQ_584ed7cc-3b6b-472a-ac32-a0948435e24b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Pushdown Accounting</ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-align:justify"><span><ix:continuation id="i9b546b3891ba4b41b4477fadeb161e6a" continuedat="i9bbc8d28c0f844309e6d669fe40b2448" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2014, the FASB issued ASU 2014-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 805): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pushdown Accounting</span></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i9bbc8d28c0f844309e6d669fe40b2448" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">. The ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change in control event occurs. If pushdown accounting is applied to an individual change in control event, that election is irrevocable. The Company elected not to apply pushdown accounting in its consolidated financial statements upon the change in control of the Company on December 27, 2019.</ix:continuation></span> See Note 6(A).</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="fact-identifier-508" continuedat="i2d6c738c31644328b1347dedec5076e5" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8zNy9mcmFnOmVjZDg2YWE3ZDg3ZjQxZjA4ZDBmZDMxMDAxMjdiOGZhL3RleHRyZWdpb246ZWNkODZhYTdkODdmNDFmMDhkMGZkMzEwMDEyN2I4ZmFfMjgwMTI_0f4d9da5-03fc-4624-b25a-fc304508b7ba" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 820)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2018-13”), which simplifies the fair value measurement disclosure requirements. The Company adopted the new standard on April 1, 2020. The adoption of ASU 2018-13 did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 808)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Clarifying the Interaction between Topic 808 and Topic 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2018-18”). This guidance is intended to reduce diversity in practice and clarify the interaction between Topic 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2018-18 provided guidance on whether certain transactions between collaborative arrangement participants should be accounted for with revenue under Topic 606. The Company adopted the new standard on April 1, 2020. The adoption of ASU 2018-18 did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 350-40) (“ASU 2018-15”), which amends ASU 2015-05, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customers Accounting for Fees in a Cloud Computing Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU 2018-15 require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as assets related to the service contract and which costs to expense. The Company adopted ASU 2018-15 using the prospective method as of April 1, 2020. The adoption of ASU 2018-15 did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 848)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. These amendments apply only to contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of reference rate reform. The amendments are effective prospectively for all entities as of March 12, 2020 through December 31, 2022. As of March&nbsp;31, 2021, the Company has not modified its contract that will be impacted by reference rate reform. The Company will continue to assess the impact the adoption of this standard will have on its consolidated financial statements and related disclosures when its contract impacted by reference rate reform is modified.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 326)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept </span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i6a2eb2ce15d24bfeb83802cb1536e2d9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i2d6c738c31644328b1347dedec5076e5" continuedat="ia97a88723b544f4c9ca562f8e8428d6a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of other-than-temporary impairment and requires credit losses on available-for-sale debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU 2016-13 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. In February 2020, the FASB issued ASU 2020-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">and Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 842) - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Topic 842), which amends the effective date of the original pronouncement for smaller reporting companies. ASC 2016-13 and its amendments will be effective for annual and interim periods beginning after December 15, 2022 for smaller reporting companies. The Company is currently assessing the impact the adoption of this new standard will have on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740) (“ASU 2019-12”), that eliminates certain exceptions to the general principles in ASC 740 related to intra-period tax allocation, deferred tax liability and general methodology for calculating income taxes. ASU 2019-12 also simplifies U.S. GAAP by making other changes for matters such as, franchise taxes that are partially based on income, transactions with a government that result in a step up in the tax basis of goodwill, separate financial statements of legal entities that are not subject to tax, and enacted changes in tax laws in interim periods. ASU 2019-12 is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period. The Company is currently assessing the impact the adoption of this standard will have on its consolidated financial statements and related disclosures.</span></div></ix:continuation></span></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="fact-identifier-511" continuedat="i8142ee989cca4f15b1655016243be8fc" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMTE0OA_d8d0e3d3-d9f0-4d79-8e8a-ca559c841181" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Fair Value Measurements</ix:nonnumeric></span></span></div><span><ix:continuation id="i8142ee989cca4f15b1655016243be8fc" continuedat="i7ade6a9060f34be18db427d418432adb" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s consolidated financial statements in accordance with U.S. GAAP requires that certain assets and liabilities be reflected at their fair value. The fair value of these financial instruments is based on valuations that include inputs that can be classified within one of three levels of a hierarchy established by U.S. GAAP (see Note 2). <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="fact-identifier-513" continuedat="i4107e4878a1e45b3958921af1a267ab0" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMTE0NQ_590baff0-0b78-4095-906b-325f52e1a7d3" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">The following table summarizes the Company’s assets and liabilities that require fair value remeasurements on a recurring basis and their respective input levels based on the fair value hierarchy (in thousands):</ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-align:center"><span><ix:continuation id="i4107e4878a1e45b3958921af1a267ab0" continuedat="ia23f25aaf53242ef84ed7e327b000f7c" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i885de4632f2f4f5e81aacf1de28d14a0_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-515" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMi0xLTEtMS0w_998e0c8c-c6dc-4108-a8f5-3b79f4c8849f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,903</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9c683190990845059125c172f9b1fa01_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-516" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMi0zLTEtMS0w_10a52bd0-5c5f-439b-9290-7cb0804d2d67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib1f73bf49238419393cd4e679f52d393_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-517" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMi01LTEtMS0w_bc8466e0-6c6b-4452-b8e4-4eaa5596153f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaf49e669868a4e9ab6d2c55a04639227_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-518" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMi03LTEtMS0w_8e112d77-75a6-47b0-b04c-a99239002ee6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,903</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i891fd5fe3ae841a08bdba3fe0440ddb0_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-519" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMy0xLTEtMS0w_8aec2840-d24d-40ac-8308-687cfba2aacd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if96e2b8e3f0a4faa80c9b4b7ee6ef3b9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-520" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMy0zLTEtMS0w_ccf40467-357f-4333-a2f5-d83c812e73c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,689</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i37b5762808e6471e8285272362002aee_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-521" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMy01LTEtMS0w_01f3e9a1-6cbf-401d-95ff-7c7410b14cc1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i58410d84411e4228b07957f367d15604_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-522" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMy03LTEtMS0w_368ad96f-c123-4a18-a9ea-b48e31928ab5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,689</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie2cf551e1ada45db84803530ba43d154_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-523" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNC0xLTEtMS0w_521fa98f-42b1-4acf-8dd9-1fbc33aad47c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iccb614ae82ff40b89b4a9bf367375a2b_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-524" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNC0zLTEtMS0w_6c890697-37bf-461c-a209-9957162ab6e3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id9a26269ffc74aa6aa735e6580e255c5_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-525" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNC01LTEtMS0w_de17be15-ce60-4c38-8dec-60ffb6307bd3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic6fa0e7020d04c22a2ca3474cd2425d6_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-526" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNC03LTEtMS0w_c43ca8ba-591e-4ecd-869b-ad74670ca1f5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i56aaf6c9864e4e498d30ad564413e854_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-527" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNS0xLTEtMS0w_94a83e40-80d7-4139-bc24-3dd3a4f071f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idc9e7b4057c44456b5e16d5ff9659b19_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-528" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNS0zLTEtMS0w_abf9a1c4-9db3-45be-b514-f8ba433291f2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,417</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9a5784f2341d4e5496417b3db6a6e72a_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-529" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNS01LTEtMS0w_0dfae3fe-f85d-406d-89ff-ee74ef834e2e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="icc4927fb5b0049f485113a70c734f1bd_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-530" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfNS03LTEtMS0w_089820b8-966f-4235-abb3-ef38d9b88e20" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,417</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i01ec2294762e4a2eafc8e26ccee9cdd4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-531" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS0xLTEtMS0xMTg2NA_77a0695d-a8e1-4d14-8e23-75bdb37761ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i01ec2294762e4a2eafc8e26ccee9cdd4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-532" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS0xLTEtMS0xMTg2NA_c1bfd230-d71a-4161-90f8-c27b6b06706f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">36,903</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1321682262914bc28a3678c5f5ceaf28_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-533" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS0zLTEtMS0xMTg2NA_11134034-87f1-4ffc-9b5e-5103d5397318" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i1321682262914bc28a3678c5f5ceaf28_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-534" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS0zLTEtMS0xMTg2NA_cc8af196-b3c6-4e12-b21d-f1b1edbea59b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33,106</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i29bd15f1b5a64babba09049ab611472c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-535" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS01LTEtMS0xMTg2NA_37fe4320-7b48-491f-8dca-6344191bb1f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i29bd15f1b5a64babba09049ab611472c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-536" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS01LTEtMS0xMTg2NA_e6df9914-9810-42a7-83aa-795443da91ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span></ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i857193c97d064fabb83622b2b3184d72_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-537" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfOS03LTEtMS0xMTg2NA_7de458ab-a89c-43dc-97d4-221b077c1ba4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">70,009</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation liabilities - stock options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i72948c6873ba49259e4cfdb9658da1eb_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-538" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTEtMS0xLTEtMTE4NDU_190910b8-74fe-4332-b41d-0807fb8539a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i63472d3e281749c888b95118c532c344_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-539" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTEtMy0xLTEtMTE4NDU_fcdcac16-60af-4cc9-96f0-f74ebbd52f7b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,113</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i23a459494ae548db92ec3041a7cba918_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-540" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTEtNS0xLTEtMTE4NDU_e2f8c306-9509-42d7-877f-36d0bf75e460" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64fe2b17225542d5a0739c08fe62ea19_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-541" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTEtNy0xLTEtMTE4NDU_dc850dea-887f-47c7-8440-daa712f2332a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,113</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation liabilities - common shares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i3d22f0608d204604b314c21ac395dc56_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-542" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTItMS0xLTEtMTE4NDU_4fd80402-c622-40e4-be1b-bf8d6df48ab3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,523</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if5d3b9559f684ecdbfde2c64fa129619_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-543" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTItMy0xLTEtMTE4NDU_57ea417c-dfe2-485e-85cc-6949984cc31d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id7e7e8729d8f4b65897a8a049c08a7ef_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-544" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTItNS0xLTEtMTE4NDU_0d5967e7-3b53-42fd-944a-ce723a00873f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i50255dd008f84caabcc561482fa93d44_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="fact-identifier-545" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTItNy0xLTEtMTE4NDU_2b0a46fe-0768-46e1-a5ba-4beba0c11874" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,523</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i01ec2294762e4a2eafc8e26ccee9cdd4_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="fact-identifier-546" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTMtMS0xLTEtMTE4NDU_0e8d5caa-4108-4764-a2d9-ad016f4533e1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,523</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i1321682262914bc28a3678c5f5ceaf28_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="fact-identifier-547" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTMtMy0xLTEtMTE4NDU_8a6eeea7-d814-4179-a321-ecea1770c1bd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,113</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i29bd15f1b5a64babba09049ab611472c_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="fact-identifier-548" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTMtNS0xLTEtMTE4NDU_a3aa84bf-b0c9-40ed-8614-612b80e271b6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i857193c97d064fabb83622b2b3184d72_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="fact-identifier-549" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjQ5ZGQ4M2JjMmIyNTRiZjRiZTNkNmZjZjdkNDVjYTg4L3RhYmxlcmFuZ2U6NDlkZDgzYmMyYjI1NGJmNGJlM2Q2ZmNmN2Q0NWNhODhfMTMtNy0xLTEtMTE4NDU_1c7a774e-3ac8-4dc9-8b33-b60fa1cfb05f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21,636</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i7ade6a9060f34be18db427d418432adb" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="ia23f25aaf53242ef84ed7e327b000f7c" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement Using:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ic4ca920475ba4c73a2da8f88212c5ab5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-552" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNC0xLTEtMS0yMTIyNg_65f30c4c-4eb0-41a0-a2dd-2f0d9356f365" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,348</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i4e334f346fa842e1b7fe7fb7067eacc2_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-553" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNC0zLTEtMS0yMTIyNg_4a68af5d-5a82-4567-b6a8-7603bec7a102" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iae280cc9cfa444ffa7de102360134b36_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-554" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNC01LTEtMS0yMTIyNg_7126e8a5-8c5d-45a3-86c8-a6d791912e10" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="idb23059f75734fc9814e788938085e12_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-555" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNC03LTEtMS0yMTIyNg_981f61f2-d17f-4329-bb4b-04143f6a3588" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,348</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i59fbe8fefb4d4af99e6fed0a9798c21e_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-556" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNS0xLTEtMS0yMTIyNg_4d040ec4-0f2b-445e-9d24-1640aa652acb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib688a00110d44bcf8d9419108d0490eb_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-557" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNS0zLTEtMS0yMTIyNg_33cab901-0a83-4038-8437-5ee3b018fbb5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,042</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibf108e4e3337490982bc5fb425e92241_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-558" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNS01LTEtMS0yMTIyNg_3b2578b5-8ce4-4e97-af0a-e9c05f8f7b9f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0cfe925475f6445a816ad4aa1f7a2bfd_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-559" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNS03LTEtMS0yMTIyNg_21f605e2-b898-4d3a-bf30-dbe64f08e901" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,042</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i578f0e94f204426a8c8544dd95205d25_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-560" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNi0xLTEtMS0yMTIyOQ_82f1a903-f333-4ab2-9095-385d6db28b6e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,348</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ifdc539f16644461d991f2f9544dbf5a4_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-561" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNi0zLTEtMS0yMTIyOQ_ab86a1c3-df24-4b1e-8e5c-9c5e066e5cb2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,042</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ibacbcb1b777a4bf0a7ac6c7fa8ba001a_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-562" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNi01LTEtMS0yMTIyOQ_6200c3b7-cc41-43e8-b902-f708e9c3f6bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i484fef3f009e468296994707b244cc57_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="fact-identifier-563" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmUwMWZkM2RlMGNlNjQwYmJiZWE2Y2M4MmViMzE3OGUzL3RhYmxlcmFuZ2U6ZTAxZmQzZGUwY2U2NDBiYmJlYTZjYzgyZWIzMTc4ZTNfNi03LTEtMS0yMTIyOQ_1937910c-5c40-4be0-93ee-656e079d33de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,390</ix:nonfraction></span>&nbsp;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in cash and cash equivalents.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes $<span><ix:nonfraction unitref="usd" contextref="i58410d84411e4228b07957f367d15604_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="fact-identifier-564" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMzI5_fd662b2c-b706-4a8f-9848-9880c38d338b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.7</ix:nonfraction></span> million in cash and cash equivalents and $<span><ix:nonfraction unitref="usd" contextref="i58410d84411e4228b07957f367d15604_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="fact-identifier-565" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMzY1_7f9f3a9a-d4c4-49b9-b409-adf43373eb9c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.0</ix:nonfraction></span> million in marketable securities.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Included in marketable securities.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes $<span><ix:nonfraction unitref="usd" contextref="i0cfe925475f6445a816ad4aa1f7a2bfd_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="fact-identifier-566" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfNDQ2_7351a965-4a7b-4c7b-9e7f-b6aaaec0c755" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.0</ix:nonfraction></span> million in cash and cash equivalents and $<span><ix:nonfraction unitref="usd" contextref="i0cfe925475f6445a816ad4aa1f7a2bfd_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="fact-identifier-567" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfNDgy_bc7dfbff-ccbc-42d8-b5df-8e255021c1f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.0</ix:nonfraction></span> million in marketable securities.</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(5) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes <span><ix:nonfraction unitref="shares" contextref="i857193c97d064fabb83622b2b3184d72_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemeasuredDuringPeriod" scale="0" id="fact-identifier-568" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMTA5OTUxMTY0Njc5Ng_62a251c0-8271-4301-aad9-b2db8d2bfc75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,281,803</ix:nonfraction></span> outstanding stock options remeasured using the Black-Scholes option-pricing model (see Note 13(H)).</span></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(6) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Includes <span><ix:nonfraction unitref="shares" contextref="i50255dd008f84caabcc561482fa93d44_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRemeasuredDuringPeriod" scale="0" id="fact-identifier-569" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMTA5OTUxMTY0NjgwNQ_6468f66c-4175-4454-bd57-ee77b0945f62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">462,705</ix:nonfraction></span> common shares remeasured using the Company’s March&nbsp;31, 2021 closing market price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i857193c97d064fabb83622b2b3184d72_I20210331" decimals="2" name="us-gaap:SharePrice" scale="0" id="fact-identifier-570" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMTA5OTUxMTY0NjgyMQ_9eab2d60-726b-4798-ac06-86d5cfec400e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.58</ix:nonfraction></span> per common share (see Note 13(H)).</span></div></ix:continuation></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended March 31, 2021, the Company’s former Principal Executive Officer’s outstanding fully-vested share-based compensation awards were reclassified from equity to liabilities following the modification of the awards to include a share repurchase feature (see Note 10(H)). The share-based compensation liabilities are remeasured each reporting period with the change in fair value recorded as share-based compensation expense in the Company’s consolidated statements of operations until the equity awards are exercised and sold to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sumitovant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or to the market or the former Principal Executive Officer has held the common shares for a period of at least six months. The Company remeasures the share-based compensation liabilities related to outstanding stock options at fair value using the Black-Scholes option pricing model for which all significant inputs are observable, either directly or indirectly, which caused them to be classified as a Level 2 measurement within the fair value hierarchy. The Company remeasures the share-based compensation liabilities related to common shares held for less than six months based on the closing market price of the Company’s common shares at each reporting period-end, which caused them to be classified as a Level 1 measurement within the fair value hierarchy.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="myov:FairValueLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="fact-identifier-571" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfOTg5NTYwNDY2ODU4OQ_25842184-16e9-4ff0-8f4f-46d2bf8daed5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes information regarding the Company’s share-based compensation liabilities (a current liability) for the year ended March 31, 2021 (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&nbsp;31, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i50395313737f4a87bae3709486199473_I20200331" decimals="-3" format="ixt:zerodash" name="myov:FairValueRecurringBasisLiabilityValue" scale="3" id="fact-identifier-572" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmZhNGNlZGU2NmE0ZTQ5MmM5NjQ5ODhjODYyNGEyZTlkL3RhYmxlcmFuZ2U6ZmE0Y2VkZTY2YTRlNDkyYzk2NDk4OGM4NjI0YTJlOWRfMS0yLTEtMS0zNTQy_1d59687b-fdbf-40fd-a7e0-c2c2336b6133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification from additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i37b59a0f9a234053ad56fc8afab847da_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:FairValueRecurringBasisLiabilityReclassifications" scale="3" id="fact-identifier-573" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmZhNGNlZGU2NmE0ZTQ5MmM5NjQ5ODhjODYyNGEyZTlkL3RhYmxlcmFuZ2U6ZmE0Y2VkZTY2YTRlNDkyYzk2NDk4OGM4NjI0YTJlOWRfMi0yLTEtMS0zNTQy_87144982-fb6c-4757-9958-990e7c43c402" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">17,473</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i37b59a0f9a234053ad56fc8afab847da_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:FairValueRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="fact-identifier-574" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmZhNGNlZGU2NmE0ZTQ5MmM5NjQ5ODhjODYyNGEyZTlkL3RhYmxlcmFuZ2U6ZmE0Y2VkZTY2YTRlNDkyYzk2NDk4OGM4NjI0YTJlOWRfMy0yLTEtMS0zNTQy_a60a6ffb-09af-408a-9fb9-1e4f03cd2396" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10,609</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i37b59a0f9a234053ad56fc8afab847da_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:FairValueRecurringBasisLiabilitySettlements" scale="3" id="fact-identifier-575" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmZhNGNlZGU2NmE0ZTQ5MmM5NjQ5ODhjODYyNGEyZTlkL3RhYmxlcmFuZ2U6ZmE0Y2VkZTY2YTRlNDkyYzk2NDk4OGM4NjI0YTJlOWRfNC0yLTEtMS0zNTQy_b8be1048-5992-4ff9-9788-a75e58b2f44c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">6,446</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&nbsp;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iadaccd1fd0144ec59b82072c231826a9_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:FairValueRecurringBasisLiabilityValue" scale="3" id="fact-identifier-576" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOmZhNGNlZGU2NmE0ZTQ5MmM5NjQ5ODhjODYyNGEyZTlkL3RhYmxlcmFuZ2U6ZmE0Y2VkZTY2YTRlNDkyYzk2NDk4OGM4NjI0YTJlOWRfNS0yLTEtMS0zNTQy_8ecda292-6504-48ba-9e69-a6c6314bca38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">21,636</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="fact-identifier-577" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfNTQ5NzU1ODE1OTEwMQ_f845d1a4-3d24-450a-8717-3cfae3452746" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the share-based compensation liabilities related to outstanding stock options was estimated as of March&nbsp;31, 2021 using the Black-Scholes option-pricing model and the following assumptions:  </span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected common share price volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i4b6b4d80d01b4760b029dda88ffcfc72_I20210331" decimals="2" name="myov:DeferredCompensationShareBasedArrangementsLiabilitiesCurrentAndNoncurrentMeasurementInput" scale="1" id="fact-identifier-578" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjhmNDZhNWUxZTNlNDQ1YTI4ZTRiN2U2N2YzOGI5M2I3L3RhYmxlcmFuZ2U6OGY0NmE1ZTFlM2U0NDVhMjhlNGI3ZTY3ZjM4YjkzYjdfMS0xLTEtMS0xOTk3Mw_53ef8f38-84ba-4fcd-b981-2d88a47f746b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">72.9</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i10aa586237574aa5b94b40ab6b856730_I20210331" decimals="2" name="myov:DeferredCompensationShareBasedArrangementsLiabilitiesCurrentAndNoncurrentMeasurementInput" scale="1" id="fact-identifier-579" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjhmNDZhNWUxZTNlNDQ1YTI4ZTRiN2U2N2YzOGI5M2I3L3RhYmxlcmFuZ2U6OGY0NmE1ZTFlM2U0NDVhMjhlNGI3ZTY3ZjM4YjkzYjdfMi0xLTEtMS0xOTk3Mw_7fa59210-57d9-472b-9378-afe239da9f65" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.06</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i90aad34de6084b32a181ae0a496e7ca6_I20210331" decimals="2" name="myov:DeferredCompensationShareBasedArrangementsLiabilitiesCurrentAndNoncurrentMeasurementInput" scale="0" id="fact-identifier-580" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjhmNDZhNWUxZTNlNDQ1YTI4ZTRiN2U2N2YzOGI5M2I3L3RhYmxlcmFuZ2U6OGY0NmE1ZTFlM2U0NDVhMjhlNGI3ZTY3ZjM4YjkzYjdfMy0xLTEtMS0xOTk3Mw_092f5a2f-3b1a-48ae-978b-3ba49cb70b91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.78</ix:nonfraction></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="if429dd30dbc445c78cf10e392deda5dd_I20210331" decimals="2" format="ixt:zerodash" name="myov:DeferredCompensationShareBasedArrangementsLiabilitiesCurrentAndNoncurrentMeasurementInput" scale="1" id="fact-identifier-581" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RhYmxlOjhmNDZhNWUxZTNlNDQ1YTI4ZTRiN2U2N2YzOGI5M2I3L3RhYmxlcmFuZ2U6OGY0NmE1ZTFlM2U0NDVhMjhlNGI3ZTY3ZjM4YjkzYjdfNC0xLTEtMS0xOTk3Mw_49d1691c-8468-4b54-b4ae-fa2bfea3f930" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the cost share advance from collaboration partner, which is included in Level 2 of the fair value hierarchy, at its estimated fair value o</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f $<span><ix:nonfraction unitref="usd" contextref="i43b42ffe7d5247a48d2613a2ba51c318_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiability" scale="6" id="fact-identifier-582" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfMTA5OTUxMTY0ODAxOA_47138ccb-cd7f-4c5f-9b2b-b1a551fd2cb5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">146.4</ix:nonfraction></span> million as of the transaction date. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 13(B), on the transaction date, the cost share advance from collaboration partner was discounted to fair value using the Company’s estimated incremental borrowing rate over the period in which the cost share advance is expected to be utilized. The recorded amount has been and will continue to be reduced each reporting period by the amount of Allowable Expenses applied to the cost share advance. There were <span><ix:nonfraction unitref="usd" contextref="ieaad3b7e595a4db6ab4652ce0ba17288_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="fact-identifier-583" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfNTQ5NzU1ODE1OTEwMg_1e8a8f82-0fe1-45d9-9dec-70dd5b068351" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i87704afbd47e4c3fbcee55bdac8de957_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="fact-identifier-584" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfNTQ5NzU1ODE1OTEwMg_942dc615-d9d7-4f3e-afcc-fb9371ed4953" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span> nonrecurring fair value assets as of March&nbsp;31, 2021 and 2020 and <span><ix:nonfraction unitref="usd" contextref="ieaad3b7e595a4db6ab4652ce0ba17288_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="fact-identifier-585" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80MC9mcmFnOjA3YTQ5ZWU1MzViYjQ3MDc5MDI3ODM3NzJjNmFmNzMxL3RleHRyZWdpb246MDdhNDllZTUzNWJiNDcwNzkwMjc4Mzc3MmM2YWY3MzFfNTQ5NzU1ODE1OTExMA_d5aea9b6-0abe-4f0f-8e1a-5214329c0407" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> nonrecurring fair value liabilities as of March&nbsp;31, 2020.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_1240"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4— <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:InventoryDisclosureTextBlock" id="fact-identifier-586" continuedat="ie9070d7c12324e25b775f331705bc05c" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGV4dHJlZ2lvbjo3MjA3MThkOGFiMGY0MWNkOWNhMDFlYjYxNjcwYTQ3Ml81NDk3NTU4MTQwNzM3_50460c7b-8746-4db2-9852-4e606f20bbd3" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Inventory</ix:nonnumeric></span></span></div><span><ix:continuation id="ie9070d7c12324e25b775f331705bc05c" continuedat="i65c0ef6efea24893b7e2381e600e0bae" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="fact-identifier-588" continuedat="i6e3fbe0cce094f35986924f669165266" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGV4dHJlZ2lvbjo3MjA3MThkOGFiMGY0MWNkOWNhMDFlYjYxNjcwYTQ3Ml81NDk3NTU4MTQwNzM5_c474c3c6-c0e2-4705-a2fa-b04cab66e6e9" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="fact-identifier-589" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGFibGU6NGE4NjA0MjA2ZjY1NDAwMmEwOWYwYmRjYjQzODFlNTAvdGFibGVyYW5nZTo0YTg2MDQyMDZmNjU0MDAyYTA5ZjBiZGNiNDM4MWU1MF8xLTItMS0xLTQyNzk_b0ae4189-e693-424d-8043-e6997f2825e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,390</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="fact-identifier-590" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGFibGU6NGE4NjA0MjA2ZjY1NDAwMmEwOWYwYmRjYjQzODFlNTAvdGFibGVyYW5nZTo0YTg2MDQyMDZmNjU0MDAyYTA5ZjBiZGNiNDM4MWU1MF8yLTItMS0xLTQyNzk_899ab75d-8bd0-4069-810f-e91e0a8475d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">773</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="fact-identifier-591" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGFibGU6NGE4NjA0MjA2ZjY1NDAwMmEwOWYwYmRjYjQzODFlNTAvdGFibGVyYW5nZTo0YTg2MDQyMDZmNjU0MDAyYTA5ZjBiZGNiNDM4MWU1MF8zLTItMS0xLTQyNzk_86eb1915-60dc-4f55-95e4-fe0f08e79999" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">448</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="fact-identifier-592" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGFibGU6NGE4NjA0MjA2ZjY1NDAwMmEwOWYwYmRjYjQzODFlNTAvdGFibGVyYW5nZTo0YTg2MDQyMDZmNjU0MDAyYTA5ZjBiZGNiNDM4MWU1MF81LTItMS0xLTQyNzk_a41562d3-80c3-49bb-9c69-2bc6482c0dd2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,611</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i65c0ef6efea24893b7e2381e600e0bae" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span><ix:continuation id="i6e3fbe0cce094f35986924f669165266" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company had <span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:InventoryNet" scale="6" id="fact-identifier-595" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjQwL2ZyYWc6NzIwNzE4ZDhhYjBmNDFjZDljYTAxZWI2MTY3MGE0NzIvdGV4dHJlZ2lvbjo3MjA3MThkOGFiMGY0MWNkOWNhMDFlYjYxNjcwYTQ3Ml8xMDk5NTExNjI5NjQ2_d9608e5d-14e9-4160-97d8-bf9871c83808" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> inventory as of March&nbsp;31, 2020.</ix:continuation></span></ix:continuation></span> </span></div><div id="iad55818e5d094e70a171c29f2aae2512_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="fact-identifier-596" continuedat="i2b92c0fb370248218fce4759049360a3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RleHRyZWdpb246NTYwNGE4MjI1NGE2NDI1NWExY2JiMjU1OGJiYTczNDBfMTEz_ccb5b68e-399b-4451-bc94-7aa29c925bd4" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Accrued Expenses and Other Current Liabilities</ix:nonnumeric></span></span></div><span><ix:continuation id="i2b92c0fb370248218fce4759049360a3" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="fact-identifier-598" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RleHRyZWdpb246NTYwNGE4MjI1NGE2NDI1NWExY2JiMjU1OGJiYTczNDBfMTEy_f6600d21-306b-4442-a82c-81e80a32abc1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2021 and 2020, accrued expenses and other current liabilities consisted of the following (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:68.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedResearchandDevelopmentCurrent" scale="3" id="fact-identifier-599" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfMS0xLTEtMS0w_c0b1211a-f8d3-4904-ab8a-144ac3ce31e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">8,544</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedResearchandDevelopmentCurrent" scale="3" id="fact-identifier-600" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfMS0zLTEtMS0w_f468c58d-7bf1-4278-9f31-bf288552aa33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">15,500</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="fact-identifier-601" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfMi0xLTEtMS0w_95fcd17d-6870-4b14-a5cc-4f19419875dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20,571</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="fact-identifier-602" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfMi0zLTEtMS0w_58fd473a-f377-4d7e-9e39-d6623c5bd809" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,309</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commercial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedCommercialExpensesCurrent" scale="3" id="fact-identifier-603" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfMy0xLTEtMS0w_1c77bead-ff42-4a42-bb2b-13b2be7224f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7,770</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" name="myov:AccruedCommercialExpensesCurrent" scale="3" id="fact-identifier-604" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfMy0zLTEtMS0w_b95b948d-10b1-4305-a8dd-26d6858ea572" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">818</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued sales discounts, rebates, and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedSalesDiscountsRebatesAndAllowancesCurrent" scale="3" id="fact-identifier-605" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNS0xLTEtMS0xMjQ3NQ_b7f67702-84d2-46b3-b49c-bf395c422b88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,315</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="myov:AccruedSalesDiscountsRebatesAndAllowancesCurrent" scale="3" id="fact-identifier-606" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNS0zLTEtMS0xMjQ3NQ_82f717a3-801e-4011-ba43-f43b81691cde" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred net product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if9360b3da6344330938a4422d2b0310e_I20210331" decimals="-3" name="us-gaap:DeferredRevenueCurrent" scale="3" id="fact-identifier-607" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNy0xLTEtMS0xNjM3OA_db0fbf13-93e2-439a-aa99-3b4cb2e92c17" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">162</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ia0b6dccd158e48bab7ae301a7d31dab4_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredRevenueCurrent" scale="3" id="fact-identifier-608" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNy0zLTEtMS0xNjM3OA_c748e290-1c51-4f3e-b151-2e75dcb1037f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional service fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-609" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNC0xLTEtMS0w_02dc5866-daa2-4b1c-8549-57209114ad76" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">935</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="fact-identifier-610" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNC0zLTEtMS0w_b831f594-512b-43b9-abe3-8426c78c266f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,126</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other expenses and tax obligations</span></td><td colspan="2" style="background-color:#bfe4ff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-611" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNi0xLTEtMS0w_1f116785-6786-415b-9bd1-04eefdb4e36a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,315</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#bfe4ff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="fact-identifier-612" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNi0zLTEtMS0w_7685003e-1316-4438-abe2-44084d3eee39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,307</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedAndOtherLiabilitiesCurrent" scale="3" id="fact-identifier-613" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNy0xLTEtMS0w_f44b0a8f-3d60-4ad1-9511-c9a2259c5611" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">44,612</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:AccruedAndOtherLiabilitiesCurrent" scale="3" id="fact-identifier-614" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80My9mcmFnOjU2MDRhODIyNTRhNjQyNTVhMWNiYjI1NThiYmE3MzQwL3RhYmxlOjU5MWZmYTUwODIxYjQwMzk4NTI4NjcxMjBlYjA4YjkwL3RhYmxlcmFuZ2U6NTkxZmZhNTA4MjFiNDAzOTg1Mjg2NzEyMGViMDhiOTBfNy0zLTEtMS0w_679f79d3-e0b7-44f8-9439-d2998f54a521" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29,060</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="fact-identifier-615" continuedat="i944bbdbaa8cb447dbc9e98e92bd882c5" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY4MTk_0f739dc8-76de-4a3c-af0c-352079d230de" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Related Party Transactions</ix:nonnumeric></span></span></div><span><ix:continuation id="i944bbdbaa8cb447dbc9e98e92bd882c5" continuedat="i08b9dfd075524844b3c700ad27f1ad36" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A) Sumitomo Dainippon Pharma Co., Ltd. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, the Company’s former controlling shareholder, Roivant Sciences Ltd. (“Roivant”), completed a transaction (the “Sumitomo-Roivant Transaction”) in which all of the Company’s outstanding common shares held directly or indirectly by Roivant and not already held by Sumitovant were transferred to Sumitovant, and Roivant transferred all of the outstanding equity of Sumitovant to Sumitomo Dainippon Pharma, resulting in Sumitovant directly, and Sumitomo Dainippon Pharma indirectly, owning <span><ix:nonfraction unitref="shares" contextref="iffb9c7aa071245da888c0085e5e94393_I20191227" decimals="INF" format="ixt:numdotdecimal" name="myov:RelatedPartyOwnershipInterestHeldByRelatedPartyShares" scale="0" id="fact-identifier-617" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTcy_38902bde-2c4f-4c68-8507-3c9c42186032" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">45,008,604</ix:nonfraction></span>, or approximately <span><ix:nonfraction unitref="number" contextref="iffb9c7aa071245da888c0085e5e94393_I20191227" decimals="3" name="myov:RelatedPartyOwnershipInterestHeldByRelatedParty" scale="-2" id="fact-identifier-618" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTkz_c30f3622-4301-4aff-bdce-2b5d66e738de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.2</ix:nonfraction></span>%, of the Company’s outstanding common shares on December&nbsp;27, 2019. As of March 31, 2021, Sumitovant directly, and Sumitomo Dainippon Pharma indirectly, own <span><ix:nonfraction unitref="shares" contextref="i3bdf6a726fa9489bbf814c38dbe12bb1_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:RelatedPartyOwnershipInterestHeldByRelatedPartyShares" scale="0" id="fact-identifier-619" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNzE4_e8b8ea39-7088-4c03-a831-adb5debbbc31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">48,641,181</ix:nonfraction></span>, or approximately <span><ix:nonfraction unitref="number" contextref="i3bdf6a726fa9489bbf814c38dbe12bb1_I20210331" decimals="3" name="myov:RelatedPartyOwnershipInterestHeldByRelatedParty" scale="-2" id="fact-identifier-620" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNzM5_52d496c2-d4ab-453a-9e96-1c0f3b0428c1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">53.5</ix:nonfraction></span>%, of the Company’s outstanding common shares. As of March 31, 2021, amounts due to Sumitomo Dainippon Pharma for reimbursement of certain third-party pass-through expenses incurred on behalf of the Company were less than $<span><ix:nonfraction unitref="usd" contextref="i31619c59bc56433da9b58960beb6deb1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="6" id="fact-identifier-621" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTQ5NzU1ODE2NTEyMw_0a356726-9d39-4c34-bcfb-099ddf1f4c56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>&nbsp;million, and are included in amounts due to related parties on the accompanying consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sumitomo Dainippon Pharma Loan Agreement </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, the Company and its subsidiary, MSG, entered into a Loan Agreement with Sumitomo Dainippon Pharma (the “Sumitomo Dainippon Pharma Loan Agreement”). Pursuant to the Sumitomo Dainippon Pharma Loan Agreement, Sumitomo Dainippon Pharma agreed to make revolving loans to the Company in an aggregate principal amount of up to $<span><ix:nonfraction unitref="usd" contextref="i42b6f9c4aba04aed805c0ad1552c617f_I20191227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="fact-identifier-622" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTE1Ng_2e3161a1-89f6-479e-b421-7e59fe3c62cd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400.0</ix:nonfraction></span> million. On December&nbsp;30, 2019, the Company borrowed an initial amount of $<span><ix:nonfraction unitref="usd" contextref="i6da7876d2d984f1989f9551f9414c11d_D20191230-20191230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="fact-identifier-623" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTIwOQ_bc6cfb17-c670-4d09-9da1-8773907cad70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113.7</ix:nonfraction></span> million under the Sumitomo Dainippon Pharma Loan Agreement, the proceeds of which were used to repay all outstanding obligations of the Company to NovaQuest Capital Management (“NovaQuest”) and Hercules Capital, Inc. (“Hercules”) and to satisfy certain other fees and expenses. Additional funds may be drawn down by the Company once per calendar quarter, subject to certain terms and conditions, including consent of the Company’s board of directors. In addition, if Sumitomo Dainippon Pharma fails to own at least a majority of the Company’s outstanding common shares, it may become unlawful under Japanese law for Sumitomo Dainippon Pharma to fund loans to the Company, and in which case the Company would not be able to continue to borrow under the Sumitomo Dainippon Pharma Loan Agreement. Interest is due and payable quarterly, and the outstanding principal amounts are due and payable in full on the <span><ix:nonnumeric contextref="ia132fcc98f8344e48bc0ade25c62e279_D20191227-20191227" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="fact-identifier-624" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY4MTc_bffdc746-3778-41e3-a08a-95dc924aa4f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five-year</ix:nonnumeric></span> anniversary of the closing date of the Sumitomo Dainippon Pharma Loan Agreement. Loans under the Sumitomo Dainippon Pharma Loan Agreement are prepayable at any time without premium or penalty upon <span><ix:nonfraction unitref="day" contextref="ia132fcc98f8344e48bc0ade25c62e279_D20191227-20191227" decimals="INF" name="myov:DebtInstrumentBusinessDayNoticePeriodforPrepayment" scale="0" id="fact-identifier-625" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMjMxMQ_bc0e5d47-d533-4fa3-82fd-6eb5dfae1002" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span> business days’ prior written notice.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i08b9dfd075524844b3c700ad27f1ad36" continuedat="i02f84e893e034f28809d0cf5d9987b51" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loans under the Sumitomo Dainippon Pharma Loan Agreement bear interest at a rate per annum equal to 3-month LIBOR plus a margin of <span><ix:nonfraction unitref="number" contextref="ic8506fd4deba4888887e458f53b8d9eb_D20191227-20191227" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="fact-identifier-627" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMjQ4Mg_bc42131d-4b28-4948-979e-e4ccf6d51017" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span>% payable on the last day of each calendar quarter. LIBOR is currently expected to be phased out by the end of 2021, and if it becomes unavailable, the Company and Sumitomo Dainippon Pharma will negotiate in good faith to select an alternative interest rate and, if applicable as a result of such alternative interest rate, margin adjustment that is consistent with industry accepted successor rates for determining a LIBOR replacement. The Company’s obligations under the Sumitomo Dainippon Pharma Loan Agreement are fully and unconditionally guaranteed by the Company and its subsidiaries. The loans and other obligations are senior unsecured obligations of the Company, MSG, and subsidiary guarantees. The Sumitomo Dainippon Pharma Loan Agreement includes customary representations and warranties and affirmative and negative covenants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sumitomo Dainippon Pharma Loan Agreement also includes customary events of default, including payment defaults, breaches of representations and warranties, breaches of covenants following any applicable cure period, cross acceleration to certain other debt, failure to pay certain final judgments, certain events relating to bankruptcy or insolvency, failure of material provisions of the loan documents to remain in full force and effect or any contest thereto by the Company or any of its subsidiaries and certain breaches by the Company under the Investor Rights Agreement. Upon the occurrence of an event of default, a default interest rate of an additional <span><ix:nonfraction unitref="number" contextref="i42b6f9c4aba04aed805c0ad1552c617f_I20191227" decimals="INF" name="myov:DebtInstrumentDefaultInterestRate" scale="-2" id="fact-identifier-628" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMzk4OQ_a9010c42-dd7e-4ac2-bcdb-30eef597a791" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.0</ix:nonfraction></span>% will apply to the outstanding principal amount of the loans, Sumitomo Dainippon Pharma may terminate its obligations to make loans to the Company and declare the principal amount of loans to become immediately due and payable, and Sumitomo Dainippon Pharma may take such other actions as set forth in the Sumitomo Dainippon Pharma Loan Agreement. Upon the occurrence of certain bankruptcy and insolvency events, the obligations of Sumitomo Dainippon Pharma to make loans to the Company would automatically terminate and the principal amount of the loans would automatically become due and payable. In addition, if it becomes unlawful for Sumitomo Dainippon Pharma to maintain the loans under the Sumitomo Dainippon Pharma Loan Agreement or within <span><ix:nonnumeric contextref="ia132fcc98f8344e48bc0ade25c62e279_D20191227-20191227" format="ixt-sec:durday" name="myov:DebtInstrumentCovenantRepaymentPeriodUponChangeinControl" id="fact-identifier-629" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNDczOQ_ba082e4c-4729-4e01-aad2-4c0a21fa5507" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">30</ix:nonnumeric></span> days of a change of control with respect to the Company, the Company would be required to repay the outstanding principal amount of the Loans.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, approximately $<span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="fact-identifier-630" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNDkwMw_5b9150aa-f3e3-46ad-b90d-41528fab8f04" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">41.3</ix:nonfraction></span> million of borrowing capacity remains available to the Company, subject to the terms of the Sumitomo Dainippon Pharma Loan Agreement, and the outstanding loan balance of $<span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="fact-identifier-631" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTA2OA_4aa93441-7706-4abf-90ab-730adba579ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">358.7</ix:nonfraction></span> million is classified as a long-term liability on the accompanying consolidated balance sheets under the caption long-term debt, less current maturities (related party). Interest expense under the Sumitomo Dainippon Pharma Loan Agreement was $<span><ix:nonfraction unitref="usd" contextref="if349c6471a15451d8608a9388e4a832b_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseRelatedParty" scale="6" id="fact-identifier-632" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTMzMg_7b6d6f7c-b9bc-4130-88e1-3deac62fde1a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.8</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i2321815be65048179f59af7408ba61d4_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseRelatedParty" scale="6" id="fact-identifier-633" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MTY1OQ_fd7c9e81-c0ff-4218-979c-6a65270ea479" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonfraction></span> million for the years ended March 31, 2021 and 2020, respectively, and is included in interest expense in the accompanying consolidated statements of operations. There was <span><ix:nonfraction unitref="usd" contextref="ia3918c63054242939eeae92e8a94c3fc_D20180401-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:InterestExpenseRelatedParty" scale="3" id="fact-identifier-634" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MTY5OQ_4bbb577d-c433-4cb9-b62d-dc5d7e204c6c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> such interest expense for the year ended March 31, 2019.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="fact-identifier-635" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTQ5NzU1ODE2MjgwNw_657001ca-09b5-453c-b63d-9bf77c56fcce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual maturities of amounts outstanding as of March 31, 2021 under the Sumitomo Dainippon Pharma Loan Agreement are as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="fact-identifier-636" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RhYmxlOjdmZTE0YWEwNzI0NTQwNWY4NjhkMTQ3OTI3OGFhMTJmL3RhYmxlcmFuZ2U6N2ZlMTRhYTA3MjQ1NDA1Zjg2OGQxNDc5Mjc4YWExMmZfMS0xLTEtMS00NjU0_dee6faaf-507e-4613-a9f6-0c70d36c8055" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="fact-identifier-637" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RhYmxlOjdmZTE0YWEwNzI0NTQwNWY4NjhkMTQ3OTI3OGFhMTJmL3RhYmxlcmFuZ2U6N2ZlMTRhYTA3MjQ1NDA1Zjg2OGQxNDc5Mjc4YWExMmZfMi0xLTEtMS00NjU0_b6b2fb91-6605-4ce4-b563-64f3ca2d5c85" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="fact-identifier-638" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RhYmxlOjdmZTE0YWEwNzI0NTQwNWY4NjhkMTQ3OTI3OGFhMTJmL3RhYmxlcmFuZ2U6N2ZlMTRhYTA3MjQ1NDA1Zjg2OGQxNDc5Mjc4YWExMmZfMy0xLTEtMS00NjU0_83ac785f-d20f-4556-99f1-ac3ef60e740e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="fact-identifier-639" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RhYmxlOjdmZTE0YWEwNzI0NTQwNWY4NjhkMTQ3OTI3OGFhMTJmL3RhYmxlcmFuZ2U6N2ZlMTRhYTA3MjQ1NDA1Zjg2OGQxNDc5Mjc4YWExMmZfNC0xLTEtMS00NjU0_e562242f-5dd2-42d8-9a91-ca2915f5a918" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">358,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie7c3c15401904be1bb4d741769a60966_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="fact-identifier-640" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RhYmxlOjdmZTE0YWEwNzI0NTQwNWY4NjhkMTQ3OTI3OGFhMTJmL3RhYmxlcmFuZ2U6N2ZlMTRhYTA3MjQ1NDA1Zjg2OGQxNDc5Mjc4YWExMmZfNS0xLTEtMS00NjU0_8f621680-029f-45c2-b005-bb0370b2c6c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">358,700</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sumitomo Dainippon Pharma Loan Commitment</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;5, 2020, the Company obtained a debt commitment letter from Sumitomo Dainippon Pharma, as amended by a letter dated September 29, 2020, and then further amended by a letter dated December&nbsp;22, 2020 (the “2020 Commitment Letter”), pursuant to which, subject to the terms and conditions set forth therein, Sumitomo Dainippon Pharma committed to enter into a new $<span><ix:nonfraction unitref="usd" contextref="i5987f96b69294f2a974591d09ad4090e_I20200805" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="fact-identifier-641" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTk5NQ_deb49248-44c0-40a4-9a10-a381b9707979" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">200.0</ix:nonfraction></span> million unsecured, low-interest, <span><ix:nonnumeric contextref="ic8d8416cdebc49a890e4f715ae8dd36f_D20200805-20200805" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="fact-identifier-642" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY4MTg_c2121e21-aef8-4638-a831-9c5dd023c1b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">five-year</ix:nonnumeric></span> term loan facility. The 2020 Commitment Letter expired in March 2021. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, the Company entered into an Investor Rights Agreement with Sumitomo Dainippon Pharma and Sumitovant (the “Investor Rights Agreement”). Pursuant to the Investor Rights Agreement, among other things, the Company agreed, at the request of Sumitovant, to register for sale, under the Securities Act of 1933, common shares beneficially owned by Sumitovant, subject to specified conditions and limitations. In addition, the Company agreed to periodically provide Sumitovant (i) certain financial statements, projections, capitalization summaries and other information and (ii) access to the Company’s books, records, facilities and employees during the Company’s normal business hours as Sumitovant may reasonably request, subject to specified limitations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investor Rights Agreement also contains certain protections for the Company’s minority shareholders for so long as Sumitomo Dainippon Pharma or certain of its affiliates beneficially owns more than <span><ix:nonfraction unitref="number" contextref="iffb9c7aa071245da888c0085e5e94393_I20191227" decimals="INF" name="myov:RelatedPartyTransactionOwnershipThresholdforAppointmentofDirectors" scale="-2" id="fact-identifier-643" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNzA4Nw_9b0accb3-3274-4f77-a7ed-0d036c3bf4c8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% of the Company’s common shares. </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i02f84e893e034f28809d0cf5d9987b51" continuedat="i472bae4abe454fef8ef0db4f56075c3b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These protections include: (i) a requirement that Sumitovant vote its shares for the election of independent directors in accordance with the recommendation of the Company’s board of directors (the “board”) or in the same proportion as the shareholders not affiliated with Sumitovant vote their shares; (ii) a requirement that the audit committee of the Company’s board be composed solely of <span><ix:nonfraction unitref="director" contextref="iffb9c7aa071245da888c0085e5e94393_I20191227" decimals="INF" format="ixt-sec:numwordsen" name="myov:RelatedPartyTransactionNumberOfIndependentDirectorsRequiredForAuditCommittee" scale="0" id="fact-identifier-645" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNzUxNA_8a6b0b7f-ad51-4e44-b631-3c86fdccc400" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three</ix:nonfraction></span> independent directors; (iii) a requirement that any transaction proposed by Sumitomo Dainippon Pharma or certain of its affiliates that would increase Sumitomo Dainippon Pharma’s beneficial ownership to over <span><ix:nonfraction unitref="number" contextref="iffb9c7aa071245da888c0085e5e94393_I20191227" decimals="INF" name="myov:RelatedPartyTransactionOwnershipThresholdforVotingRights" scale="-2" id="fact-identifier-646" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNzcyNQ_8a860ba8-5e62-4adf-b45a-322d33b39c89" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60</ix:nonfraction></span>% of the outstanding voting power of the Company must be approved by the Company’s audit committee (if occurring prior to December 27, 2022), and be conditioned on the approval of shareholders not affiliated with Sumitovant approving the transaction by a majority of the common shares held by such shareholders; and a requirement that any related person transactions between Sumitomo Dainippon Pharma or certain of its affiliates and the Company must be approved by the Company’s audit committee.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Investor Rights Agreement, the Company also agreed that at all times that Sumitomo Dainippon Pharma beneficially owns more than <span><ix:nonfraction unitref="number" contextref="iffb9c7aa071245da888c0085e5e94393_I20191227" decimals="INF" name="myov:RelatedPartyTransactionOwnershipThresholdforRightofOwnershipPercentageMaintenance" scale="-2" id="fact-identifier-647" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfODM2Nw_82bb0366-cd21-49aa-b2a8-5a6dc038f20c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% of the Company’s common shares, Sumitomo Dainippon Pharma, by purchasing common shares in the open market or from the Company in certain specified circumstances, will have the right to maintain its percentage ownership in the Company’s common shares in the event of a financing event or acquisition event conducted by the Company, or specified other events, subject to specific conditions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(B) Sumitovant</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&nbsp;18, 2020, the Company and Sumitovant entered into a consulting agreement, as amended on November&nbsp;9, 2020, pursuant to which Sumitovant provided consulting services to the Company to support the Company in commercial planning, commercial launch activities and implementation. Adele Gulfo, Sumitovant’s Chief Business and Commercial Development Officer and a member of the Company’s board of directors, provided services to the Company on behalf of Sumitovant under this agreement. The term of the consulting agreement with Sumitovant expired on March 31, 2021. For the year ended March 31, 2021, the Company incurred $<span><ix:nonfraction unitref="usd" contextref="i5756aa52883647099d0210d84468a1de_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-648" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfOTI5NQ_ee90980b-86a3-4965-b1db-dbcf3d819119" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonfraction></span> million of expense under this consulting agreement, which is included in selling, general and administrative (“SG&amp;A”) expenses in the accompanying consolidated statements of operations. In addition, for the year ended March 31, 2021, the Company agreed to reimburse Sumitovant for certain other third-party pass-through expenses that it incurred on behalf of the Company. These expenses, totaling $<span><ix:nonfraction unitref="usd" contextref="i2424089909134b219d8b45206607f606_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-649" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MDE4MQ_6b429cd4-f204-424c-9e4c-b4aa4012ebb4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.7</ix:nonfraction></span> million are included in SG&amp;A expense in the accompanying consolidated statements of operations. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s outstanding obligation to Sumitovant is $<span><ix:nonfraction unitref="usd" contextref="i3bdf6a726fa9489bbf814c38dbe12bb1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="6" id="fact-identifier-650" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfOTU5Mg_c009d211-0cc3-49e1-96c4-c30782e3b055" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million and is included in amounts due to related parties on the accompanying consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Sunovion Pharmaceuticals Inc.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Access Services Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;1, 2020, the Company’s subsidiary, MSG, entered into the Market Access Services Agreement, as amended, with Sunovion Pharmaceuticals Inc. (“Sunovion”), a subsidiary of Sumitomo Dainippon Pharma. Pursuant to the Market Access Services Agreement, among other things, Sunovion agreed to provide to MSG certain market access services with respect to the distribution and sale of ORGOVYX (“Prostate Cancer Product”) and relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg and norethindrone acetate 0.5 mg) (“Women’s Health Product,” and collectively with Prostate Cancer Product, the “Products”, and each a “Product”), including, among other things: (i) adding the Products to Sunovion’s agreements with its third party logistics providers; (ii) adding the Women’s Health Product to certain of Sunovion’s contracts with wholesalers, group purchasing organizations and integrated delivery networks and negotiating rates for the Products with certain market access customers; (iii) providing order-to-cash services; (iv) providing certain employees to provide market access account director services; (v) performing activities required in connection with supporting and maintaining contracts between the Company and market access customers for the coverage, purchase, or dispensing of the Products; (vi) managing the validation, processing and payment of rebates, chargebacks, and certain administrative, distribution and service fees related to the Products; (vii) providing MSG with price reporting metrics and other information required to allow the Company to comply with applicable government price reporting requirements; (viii) coordinating with MSG and any applicable wholesalers and distributors to address any recalls, investigations, or product holds; (ix) configuring, or causing to be configured, the appropriate software systems to enable Sunovion to perform its obligations under the Market Access Services Agreement; and (x) providing training and certain other ancillary support services to facilitate the foregoing. Pursuant to this agreement, Sunovion will also provide certain services to the Company to enable the Company to comply with its obligations under the State Transparency Laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MSG, in turn, appointed Sunovion as the exclusive distributor of the Women’s Health Product and a non-exclusive distributor of the Prostate Cancer Product, each in the United States, including all of its territories and possessions. </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i472bae4abe454fef8ef0db4f56075c3b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to facilitate Sunovion’s provision of these services, MSG agreed, among other things, to: (i) grant Sunovion a non-exclusive license under all intellectual property owned or controlled by MSG, solely for Sunovion’s use in connection with its performance of the contemplated services; (ii) provide Sunovion periodic reports of sales projections and estimated volume requirements, as well as such other information as Sunovion reasonably requests or may need to perform the services; (iii) comply with the provisions of any agreements between Sunovion and third parties pursuant to which the Products will be distributed or sold; (iv) cooperate with certain investigations related to orders and audits of MSG’s quality systems solely related, as reasonably determined by Myovant, to Sunovion’s performance of certain regulatory services, at Sunovion’s costs; and (v) promptly notify Sunovion in the event relugolix is recalled.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the services, MSG has paid and will continue to pay Sunovion an agreed-upon monthly service charge for each of the first two years of the Market Access Services Agreement term and any agreed regulatory and training service charges. After the second year of the Market Access Services Agreement term, the monthly service charges will be determined by the parties. In addition, MSG also agreed to (x) reimburse Sunovion for any pass-through expenses it incurs while providing the services, and (y) establish an escrow fund for use by Sunovion when managing any rebates, chargebacks and similar fees. As of March 31, 2021, amounts held in this escrow fund are included in restricted cash under the caption other assets on the accompanying consolidated balance sheets. For the year ended March 31, 2021, the Company incurred $<span><ix:nonfraction unitref="usd" contextref="i098be655fd164bf8bb18c9e6456e5b1d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-652" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MzkwNw_018336cc-c1ef-4726-a34b-5f0dfa2d4e28" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.8</ix:nonfraction></span> million under this agreement (inclusive of third-party pass-through costs billed to the Company) of which $<span><ix:nonfraction unitref="usd" contextref="i13eeda6118504b7587cf747dc8a8c35b_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-653" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMjc0ODc3OTA5NTIwNg_ab22ee1e-ad10-4141-b3f7-d933ca028ab5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.7</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i3bc1b689495d4b0ea89f1121a0f7efed_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-654" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MTk3NA_1287f541-84ea-4ec3-a98b-aa8909cdbee4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million of expenses are included in SG&amp;A expenses and R&amp;D expenses, respectively, in the accompanying consolidated statement of operations. As of March 31, 2021, the Company’s outstanding obligation pursuant to this agreement is $<span><ix:nonfraction unitref="usd" contextref="id1448dada7e44c119525efcd8834611b_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="6" id="fact-identifier-655" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTQzMTI_d5064f53-5372-4493-8e39-90039fd4fcea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.4</ix:nonfraction></span> million and is included in amounts due to related parties on the accompanying consolidated balance sheets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Market Access Services Agreement also contains customary representations and warranties by the parties and customary provisions related to confidentiality, indemnification and insurance. The initial term of the Market Access Services Agreement is <span><ix:nonnumeric contextref="i8d3491bf2316473eac9c17ba0357696f_D20200801-20200801" format="ixt-sec:durwordsen" name="myov:RelatedPartyTransactionAgreementTerm" id="fact-identifier-656" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTQ2ODU_545c08af-296d-4f2f-9584-a400460cb57d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">three years</ix:nonnumeric></span>. Thereafter, the term will be automatically extended for <span><ix:nonnumeric contextref="i8d3491bf2316473eac9c17ba0357696f_D20200801-20200801" format="ixt-sec:durwordsen" name="myov:RelatedPartyTransactionAgreementExtensionTerm" id="fact-identifier-657" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY4MDk_82e518db-ed58-45d4-97cc-cfc14e36daed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one-year</ix:nonnumeric></span> periods, unless either party provides notice of its intent not to renew the Market Access Services Agreement at least nine (<span><ix:nonnumeric contextref="i8d3491bf2316473eac9c17ba0357696f_D20200801-20200801" format="ixt-sec:durmonth" name="myov:RelatedPartyTransactionTerminationNoticePeriod" id="fact-identifier-658" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY4MTU_36bcd92d-b3ae-42fc-99dd-ef76b887d97f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9</ix:nonnumeric></span>) months prior to the expiration of the applicable term. Either party may also terminate the Market Access Services Agreement prior to the end of its term in the event of an uncured material breach by the other party, if there are certain changes of law, or if such other party becomes insolvent or undergoes a change of control. MSG may also terminate the Market Access Services Agreement with respect to one or both Products if Sunovion fails to satisfy certain market access milestones or for convenience upon payment of a break-up fee.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(D) Roivant Sciences Ltd.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the closing of the Sumitomo-Roivant Transaction described in Note 6(A), on December&nbsp;27, 2019 all of the Company’s outstanding common shares held directly or indirectly by Roivant and not already held by Sumitovant were transferred to Sumitovant, and Roivant transferred all of the outstanding equity of Sumitovant to Sumitomo Dainippon Pharma. As a result of the transfer of these common shares, Roivant no longer beneficially owns any common shares of the Company. On December&nbsp;27, 2019, the then existing Information Sharing and Cooperation Agreement between the Company and Roivant, the then existing Services Agreements between the Company and certain of its subsidiaries and Roivant and certain of its subsidiaries, and the then existing Option Agreement between the Company and Roivant were terminated. For the years ended March&nbsp;31, 2020 and 2019, the Company paid or reimbursed Roivant approximately $<span><ix:nonfraction unitref="usd" contextref="ib86468a4aec1412fa885b2c37c4d74f4_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-659" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTYzMTU_c5073d20-7f50-4b2d-b84b-5afc9c79072d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span>&nbsp;million and $<span><ix:nonfraction unitref="usd" contextref="i1ef90652a2774279a6894949a90858ce_D20180401-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-660" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MDIyMA_bfa393a2-2dcd-46d4-8ac5-08af9e5da642" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.8</ix:nonfraction></span>&nbsp;million, respectively, under the terms of the then existing Services Agreements. In addition, the Company recorded share-based compensation expense allocated from Roivant of $<span><ix:nonfraction unitref="usd" contextref="i26ee01ab67dc4d45a073e3ba7692b58d_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-661" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY0OTE_8c7424a1-eae5-4a93-837a-26ceaa9b296c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i4edf3e64c51546e9a494ccfb75044950_D20180401-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="6" id="fact-identifier-662" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTA5OTUxMTY1MDI0OA_72eba956-62e3-4887-b22c-d1b429e23bcb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span> million for the years ended March&nbsp;31, 2020 and 2019, respectively. <span><ix:nonfraction unitref="usd" contextref="i89a0be85f2a94755a4b41da13a0951d4_D20200401-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CostsAndExpensesRelatedParty" scale="0" id="fact-identifier-663" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY1MzY_e48908df-d07e-497f-b240-bd6f3ab24a5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonfraction></span> amounts were incurred during the year ended March 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company sold to Roivant <span><ix:nonfraction unitref="shares" contextref="i583dba94ffec43e3a6c5b60504593422_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-664" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTQ5NzU1ODE2Mjg0Ng_92105680-c9c8-4ad1-89b9-4fd6b1ceae5a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,110,015</ix:nonfraction></span> of its common shares at a purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i3ac1ba231f864c0ba68c62cd4ac8c6fa_I20180430" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-665" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTQ5NzU1ODE2Mjg1Nw_9d4e2e76-4d9e-406b-b80e-750e67aba39e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.27</ix:nonfraction></span> per common share, for gross proceeds of $<span><ix:nonfraction unitref="usd" contextref="i583dba94ffec43e3a6c5b60504593422_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-666" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfNTQ5NzU1ODE2Mjg2NQ_3143ab1a-56d6-442e-82da-c19b538239ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22.5</ix:nonfraction></span>&nbsp;million, in a private placement. In addition, Roivant purchased <span><ix:nonfraction unitref="shares" contextref="i3aeedb3fe99b483c96f39fb1ee6667d0_D20190604-20190604" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-667" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY2MTA_fc67d27a-c9cf-4e27-91b3-f9786c5e7082" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,424,242</ix:nonfraction></span> of the Company’s common shares in the Company’s June&nbsp;4, 2019 underwritten public equity offering at the same price offered to the public of $<span><ix:nonfraction unitref="usdPerShare" contextref="i9151d09e403a4f679ee57f92a9e435db_I20190604" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-668" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY3NDM_175fd5b4-61f9-4b1e-b976-96aed8c8aa68" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.25</ix:nonfraction></span> per common share, for a total purchase price of $<span><ix:nonfraction unitref="usd" contextref="i3aeedb3fe99b483c96f39fb1ee6667d0_D20190604-20190604" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-669" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80Ni9mcmFnOjZjMzY3NWEyODBiYzQ4YzQ4YTBkYWFjNjdhNjRiNmZkL3RleHRyZWdpb246NmMzNjc1YTI4MGJjNDhjNDhhMGRhYWM2N2E2NGI2ZmRfMTY3OTQ_6b4b39ee-3d3c-4824-a3ff-91add5639375" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.0</ix:nonfraction></span> million </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(se</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e Note 9).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(E) Amended and Restated Bye-Laws</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2019, the Company’s board of directors approved, subject to the closing of the Sumitomo-Roivant transaction and shareholder approval and certain other conditions, the adoption of the Company’s Fifth Amended and Restated Bye-Laws (the “New Bye-Laws”), which amended and restated the Company’s bye-laws to, among other things, (i) remove the procedures established in June 2019 providing Roivant with the power, under certain circumstances, to appoint a majority of directors on the Company’s board and related powers, (ii) revise certain other aspects of the Company’s corporate governance and (iii) make other minor wording changes and additions, removal and revisions of defined terms. The New Bye-Laws became effective on January 23, 2020.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_49"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:DebtDisclosureTextBlock" id="fact-identifier-670" continuedat="if6cd7727006f4b46ba6092a449ccd09e" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfNjcy_6f81afcf-acb8-4714-bd3e-4fa7e546f95b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Financing Arrangements </ix:nonnumeric></span></span></div><span><ix:continuation id="if6cd7727006f4b46ba6092a449ccd09e" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A) NovaQuest </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company, its subsidiaries, as guarantors, and NovaQuest entered into (i) a Securities Purchase Agreement (the “NovaQuest Securities Purchase Agreement”) and (ii) an Equity Purchase Agreement (the “NovaQuest Equity Purchase Agreement”). Pursuant to the NovaQuest Securities Purchase Agreement, the Company issued $<span><ix:nonfraction unitref="usd" contextref="ie6ec7b5f521a49cfbdf29d3e1054fe6d_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="fact-identifier-672" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDI2Mg_9890c234-5bf4-45eb-8eef-fa90aa902eed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">60.0</ix:nonfraction></span> million aggregate principal amount of notes, of which $<span><ix:nonfraction unitref="usd" contextref="iedb7af4431d74692aeea06e9b6f26b22_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="fact-identifier-673" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDI4MA_ee8712c7-ffb5-4d5d-a5aa-8d571d66ddc4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.0</ix:nonfraction></span> million was issued in October 2017 and $<span><ix:nonfraction unitref="usd" contextref="i511b27955033485ca29467861a8a30c1_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="fact-identifier-674" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDMxNQ_b864e9b2-a8c1-4612-bbd6-9a81da5fd70a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54.0</ix:nonfraction></span> million was issued in December 2018. Concurrent with each purchase of notes, NovaQuest was obligated to purchase up to $<span><ix:nonfraction unitref="usd" contextref="ie6ec7b5f521a49cfbdf29d3e1054fe6d_I20171031" decimals="INF" format="ixt:numdotdecimal" name="myov:DebtInstrumentEquityCommitment" scale="6" id="fact-identifier-675" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDM3Nw_3b893d13-e3c8-4d26-a2bb-f85c6a5760ec" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span> million of the Company’s common shares on a pro rata basis, subject to certain terms and conditions. With the issuance of $<span><ix:nonfraction unitref="usd" contextref="iedb7af4431d74692aeea06e9b6f26b22_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="fact-identifier-676" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDM5Ng_ee8712c7-ffb5-4d5d-a5aa-8d571d66ddc4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.0</ix:nonfraction></span> million aggregate principal amount of notes in October 2017, NovaQuest purchased <span><ix:nonfraction unitref="shares" contextref="i3c6a7e43a07a445bb6ee43204163e121_D20171001-20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-677" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDQyNQ_a5f2bd21-c1a4-4bd1-9f07-b6fbde8a4c81" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">138,361</ix:nonfraction></span> common shares for $<span><ix:nonfraction unitref="usd" contextref="i3c6a7e43a07a445bb6ee43204163e121_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-678" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDQ0MA_3ab3bd9e-ad36-40f5-b69f-59a48b0f7be2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.0</ix:nonfraction></span> million, and with the issuance of $<span><ix:nonfraction unitref="usd" contextref="i511b27955033485ca29467861a8a30c1_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="6" id="fact-identifier-679" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDQ1OQ_b864e9b2-a8c1-4612-bbd6-9a81da5fd70a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">54.0</ix:nonfraction></span> million aggregate principal amount of notes in December 2018, NovaQuest purchased <span><ix:nonfraction unitref="shares" contextref="i17c9577c2c374eb9b251cc212818a8ce_D20181201-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-680" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDQ5MQ_5b2ee9c7-0dca-428c-9acf-7bfd8f010444" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,082,977</ix:nonfraction></span> common shares for $<span><ix:nonfraction unitref="usd" contextref="i17c9577c2c374eb9b251cc212818a8ce_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-681" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDUwNw_2cbd8b09-75ec-4296-ac9b-e3f265103c4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18.0</ix:nonfraction></span> million. Pursuant to the NovaQuest Equity Purchase Agreement, NovaQuest committed to purchase an additional $<span><ix:nonfraction unitref="usd" contextref="i2b181681ceba475a83f43380db82ff1e_I20171031" decimals="INF" format="ixt:numdotdecimal" name="myov:OptionIndexedtoIssuersEquityNominalValue" scale="6" id="fact-identifier-682" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDUzMw_ab7f5c17-bef9-4363-b47d-0da216ed9574" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20.0</ix:nonfraction></span> million of the Company’s common shares from time to time at the Company’s discretion. In December 2018, the Company exercised this option and issued and sold <span><ix:nonfraction unitref="shares" contextref="iae586a67793b4c4081bca0c227d89254_D20181201-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-683" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDU2NA_422ce442-e714-468c-86b7-41dfbad9e1b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,203,307</ix:nonfraction></span> common shares for $<span><ix:nonfraction unitref="usd" contextref="iae586a67793b4c4081bca0c227d89254_D20181201-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-684" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDU4MA_f357d3c8-90d5-4e0b-932f-7e81f985840e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.0</ix:nonfraction></span> million. The notes bore interest at a rate of <span><ix:nonfraction unitref="number" contextref="ie6ec7b5f521a49cfbdf29d3e1054fe6d_I20171031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="fact-identifier-685" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDU5Ng_d7e5769f-ff72-4fa3-92fc-f45d761ca082" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15</ix:nonfraction></span>% per annum, of which <span><ix:nonfraction unitref="number" contextref="ie6ec7b5f521a49cfbdf29d3e1054fe6d_I20171031" decimals="INF" name="myov:DebtInstrumentInterestRateStatedQuarterlyRate" scale="-2" id="fact-identifier-686" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDYwMQ_5facf6cc-4105-48cd-b587-6f7ad76d3dbf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5</ix:nonfraction></span>% was payable quarterly, and <span><ix:nonfraction unitref="number" contextref="ie6ec7b5f521a49cfbdf29d3e1054fe6d_I20171031" decimals="INF" name="myov:DebtInstrumentInterestRateStatedDeferredRate" scale="-2" id="fact-identifier-687" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDYwNw_a96512df-3095-45d4-87a5-6900b725e9a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonfraction></span>% was payable on a deferred basis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company repaid all of its obligations to NovaQuest on December 31, 2019 including $<span><ix:nonfraction unitref="usd" contextref="ibb34819b1fb34ad7a90edd9186712354_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:RepaymentsofDebtPrincipal" scale="6" id="fact-identifier-688" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDY2MQ_500741c7-5328-4e9c-8c5d-e75ef7245a25" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">60.0</ix:nonfraction></span> million of principal repayment of the notes, accrued and unpaid interest of $<span><ix:nonfraction unitref="usd" contextref="ibb34819b1fb34ad7a90edd9186712354_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:RepaymentsofDebtAccruedInterest" scale="6" id="fact-identifier-689" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDY3OQ_5284bfb0-c76f-4163-b271-c1ceb649d6a3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">7.6</ix:nonfraction></span> million, and an early redemption fee of $<span><ix:nonfraction unitref="usd" contextref="ibb34819b1fb34ad7a90edd9186712354_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:PaymentforDebtPrepaymentCost" scale="6" id="fact-identifier-690" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDY5OA_230b8380-895b-44a5-9cee-d50aa9a1e93a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.4</ix:nonfraction></span> million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(B) Hercules</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company, its subsidiaries, as guarantors, and Hercules entered into a Loan Agreement (the “Hercules Loan Agreement”), which provided up to $<span><ix:nonfraction unitref="usd" contextref="if31bc18712f54ed5b7976efc86b9431a_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="fact-identifier-691" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDczNA_1b89f61c-51d4-4525-9f10-aaccd2ed6377" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40.0</ix:nonfraction></span> million principal amount of term loans (the “Term Loans”). A first tranche of $<span><ix:nonfraction unitref="usd" contextref="if31bc18712f54ed5b7976efc86b9431a_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="fact-identifier-692" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDc1Mg_912c66a1-29c3-497e-8498-703e513f9cf3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25.0</ix:nonfraction></span> million principal amount was funded upon execution of the Hercules Loan Agreement in October 2017 and the remaining $<span><ix:nonfraction unitref="usd" contextref="i9a537794db3241879fd7283f5a37d6e0_I20180331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="fact-identifier-693" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDgwMg_dfbd8b3a-0040-4e90-a269-c4a582381a08" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.0</ix:nonfraction></span> million principal amount was funded in March 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loans bore interest at a variable per annum rate at the greater of (i) the prime rate plus <span><ix:nonfraction unitref="number" contextref="i60b353bff16f4f979281cb0eeb5bd76b_D20171001-20171031" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="fact-identifier-694" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDgxMA_b104d212-99a6-4144-8814-663c68dc0948" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4</ix:nonfraction></span>% and (ii) <span><ix:nonfraction unitref="number" contextref="if31bc18712f54ed5b7976efc86b9431a_I20171031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="fact-identifier-695" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDgxOA_6c0d0a0b-5423-4699-860d-8c04b7641193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.25</ix:nonfraction></span>%. The scheduled maturity date of the Term Loans was November&nbsp;1, 2021. The Company was obligated to make monthly interest payments during the Interest-only Period (through June&nbsp;1, 2020), subject to certain terms and conditions, followed by monthly installments of principal and interest through the maturity date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with each funding of the Term Loans, the Company was required to issue to Hercules a warrant (the “Warrants”) to purchase a number of its common shares equal to <span><ix:nonfraction unitref="number" contextref="id6a9698cfea346919d3afa18e9509386_I20171031" decimals="INF" name="myov:ClassofWarrantorRightMaximumPercentageofPrincipalofDebtInstrumentAllowedtobeExercisable" scale="-2" id="fact-identifier-696" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDg2NQ_5c40093e-2ee9-4b43-8de8-e398ac8e58d2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3</ix:nonfraction></span>% of the principal amount of the relevant Term Loan funded divided by the exercise price, which was based on the lowest three-day volume-weighted average price for the three consecutive trading days prior to the funding date for such Term Loan. The Warrants may be exercised on a cashless basis and are immediately exercisable through the seventh anniversary of the applicable funding date. In connection with the first tranche funded under the Hercules Loan Agreement, the Company issued a Warrant to Hercules exercisable for an aggregate of <span><ix:nonfraction unitref="shares" contextref="i517a68709a264788ae218910401dd878_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="fact-identifier-697" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDg3NA_3a5fb68d-f667-445b-b263-c2207898f583" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">49,800</ix:nonfraction></span> of its common shares at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i517a68709a264788ae218910401dd878_I20171031" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-698" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDg4Mw_7a7960da-abed-45ad-a4c0-80e0b08418b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">15.06</ix:nonfraction></span> per common share. Concurrent with the funding of the second tranche, the Company issued a Warrant to Hercules exercisable for an aggregate of <span><ix:nonfraction unitref="shares" contextref="i19cc100bd7eb48298cf42e393b74368c_I20171031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="fact-identifier-699" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDg5Mg_9dc2cfdd-12f3-4630-8138-2fc0323d5978" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">23,910</ix:nonfraction></span> of its common shares at an exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i19cc100bd7eb48298cf42e393b74368c_I20171031" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="fact-identifier-700" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDkwMQ_23fd0cbf-315b-453c-8ec6-d31ee424180c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18.82</ix:nonfraction></span> per common share. The total <span><ix:nonfraction unitref="shares" contextref="ia28abb24d77e4e27941b5b8085f308a4_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="fact-identifier-701" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDkxMA_983a7ae3-bbe8-4326-be63-b4029cb753e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">73,710</ix:nonfraction></span> warrants issued to Hercules were outstanding and exercisable as of March&nbsp;31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company repaid all of its obligations to Hercules on December&nbsp;31, 2019, including $<span><ix:nonfraction unitref="usd" contextref="i10afd77d191141b282bd2f6c59d14a68_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:RepaymentsofDebtPrincipal" scale="6" id="fact-identifier-702" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDk3Mg_3d75e633-a99b-4777-aae9-c9640a7abfab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">40.0</ix:nonfraction></span> million of principal repayment of the Term Loans, accrued and unpaid interest of $<span><ix:nonfraction unitref="usd" contextref="i10afd77d191141b282bd2f6c59d14a68_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:RepaymentsofDebtAccruedInterest" scale="6" id="fact-identifier-703" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NDk5MA_f59b9f60-bee2-4173-9520-29a2c8649099" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.3</ix:nonfraction></span> million, a prepayment penalty of $<span><ix:nonfraction unitref="usd" contextref="i10afd77d191141b282bd2f6c59d14a68_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:PaymentforDebtPrepaymentCost" scale="6" id="fact-identifier-704" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NTAwOA_975d33a4-1477-423d-8f56-551c24ae84c2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.4</ix:nonfraction></span> million, and an end of term charge of $<span><ix:nonfraction unitref="usd" contextref="i10afd77d191141b282bd2f6c59d14a68_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="myov:PaymentforDebtExtinguishmentCost" scale="6" id="fact-identifier-705" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMTA5OTUxMTY0NTAyNg_0ce35cf0-3940-4319-a777-d86cdc4f0054" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2.6</ix:nonfraction></span> million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Extinguishment of Debt</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;27, 2019, the Company and its subsidiary, MSG, entered into the Sumitomo Dainippon Pharma Loan Agreement, which is further discussed in Note 6(A). On December&nbsp;30, 2019, the Company borrowed an initial amount of $<span><ix:nonfraction unitref="usd" contextref="i6da7876d2d984f1989f9551f9414c11d_D20191230-20191230" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="6" id="fact-identifier-706" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfNjQ_bc6cfb17-c670-4d09-9da1-8773907cad70" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">113.7</ix:nonfraction></span> million under the Sumitomo Dainippon Pharma Loan Agreement, the proceeds of which were used to repay all outstanding obligations with Hercules and NovaQuest and to satisfy certain other fees and expenses. The repayments resulted in a loss on extinguishment of debt of $<span><ix:nonfraction unitref="usd" contextref="ib32c3f94129e4d8dbefac7fa4eab5150_D20190401-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="fact-identifier-707" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl80OS9mcmFnOjFkNGJiYWM2MzVlMDQ5ODZhMWY3ZWYxNDU0OWZjNWY5L3RleHRyZWdpb246MWQ0YmJhYzYzNWUwNDk4NmExZjdlZjE0NTQ5ZmM1ZjlfMzIx_f8e8e33b-e378-47ff-b2fd-d00b286e2040" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.9</ix:nonfraction></span> million, which is included under the caption loss on extinguishment of debt in the accompanying consolidated statements of operations for the year ended March 31, 2020. The loss on extinguishment of debt was calculated as the difference between the carrying amount of the debt and the amounts paid to retire the debt.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="fact-identifier-708" continuedat="ib60606911ad64bf3a23d5e4a756d6cb3" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMjkzOA_4277572e-05b8-4af7-9629-2dd0fd3feabe" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Income Taxes</ix:nonnumeric></span></span></div><span><ix:continuation id="ib60606911ad64bf3a23d5e4a756d6cb3" continuedat="ib14d9e997c01487d85b59520222000e2" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="fact-identifier-710" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY3Mw_8446eccb-05ab-461a-9559-8e3480cdf737" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss before income taxes and the related tax expense are as follows (in thousands):</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before income taxes:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i047d00c0aa49447f86371a50ead75251_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-711" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMy0xLTEtMS0yNTM5_e4b3c8e1-cb01-4430-9a74-5c962eccdb54" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,663</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="if8d0c33fa7d641b3a55d026773e9791f_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-712" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMy0zLTEtMS0yNTM5_22d842a5-b30b-430b-aae1-fb1dfb4f6f67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">29,509</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="iba5f1ef5b53f477382efecb52f98ad5b_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-713" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMy01LTEtMS0yNTM5_a11d37c1-8214-4c15-aed1-7d4cd09d5d0e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,246</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i0bc872e5bed54456af67853bb6d75ea5_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-714" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNC0xLTEtMS0yNTM5_8bb5bc00-04c7-4b92-ab32-de062f1afd9a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">201,673</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i397ea0b6bb4c48888fb9e05fb2d644a8_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-715" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNC0zLTEtMS0yNTM5_eaf50068-4fa0-462c-a0f4-df44be36c484" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">239,666</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="ie717b325af6b452c9511eec4b94e1d0f_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-716" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNC01LTEtMS0yNTM5_f1f4bc12-f466-4f69-8a5a-ed162c05540a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">247,445</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="fact-identifier-717" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNS0xLTEtMS0yNTM5_8c11cb0b-ef83-4205-bb25-7d953afae2b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,310</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="fact-identifier-718" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNS0zLTEtMS0yNTM5_aedef5c0-648d-4be4-a2c4-a1d8cf7ea6d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,054</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="fact-identifier-719" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNS01LTEtMS0yNTM5_5a393380-4d23-4210-a9c2-c9df143d3695" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,357</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i117e18ee6bd0423daab8385d7f6a7dd5_D20200401-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-720" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNi0xLTEtMS0yNTM5_9d77aaf2-5878-426b-8225-9f8d1c3e430b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">152</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i836bc805fa8a40eabe761ae065cc0ac2_D20190401-20200331" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-721" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNi0zLTEtMS0yNTM5_b124001b-8667-4705-98c0-3c5db89d288c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i9ed39e866d0540169f628f2b8a83e88b_D20180401-20190331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="fact-identifier-722" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNi01LTEtMS0yNTM5_9e117c74-90c5-4684-b038-c263b03bb043" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss before income taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="fact-identifier-723" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNy0xLTEtMS0yNTM5_4739df87-bc06-4091-88d5-81be91eefdd2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">254,798</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="fact-identifier-724" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNy0zLTEtMS0yNTM5_1f706ab8-61e9-4047-b5ee-5c74f90c19a1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">288,228</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="fact-identifier-725" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfNy01LTEtMS0yNTM5_d9d2190a-91a9-4d08-8356-e458c1d4931d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">273,075</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current taxes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i047d00c0aa49447f86371a50ead75251_D20200401-20210331" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-726" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTAtMS0xLTEtMjUzOQ_4627d6fe-7ead-4e05-85d7-90a6cfe2af61" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">335</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if8d0c33fa7d641b3a55d026773e9791f_D20190401-20200331" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-727" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTAtMy0xLTEtMjUzOQ_f3a9b127-24f2-47ef-9110-e526198ecd1d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">758</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iba5f1ef5b53f477382efecb52f98ad5b_D20180401-20190331" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-728" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTAtNS0xLTEtMjUzOQ_20cbb327-e60b-4b43-a226-c2254f973644" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">473</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0bc872e5bed54456af67853bb6d75ea5_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-729" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTEtMS0xLTEtMjUzOQ_5df45611-9b4e-4fbf-9456-80f0d4505df2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i397ea0b6bb4c48888fb9e05fb2d644a8_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-730" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTEtMy0xLTEtMjUzOQ_43dfad92-5cdd-457a-acee-0c90d199358c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie717b325af6b452c9511eec4b94e1d0f_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-731" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTEtNS0xLTEtMjUzOQ_cce4a0d3-77f0-4ded-862e-149b734aea86" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="fact-identifier-732" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTItMS0xLTEtMjUzOQ_f3f0c235-129c-4da8-a535-3bb3f542f4d8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="fact-identifier-733" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTItMy0xLTEtMjUzOQ_65530dc6-fb8e-49c4-be4d-d66eddf6338a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="fact-identifier-734" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTItNS0xLTEtMjUzOQ_433faedf-7bad-4884-b0ef-06ce4f0a6fde" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i117e18ee6bd0423daab8385d7f6a7dd5_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-735" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTMtMS0xLTEtMjUzOQ_a4e96c49-49e4-4abe-a09d-6c2be081231b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i836bc805fa8a40eabe761ae065cc0ac2_D20190401-20200331" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-736" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTMtMy0xLTEtMjUzOQ_880795c0-87e0-40bd-9717-fa58f77fb887" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9ed39e866d0540169f628f2b8a83e88b_D20180401-20190331" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="fact-identifier-737" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTMtNS0xLTEtMjUzOQ_bc0f71b5-91ba-4f19-8658-8d33e64d2cd5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-738" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTQtMS0xLTEtMjUzOQ_8ea5bf83-8a00-4b93-b8ad-3c7ec9288fef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-739" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTQtMy0xLTEtMjUzOQ_7815ae89-23e9-4090-b2e9-fd98e9332b4d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">761</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-740" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTQtNS0xLTEtMjUzOQ_b73e4b4b-75b8-4da6-b09b-a52c70ff3032" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i047d00c0aa49447f86371a50ead75251_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-741" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTYtMS0xLTEtMjUzOQ_ec036656-a0ae-40da-b596-d2dfbfa9eb3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="if8d0c33fa7d641b3a55d026773e9791f_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-742" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTYtMy0xLTEtMjUzOQ_a12de136-ce59-4e81-b72c-4b8942243e60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iba5f1ef5b53f477382efecb52f98ad5b_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-743" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTYtNS0xLTEtMjUzOQ_0936fe13-09ec-451f-be66-4b1a671046c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0bc872e5bed54456af67853bb6d75ea5_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-744" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTctMS0xLTEtMjUzOQ_d89fbf3e-fa37-40d8-9c92-25bb3b14cfa8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i397ea0b6bb4c48888fb9e05fb2d644a8_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-745" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTctMy0xLTEtMjUzOQ_ba4fc1d1-43a7-45bb-af4c-4734fb622f8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ie717b325af6b452c9511eec4b94e1d0f_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-746" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTctNS0xLTEtMjUzOQ_edd6d49e-b626-4a82-b440-5fffcd78dae6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bermuda</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-747" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTgtMS0xLTEtMjUzOQ_9c25128b-8065-4672-b1e5-4205c213d56a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-748" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTgtMy0xLTEtMjUzOQ_e2fb6769-ae43-4fbf-8d7c-6eb27e9f4f2b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-749" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTgtNS0xLTEtMjUzOQ_1def9437-c823-4a33-8486-bf119c4d92f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i117e18ee6bd0423daab8385d7f6a7dd5_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-750" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTktMS0xLTEtMjUzOQ_ca87916e-bd87-4bde-a5f7-6e216a415e7e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i836bc805fa8a40eabe761ae065cc0ac2_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-751" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTktMy0xLTEtMjUzOQ_dc6946e9-30d7-472b-bd15-e4a5e3d320e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9ed39e866d0540169f628f2b8a83e88b_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-752" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMTktNS0xLTEtMjUzOQ_f54b6fa7-4a13-4e99-842f-32f5dff8aef6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-753" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMjAtMS0xLTEtMjUzOQ_cf063250-5692-4207-9168-bb806d640af6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-754" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMjAtMy0xLTEtMjUzOQ_5a1b0269-3c16-4d9d-90c6-25c7da7a28e9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="fact-identifier-755" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMjAtNS0xLTEtMjUzOQ_6801231a-6107-4c06-a6bb-e3ed1f079011" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-756" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMjEtMS0xLTEtMjUzOQ_8c066efc-3bd9-465a-bd2d-53ba3ed1e561" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-757" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMjEtMy0xLTEtMjUzOQ_c8bf8c08-dfb9-4636-8296-413030751824" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">761</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-758" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmJkOGJkOTBiYzhhNzRiZTU4NjBmN2UyYWY1ZDdlYWU1L3RhYmxlcmFuZ2U6YmQ4YmQ5MGJjOGE3NGJlNTg2MGY3ZTJhZjVkN2VhZTVfMjEtNS0xLTEtMjUzOQ_ef65a67b-3406-4d24-8add-37214b6bf2a2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily United States state and local, Ireland and United Kingdom activity.</span></div></ix:nonnumeric></span><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="fact-identifier-759" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY3NA_7c7abe52-d13e-4f8f-aac3-31043cb224d3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense computed at the Bermuda statutory rate to income tax expense reflected in the consolidated statements of operations is as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.914%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.921%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at Bermuda statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="fact-identifier-760" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMi0yLTEtMS0yNTM5_0c7b95f5-6c81-4a12-9ac9-2667bc47e80f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-761" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMi00LTEtMS0yNTM5_f65f232a-1274-445a-a613-d86485117cff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="fact-identifier-762" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMi02LTEtMS0yNTM5_83f7c764-bb62-4f54-94f0-f23de4d6b1f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-763" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMi04LTEtMS0yNTM5_08df504f-8fe0-4d8d-9108-ee97dcafed4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="fact-identifier-764" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMi0xMC0xLTEtMjUzOQ_fe66e860-671e-4743-aee0-2567cf90d6f6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="fact-identifier-765" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMi0xMi0xLTEtMjUzOQ_6647eca0-7beb-4cb9-a67d-891790d339b1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="fact-identifier-766" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMy0yLTEtMS0yNTM5_51b4ed43-7b79-4be5-9761-40e80b0482a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,622</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-767" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMy00LTEtMS0yNTM5_5504e57e-14ea-4bdf-b2de-36ec49385133" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14.77</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="fact-identifier-768" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMy02LTEtMS0yNTM5_7c542dbb-37ab-4817-952a-0ec47882be83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,056</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-769" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMy04LTEtMS0yNTM5_9bbf1ba8-fa81-498a-8c88-64b4288d8f83" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">13.90</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="fact-identifier-770" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMy0xMC0xLTEtMjUzOQ_dfcb7d61-057e-4c7a-8743-ca38e6e3d58e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31,252</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="fact-identifier-771" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMy0xMi0xLTEtMjUzOQ_e377c5f0-9905-4ab3-a51f-2031f26e305d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.44</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of changes in enacted income tax rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="fact-identifier-772" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNC0yLTEtMS0yNTM5_1561f0f9-0e18-4a6b-b6ce-dc200d9dec38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-773" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNC00LTEtMS0yNTM5_258d73be-6075-4aa8-8c57-72519931ff4a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="fact-identifier-774" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNC02LTEtMS0yNTM5_7ad5d701-4672-47ab-a77f-96f4b9fe693c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">27,150</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-775" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNC04LTEtMS0yNTM5_93ea38a7-57a8-41a1-b15f-2756c6575b03" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.42</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="fact-identifier-776" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNC0xMC0xLTEtMjUzOQ_cdb6e66b-7582-4793-b6e1-26b37c02468e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="fact-identifier-777" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNC0xMi0xLTEtMjUzOQ_3f6482e2-0ce7-4102-84ce-021c8c086d47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency remeasurement effects on Swiss deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="myov:EffectiveIncomeTaxRateReconciliationForeignCurrencyTranslationAmount" scale="3" id="fact-identifier-778" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS0yLTEtMS0yMDE5OA_99737917-42ae-47a8-9373-7b3dbe7dddda" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">13,742</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" name="myov:EffectiveIncomeTaxRateReconciliationForeignCurrencyTranslationPercent" scale="-2" id="fact-identifier-779" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS00LTEtMS0yMDE5OA_5af92962-6908-4a21-924c-abaaf4630765" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">5.39</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationForeignCurrencyTranslationAmount" scale="3" id="fact-identifier-780" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS02LTEtMS0yMDE5OA_e8fc43ec-3091-401c-9fea-5d4cf860a8df" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationForeignCurrencyTranslationPercent" scale="-2" id="fact-identifier-781" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS04LTEtMS0yMDE5OA_7845a3e7-8372-4212-b515-fa79de44841f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationForeignCurrencyTranslationAmount" scale="3" id="fact-identifier-782" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS0xMC0xLTEtMjAxOTg_fe602e4a-2a08-42a1-8c8f-c60da22ee92b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationForeignCurrencyTranslationPercent" scale="-2" id="fact-identifier-783" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS0xMi0xLTEtMjAxOTg_c85cdcab-76ef-46d5-a3b2-1078a06e29a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officer’s non-deductible share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementOfficersAmount" scale="3" id="fact-identifier-784" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi0yLTEtMS0yMDE5OA_059df137-297c-4610-81de-f8f3923ea8c4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">9,590</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" sign="-" name="myov:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementOfficersPercent" scale="-2" id="fact-identifier-785" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi00LTEtMS0yMDE5OA_215b420b-f807-43a6-8e2f-9d385da57239" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.76</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementOfficersAmount" scale="3" id="fact-identifier-786" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi02LTEtMS0yMDE5OA_21742177-7378-41af-8de9-ca6a6d6116ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementOfficersPercent" scale="-2" id="fact-identifier-787" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi04LTEtMS0yMDE5OA_4dce3def-8a69-4a6d-8bbb-1ca5f2e3b9dc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementOfficersAmount" scale="3" id="fact-identifier-788" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi0xMC0xLTEtMjAxOTg_0ce9eb5c-6445-43f2-82a7-7688506770e2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" format="ixt:zerodash" name="myov:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementOfficersPercent" scale="-2" id="fact-identifier-789" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi0xMi0xLTEtMjAxOTg_ddff3ca8-61ee-4ed2-8078-f2d5142afbf6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D tax credits (net of uncertain tax positions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="fact-identifier-790" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS0yLTEtMS0yNTM5_691b3ce1-4b35-4bd8-ade2-061a7f008d44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,771</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="fact-identifier-791" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS00LTEtMS0yNTM5_1f283a26-1829-46d3-a414-d232589c76b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.48</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="fact-identifier-792" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS02LTEtMS0yNTM5_3ae34a44-05a9-43fe-a5e2-3501bdaac69b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,208</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="fact-identifier-793" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS04LTEtMS0yNTM5_682062d1-d3f7-436f-9c6a-b11743d0cb31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.42</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="fact-identifier-794" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS0xMC0xLTEtMjUzOQ_d69f09ff-502c-4c3a-b30b-362564f2401a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="fact-identifier-795" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNS0xMi0xLTEtMjUzOQ_04205f96-2a15-4dc3-bf79-0f8ed3855a49" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation deferral adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="myov:EffetiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementDeferralAdjustmentAmount" scale="3" id="fact-identifier-796" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi0yLTEtMS0yNTM5_837b0fd4-74ec-4f4e-b685-4fc213584441" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,364</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" name="myov:EffetiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementDeferralAdjustmentPercent" scale="-2" id="fact-identifier-797" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi00LTEtMS0yNTM5_ad562108-1b34-412a-80e8-2507a8620b56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.71</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:EffetiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementDeferralAdjustmentAmount" scale="3" id="fact-identifier-798" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi02LTEtMS0yNTM5_658c1f75-7255-4b72-bc80-53c277abd971" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4,089</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" sign="-" name="myov:EffetiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementDeferralAdjustmentPercent" scale="-2" id="fact-identifier-799" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi04LTEtMS0yNTM5_283c4d46-9e75-47fe-9f38-f920c6db8333" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.42</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="myov:EffetiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementDeferralAdjustmentAmount" scale="3" id="fact-identifier-800" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi0xMC0xLTEtMjUzOQ_6d94cc38-ba5d-4295-b420-1c1a6482dd60" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" format="ixt:zerodash" name="myov:EffetiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedPaymentArrangementDeferralAdjustmentPercent" scale="-2" id="fact-identifier-801" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfNi0xMi0xLTEtMjUzOQ_2e0fe245-1ffa-4fda-bd1a-a959b9e0767b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="fact-identifier-802" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfOC0yLTEtMS0yNTM5_1f96b4ab-d031-4f3f-ba0f-17062622b4bf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50,333</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-803" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfOC00LTEtMS0yNTM5_398d62b7-e1aa-461e-84f8-6393e60e0310" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19.75</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="fact-identifier-804" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfOC02LTEtMS0yNTM5_91c1cbd2-19c5-4fa3-8e2c-cccc9fe59905" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">65,193</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-805" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfOC04LTEtMS0yNTM5_2b16af82-5a4f-4a96-845a-dcfe47cd5763" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22.62</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="fact-identifier-806" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfOC0xMC0xLTEtMjUzOQ_31f39c50-10e3-4020-a2f3-84d456797f59" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">32,335</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="fact-identifier-807" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfOC0xMi0xLTEtMjUzOQ_8cbdb055-68ae-45ff-aff4-195cf8109c02" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.83</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="fact-identifier-808" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTAtMi0xLTEtMjUzOQ_b1f50986-29d2-43d4-975a-731ed2522903" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">88</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="fact-identifier-809" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTAtNC0xLTEtMjUzOQ_d8eb13da-458e-417b-aa4c-40d3af7d64cd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.03</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="fact-identifier-810" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTAtNi0xLTEtMjUzOQ_0fa991ba-8fc3-4ca9-b43f-64915d2d5acf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">107</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="fact-identifier-811" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTAtOC0xLTEtMjUzOQ_cfc25a88-1224-40c5-9486-d1ecedc36820" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.04</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="fact-identifier-812" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTAtMTAtMS0xLTI1Mzk_47bb6e49-61fd-4033-a809-f5c266fb7fbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">607</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="fact-identifier-813" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTAtMTItMS0xLTI1Mzk_ccb9123c-75cd-47bf-b112-6428773e45e6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.22</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax expense </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-814" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTEtMi0xLTEtMjUzOQ_0033a63c-ca95-47eb-be35-8adc16eafa5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">336</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-815" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTEtNC0xLTEtMjUzOQ_2d139201-6614-475c-952f-41c467ab820b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-816" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTEtNi0xLTEtMjUzOQ_5a6b99c9-9bcc-4a62-bc94-a977d1f8d235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">761</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-817" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTEtOC0xLTEtMjUzOQ_c5e1ae36-ae96-4ab5-b7a3-8ee86d91660b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="fact-identifier-818" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTEtMTAtMS0xLTI1Mzk_68612a95-64cd-45ce-995f-c37ae28982be" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">476</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-819" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmYxNGIxNjRmN2UwMjQ4M2E4NzVlYWFkMDk5ODgwOTFjL3RhYmxlcmFuZ2U6ZjE0YjE2NGY3ZTAyNDgzYTg3NWVhYWQwOTk4ODA5MWNfMTEtMTItMS0xLTI1Mzk_24707076-5707-4978-8678-8a70ffd98ba2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.17</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Primarily related to current tax on United States operations including permanent differences as well as operations in Switzerland and the United Kingdom at rates different than the Bermuda rate.</span></div></ix:nonnumeric></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="ib14d9e997c01487d85b59520222000e2" continuedat="i45f6ec7a1e4c47a2b53f9f7724f42375" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective tax rate for the years ended March 31, 2021, 2020 and 2019 was (<span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-821" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTA3OA_784cc55a-99ee-4d4e-ac3b-af04115603ca" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.13</ix:nonfraction></span>)%. (<span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-822" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTA4Mg_8f695854-e5a5-410c-ace6-dffab27658c3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.26</ix:nonfraction></span>)%, and (<span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="fact-identifier-823" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTA4Ng_0870a301-0412-4359-856f-3e5812d304bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="true" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.17</ix:nonfraction></span>)%, respectively, and is driven by the Company’s jurisdictional earnings by location and a valuation allowance that eliminates the Company’s global net deferred tax assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="fact-identifier-824" continuedat="i1e7137ca5197492188e0ff68b221e8d9" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY3NQ_dba88f0e-0519-43c6-b63e-2462bc4fe025" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Significant components of the deferred tax assets and liabilities as of March&nbsp;31, 2021 and 2020 are as follows (in thousands): </ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-align:justify"><span><ix:continuation id="i1e7137ca5197492188e0ff68b221e8d9" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="fact-identifier-826" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMy0xLTEtMS0yNTM5_12bd8dbb-0a45-4694-859e-6fd9f492ad7a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,967</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="fact-identifier-827" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMy0zLTEtMS0yNTM5_80a915ab-0411-45e5-a2ae-d26c58c15019" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6,521</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="fact-identifier-828" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNC0xLTEtMS0yNTM5_863c46ec-5830-405c-817b-40438968f8ce" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">119,701</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="3" id="fact-identifier-829" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNC0zLTEtMS0yNTM5_6d95b6eb-f4a2-4715-abfe-25cf38a874f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84,694</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="fact-identifier-830" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNS0xLTEtMS0yNTM5_b8ccb8b4-3320-4578-94bf-37d4194a6612" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,649</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="fact-identifier-831" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNS0zLTEtMS0yNTM5_2a670296-4e1a-41d2-a6c3-6e157e6d7164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,573</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="fact-identifier-832" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNi0xLTEtMS0yNTM5_08b94422-774d-4bc4-afaf-3d6591e844c9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58,830</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="fact-identifier-833" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNi0zLTEtMS0yNTM5_ab3f9740-fafe-4b4b-ac9b-cee839832d74" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">52,922</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:DeferredTaxAssetsLeasingArrangements" scale="3" id="fact-identifier-834" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNy0xLTEtMS0yNTM5_601d08ba-99c8-4028-ba33-5bb903f852b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,317</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="myov:DeferredTaxAssetsLeasingArrangements" scale="3" id="fact-identifier-835" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfNy0zLTEtMS0yNTM5_e453afa9-bf95-4d3f-a077-d8258adde80d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">2,633</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-836" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfOC0xLTEtMS0yNTM5_1d68474b-4343-47d7-8c1b-538af876ba42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,080</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="fact-identifier-837" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfOC0zLTEtMS0yNTM5_e9c0c87f-a72d-4d2e-ab39-4d72351f2415" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,936</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="fact-identifier-838" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfOS0xLTEtMS0yNTM5_1e667bb5-0ac5-4f4e-a62c-76a6f0a4be18" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">210,544</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="fact-identifier-839" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfOS0zLTEtMS0yNTM5_90cb83b3-6fc2-4e2f-b3dc-2bc1303d1e39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">160,279</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="fact-identifier-840" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTAtMS0xLTEtMjUzOQ_05dd6923-d457-450f-a8a6-efe8f5d06672" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">207,858</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="fact-identifier-841" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTAtMy0xLTEtMjUzOQ_1968c7c1-a89f-44d4-96e5-21d8b029a947" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">157,525</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="fact-identifier-842" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTItMS0xLTEtMjUzOQ_98e85762-665c-42c2-ab59-fc224e4e3e75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">651</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="fact-identifier-843" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTItMy0xLTEtMjUzOQ_302a0a30-c2ba-484b-bd10-eb9b85b5f908" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">409</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="fact-identifier-844" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTMtMS0xLTEtMjUzOQ_0e2266c7-0a37-41b4-9c5e-755938ea87bb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,035</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="fact-identifier-845" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTMtMy0xLTEtMjUzOQ_e2e62709-bf56-4934-ac9a-4cd2f0a9149c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,345</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="fact-identifier-846" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTQtMS0xLTEtMjUzOQ_cd1af5ca-3824-4169-809b-1361cae64fd0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="fact-identifier-847" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOjlmMDFlMzQ2NjAwZTQ5MmM5OTkzNzViMzU4YzhiMjZhL3RhYmxlcmFuZ2U6OWYwMWUzNDY2MDBlNDkyYzk5OTM3NWIzNThjOGIyNmFfMTQtMy0xLTEtMjUzOQ_3fec118e-54b5-4a8f-9001-86bd32db6178" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s net operating losses in Switzerland, Ireland, and the United Kingdom were $<span><ix:nonfraction unitref="usd" contextref="i90a89ad745cc4430a45ae443473d907e_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="fact-identifier-848" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTY4Ng_ce6d2c51-3082-470f-b1fb-ff7b91fcd76a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">876.0</ix:nonfraction></span> million, $<span><ix:nonfraction unitref="usd" contextref="ia1b05c42fa7946719c0649d510655f73_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="fact-identifier-849" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTY5MA_4aff25fa-03b2-4b29-a35b-2b78bcaf499a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million, and $<span><ix:nonfraction unitref="usd" contextref="ia050f9c6320246b68eaaa2414e7bf09d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="fact-identifier-850" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTY5NA_1300563d-7355-433b-bfdb-67b239724fe2" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">31.0</ix:nonfraction></span> million, respectively. The Switzerland net operating losses will begin to expire on March&nbsp;31, 2025. The net operating losses in Ireland and the United Kingdom can be carried forward indefinitely with annual usage limitations where applicable. As of March 31, 2021, the Company has research and development credit carryforwards in the United States in the amount of $<span><ix:nonfraction unitref="usd" contextref="i14cb036be58049a5a1e6ef1933f1f5d9_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-851" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTcyMg_12631789-ec67-4a5b-91b9-36855b1b5515" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.7</ix:nonfraction></span> million</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which will begin to expire on March&nbsp;31, 2038 and in California in the amount of $<span><ix:nonfraction unitref="usd" contextref="ie27c0afbf0b9429b90af8a081e74358f_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="fact-identifier-852" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTcyNg_31b2aa28-29b3-402e-9071-057336d3b274" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.3</ix:nonfraction></span> million which can be carried forward indefinitely.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. Due to the Company’s cumulative loss position which provides significant negative evidence which is difficult to overcome, the Company has recorded a valuation allowance of $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="fact-identifier-853" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTYzOTY3NA_1ce6e9d2-8d49-4260-824c-b2570ec5d69f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">207.9</ix:nonfraction></span> million as of March&nbsp;31, 2021 representing the portion of the deferred tax asset that is not more likely than not to be realized. The amount of the deferred tax asset considered realizable, could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the proper amount, if any, required for a valuation allowance.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are outside basis differences related to the Company’s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions generally provides for exemption from tax for most overseas profits, subject to certain exceptions.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. tax attributes may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986 (the “Code”), and similar state provisions if the Company experiences one or more ownership changes, which would limit the amount of the tax attributes that can be utilized to offset future taxable income. In general, an ownership change as defined by Section 382, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. If a change in ownership occurs in the future, the R&amp;D credit carryforwards could be eliminated or restricted. The Company experienced an ownership change for the purposes of Section 382 and 383 of the Code in December 2019 as a result of the Sumitomo-Roivant Transaction (see Note 6(A)). The ownership change did not result in the forfeiture of any credits generated prior to this date. If a change in ownership occurs in the future, the tax attributes could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i45f6ec7a1e4c47a2b53f9f7724f42375" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to tax and will file income tax returns in the United Kingdom, Switzerland, Ireland, and the United States federal and certain state and local jurisdictions. The Company is subject to tax examinations for tax years ended March&nbsp;31, 2018 and forward in all applicable income tax jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="fact-identifier-855" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY3Ng_405e92f3-de9a-433a-8843-04348b6998d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity related to unrecognized tax benefits for the years ended March 31, 2021, 2020, and 2019 is as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of period balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-856" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMS0xLTEtMS0yNTM5_7f05e9df-7c31-4df8-bff5-a55197f4527b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,177</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-857" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMi0zLTEtMS0xMDgwMg_53b85ae9-5e1a-4bd7-a1dd-f556ce9effa1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaaaac77afb624e62b09f40c92b485ea0_I20180331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-858" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMi01LTEtMS0xMDgwMg_7fa13dba-4394-45c2-9bf9-a3513a417ce6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases — prior period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-859" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMi0xLTEtMS0yNTM5_a568288f-d49d-4de8-a8c6-6ac061eefa3a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-860" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMy0zLTEtMS0xMDgwMg_2809dde0-cab1-4c28-b143-6be70865e508" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,067</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-861" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMy01LTEtMS0xMDgwMg_bb5605ec-1ac2-4f51-8e97-d87e44db7e91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross decreases — prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-862" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfMy0xLTEtMS0yNTM5_f71f8361-e7c1-4de8-87a2-a871b280f431" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">128</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-863" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNC0zLTEtMS0xMDgwMg_48137d81-683a-4a9a-b871-da91997f512d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="fact-identifier-864" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNC01LTEtMS0xMDgwMg_e41bed6d-3eac-4931-8079-d1f48f27e9a7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross increases — current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="fact-identifier-865" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNC0xLTEtMS0yNTM5_dbb377ca-62b1-42fb-b3d0-d687656b7cf6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,355</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="fact-identifier-866" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNS0zLTEtMS0xMDgwMg_9dc281b3-a8c0-4db5-9c31-13dce98030dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,110</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="fact-identifier-867" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNS01LTEtMS0xMDgwMg_e0093485-2915-402b-9ff2-bd23b2974a43" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of period balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-868" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNS0xLTEtMS0yNTM5_14a13b68-5dc1-4d03-9799-e880a8051c38" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,404</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-869" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNi0zLTEtMS0xMDgwMg_9a6db054-3d5d-4ee3-979d-6feed6c20fbd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,177</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="fact-identifier-870" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RhYmxlOmQxYTMwOWVhMjYyMDQzNmU4NmRiOGIwYjVhYTlkYTcwL3RhYmxlcmFuZ2U6ZDFhMzA5ZWEyNjIwNDM2ZTg2ZGI4YjBiNWFhOWRhNzBfNi01LTEtMS0xMDgwMg_4a71e0cb-1151-44a9-9165-4352b6dc9ea0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the tax year ended March 31, 2021, the Company’s unrecognized tax benefits increased by $<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="6" id="fact-identifier-871" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTY1NTMzOQ_f9c6ecc3-ab3a-4606-8622-8d7cb4adc2e8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.2</ix:nonfraction></span> million, primarily associated with the Company’s U.S. Federal and California R&amp;D tax credits. During the tax year ended March 31, 2020, the Company’s unrecognized tax benefits increased by $<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" scale="6" id="fact-identifier-872" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTY1NTMzMg_e9e9ba42-5417-4900-9385-c3b861e55b47" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.2</ix:nonfraction></span> million, primarily associated with the Company’s U.S. Federal and California R&amp;D tax credits. As of March 31, 2021, the Company had unrecognized tax benefits of $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="fact-identifier-873" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMTA5OTUxMTY1NTMwNQ_2dc8889a-c3ad-428c-81f0-4740fdccf110" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.4</ix:nonfraction></span> million that if recognized would have an immaterial effect on the Company’s effective tax rate. The Company does <span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" scale="0" id="fact-identifier-874" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY4Ng_3e533794-3fe8-4e29-ba16-35fafce04131" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span>t expect that there will be a significant change in the unrecognized tax benefits over the next twelve months. Due to the existence of the valuation allowance, future changes in the Company’s unrecognized tax benefits will not impact the effective tax rate. The Company had <span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="fact-identifier-875" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY3OA_e015b15a-9ca1-4842-b6e4-099b375cc10e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> accrual for interest or penalties on its consolidated balance sheets at March&nbsp;31, 2021 and 2020, and had <span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="fact-identifier-876" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY5NA_10e44854-0134-4b7d-ad87-fb4a6edcda8d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="fact-identifier-877" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY5NA_3cf2e964-ec03-4c74-bf27-24bad259535b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="fact-identifier-878" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfNTQ5NzU1ODE2NjY5NA_573f37bb-24bc-4992-87c4-ab5aa8b31f8f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span></ix:nonfraction></span>t recognized interest and/or penalties in its consolidated statements of operations for any of the years ended March 31, 2021, 2020 and 2019.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, many governments have enacted measures to provide aid and economic stimulus. These measures include deferring the due dates of tax payments and other changes to income and non-income-based-tax laws as well as providing direct government assistance through grants and forgivable loans. On March&nbsp;27, 2020, the U.S. Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to the COVID-19 pandemic and the negative impacts that it is having on the global economy and U.S. companies. The CARES Act includes measures to assist companies, including temporary changes to income and non-income-based tax laws. The Company implemented certain provisions of the CARES Act, such as deferring employer payroll taxes through the end of calendar year 2020. As of March 31, 2021, the Company has deferred $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:SocialSecurityTaxEmployerDeferralCARESAct" scale="6" id="fact-identifier-879" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMjU0MQ_d9868e26-bdef-4f41-9c4b-4ca7e4599cff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.8</ix:nonfraction></span> million of employer payroll taxes, of which 50% are required to be deposited by December 2021 and the remaining 50% by December 2022. The current portion of the deferred payroll tax liability of $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:SocialSecurityTaxEmployerDeferralCARESActCurrent" scale="6" id="fact-identifier-880" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMjczMQ_d4c953e5-47a0-4790-96cf-d74808da9370" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span> million is included in accrued expenses and other current liabilities and the non-current portion of the deferred payroll tax liability of $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:SocialSecurityTaxEmployerDeferralCARESActNoncurrent" scale="6" id="fact-identifier-881" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81Mi9mcmFnOjU3MTg3ZWQ2NmY4MjQ1ZTNhMzU5MGQ5MjBhYmIyZWJiL3RleHRyZWdpb246NTcxODdlZDY2ZjgyNDVlM2EzNTkwZDkyMGFiYjJlYmJfMjgzNQ_203d38fa-9e2f-4c68-b12b-8051b1a55245" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.9</ix:nonfraction></span> million is included in other liabilities on the accompanying consolidated balance sheets.</span></div></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_55"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="fact-identifier-882" continuedat="i50e9425650244071a67a66259a2cd9a4" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTY3MA_1395819c-1297-4ca6-ad98-5cd4e75d57db" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Shareholders’ Equity (Deficit)</ix:nonnumeric></span></span></div><span><ix:continuation id="i50e9425650244071a67a66259a2cd9a4" continuedat="ibdf550fda112470091c863749999be7b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A) Overview</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s Memorandum of Association, filed on February 2, 2016 in Bermuda, authorized the creation of <span><ix:nonfraction unitref="class" contextref="idbe6fbaf66b8452f81c58753e6162dbe_I20160202" decimals="INF" format="ixt-sec:numwordsen" name="myov:CommonStockNumberOfClassesOfStock" scale="0" id="fact-identifier-884" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYyOTk2Nw_ecd31998-4dcc-42bd-af7a-800b7febf7c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span> class of shares. As of March 31, 2021, the Company had <span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="fact-identifier-885" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzMDA3Nw_10cd97a5-ea6a-4023-9898-5a58d652e82e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">564,111,242</ix:nonfraction></span> shares authorized with a par value of $<span><ix:nonfraction unitref="usdPerShare" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="9" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="fact-identifier-886" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzMDA4MQ_6e35da1e-2094-4090-bdd1-52dac9a3a73a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.000017727</ix:nonfraction></span> per share.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(B) Underwritten Public Equity Offering of Common Shares</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&nbsp;4, 2019, the Company completed an underwritten public equity offering of <span><ix:nonfraction unitref="shares" contextref="ia4b15f058a9d4ed3a6aad08a0a1f4339_D20190604-20190604" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-887" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMjc0ODc3OTA3Mjc4Mg_432e3d3a-1663-493c-b3f9-06ce48c2a707" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17,424,243</ix:nonfraction></span> of its common shares at a public offering price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i31ea3c0b682048259654ea71d2e26d84_I20190604" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-888" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMjc0ODc3OTA3MjgzNw_e877405b-35d4-4c80-99a6-ebef022cf709" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.25</ix:nonfraction></span> per common share. After deducting the underwriting discounts and commissions and offering costs paid by the Company, the net proceeds to the Company in connection with the underwritten public equity offering, including from the exercise of the underwriters’ option to purchase additional common shares, were approximately $<span><ix:nonfraction unitref="usd" contextref="ia4b15f058a9d4ed3a6aad08a0a1f4339_D20190604-20190604" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-889" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMjc0ODc3OTA3MzE2Mw_f1c26a64-e2ea-4d11-8530-34de6db21cc5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">134.5</ix:nonfraction></span> million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Private Placement with Former Majority Shareholder</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into a share purchase agreement with Roivant, its former majority shareholder, pursuant to which the Company sold to Roivant <span><ix:nonfraction unitref="shares" contextref="i99c173fc4a03493fa8326c6e2dc82492_D20180401-20180430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-890" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDQwMQ_d024cf1e-7a90-4663-8012-e7bea6838ad6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,110,015</ix:nonfraction></span> of its common shares at a purchase price of $<span><ix:nonfraction unitref="usdPerShare" contextref="i7c2361102bdb408e86893b0add5297f9_I20180430" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-891" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDQxMA_da02fb82-5c91-4a0d-9d5e-2ea48f0ca446" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">20.27</ix:nonfraction></span> per common share, for gross proceeds of $<span><ix:nonfraction unitref="usd" contextref="i99c173fc4a03493fa8326c6e2dc82492_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-892" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDQyNg_183a85f7-e46c-4317-a5ce-b03db0273930" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22.5</ix:nonfraction></span> million, in a private placement.</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="ibdf550fda112470091c863749999be7b" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(D) At-the-Market Equity Offering Program</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”), to sell its common shares having an aggregate offering price of up to $<span><ix:nonfraction unitref="usd" contextref="i1b87553fb87b4999b2ca0bcb634c4d5a_I20180430" decimals="INF" format="ixt:numdotdecimal" name="myov:SaleofStockAuthorizedAmount" scale="6" id="fact-identifier-894" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMjU5_2592dd94-1ca9-4673-bc2c-13e3f6ced347" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100.0</ix:nonfraction></span> million from time to time through an “at-the-market” equity offering program under which Cowen acted as the Company’s agent. During the years ended March&nbsp;31, 2020 and 2019, the Company issued and sold <span><ix:nonfraction unitref="shares" contextref="i9617fb45d9424787a8eafd2ba4e4de52_D20190401-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-895" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDM0Ng_27e85c73-b50f-48e8-bd64-f67899dc8d63" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">106,494</ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="ic2976f6ca9974c84a27bd4800eb31e6a_D20180401-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-896" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDM1MA_bce9a5f4-c002-4bc0-be31-89869bfe01cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,970,129</ix:nonfraction></span>, respectively, of its common shares under the Sales Agreement. The common shares were sold at a weighted-average price of $<span><ix:nonfraction unitref="usdPerShare" contextref="iad4e1aedd77242baab4668c4efdf0daa_I20200331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-897" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDMzMw_eee6ae1b-1c9e-4e77-bc03-06664d22c580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24.65</ix:nonfraction></span> and $<span><ix:nonfraction unitref="usdPerShare" contextref="i2c23fa554dc24d70ab6393e0fd1f4b90_I20190331" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="fact-identifier-898" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDM0MQ_657b41c4-eda0-419f-ada6-dd56311a6cbc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">21.91</ix:nonfraction></span>, respectively, per common share for aggregate net proceeds to the Company of approximately $<span><ix:nonfraction unitref="usd" contextref="i9617fb45d9424787a8eafd2ba4e4de52_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-899" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDM1NA_851f3aea-6ed5-433a-bd0f-cb668bdc75fa" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.5</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="ic2976f6ca9974c84a27bd4800eb31e6a_D20180401-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="fact-identifier-900" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfMTA5OTUxMTYzNDM3MA_ad24d392-1ead-45a9-a694-a59080409d7b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">84.1</ix:nonfraction></span> million, respectively, after deducting underwriting commissions and offering costs paid by the Company. <span><ix:nonfraction unitref="shares" contextref="ife8399c5bfe14297aeae28b517791725_D20200401-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="fact-identifier-901" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81NS9mcmFnOjE1NDA4YjFlNDJkNTQzODE5NGI3MTk5MGZlMjBmZmExL3RleHRyZWdpb246MTU0MDhiMWU0MmQ1NDM4MTk0YjcxOTkwZmUyMGZmYTFfNjc1_53e861e8-512a-463f-bc4c-937ba6980cc1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">No</ix:nonfraction></span> shares were sold under the Sales Agreement during the year ended March 31, 2021. The “at-the-market” equity offering program expired in March 2021.</span></div></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="fact-identifier-902" continuedat="iaba2dd2d79134986951cb13cb0566be1" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNDY1Nw_603b3ad2-dbac-487e-ad03-b7a0a7677de0" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Share-Based Compensation</ix:nonnumeric></span></span></div><span><ix:continuation id="iaba2dd2d79134986951cb13cb0566be1" continuedat="i01b38b288e5e44338ac3e4122c022f43" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <span><ix:nonfraction unitref="plan" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="myov:ShareBasedCompensationArrangementByShareBasedCompensationPaymentAwardNumberOfPlans" scale="0" id="fact-identifier-904" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODE0MzU1NA_a7caee44-b768-4f1f-afd5-cb6683d438a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">two</ix:nonfraction></span> share-based compensation plans, the Myovant Sciences Ltd. 2020 Inducement Plan and the Myovant Sciences Ltd. 2016 Equity Incentive Plan (collectively, the “Equity Plans”).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A) 2020 Inducement Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the compensation committee of the Company’s board of directors adopted the Myovant Sciences Ltd. 2020 Inducement Plan (the “2020 Inducement Plan”), which, subject to the adjustment provisions thereof, reserved <span><ix:nonfraction unitref="shares" contextref="i32426dc54f2e4f90a2e28216c0ba82f3_I20201130" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="fact-identifier-905" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNDcx_8e6218de-bf36-4f42-8f68-e2e02c610e31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.0</ix:nonfraction></span> million shares of the Company’s common shares for issuance. The 2020 Inducement Plan was adopted without shareholder approval pursuant to the Listed Company Manual Rule 303A.08 (“Rule 303A.08”) of the New York Stock Exchange (the “NYSE”). The 2020 Inducement Plan provides for the grant of restricted stock units and non-qualified stock options, and contains terms and conditions intended to comply with the inducement award exception under the NYSE rules. In accordance with Rule 303A.08, awards under the 2020 Inducement Plan may only be made to individuals not previously employees of the Company, or being rehired following a bona fide period of interruption of employment, as an inducement material to such individuals’ entering into employment with the Company. An award is a right to receive the Company’s common shares pursuant to the 2020 Inducement Plan pursuant to a restricted stock unit award or a non-qualified stock option award. As of March&nbsp;31, 2021, there were less than <span><ix:nonfraction unitref="shares" contextref="i3b8b6bed0cf54930a7276e9765285fb2_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="fact-identifier-906" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODIwMzEwNA_ac099f3e-7624-48b2-b2c3-329fbf953e7c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span>&nbsp;million common shares available for future issuance under the 2020 Inducement Plan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(B) 2016 Equity Incentive Plan</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company adopted its 2016 Equity Incentive Plan, as amended (the “2016 Plan”), under which <span><ix:nonfraction unitref="shares" contextref="i53c956a8a25046c3a5d7c63adaa2143e_I20160630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="fact-identifier-907" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTY1NQ_73cfc133-bd26-4063-a9bb-14d50a5f3917" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.5</ix:nonfraction></span> million common shares were originally reserved for issuance. Pursuant to the “evergreen” provision contained in the 2016 Plan, the number of common shares reserved for issuance under the 2016 Plan automatically increases on April 1 of each year, commencing on (and including) April 1, 2017 and ending on (and including) April 1, 2026, in an amount equal to <span><ix:nonfraction unitref="number" contextref="i53c956a8a25046c3a5d7c63adaa2143e_I20160630" decimals="2" name="myov:CommonStockCapitalSharesReservedforIssuanceAnnualPercentageIncreaseasaPercentageofCommonStockOutstanding" scale="-2" id="fact-identifier-908" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjAwNw_66325703-ece4-4dd0-acfb-523c7c686da3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">4</ix:nonfraction></span>% of the total number of shares of the Company’s capital stock outstanding on March 31 of the preceding fiscal year, or a lesser number of shares as determined by the Company’s board of directors. On April 1, 2020, the number of common shares authorized for issuance under the 2016 Plan increased automatically by <span><ix:nonfraction unitref="shares" contextref="i5241b229576a4e2cbf7ec1780e27f524_D20200401-20200401" decimals="-5" format="ixt:numdotdecimal" name="myov:CommonStockIncreaseDecreaseinCapitalSharesReservedforIssuance" scale="6" id="fact-identifier-909" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY4MDIzMg_feb32ba4-05f9-41e4-b028-30a1142bd075" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.6</ix:nonfraction></span> million shares in accordance with the evergreen provision. As of March&nbsp;31, 2021, a total of <span><ix:nonfraction unitref="shares" contextref="i75760b3f086640beb44c84b01be1dfd6_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="6" id="fact-identifier-910" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjM4Ng_3f97a991-b4be-4816-931b-47e3086ef773" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.3</ix:nonfraction></span> million common shares were available for future issuance under the 2016 Plan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s employees, directors, officers and consultants are eligible to receive non-qualified and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other share awards under the 2016 Plan.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Stock Option Repricing </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&nbsp;26, 2019 (the “repricing date”), the Company’s board of directors approved a stock option repricing program (the “repricing”) whereby certain previously granted and still outstanding vested and unvested stock options held by current employees and certain executives were repriced on a <span><ix:nonfraction unitref="number" contextref="i2f7e93d9c2ac463186f432b565e4eff3_D20190826-20190826" decimals="INF" format="ixt-sec:numwordsen" name="myov:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsRepricingRatio" scale="0" id="fact-identifier-911" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODE3MDI5OQ_74ee3090-2b25-4c24-894c-4e8efe68362d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one</ix:nonfraction></span>-for-one basis to $<span><ix:nonfraction unitref="usdPerShare" contextref="i28fc3cb4eabd47658f50a411778d7d2a_I20190826" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-912" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE2OQ_02a84f1c-f43b-4e51-b81b-913c90bf7303" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.78</ix:nonfraction></span> per share, which represented the closing market price of the Company’s common shares on the repricing date. To be eligible to participate in the stock option repricing program, <span><ix:nonfraction unitref="shares" contextref="i4bb854f2f89245be9c6674d2122cd54a_I20190826" decimals="INF" format="ixt:numdotdecimal" name="myov:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedOutstandingSubjecttoRestrictionPeriod" scale="0" id="fact-identifier-913" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE3Mw_c46abcc9-21cf-465e-99ff-2c25ad898149" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">735,428</ix:nonfraction></span> vested stock options to certain executives as of the repricing date were subject to a <span><ix:nonnumeric contextref="iba9dbf39a9ec48f08ffc4b4c6f83da16_D20190826-20190826" format="ixt-sec:durwordsen" name="myov:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedOutstandingRestrictionPeriod" id="fact-identifier-914" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODE3MDMyOA_686aaadb-9703-4e0c-9839-7b57e5bc0994" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one-year</ix:nonnumeric></span> exercise restriction period beginning from the repricing date. No other terms of the repriced stock options were modified, and the repriced stock options have vested and will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the repricing, <span><ix:nonfraction unitref="shares" contextref="ib1cbbf17f4a349698c18de77532fec91_I20190825" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="fact-identifier-915" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE4MQ_a09257f2-8906-40c6-8ea6-b9d9768a36a4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,095,013</ix:nonfraction></span> vested and unvested stock options outstanding with original exercise prices ranging from $<span><ix:nonfraction unitref="usdPerShare" contextref="i7811a97ef23b4fd2a2148d9e87cb4926_I20190825" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-916" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE4NQ_4a39c146-24b4-453f-8923-3b5c5d9ba304" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.82</ix:nonfraction></span> to $<span><ix:nonfraction unitref="usdPerShare" contextref="id71ac72af0e646d9abe133492e4c342b_I20190825" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-917" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE4OQ_0ab64a84-5ff1-419f-9f17-152ef2b1c2b9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">24.44</ix:nonfraction></span>, and a median exercise price of $<span><ix:nonfraction unitref="usdPerShare" contextref="ia096d573ae55428e8102aa9304361433_I20190825" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-918" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE5Mw_eef7838f-f631-4929-84ac-ed2d959b8de4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">17.28</ix:nonfraction></span> per share, were repriced under this program. The repricing resulted in one-time incremental stock-based compensation expense of $<span><ix:nonfraction unitref="usd" contextref="i2f7e93d9c2ac463186f432b565e4eff3_D20190826-20190826" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1" scale="6" id="fact-identifier-919" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY1OTE1Mw_bdaeadb0-ddfe-4208-b74a-e763244a4a37" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.2</ix:nonfraction></span> million, which is being recognized over the remaining term of the repriced stock options.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(D) Stock Options</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each non-qualified stock option has an exercise price equal to the fair market value of the Company’s common shares on the date of grant. Stock options granted to employees generally vest over a <span><ix:nonnumeric contextref="ifb05b7ba93bf4df3b372ea71154cc993_D20200401-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="fact-identifier-920" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODIwMTUyOQ_9bf78b56-4696-46e7-b07a-178dc4e18096" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">four-year</ix:nonnumeric></span> period. Initial stock options granted to non-</span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i01b38b288e5e44338ac3e4122c022f43" continuedat="i2aab98d714c24f31b3170b1ecf3dde17" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">executive members of the Company’s board of directors vest over a <span><ix:nonnumeric contextref="i70c22e7ba07e49bca70d22170efedbfc_D20200401-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="fact-identifier-922" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODIwMTU0Mg_08b2f89a-90fe-4eed-918e-1ecb6f4cfbbf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">three-year</ix:nonnumeric></span> period. One third of the shares subject to such stock options vest on the first anniversary of the grant date, with the balance of the shares vesting in eight equal quarterly installments thereafter, subject to subject in each case to continued service through each of the vesting dates.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual stock options granted to non-executive members of the Company’s board of directors vest in full on the earlier to occur of (i) the first (1st) anniversary of the date of grant and (ii) the day immediately prior to the date of the annual general meeting of shareholders for the year following the year in which the grant is made, subject in each case to continued service through the vesting date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each non-qualified stock option award has a maximum term of <span><ix:nonnumeric contextref="i36f53a993a4146c1888a0c675b260515_D20200401-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="fact-identifier-923" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODE5MjM4MA_163127f9-9a69-4f4d-9064-6b7371d162f1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10</ix:nonnumeric></span> years from the date of grant, subject to the earlier cancellation prior to vesting upon cessation of service to the Company. Options that are forfeited or expire are available for future grants.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="fact-identifier-924" continuedat="ib28194066dd640f3a528105f39e77bc4" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNDY2OA_ebd688b4-c144-4db0-a3ad-e4cfafab13b1" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for stock options for the year ended March 31, 2021 is included in the following table:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.391%"><tbody><tr><td style="width:1.0%"></td><td style="width:44.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Options</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March&nbsp;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="fact-identifier-925" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMS0xLTEtMS0w_3b8ac1b4-5895-41aa-954e-4509c2a5c491" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,723,302</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-926" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfOS0zLTEtMS0xMjc5Mg_a690c83c-32e5-47f3-ab7a-05db0aaa0cbe" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.25</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="fact-identifier-927" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfOS01LTEtMS0xMjgwOQ_3edca495-346d-4c34-9f8d-c548b544ac03" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.08</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-928" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfOS03LTEtMS0xMjgwOQ_177a3cd1-85b2-4d7e-ad3f-f509d017e246" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4,146</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="fact-identifier-929" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMi0xLTEtMS0w_f41df8f2-89ac-48a5-94d2-eebac35db80a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,985,765</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-930" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTAtMy0xLTEtMTI3OTI_f8f714fa-5c92-4211-a4d8-7bf16b78aca4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.88</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="fact-identifier-931" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMy0xLTEtMS0w_341c5641-9fae-4d91-8004-1733be1ba44c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">905,776</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-932" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTEtMy0xLTEtMTI3OTI_cd80acf0-bd23-4c94-872e-6b670ba12ae8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.41</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="fact-identifier-933" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfNC0xLTEtMS0w_a156f483-6226-40cb-add3-6e5b857bbf84" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">509,960</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="fact-identifier-934" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTItMy0xLTEtMTI3OTI_9d3d5ffd-1d18-4b50-bedf-d206c0e10ecc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.32</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at March&nbsp;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="fact-identifier-935" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfNi0xLTEtMS0w_7900179d-a0a4-4edf-b56c-f5ab235d7fd6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,293,331</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-936" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTMtMy0xLTEtMTI3OTU_260e681d-d9ab-4f9e-9c6e-d9551b90ee7b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.90</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="fact-identifier-937" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTMtNS0xLTEtMTI4MDk_62b2f0d4-528d-4b4c-a975-2e2cd6a5d6fd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.48</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="fact-identifier-938" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTMtNy0xLTEtMTI4MDk_8a5b8510-53e8-4f39-8743-0e20ee204443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,699</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at March&nbsp;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="fact-identifier-939" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfNy0xLTEtMS0w_4a312f00-dc65-4d10-9aeb-c6af966da8cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8,293,331</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="fact-identifier-940" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTQtMy0xLTEtMTI3OTk_3dc3add0-9597-45af-bb38-05a2cce76b1e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.90</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="fact-identifier-941" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTQtNS0xLTEtMTI4MDk_4d6833c0-19d0-40f6-8f91-7d4602939f8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.48</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="fact-identifier-942" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTQtNy0xLTEtMTI4MDk_639704c5-8fcd-4d93-9139-596a9bb1a051" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90,699</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at March&nbsp;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="fact-identifier-943" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfOS0xLTEtMS0w_48949af2-1174-47f6-85f0-0916cde22a44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,219,403</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="fact-identifier-944" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTUtMy0xLTEtMTI3OTk_a3763d0d-3b57-4118-b3ae-c38ab320e105" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.77</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="fact-identifier-945" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTUtNS0xLTEtMTI4MDk_9c77537b-f33f-4012-a74a-431cf49771f4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5.26</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="fact-identifier-946" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjg5MmIzYWFkMDI3YzQ2YzY5Y2NjMWViNGVhZWE4ZDM2L3RhYmxlcmFuZ2U6ODkyYjNhYWQwMjdjNDZjNjljY2MxZWI0ZWFlYThkMzZfMTUtNy0xLTEtMTI4MDk_5d92c71d-8326-4557-92dc-ada5cd7a731a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">58,419</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, 2020 and 2019, there were <span><ix:nonfraction unitref="shares" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="fact-identifier-947" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MDI4NQ_48949af2-1174-47f6-85f0-0916cde22a44" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5,219,403</ix:nonfraction></span>, <span><ix:nonfraction unitref="shares" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="fact-identifier-948" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MDI4OQ_cd1e36e4-1302-46c5-937c-8ef9546a0528" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,009,080</ix:nonfraction></span> and <span><ix:nonfraction unitref="shares" contextref="ib0db7a698575433cb3c4c18d7405a592_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="fact-identifier-949" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MDI5Mw_70459c40-c8dc-4954-8f3a-1f4abb21e0d1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,581,810</ix:nonfraction></span> vested stock options outstanding, respectively. Pursuant to the Separation and General Release Agreement with the Company’s former Principal Executive Officer, the vesting of a total of <span><ix:nonfraction unitref="shares" contextref="i90720c8c13874fdfa2b23bc51da1625c_D20210111-20210111" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" id="fact-identifier-950" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2NzY2NA_f7c43dd0-b127-4d2e-bb68-348a6dd5a71e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">631,850</ix:nonfraction></span> stock options was accelerated on January 11, 2021 (see Note 10(H)). As a result of the change in control of the Company described in Note 6(A), the vesting of <span><ix:nonfraction unitref="shares" contextref="i96bf59ca87ae4224a3f6fafdb761f652_D20191227-20191227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" id="fact-identifier-951" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MDQxMA_5e6acbdb-0331-4032-8714-96af3fca4e5d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">849,212</ix:nonfraction></span> stock options was accelerated on December&nbsp;27, 2019.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="fact-identifier-952" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNTQ5NzU1ODE4MDQ3MA_6168a684-e8ae-4198-8f3d-540e22d86247" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes option-pricing model applying the weighted average assumptions in the following table:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected common share price volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-953" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfMi0xLTEtMS0xMzMyNQ_2d7c5287-bc17-4cb6-adb8-c2c14966bd4b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">75.7</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-954" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfMi0zLTEtMS0xMzMyNQ_d4eb4554-6d91-4fa7-b533-95ffc258f16d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">69.5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="fact-identifier-955" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfMi01LTEtMS0xNDYzMQ_63b49f50-59e7-4415-a5ec-870c1c5e3087" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">71.6</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected risk free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-956" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfMy0xLTEtMS0xMzMyNQ_8b85ba5d-f10b-4994-b597-fa0a0dbd6aae" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.47</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-957" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfMy0zLTEtMS0xMzMyNQ_e4d856c2-1a4a-44ec-82ac-1cceb53e682f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.05</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="fact-identifier-958" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfMy01LTEtMS0xNDYzMQ_59525a2a-f6c6-4093-aa1f-76e7374ae0ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term, in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="fact-identifier-959" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfNC0xLTEtMS0xMzMyNQ_3993cc10-df7c-4b15-b9c1-c071e57f9016" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.21</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="fact-identifier-960" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfNC0zLTEtMS0xMzMyNQ_fa85e354-f717-4bd8-b973-b2cf2d9d0f7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.17</ix:nonnumeric></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonnumeric contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="fact-identifier-961" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfNC01LTEtMS0xNDYzMQ_1a059365-6fa7-4220-af7d-785c8fa1f0ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6.23</ix:nonnumeric></span></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="fact-identifier-962" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfNS0xLTEtMS0xMzMyNQ_74f4d02d-06a4-452f-a250-fea7c27bbc50" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="fact-identifier-963" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfNS0zLTEtMS0xMzMyNQ_6e703ea2-1fe8-4a0b-bb75-cc0900f6dbc8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="number" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="1" id="fact-identifier-964" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmUwNjQzYzBjYmYxNTQ4MmU4ZDc1ZTk0MDcxYjMxNjMzL3RhYmxlcmFuZ2U6ZTA2NDNjMGNiZjE1NDgyZThkNzVlOTQwNzFiMzE2MzNfNS01LTEtMS0xNDYzMQ_c27deb74-930a-49db-bc6f-0756d2a7851d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div></ix:nonnumeric></span><span><ix:continuation id="ib28194066dd640f3a528105f39e77bc4" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information regarding stock options is set forth below (in thousands, except per share data).</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:53.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intrinsic value of options exercised</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="fact-identifier-966" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfMi0xLTEtMS0xMzAwMg_52dd0724-1ce1-4655-b494-044442465d19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,154</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="fact-identifier-967" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfMi0zLTEtMS0xMzAwMg_7672e98f-aaf4-4611-b516-61240373fad8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,036</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="fact-identifier-968" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfMi01LTEtMS0xMzAwMg_ece78fc5-a619-4dc6-9bc7-e00279f4dc93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,167</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant date fair value of options vested</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="fact-identifier-969" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfMy0xLTEtMS0xMzAwMg_a4da337f-2bf9-461b-b29f-f18e70a6e284" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">19,923</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="fact-identifier-970" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfMy0zLTEtMS0xMzAwMg_2eb96cc9-1a42-4785-9988-4c7e5ac426dd" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,112</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" id="fact-identifier-971" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfMy01LTEtMS0xMzAwMg_79670c92-b889-477d-9bf5-ce5b904153cf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,409</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share of options granted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-972" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfNC0xLTEtMS0xMzAwMg_f8b4d551-4280-47f9-ac28-7277c68e257f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.22</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-973" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfNC0zLTEtMS0xMzAwMg_08a26a49-a544-44aa-901a-3d515b93c16a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.54</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-974" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjFlNDQwYWI3Zjc1MTQxYzJiMmNjNjdhZjM0YTYxODU5L3RhYmxlcmFuZ2U6MWU0NDBhYjdmNzUxNDFjMmIyY2M2N2FmMzRhNjE4NTlfNC01LTEtMS0xMzAwMg_d25f1437-2c43-46d8-8c54-9b83b949d59a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14.10</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:continuation></span></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i2aab98d714c24f31b3170b1ecf3dde17" continuedat="ib91f181210ac468a8695b23c45faf527" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(E) Restricted Stock Awards and Restricted Stock Units </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (“RSU”) are share awards that, upon vesting, will deliver to the holder shares of the Company’s common shares. RSUs generally vest over a four-year period. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="fact-identifier-976" continuedat="i9d48d6e6e95d44f2b552e12167c04e8f" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNDY2Mg_e78aff0b-cf58-41fa-a06d-1fb4db1df47b" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Activity for restricted stock awards (“RSA”) and RSUs for the year ended March 31, 2021 is included in the following table: </ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-align:center"><span><ix:continuation id="i9d48d6e6e95d44f2b552e12167c04e8f" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March&nbsp;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia1058bec0d4b47e691d283c4993b14c8_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="fact-identifier-978" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMS0xLTEtMS0w_9b143297-ce08-496e-8126-ab16222f49d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,280,312</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ia1058bec0d4b47e691d283c4993b14c8_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-979" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfOS0zLTEtMS0xMjYwNg_21368ae0-c6e6-47c7-a181-8192e20dd84d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.71</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="fact-identifier-980" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMi0xLTEtMS0w_22f6b96f-e194-4ea4-a3c7-909a32b31c08" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,356,865</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-981" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMTAtMy0xLTEtMTI2MDY_bd84aefc-9142-468b-8373-a721e5a5a540" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.52</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="fact-identifier-982" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMy0xLTEtMS0w_7981b4b0-637d-4bc2-b98a-b62dadc2c0a6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,041,684</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-983" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMTEtMy0xLTEtMTI2MDY_179c8c30-cf52-4a6b-8638-a5cc5a5f51bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11.17</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="fact-identifier-984" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfNC0xLTEtMS0w_164313ab-5bb4-41a7-8a51-a16da56674bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">400,931</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="if78893b8c52e410ea745b31dc4e2b7e4_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-985" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMTItMy0xLTEtMTI2MDY_680dda5e-89b3-4f93-8428-f5cf6e722e5e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9.03</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March&nbsp;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="ia1737e566bd44f8b8435e57c4feba528_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="fact-identifier-986" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfNS0xLTEtMS0w_c0982427-6ac5-44d5-81f4-5396e38f5f03" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,194,562</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="ia1737e566bd44f8b8435e57c4feba528_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-987" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmQ5YzUyZjNiNzMxZjQzZDdiZTJjMDYwZjAzNTQzOWQ1L3RhYmxlcmFuZ2U6ZDljNTJmM2I3MzFmNDNkN2JlMmMwNjBmMDM1NDM5ZDVfMTMtMy0xLTEtMTI2MDY_cfe21725-2380-481a-be3b-6bffc8a5ff09" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.68</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSAs vested during the years ended March 31, 2021, 2020, and 2019 was $<span><ix:nonfraction unitref="usd" contextref="i304044cb65b442898864be253c282710_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-988" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MTA5OQ_89227984-fe60-44f1-aa3d-f823b7f044e4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.4</ix:nonfraction></span> million, $<span><ix:nonfraction unitref="usd" contextref="i58f241cf3fa24ccea9c80d6ec35d1efe_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-989" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MTEwMw_46170680-501c-4045-9f0a-067ad63bf98d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i50fc65ab07b54ae597dfaf23f929a717_D20180401-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-990" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MTEwNw_b4fad90f-b5b5-4a9f-9365-bb9e8405121e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.4</ix:nonfraction></span> million, respectively. The total fair value of RSUs vested during the years ended March 31, 2021, 2020, and 2019 was $<span><ix:nonfraction unitref="usd" contextref="id805a53b9e34474c87c15f68904f6e27_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-991" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MTExMQ_938270d1-6926-479e-af02-a3f667660b13" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.3</ix:nonfraction></span> million, $<span><ix:nonfraction unitref="usd" contextref="i24619cb8370c4b89881651dafb755384_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-992" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MTExNg_95e41356-6a9b-4a0d-865d-41d01062f912" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i6d57aa4bb3604940926187a3dc104911_D20180401-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-993" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2MTEyMA_2d1138d7-1cee-43c3-bb92-2a4b0114546e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.1</ix:nonfraction></span> million, respectively. Pursuant to the Separation and General Release Agreement with the Company’s former Principal Executive Officer, the vesting of RSUs and RSAs covering a total of <span><ix:nonfraction unitref="shares" contextref="i7ebbcc65387e437fa11813698fd3cc6f_D20210111-20210111" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" id="fact-identifier-994" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2NzYxMA_2e01c596-2e0f-45c7-ac7c-09667ff35f67" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">761,770</ix:nonfraction></span> common shares was accelerated on January 11, 2021 (see Note 10(H)).</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(F) Performance Share Units</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="fact-identifier-995" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNDY1NA_8327ff62-0749-43e2-bc78-f609c3137024" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for performance share units (“PSU”) for the year ended March 31, 2021 is included in the following table: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March&nbsp;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i9149eff2546a482b9623ca978c96029e_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="fact-identifier-996" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfMS0xLTEtMS0w_2214151e-bf50-4238-8502-5dc6d6b5ff19" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">299,870</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i9149eff2546a482b9623ca978c96029e_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-997" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfNS0zLTEtMS0xNDc5Nw_443ead51-91b8-44d2-8670-75e06e9fa553" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="fact-identifier-998" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfMi0xLTEtMS0w_6a3b046d-2283-45ba-a1aa-99ae89612723" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">568,976</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-999" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfNi0zLTEtMS0xNDc5Nw_7ada80dd-68c4-44a4-b818-3303247c95d0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">8.08</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="fact-identifier-1000" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfMy0xLTEtMS0w_a4ba5dbc-14c3-4127-81f6-a074297a903c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">454,758</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-1001" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfNy0zLTEtMS0xNDc5Nw_1eecadce-5bf0-4b1e-9e45-105504222756" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.98</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="shares" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="fact-identifier-1002" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfNC0xLTEtMS0w_eee28b0c-f28c-4a69-955e-ec575ba862d5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">37,415</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-1003" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfOC0zLTEtMS0xNDc5Nw_22cec394-77e3-4489-beb3-3e4971a41112" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.78</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested balance at March&nbsp;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="shares" contextref="id9282900d85f4e61a6640fa57fa2d94e_I20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="fact-identifier-1004" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfNS0xLTEtMS0w_6dfdbe44-6894-4eda-a350-a2a166dc097a" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">376,673</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usdPerShare" contextref="id9282900d85f4e61a6640fa57fa2d94e_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="fact-identifier-1005" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOjUxY2U0NjMyODc1NzQ4YjFiYTAyZTE1ZTYzM2FiMzE4L3RhYmxlcmFuZ2U6NTFjZTQ2MzI4NzU3NDhiMWJhMDJlMTVlNjMzYWIzMThfOS0zLTEtMS0xNDc5Nw_c04aa4ce-8069-4208-902e-d1e36cf6c604" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7.99</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The vesting of PSUs requires that certain performance conditions are achieved during the performance period and is subject to the employee’s continued service requirements. The total fair value of PSUs vested during the years ended March 31, 2021 and 2020 was $<span><ix:nonfraction unitref="usd" contextref="i08e2afc66aaf40bb8d215145eabe9e54_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-1006" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY3MDM5OQ_46e83285-cf14-4339-b1f3-e856efb24def" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3.6</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i8aebd06af1e64f6886dbabbe89d571c9_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="fact-identifier-1007" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY3MDQwMw_8b464c87-2884-4eef-b0f0-8111bd580041" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.8</ix:nonfraction></span> million, respectively. No PSUs vested in the year ended March 31, 2019. Pursuant to the Separation and General Release Agreement with the Company’s former Principal Executive Officer, the vesting of PSUs covering a total of <span><ix:nonfraction unitref="shares" contextref="i2f8caf25584b4da188a7de5664bd00e8_D20210111-20210111" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" id="fact-identifier-1008" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjc0ODc3OTExNzIxMQ_6e287a68-217b-4c9a-bea9-67c1f928aeff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">301,659</ix:nonfraction></span> common shares was accelerated on January 11, 2021 (see Note 10(H)). As a result of the change in control of the Company described in Note 6(A), the vesting of certain PSUs covering a total of <span><ix:nonfraction unitref="shares" contextref="i9a71c67d637d45b4aae1044295a0d400_D20191227-20191227" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" scale="0" id="fact-identifier-1009" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY2NzY1MA_b41a781a-c37c-4490-8941-3491818347c7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">108,640</ix:nonfraction></span> common shares was accelerated on December&nbsp;27, 2019. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(G) Share-Based Compensation Expense</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="myov:ScheduleofSharebasedCompensationArrangementAllocationofRecognizedPeriodCostsTableTextBlock" id="fact-identifier-1010" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfNDY2Nw_d1b36c31-701e-4a5f-ad34-d1763a519193" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense recognized as:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i9363e7bcddf6409d9aeaee3886fe120a_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1011" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfMy01LTEtMS0w_be94b7ee-0c2f-4698-8098-a5f406def1e5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,049</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i6b0ef5ffb409492c9f1ad8de38a11d0f_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1012" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfMy03LTEtMS0w_fd7f3f18-ba77-47c2-8eb0-43dd3ef01ff1" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,524</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i55758c0b672b4d2190b469f98d727337_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1013" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfMy05LTEtMS02MTkz_e063e19b-d576-49de-ac37-76c5867a52e7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">7,161</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i0b349076eee24e72985f2f7149553ff4_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1014" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfNC01LTEtMS0w_933fed2d-e207-4c77-9236-471600630aa6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">39,627</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="iaa4b19acee2240339519e89669f21fb1_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1015" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfNC03LTEtMS0w_302fa256-b7ca-425b-9544-7b1e19ba2563" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">25,727</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ib810827a8c0640e9be2f9040c365c032_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1016" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfNC05LTEtMS02MTkz_ec475e69-7e75-48c8-bdd9-c232824117a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">11,535</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1017" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfNS01LTEtMS0w_523394f8-9768-4bc2-aa5d-a8046c830cc9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">53,676</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1018" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfNS03LTEtMS0w_7a7196e0-764c-4c2d-a5fb-f169e97c9dbf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,251</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="fact-identifier-1019" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RhYmxlOmIxYzJiZjFmZmFkMTRjMzI5Yjc5ZmM0NmVjNDI0MDUzL3RhYmxlcmFuZ2U6YjFjMmJmMWZmYWQxNGMzMjliNzlmYzQ2ZWM0MjQwNTNfNS05LTEtMS02MTkz_bbcade63-3a24-41a5-86c1-6b7914d97893" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">18,696</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unrecognized share-based compensation expense was approximately $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="fact-identifier-1020" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMzY3MQ_aa9b8bab-3435-4810-85b9-d8ccdc6ce164" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">62.4</ix:nonfraction></span> million as of March&nbsp;31, 2021 and is expected to be recognized over a weighted-average period of approximately <span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="fact-identifier-1021" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMzc2NA_89cadfa0-f77d-413c-a114-54124400b391" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.9</ix:nonnumeric></span> years. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense included in SG&amp;A expense for the year ended March 31, 2021 includes $<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:ShareBasedPaymentArrangementAccelerationModificationAndRemeasurementOfAwardsCost" scale="6" id="fact-identifier-1022" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMTA5OTUxMTY4OTc3NQ_a02c6bfe-ee27-4768-afcb-26702b4468ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25.7</ix:nonfraction></span>&nbsp;million of incremental expense as a result of the separation of the Company’s former Principal Executive Officer (see Note 10(H)). Share-based compensation expense included in SG&amp;A and R&amp;D expense for the year ended March 31, 2020 includes $<span><ix:nonfraction unitref="usd" contextref="iaa4b19acee2240339519e89669f21fb1_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="fact-identifier-1023" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMzg3Nw_7cd1f3b5-cc4a-4bb1-90a3-638c763ed26d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.2</ix:nonfraction></span> million </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="ib91f181210ac468a8695b23c45faf527" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<span><ix:nonfraction unitref="usd" contextref="i6b0ef5ffb409492c9f1ad8de38a11d0f_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" scale="6" id="fact-identifier-1025" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjc0ODc3OTEyNDIzOQ_b54e8f01-9423-4f30-a2ce-52f6db839207" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.8</ix:nonfraction></span> million, respectively, related to the accelerated vesting of certain share-based payment awards as a result of the change in control of the Company described in Note 6(A).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(H) Separation Agreement with Former Principal Executive Officer</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a Separation and General Release Agreement with its former Principal Executive Officer. Pursuant to the terms of this agreement, all of the former Principal Executive Officer’s then outstanding and unvested equity awards became fully vested. In addition, the post-termination period during which the former Principal Executive Officer may exercise her outstanding stock options was extended to 12 months. The former Principal Executive Officer has granted Sumitovant or any Sumitovant affiliate a right of first refusal to purchase her common shares of the Company under certain circumstances and provide the Company and its affiliates a general release of claims. Share-based compensation expense included in SG&amp;A expense for the  year ended March 31, 2021 includes $<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:ShareBasedPaymentArrangementAccelerationModificationAndRemeasurementOfAwardsCost" scale="6" id="fact-identifier-1026" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjc0ODc3OTEzMzMzNg_a02c6bfe-ee27-4768-afcb-26702b4468ff" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25.7</ix:nonfraction></span>&nbsp;million related to the acceleration, modification, and remeasurement of these awards.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the repurchase feature described above, the outstanding awards were reclassified from additional paid-in capital to current liabilities. The share-based compensation liabilities have been and will continue to be remeasured at fair value each reporting period end, with the change in fair value recorded as share-based compensation expense within SG&amp;A until the stock options are exercised and the common shares are sold to Sumitovant, to the market, or otherwise settled, or the former Principal Executive Officer has held the common shares for a period of at least six months (see Note 3). As of March 31, 2021, a total of <span><ix:nonfraction unitref="shares" contextref="i857193c97d064fabb83622b2b3184d72_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRemeasuredDuringPeriod" scale="0" id="fact-identifier-1027" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjc0ODc3OTEyNjE2Ng_62a251c0-8271-4301-aad9-b2db8d2bfc75" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1,281,803</ix:nonfraction></span> outstanding stock options and a total of <span><ix:nonfraction unitref="shares" contextref="i50255dd008f84caabcc561482fa93d44_I20210331" decimals="INF" format="ixt:numdotdecimal" name="myov:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsRemeasuredDuringPeriod" scale="0" id="fact-identifier-1028" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl81OC9mcmFnOmQxYzI4ZGE3ZTIyOTRiNmU5YjdlNGZiOTMyODRjYWZlL3RleHRyZWdpb246ZDFjMjhkYTdlMjI5NGI2ZTliN2U0ZmI5MzI4NGNhZmVfMjc0ODc3OTEyNjIzNQ_6468f66c-4175-4454-bd57-ee77b0945f62" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">462,705</ix:nonfraction></span> common shares remain subject to the right of first refusal. The former Principal Executive Officer’s outstanding stock options remain exercisable through January&nbsp;11, 2022.</span></div></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_1220"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:DefinedContributionPlanTextBlock" id="fact-identifier-1029" continuedat="ia6dbf7da1c21426e8ca743534c973098" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjIwL2ZyYWc6NDliYTRkNGFmZTU5NDY0ZDg1ZDczMDVmZWI0YjY4NDUvdGV4dHJlZ2lvbjo0OWJhNGQ0YWZlNTk0NjRkODVkNzMwNWZlYjRiNjg0NV81NDk3NTU4MTQxMzA0_1ca54848-cbc0-4bb5-b4f5-fddceb9a102d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Defined Contribution Plan</ix:nonnumeric></span></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ia6dbf7da1c21426e8ca743534c973098" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">The Company sponsors a defined contribution plan pursuant to Section 401(k) of the U.S. Internal Revenue Code that allows eligible participants to contribute up to <span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="fact-identifier-1031" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjIwL2ZyYWc6NDliYTRkNGFmZTU5NDY0ZDg1ZDczMDVmZWI0YjY4NDUvdGV4dHJlZ2lvbjo0OWJhNGQ0YWZlNTk0NjRkODVkNzMwNWZlYjRiNjg0NV81NDk3NTU4MTQxMzEw_f6d8bfb4-a496-46ed-a5d4-53f6607af806" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">90</ix:nonfraction></span>% of their eligible compensation, subject to maximum deferral limits specified by the Internal Revenue Code. Beginning in February 2020, the Company implemented a discretionary employer matching contribution of $0.50 for every $1.00 contributed by a participating employee up to <span><ix:nonfraction unitref="number" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="fact-identifier-1032" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjIwL2ZyYWc6NDliYTRkNGFmZTU5NDY0ZDg1ZDczMDVmZWI0YjY4NDUvdGV4dHJlZ2lvbjo0OWJhNGQ0YWZlNTk0NjRkODVkNzMwNWZlYjRiNjg0NV81NDk3NTU4MTQxMzA2_a52ec8e3-6d1f-44f8-b21c-eaa363b380b8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">6</ix:nonfraction></span>% of the employee’s eligible compensation, which such matching contributions becoming fully vested immediately. For the years ended March 31, 2021 and 2020, the Company recorded total expense for matching contributions of $<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="fact-identifier-1033" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjIwL2ZyYWc6NDliYTRkNGFmZTU5NDY0ZDg1ZDczMDVmZWI0YjY4NDUvdGV4dHJlZ2lvbjo0OWJhNGQ0YWZlNTk0NjRkODVkNzMwNWZlYjRiNjg0NV8xMDk5NTExNjI4NjUx_6dc2baf8-9587-4892-bb6d-7b3240a6662b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1.6</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="fact-identifier-1034" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjIwL2ZyYWc6NDliYTRkNGFmZTU5NDY0ZDg1ZDczMDVmZWI0YjY4NDUvdGV4dHJlZ2lvbjo0OWJhNGQ0YWZlNTk0NjRkODVkNzMwNWZlYjRiNjg0NV8xMDk5NTExNjI4NjQ0_8ad64743-4fe1-4556-880d-9df40f8dd151" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million, respectively. There were <span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="fact-identifier-1035" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjIwL2ZyYWc6NDliYTRkNGFmZTU5NDY0ZDg1ZDczMDVmZWI0YjY4NDUvdGV4dHJlZ2lvbjo0OWJhNGQ0YWZlNTk0NjRkODVkNzMwNWZlYjRiNjg0NV8xMDk5NTExNjI4NTU0_d3ff97ab-1ad3-4876-ba6d-b826d6198448" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span> matching contributions for the year ended March 31, 2019.</ix:continuation></span></span></div><div id="iad55818e5d094e70a171c29f2aae2512_1212"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="fact-identifier-1036" continuedat="i4804e059b46641338b43734a9f5c6732" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl81NDk3NTU4MTQ2ODk4_0de561fd-ed71-4962-9ca7-b748dc55a671" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Leases</ix:nonnumeric></span></span></div><span><ix:continuation id="i4804e059b46641338b43734a9f5c6732" continuedat="i9602a5216b654ed59fc8a1e4c907e81a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span><ix:continuation id="ia97a88723b544f4c9ca562f8e8428d6a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2016-2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Topic 842) as of April 1, 2019 on a modified retrospective basis and did not restate comparative periods as permitted under the transition guidance. The Company elected the practical expedient not to apply the recognition and measurement guidance of Topic 842 to short-term leases.</span></ix:continuation></span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases <span><ix:nonfraction unitref="sqft" contextref="i9869138a4ffc4913b7c3be038c825154_I20210331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="fact-identifier-1039" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMwODY1_2646df54-e90b-496e-baf7-7859927bf3b7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,232</ix:nonfraction></span> square feet of office space located in Brisbane, California pursuant to a lease agreement, as amended, that expires in May 2026. The Company has the option to extend the lease term for an additional <span><ix:nonnumeric contextref="i9869138a4ffc4913b7c3be038c825154_I20210331" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="fact-identifier-1040" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xNjQ5MjY3NDQyMjA1_b2768454-c600-4423-9685-f05f39c3846c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">seven years</ix:nonnumeric></span> but is not reasonably certain that it will exercise the option and has therefore excluded it from the lease term. The lease agreement, as amended, required the Company to deliver an irrevocable standby letter of credit in the amount of $<span><ix:nonfraction unitref="usd" contextref="i9869138a4ffc4913b7c3be038c825154_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="fact-identifier-1041" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMwODc3_08129844-0aec-40b2-8ecd-49a63fcb63b4" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.5</ix:nonfraction></span> million to the landlord, the amount of which is subject to reduction to approximately $<span><ix:nonfraction unitref="usd" contextref="i9869138a4ffc4913b7c3be038c825154_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:LesseeOperatingLeaseRestrictionorCovenantReducedLetterofCreditifConditionsareMet" scale="6" id="fact-identifier-1042" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMwODg0_1e93763d-ddeb-4925-b6bb-c800156d0319" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.2</ix:nonfraction></span> million if certain conditions are met.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company subleases an additional <span><ix:nonfraction unitref="sqft" contextref="if4171948bbae41ff91528d566150c7fa_I20210331" decimals="0" format="ixt:numdotdecimal" name="myov:LesseeOperatingSubleaseAreaofLeased" scale="0" id="fact-identifier-1043" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMwODY5_981c9518-bc50-408c-a4f8-c9413e316306" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">20,116</ix:nonfraction></span> square feet of office space within the same building as its current corporate office space located in Brisbane, California. The sublease term expires in February 2024. The sublease required the Company to deliver an irrevocable standby letter of credit to the sublessor for the duration of the lease in the amount of $<span><ix:nonfraction unitref="usd" contextref="if4171948bbae41ff91528d566150c7fa_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="fact-identifier-1044" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMwODk1_9be8d508-6ef6-44f1-955d-e75359676610" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.2</ix:nonfraction></span> million.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a agreement to lease fleet vehicles along with certain services whereby the Company leases vehicles to be delivered by the lessor from time to time with various monthly costs depending on the vehicles delivered for a term of one year, commencing on each corresponding delivery date. The leased vehicles are for use by eligible employees of the Company’s commercial operations. The Company maintains a letter of credit of $<span><ix:nonfraction unitref="usd" contextref="id4569e20bd4b438cb3359b35b3188cb9_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="fact-identifier-1045" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8yNzQ4Nzc5MDc4NTI3_988fb073-6fee-45af-89d1-d4fcd4cfd27f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span> million as collateral in favor of the lessor. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no other significant operating, financing, or short-term leases. </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i9602a5216b654ed59fc8a1e4c907e81a" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:LeaseCostTableTextBlock" id="fact-identifier-1047" continuedat="i0a5f3ea7bcf44604b6db2f053ad223dd" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl81NDk3NTU4MTQ2ODk5_cdf5ec7f-8947-426c-bc8f-5c57326b54b5" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes rent expense on a straight-line basis over the non-cancelable term of its operating leases. For the years ended March 31, 2021 and 2020, the components of operating lease and short-term lease expenses were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-1048" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml8yLTEtMS0xLTM3Njk_86f4a579-5fb5-4ed5-b67b-b94076b049ef" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,914</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="fact-identifier-1049" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml8xLTEtMS0xLTM2MTM_3f58a8e6-8117-4228-9850-407b334c62ac" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,496</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="fact-identifier-1050" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml8zLTEtMS0xLTM3Njk_bb23047c-fcb3-401a-a105-4555d8777b93" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">5</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ShortTermLeaseCost" scale="3" id="fact-identifier-1051" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml8zLTMtMS0xLTM3NjQ_26146027-6baa-449e-a6d0-f1ca3398a335" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="fact-identifier-1052" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml80LTEtMS0xLTM3Njk_1bb9d7aa-28eb-4c5f-ba83-40e9ad6ff414" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">538</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="fact-identifier-1053" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml8zLTEtMS0xLTM2MTM_6e97158a-11d2-410d-ad6d-d40e86d99b7d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">225</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="fact-identifier-1054" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml81LTEtMS0xLTM3Njk_33d0e69b-a434-48a2-9a26-35c370ded919" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,457</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="fact-identifier-1055" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6OTJiNDU1MGVlMWE0NGM3MDg1ZDdhM2JkODdiY2Y5ODIvdGFibGVyYW5nZTo5MmI0NTUwZWUxYTQ0YzcwODVkN2EzYmQ4N2JjZjk4Ml80LTEtMS0xLTM2MTM_c5983f79-4411-429b-b56f-21ba2bc7639f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,721</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Variable lease cost includes common area maintenance and utilities costs that are not included in operating lease liabilities and are expensed as incurred, and maintenance and one-time charges related to the short-term leases.</span></div></ix:nonnumeric></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the adoption of Topic 842 on April 1, 2019, under Topic 840, rent expense was $<span><ix:nonfraction unitref="usd" contextref="i2fb31e1566654000ab7f0c346bf04898_D20180401-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="fact-identifier-1056" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8yNzQ4Nzc5MDgwODQ3_50cd6b38-3a68-486b-9488-4e6476c6bf88" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2.1</ix:nonfraction></span> million for the year ended March 31, 2019. </span></div><span><ix:continuation id="i0a5f3ea7bcf44604b6db2f053ad223dd" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information related to the Company’s operating lease right-of-use assets and operating lease liabilities was as follows for the years ended March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-1058" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MjQyNTU1ZWEzYjk5NDcwNDhhNTY5YjYwZmY4Y2U4ZDcvdGFibGVyYW5nZToyNDI1NTVlYTNiOTk0NzA0OGE1NjliNjBmZjhjZThkN18yLTEtMS0xLTM4NTk_280c44a9-c485-43d5-966c-05f3f02a199b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,939</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="fact-identifier-1059" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MjQyNTU1ZWEzYjk5NDcwNDhhNTY5YjYwZmY4Y2U4ZDcvdGFibGVyYW5nZToyNDI1NTVlYTNiOTk0NzA0OGE1NjliNjBmZjhjZThkN18xLTEtMS0xLTM2MTM_b8ce57ec-771b-4cf5-b0ea-a9e71411d8f8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,289</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="fact-identifier-1060" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MjQyNTU1ZWEzYjk5NDcwNDhhNTY5YjYwZmY4Y2U4ZDcvdGFibGVyYW5nZToyNDI1NTVlYTNiOTk0NzA0OGE1NjliNjBmZjhjZThkN18zLTEtMS0xLTM4NTk_b4ccfe8e-62aa-4d3a-b3e7-30084a3b5b33" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i64014c60d448460e85581076c2cd76d0_D20190401-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="fact-identifier-1061" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MjQyNTU1ZWEzYjk5NDcwNDhhNTY5YjYwZmY4Y2U4ZDcvdGFibGVyYW5nZToyNDI1NTVlYTNiOTk0NzA0OGE1NjliNjBmZjhjZThkN18yLTEtMS0xLTM2MTM_7dc26e80-42d1-435f-ab84-ba1c9e3aa26d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12,237</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:continuation></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s operating leases had a weighted average remaining lease term of <span><ix:nonnumeric contextref="i9869138a4ffc4913b7c3be038c825154_I20210331" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="fact-identifier-1062" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMyNjY2_582c8ab3-baf5-4790-804b-e1bb1c18d4d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">4.7</ix:nonnumeric></span> years and a weighted average discount rate of <span><ix:nonfraction unitref="number" contextref="i9869138a4ffc4913b7c3be038c825154_I20210331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="fact-identifier-1063" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl8xMDk5NTExNjMyNjcw_6bfcf3b9-5017-4243-8660-d51f515a308b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">12.3</ix:nonfraction></span>%.</span></div><span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="fact-identifier-1064" escape="true" inside-table="false" text-block-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGV4dHJlZ2lvbjozZmM3MmYyOWIyNjc0YjAzYWE4YWM1MzlkMjQzZGU2Zl81NDk3NTU4MTQ2OTAx_4fe2b115-9ba6-433d-ab67-b7da31dc98d9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, maturities of operating lease liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:84.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="fact-identifier-1065" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl8xLTEtMS0xLTM2MTM_33c95fa8-574c-4b46-9078-7ded829486b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,028</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="fact-identifier-1066" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl8yLTEtMS0xLTM2MTM_55437b4c-e887-4028-9a40-a57377deb440" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,127</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="fact-identifier-1067" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl8zLTEtMS0xLTM2MTM_2fb4a1a3-9e42-4839-ab98-aee3fccae1c6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,053</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="fact-identifier-1068" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl80LTEtMS0xLTM2MTM_7162383e-3e0f-424a-b3cd-8f6878de0738" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,409</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="fact-identifier-1069" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl81LTEtMS0xLTM2MTM_40fa4dcd-cf0d-4877-abca-58feb50b5e1b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">2,482</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="fact-identifier-1070" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl82LTEtMS0xLTM2MTM_018eb7c4-d81a-4732-a69c-e7286c7e78ab" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">416</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="fact-identifier-1071" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl83LTEtMS0xLTM2MTM_f6dbbee4-0b23-4302-bb65-6ba9eb4d733c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">14,515</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="fact-identifier-1072" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl84LTEtMS0xLTM2MTM_941217d5-faef-4886-b284-7819401c7903" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">3,519</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="fact-identifier-1073" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl85LTEtMS0xLTM2MTM_37c908e1-03a9-4568-a688-ec0e6eec470f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10,996</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less operating lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="fact-identifier-1074" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl8xMC0xLTEtMS0zNjEz_a0fbc03c-0073-4df7-a528-f053e87c73c5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">1,807</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, long-term portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="fact-identifier-1075" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl8xMjEyL2ZyYWc6M2ZjNzJmMjliMjY3NGIwM2FhOGFjNTM5ZDI0M2RlNmYvdGFibGU6MDE5YTQxOTI3Nzg3NDFkMTgyYWJkYjQwYmJhMzE5MmYvdGFibGVyYW5nZTowMTlhNDE5Mjc3ODc0MWQxODJhYmRiNDBiYmEzMTkyZl8xMS0xLTEtMS0zNjEz_97558a8b-cc57-415b-ba91-1965a1817cf7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">9,189</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">s lease agreements do not provide an implicit rate. The imputed interest was determined using the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> incremental borrowing rate, which represents an estimated rate of interest that it would have to pay to borrow equivalent funds on a collateralized basis over a similar term at the lease inception date.</span></div></ix:nonnumeric></span></ix:continuation></span><div id="iad55818e5d094e70a171c29f2aae2512_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="myov:LicenseAgreementAndCollaborativeDisclosureTextBlock" id="fact-identifier-1076" continuedat="i75058946838d41c2a5e76d5faffa2eb5" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTQxOTE_eeb5d93a-029a-4d92-b848-4c280f9ad0b5" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">Collaboration and License Agreements</ix:nonnumeric></span></span></div><span><ix:continuation id="i75058946838d41c2a5e76d5faffa2eb5" continuedat="i47abe2d2323848929d084606bea14a01" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A) Richter Development and Commercialization Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&nbsp;30, 2020, the Company entered into an exclusive license agreement for Richter to commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia, and New Zealand (the “Richter Development and Commercialization Agreement”). Under the agreement, the Company received an upfront payment of $<span><ix:nonfraction unitref="usd" contextref="ib15ef4be74c044cfa83fb759b9e4b67a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="fact-identifier-1078" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTAx_52cfdffa-4d5e-4e7d-86e9-476619b0ecde" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40.0</ix:nonfraction></span> million on March&nbsp;31, 2020, is eligible to receive up to $<span><ix:nonfraction unitref="usd" contextref="i548d8ee3aebb4ee2b6dee329307a72d2_I20200330" decimals="-5" format="ixt:numdotdecimal" name="myov:LicenseAgreementRegulatoryMilestonesMaximumValue" scale="6" id="fact-identifier-1079" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTQw_76b97d6f-a664-406c-9dd4-52eb315b8c42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">40.0</ix:nonfraction></span> million in regulatory milestone payments (of which $<span><ix:nonfraction unitref="usd" contextref="i3a36b0d7806242bb988c0664ee8df284_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueAdditions" scale="6" id="fact-identifier-1080" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTg2_02a6b0de-e859-4d74-b16e-3cc38c112433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million was received in April 2020), $<span><ix:nonfraction unitref="usd" contextref="i548d8ee3aebb4ee2b6dee329307a72d2_I20200330" decimals="-5" format="ixt:numdotdecimal" name="myov:LicenseAgreementSalesRelatedMilestonesMaximumValue" scale="6" id="fact-identifier-1081" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjEw_3c0b8216-89d5-47cc-9f8f-0902e3efe411" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">107.5</ix:nonfraction></span> million in sales-related milestones, and tiered royalties on net sales following regulatory approval. Under the terms of the agreement, the Company will </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i47abe2d2323848929d084606bea14a01" continuedat="i7dfb5cd63a5545189d50c1abbe8acb5d" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to lead global development of relugolix combination tablet. The Company has also agreed to assist Richter in transferring manufacturing technology from the Company’s CMOs to Richter to enable Richter to manufacture relugolix combination tablet. The Company has agreed to supply Richter with quantities of relugolix combination tablet for its territories pursuant to the Company’s agreements with its CMOs. Richter will be responsible for local clinical development, manufacturing, and all commercialization activities for its territories. The Company has also granted Richter an option to collaborate with the Company on relugolix combination tablet for future indications in women’s health other than fertility. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the transaction price under the Richter Development and Commercialization Agreement totaled $<span><ix:nonfraction unitref="usd" contextref="ib15ef4be74c044cfa83fb759b9e4b67a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="fact-identifier-1083" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTYyNg_bfccbb7e-f60a-4f86-80b9-cb58f708574d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">50.0</ix:nonfraction></span> million, consisting of the upfront payment of $<span><ix:nonfraction unitref="usd" contextref="ib15ef4be74c044cfa83fb759b9e4b67a_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="fact-identifier-1084" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTY2Nw_52cfdffa-4d5e-4e7d-86e9-476619b0ecde" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40.0</ix:nonfraction></span> million received on March&nbsp;31, 2020 and a $<span><ix:nonfraction unitref="usd" contextref="i3a36b0d7806242bb988c0664ee8df284_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueAdditions" scale="6" id="fact-identifier-1085" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTY5MQ_02a6b0de-e859-4d74-b16e-3cc38c112433" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million regulatory milestone payment received in April 2020. No other regulatory milestones, sales-related milestones, or royalties on net sales following regulatory approval were included in the transaction price given the substantial uncertainty related to their achievement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that Richter represented a customer and applied relevant guidance from ASC 606 to evaluate the accounting under the Richter Development and Commercialization Agreement. In accordance with this guidance, the Company identified one material combined performance obligation to grant a license to Richter to certain of its intellectual property and to deliver certain clinical and regulatory data packages for relugolix combination therapy, the drug used for both potential indications of uterine fibroids and endometriosis. The Company determined that its grant of a license to Richter to certain of its intellectual property was not distinct from the delivery of certain clinical and regulatory data packages pertaining to relugolix combination therapy. In evaluating the appropriate measure for the Company’s performance under the combined performance obligation, the Company determined that revenues should be recognized as data packages are delivered to Richter based on the relative value of the data packages delivered to date compared to the totality of the data packages it is obligated to deliver under the Richter Development and Commercialization Agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recogni</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion. Based upon the Company’s assessment of its progress toward delivering relugolix combination therapy clinical and regulatory data packages to Richter, the Company concluded that as of March&nbsp;31, 2021, it had satisfied approximately two-thirds of the combined performance obligation. As a result, the Company recognized $<span><ix:nonfraction unitref="usd" contextref="i5cadb7c1daa7462598ef501d9080b3db_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="fact-identifier-1086" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMzYwNA_3397e9e3-fdfc-4318-a861-575b5656a338" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">33.3</ix:nonfraction></span> million of the transaction price as license and milestone revenue during the year ended March 31, 2021. There were <span><ix:nonfraction unitref="usd" contextref="i1b63da2c0ef541a290ca09a7f8a95eb2_D20190401-20200331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="fact-identifier-1087" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMzY5MQ_92cf1a59-d669-44ef-86e1-36330df84900" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="i9657129676304a97b4d602ca97c7f65a_D20180401-20190331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="fact-identifier-1088" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMzY5MQ_d3be583e-03e6-4f54-9d48-b8dd6ae5888f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">no</ix:nonfraction></span></ix:nonfraction></span> amounts recognized in the comparable prior year periods. As the Company currently expects to deliver the remaining substantive relugolix combination therapy data packages to Richter in the first quarter of the fiscal year ending March 31, 2022, the Company has recorded the remaining $<span><ix:nonfraction unitref="usd" contextref="ia9e2f61c09c543a3824cb5ffdba7b10d_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="fact-identifier-1089" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMzk4OA_fdd99895-163a-449e-8505-88907a49c9b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">16.7</ix:nonfraction></span> million of the transaction price as deferred revenue, a current liability, on the accompanying consolidated balance sheets as of March&nbsp;31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Richter Development and Commercialization Agreement shall expire on a country-by-country basis upon expiry of the Royalty Term for the Product in a country in the Richter Territory. The Richter Development and Commercialization Agreement may be terminated in its entirety or on a country-by-country basis by mutual consent of the parties, or by either party for the uncured material breach of other party, for bankruptcy of the other party, and for certain other reasons in accordance with the terms of the Richter Development and Commercialization Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(B) Pfizer Collaboration and License Agreement</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&nbsp;26, 2020, the Company’s subsidiary, MSG, and Pfizer, entered into a collaboration and license agreement (the “Pfizer Collaboration and License Agreement”), pursuant to which the Company and Pfizer will collaborate to jointly develop and commercialize relugolix in oncology and women’s health in the U.S. and Canada (the “Co-Promotion Territory”). In addition, Pfizer also received an option to acquire exclusive commercialization and development rights to relugolix in oncology outside the Co-Promotion Territory, excluding certain Asian countries (the “Pfizer Territory”). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Co-Promotion Territory, the Company and Pfizer will equally share profits and certain expenses, including certain pre-launch inventory costs incurred by the Company prior to the effective date of the Pfizer Collaboration and License Agreement (the “Allowable Expenses”). The Company will remain responsible for regulatory interactions and drug supply and will continue to lead clinical development for relugolix combination tablet in the women’s health indications, while development for ORGOVYX will be shared equally among the parties.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Co-Promotion Territory, the Company will be the principal on all sales transactions with third parties and will recognize <span><ix:nonfraction unitref="number" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" name="myov:CollaborativeArrangementPercentageOfRevenueRecognized" scale="-2" id="fact-identifier-1090" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTQxNQ_3b4a6ac3-3cb6-4a3b-a77f-25f4b621f1da" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100</ix:nonfraction></span>% of product sales to third parties as revenue from contracts with customers. The Company concluded that based on the principal vs. agent guidance in ASC 606, it has primary responsibility for fulfilling customer orders, controls inventory before it is sold to third party customers, assumes the risk of inventory loss, and maintains discretion in establishing product price. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Pfizer Collaboration and License Agreement, the Company received an upfront payment of $<span><ix:nonfraction unitref="usd" contextref="iedbcb7ee89d145d38a3c70f01ca35893_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="myov:ProceedsFromCollaboratorsAndLicenseFeesReceived" scale="6" id="fact-identifier-1091" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTkwOQ_45714bf2-332c-4dc8-a056-d6351f03981f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">650.0</ix:nonfraction></span> million in December 2020, and is eligible to receive up to $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementMilestonesMaximumValue" scale="9" id="fact-identifier-1092" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTk1Mg_a654ea83-e25e-4154-b9fc-b15ae776c443" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.7</ix:nonfraction></span> billion of additional milestone payments, including two regulatory milestones of $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementRegulatoryMilestonesMaximumValue" scale="6" id="fact-identifier-1093" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjAyOA_bf0a7e6a-b330-4444-9f55-10ee601a5ced" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100.0</ix:nonfraction></span> million upon each FDA approval for relugolix combination tablet in uterine fibroids and endometriosis ($<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementRegulatoryMilestonesMaximumAggregateValue" scale="6" id="fact-identifier-1094" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjEyNg_ef547aa1-97fa-4ab9-bb1e-6bf842d1a331" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">200.0</ix:nonfraction></span> million in the aggregate), and tiered sales milestones of up to $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementSalesRelatedMilestonesMaximumValue" scale="9" id="fact-identifier-1095" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjE4NQ_95e4b5a2-6be4-4b73-ba2e-7f0fc2b19fed" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.5</ix:nonfraction></span> billion upon reaching certain </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i7dfb5cd63a5545189d50c1abbe8acb5d" continuedat="iebe60ced8eaf4f59bb40fce8834eff03" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thresholds of annual net sales for oncology and the combined women’s health indications in the Co-Promotion Territory. In addition, if Pfizer exercises its option to acquire exclusive commercialization and development rights to relugolix in oncology in the Pfizer Territory, the Company will receive an option exercise fee of $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementOptionExerciseFeeValue" scale="6" id="fact-identifier-1097" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjUzNg_8ea92eb7-fd17-4633-9e20-b26263cf7002" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.0</ix:nonfraction></span> million, will also be eligible to receive double-digit royalties on net sales of relugolix in the Pfizer Territory, and Pfizer will bear <span><ix:nonfraction unitref="number" contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" decimals="INF" name="myov:CollaborativeArrangementAgreementCostsCoveredByPartyToCollaborativeArrangementPercent" scale="-2" id="fact-identifier-1098" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjY2Nw_bed65df1-078c-4bfb-8ffd-8897fbaf8ba9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100</ix:nonfraction></span>% of costs incurred in the Pfizer Territory. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Pfizer Collaboration and License Agreement, the Company will bear Pfizer’s share of Allowable Expenses, up to a maximum of $<span><ix:nonfraction unitref="usd" contextref="ia215322f49eb490fa54bee4a811c68fd_D20210101-20211231" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyAmount" scale="6" id="fact-identifier-1099" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjg2Ng_cab495ad-96a7-411c-b765-0f42768f0dea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100.0</ix:nonfraction></span> million for calendar year 2021 and up to a maximum of $<span><ix:nonfraction unitref="usd" contextref="i85080f48e14b4807a46e2a1d09c8d3b0_D20220101-20221231" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyAmount" scale="6" id="fact-identifier-1100" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNjkxNQ_9b251957-4a26-4420-8d83-e384c5ff0e3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.0</ix:nonfraction></span> million for calendar year 2022. Any unused portion will carry over into the subsequent calendar years until the Company has assumed in aggregate $<span><ix:nonfraction unitref="usd" contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="fact-identifier-1101" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNzA1NQ_16cc8b80-a4a1-424e-a86c-23eea8d85b29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150.0</ix:nonfraction></span> million of Pfizer’s share of the Allowable Expenses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Pfizer Collaboration and License Agreement continues until no products are sold and all development activities have terminated in the Co-Promotion Territory and, in the case that Pfizer exercises its option for relugolix in the Pfizer Territory, on the last to expire royalty term with respect to a country in the Pfizer Territory. The Pfizer Collaboration and License Agreement may be terminated early by either party for the uncured material breach of the other party or for bankruptcy or other insolvency proceeding of the other party. In addition, Pfizer has certain other termination rights and may terminate the Pfizer Collaboration and License Agreement early upon providing written notice to the Company pursuant to the terms of the Pfizer Collaboration and License Agreement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the Pfizer Collaboration and License Agreement and determined that it meets both criteria to be considered a collaborative agreement within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: active participation by both parties and exposures to significant risks and rewards dependent on the commercial success of the activities. Although the Company is lead party and will perform many activities, both development and commercialization responsibilities are assigned between parties and both parties participate on joint steering and other committees overseeing the collaboration activities. Both parties are exposed to significant risks and rewards based on the economic outcomes of the collaboration through cost sharing and profit (loss) sharing provisions. Net payments to/from Pfizer for Pfizer’s share of the net profits and Allowable Expenses will be disaggregated and presented in the Company’s consolidated statements of operations according to the nature of the expense (e.g., collaboration expense, R&amp;D expenses, or SG&amp;A expenses). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, the Company received a $<span><ix:nonfraction unitref="usd" contextref="iedbcb7ee89d145d38a3c70f01ca35893_D20201201-20201231" decimals="-5" format="ixt:numdotdecimal" name="myov:ProceedsFromCollaboratorsAndLicenseFeesReceived" scale="6" id="fact-identifier-1102" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfOTA1NQ_45714bf2-332c-4dc8-a056-d6351f03981f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">650.0</ix:nonfraction></span> million upfront payment from Pfizer in December 2020, of which $<span><ix:nonfraction unitref="usd" contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="fact-identifier-1103" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfOTEwMg_16cc8b80-a4a1-424e-a86c-23eea8d85b29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150.0</ix:nonfraction></span>&nbsp;million is Pfizer’s advanced reimbursement for Pfizer’s share of Allowable Expenses (up to $<span><ix:nonfraction unitref="usd" contextref="ia215322f49eb490fa54bee4a811c68fd_D20210101-20211231" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyAmount" scale="6" id="fact-identifier-1104" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfOTE4OA_cab495ad-96a7-411c-b765-0f42768f0dea" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">100.0</ix:nonfraction></span> million for calendar year 2021 and up to $<span><ix:nonfraction unitref="usd" contextref="i85080f48e14b4807a46e2a1d09c8d3b0_D20220101-20221231" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyAmount" scale="6" id="fact-identifier-1105" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfOTIyNA_9b251957-4a26-4420-8d83-e384c5ff0e3d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.0</ix:nonfraction></span> million for calendar year 2022). The Company concluded that the prepayment by Pfizer of its share of Allowable Expenses represents a significant financing component since the Company received the cash flows at the outset of the arrangement, rather than over a <span><ix:nonnumeric contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" format="ixt-sec:durwordsen" name="myov:CollaborativeArrangementAgreementCostsReimbursementsCoveredByCompanyRepaymentPeriod" id="fact-identifier-1106" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTQxOTI_10f74313-7ee1-46e5-9725-74d738053e22" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">two-year</ix:nonnumeric></span> period. Accordingly, the Company reduced the amount of the advanced reimbursement by approximately $<span><ix:nonfraction unitref="usd" contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiabilityCostsRecognizedAsFinancingCosts" scale="6" id="fact-identifier-1107" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfOTU4Ng_7752abf2-bf24-4388-825f-c3fe32627b35" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">3.6</ix:nonfraction></span> million, representing the implied financing costs based on the Company’s incremental borrowing rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that was derived based on the Sumitomo Dainippon Pharma Loan Agreement, and recorded the discounted value of $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiability" scale="6" id="fact-identifier-1108" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0ODgyMQ_1e9d4ebc-6b13-4e5a-ac9d-74f5536cd4f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">146.4</ix:nonfraction></span> million on the consolidated balance sheet as a deposit liability (cost share advance from collaboration partner) as of the transaction date, split between a current and a non-current portion, based on the expected timing of Allowable Expenses subject to cost share. The financing component has been and will continue to be accreted to interest expense utilizing a method that approximates the effective yield method over the period in which the cost share advance is expected to be used. The remainder of the upfront payment of $<span><ix:nonfraction unitref="usd" contextref="i46646f25f2014144b1e98e9522ea3954_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="6" id="fact-identifier-1109" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0ODgyOA_56b3ea9a-a83b-4a32-8740-9bbb04c42557" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">503.6</ix:nonfraction></span> million was recorded as deferred revenue and has been and will continue to be recognized as collaboration revenue on a straight-line basis over the estimated term of the agreement of <span><ix:nonnumeric contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" format="ixt-sec:durwordsen" name="myov:DeferredRevenueRecognitionPeriod" id="fact-identifier-1110" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA0MzQ_973a38de-adb8-4e49-a07f-254a372b33de" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">six years</ix:nonnumeric></span>, which was estimated by the Company based upon the terms of the Pfizer Collaboration and License Agreement, including the termination provisions contained therein. The Company determined straight-line amortization to be appropriate because the upfront payment represents payment for Pfizer’s right to participate in the collaboration activities, including both commercialization and development activities, which are expected to be realized evenly over this period. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The achievement of regulatory milestones is outside of the Company’s control and therefore is not deemed probable at contract inception. Amounts associated with the regulatory milestones will not initially be recognized. Upon achievement of the related regulatory milestone, cumulative catch-up revenue will be recorded in the period in which the respective regulatory milestone is achieved, and the remainder will be recognized over the remaining contract term. The Company determined that, conceptually, the milestone payments represent payment for development activities that will continue to benefit the collaboration as the products move toward commercialization. Accordingly, the recognition of revenue associated with the regulatory milestones follows the same amortization model as the upfront payment described above.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the development milestones, sales-based milestone payments will not initially be recognized due to the uncertainty associated with the future commercial outcomes of relugolix and relugolix combination tablet. Upon achievement, the sales-based milestones will be recognized as revenue immediately in the period when the annual sales thresholds are met as the payments represent consideration for past activities that are completed and culminated in the annual sales thresholds being met. </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="iebe60ced8eaf4f59bb40fce8834eff03" continuedat="ie01c505da7f540be82b644b83481d5dc" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due to collaboration partner as of March&nbsp;31, 2021 totaling approximately $<span><ix:nonfraction unitref="usd" contextref="i734cf075e84444f4acaa76dbe31c5fc1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:AccruedLiabilitiesCollaborationAgreementCurrent" scale="6" id="fact-identifier-1112" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0ODYwOQ_dce84012-39e4-4bef-92bd-b1ae1e09e92e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.9</ix:nonfraction></span> million consisted of $<span><ix:nonfraction unitref="usd" contextref="i734cf075e84444f4acaa76dbe31c5fc1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:AccruedLiabilitiesCollaborationAgreementShareOfProfitsCurrent" scale="6" id="fact-identifier-1113" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0ODYyOQ_e557c64a-e2f2-4c3d-80f8-594bd4468578" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">1.8</ix:nonfraction></span> million payable to Pfizer for Pfizer’s <span><ix:nonfraction unitref="number" contextref="i734cf075e84444f4acaa76dbe31c5fc1_I20210331" decimals="INF" name="myov:CollaborativeArrangementPercentageOfRevenueRecognizedByCounterparty" scale="-2" id="fact-identifier-1114" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfNTQ5NzU1ODE1OTk5NQ_5dddc06a-48f3-4992-8dad-000a781537bc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50</ix:nonfraction></span>% share of net profits on sales of ORGOVYX in the U.S. and approximately $<span><ix:nonfraction unitref="usd" contextref="i734cf075e84444f4acaa76dbe31c5fc1_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:AccruedLiabilitiesCollaborationAgreementReimbursementOfExpensesCurrent" scale="6" id="fact-identifier-1115" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0ODY1Mg_5df14592-cc25-4688-9710-31f87e5cb7cb" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">0.1</ix:nonfraction></span> million reimbursement of Allowable Expenses incurred by Pfizer. There were no amounts due to collaboration partner as of March&nbsp;31, 2020.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="INF" format="ixt:numdotdecimal" name="myov:LicenseAgreementOptionExerciseFeeValue" scale="6" id="fact-identifier-1116" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTIyNjI_8ea92eb7-fd17-4633-9e20-b26263cf7002" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">50.0</ix:nonfraction></span> million option for an exclusive license in the Pfizer Territory does not give rise to a material right since the option fee, coupled with the net royalty payments, reflects its standalone selling price. As such, the option is not considered a unit of account under the present arrangement and will be assessed for accounting purposes if and when exercised. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 13(C) for a description of the Company’s contract liabilities and changes in these contract liabilities for the year ended March 31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Contract Balances</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract liabilities when cash payments are received or due in advance of the Company’s performance pursuant to license and collaboration agreements. The Company’s contract liabilities consist of deferred revenue and a cost share advance from its collaboration partner, Pfizer. <span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="myov:ScheduleOfLicenseAndCollaborativeAgreementsTableTextBlock" id="fact-identifier-1117" continuedat="i0928a4d5c99640d494a3f1ed2f657a80" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTQxOTA_89823cd1-ee98-484c-a59d-0527a44d646d" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">The following table presents changes in the Company’s contract liabilities during the year ended March 31, 2021 (in thousands):</ix:nonnumeric></span></span></div><span><ix:continuation id="i0928a4d5c99640d494a3f1ed2f657a80" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:30.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March&nbsp;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Imputed Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March&nbsp;31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="ida9dd4331929457f91d25ee1d11bdf22_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="3" id="fact-identifier-1119" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfMy0xLTEtMS0w_cbfe6c9b-00ce-47ed-bc62-71caeb1cbad3" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">40,000</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fca78b28e13473bbba9cab0265c782f_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueAdditions" scale="3" id="fact-identifier-1120" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfMy0zLTEtMS0w_a06dbda4-3615-4d0e-9b77-2ff8c1269835" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">513,620</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i2fca78b28e13473bbba9cab0265c782f_D20200401-20210331" decimals="-3" format="ixt:zerodash" name="myov:DeferredRevenueImputedInterest" scale="3" id="fact-identifier-1121" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfMy01LTEtMS0w_1f9501d9-ab8d-4853-9ff5-ab99b842eb42" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i2fca78b28e13473bbba9cab0265c782f_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueRevenueRecognized1" scale="3" id="fact-identifier-1122" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfMy03LTEtMS0w_44c68514-600f-400b-8e7a-3c61e7f20c0d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">55,687</ix:nonfraction></span>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i273b2f938fcd4cc28208ee0ff9943fc0_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="3" id="fact-identifier-1123" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfMy05LTEtMS0w_e62232c4-76cc-455a-b6a0-cea43c3779d6" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">497,933</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost share advance from collaboration partner </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="-3" format="ixt:zerodash" name="myov:CollaborativeArrangementLiability" scale="3" id="fact-identifier-1124" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfNC0xLTEtMS0w_7a7cd92e-61d8-4219-a5d5-e67aeb8e9390" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">—</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="3" id="fact-identifier-1125" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfNC0zLTEtMS0w_a590124a-69d0-477f-a4df-ee7a70048235" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">146,384</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" name="myov:CollaborativeArrangementImputedInterest" scale="3" id="fact-identifier-1126" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfNC01LTEtMS0w_642306ed-c15a-4485-bfd3-ca47d774a17d" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">635</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:PaymentsForCollaborativeArrangement" scale="3" id="fact-identifier-1127" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfNC03LTEtMS0w_cadce858-10f7-4823-8cdd-eff5aa954e91" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25,157</ix:nonfraction></span>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-3" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiability" scale="3" id="fact-identifier-1128" inside-table="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RhYmxlOjRlMmU1MzQwMjJlNTRhNGFhMWMwN2JkMmY5ZmUzNGU3L3RhYmxlcmFuZ2U6NGUyZTUzNDAyMmU1NGE0YWExYzA3YmQyZjlmZTM0ZTdfNC05LTEtMS0w_c22c820e-4c53-4c6e-90e5-e0b56cee5c1b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">121,862</ix:nonfraction></span>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes $<span><ix:nonfraction unitref="usd" contextref="i273b2f938fcd4cc28208ee0ff9943fc0_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="6" id="fact-identifier-1129" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0OTc2MA_1e32e74b-b861-4c89-be33-77b6707eab56" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">100.6</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="i273b2f938fcd4cc28208ee0ff9943fc0_I20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueNoncurrent" scale="6" id="fact-identifier-1130" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0OTc3OA_c0553b10-90a6-4105-a19d-799df0fe15f0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">397.4</ix:nonfraction></span> million presented as current and non-current, respectively, on the consolidated balance sheet as of March&nbsp;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Includes $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiabilityCurrent" scale="6" id="fact-identifier-1131" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0OTc5NQ_f531745b-6385-40e3-9a5f-3b80823039a9" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">92.4</ix:nonfraction></span> million and $<span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiabilityNoncurrent" scale="6" id="fact-identifier-1132" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY0OTgxMQ_c3ac3945-4113-44e2-b7f6-caaf04fb2acf" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">29.4</ix:nonfraction></span> million presented as current and non-current, respectively, on the consolidated balance sheet as of March&nbsp;31, 2021.</span></div></ix:continuation></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <span><ix:nonfraction unitref="usd" contextref="id4958360cbf8427f96c2932708912fc8_I20210331" decimals="INF" format="ixt-sec:numwordsen" name="myov:DueFromCollaborators" scale="0" id="fact-identifier-1133" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTMyMTg_043b8750-10f8-42d0-90c4-d3a451bff483" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction unitref="usd" contextref="i04e16053900e4008a01ad86b6cb3f057_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="myov:DueFromCollaborators" scale="0" id="fact-identifier-1134" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTMyMTg_ae710dcc-2966-45e3-a5a6-7b5d0a24bf8e" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">no</ix:nonfraction></span></ix:nonfraction></span> contract assets as of March&nbsp;31, 2021 and 2020. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended March 31, 2021, deferred revenue increased by $<span><ix:nonfraction unitref="usd" contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="fact-identifier-1135" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTMzNTY_464fe5c1-26a4-4aeb-9683-ec96e93fc130" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="true" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">457.9</ix:nonfraction></span> million. The increase was the net result of a $<span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueAdditions" scale="6" id="fact-identifier-1136" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTMzOTc_1a7d9209-bdea-4c3e-ac55-40599566e85b" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">503.6</ix:nonfraction></span> million upfront payment received from Pfizer (see Note 13(B)) and a $<span><ix:nonfraction unitref="usd" contextref="i5cadb7c1daa7462598ef501d9080b3db_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueAdditions" scale="6" id="fact-identifier-1137" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM0NjA_ed9aa42e-2b0a-4c1d-962d-d30d09aeac31" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">10.0</ix:nonfraction></span> million regulatory milestone payment received from Richter (see Note 13(A)), partially offset by the recognition of $<span><ix:nonfraction unitref="usd" contextref="i5cadb7c1daa7462598ef501d9080b3db_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:DeferredRevenueRevenueRecognizedDuringPeriod" scale="6" id="fact-identifier-1138" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM1NzE_cab29d36-e2ff-4335-942f-7172da7bcec0" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">33.3</ix:nonfraction></span> million of license and milestone revenue related to the Richter Development and Commercialization Agreement and the recognition of $<span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="fact-identifier-1139" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM2OTc_236a51b8-7a53-4e14-a3a2-df0da48d1232" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false"><span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="6" id="fact-identifier-1140" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM2OTc_e00ca6c9-3384-4586-9d12-83171cf83f64" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">22.4</ix:nonfraction></span></ix:nonfraction></span>&nbsp;million of collaboration revenue related to the Pfizer Collaboration and License Agreement.</span></div></ix:continuation></span><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="ie01c505da7f540be82b644b83481d5dc" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">During the year ended March 31, 2021, cost share advance from collaboration partner increased by $<span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:IncreaseDecreaseInCollaborativeArrangementLiability" scale="6" id="fact-identifier-1142" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM4ODI_c7b83dd2-d67f-4dba-a2c2-13fa4d2ee184" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">121.9</ix:nonfraction></span>&nbsp;million. The increase was the net result of the cost share advance of $<span><ix:nonfraction unitref="usd" contextref="if88b1311809844dc8de95731d40742f4_D20201226-20201226" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="fact-identifier-1143" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM5NDc_16cc8b80-a4a1-424e-a86c-23eea8d85b29" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">150.0</ix:nonfraction></span>&nbsp;million (discounted to a present value of $<span><ix:nonfraction unitref="usd" contextref="i4a9e43d4547546e58bff6661329d1f19_I20201226" decimals="-5" format="ixt:numdotdecimal" name="myov:CollaborativeArrangementLiability" scale="6" id="fact-identifier-1144" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTM5ODQ_999f7cee-c64a-451a-bdd5-87ff912e8f1f" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">146.4</ix:nonfraction></span>&nbsp;million) received from Pfizer (see Note 13(B)), partially offset by the application $<span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:PaymentsForCollaborativeArrangement" scale="6" id="fact-identifier-1145" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTQwNjM_83b89306-2e27-4914-be29-7c9eaffcf7d7" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true"><span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="myov:PaymentsForCollaborativeArrangement" scale="6" id="fact-identifier-1146" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTQwNjM_cc60788e-e384-459c-842f-530baca94ce8" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">25.2</ix:nonfraction></span></ix:nonfraction></span>&nbsp;million of shared Allowable Expenses and accretion of the implied financing component of $<span><ix:nonfraction unitref="usd" contextref="ib8caff843e644adab2aaaa06f74f80ca_D20200401-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="fact-identifier-1147" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82MS9mcmFnOjNhN2ZiYTBhNjZhYTRmOGRiZjY4OWRmMGRjODAyYzgzL3RleHRyZWdpb246M2E3ZmJhMGE2NmFhNGY4ZGJmNjg5ZGYwZGM4MDJjODNfMTA5OTUxMTY1MDA2Nw_eeca81c6-93ab-413f-a900-e45f734b94b5" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="true" istextonly="false" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">0.6</ix:nonfraction></span> million.</ix:continuation></span> </span></div><div id="iad55818e5d094e70a171c29f2aae2512_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14—<span class="float-left text-block-indicator-left position-absolute" title="One or more textblock facts are between this symbol and the right side symbol."></span><span class="float-right text-block-indicator-right position-absolute" title="One or more textblock facts are between this symbol and the left side symbol."></span><span><ix:nonnumeric contextref="i85fa1349fcb4457c8ba5aba5779b7c3d_D20200401-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="fact-identifier-1148" continuedat="i500c4c224b8c46b69cb7901d3ab884b7" escape="true" inside-table="false" continued-main-taxonomy="true" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfNjQ4Ng_d7295d02-e4da-4f16-8ffa-c8d6f19ac971" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="true" iscustomonly="false">Commitments and Contingencies</ix:nonnumeric></span></span></div><span><ix:continuation id="i500c4c224b8c46b69cb7901d3ab884b7" continuedat="i1393918fd9794c808057d2552337bd39" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(A) Legal Contingencies</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such liability can be reasonably estimated. For cases in which the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the loss contingency, including an estimable range, if possible. The Company is currently not involved in any material legal proceedings.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(B) Contract Service Providers</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements with contract service providers to assist in the performance of its R&amp;D and clinical and commercial manufacturing activities. Subject to required notice periods and the Company’s obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, clinical and commercial </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><span><ix:continuation id="i1393918fd9794c808057d2552337bd39" continuedat="i20b1bf6770a24c13ae4a91d05eb6bac7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(C) Indemnification Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to indemnify its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director was serving at the Company’s request in such capacity. The maximum amount of potential future indemnification liability is unlimited; however, the Company holds directors’ and officers’ liability insurance which limits the Company’s exposure and may enable it to recover a portion of any future amounts paid. In the normal course of business, the Company also enters into contracts and agreements with service providers and other parties with which it conducts business that contain indemnification provisions pursuant to which the Company has agreed to indemnify the party against certain types of third-party claims. The Company has agreed to indemnify Sumitomo Dainippon Pharma against certain losses, claims, liabilities and related expenses incurred by Sumitomo Dainippon Pharma, subject to the terms of the Sumitomo Dainippon Pharma Loan Agreement and the Investor Rights Agreement. The Company has also agreed to indemnify Sunovion against certain losses, claims, liabilities and related expenses incurred by Sunovion, subject to the terms of the Market Access Services Agreement, as amended. The Company has not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related accruals have been established.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(D) Takeda Agreements</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2016, Takeda Pharmaceuticals International AG (“Takeda”), a subsidiary of Takeda Pharmaceutical Company Limited, the originator of relugolix, granted the Company a worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive right to develop and commercialize MVT-602 in all countries worldwide. Pursuant to the license agreement (the “Takeda License Agreement”), Takeda granted to the Company an exclusive, royalty-bearing license under certain patents and other intellectual property controlled by Takeda to develop and commercialize relugolix and MVT-602, and products containing these compounds for all human diseases and conditions. Under the Takeda License Agreement, the Company will pay Takeda a fixed, high single-digit royalty on net sales of relugolix and MVT-602 products in the Company’s territory, subject to certain agreed reductions. Takeda will pay the Company a royalty at the same rate on net sales of relugolix products for prostate cancer in the Takeda Territory, subject to certain agreed reductions. Royalties are required to be paid, on a product-by-product and country-by-country basis, until the latest to occur of the expiration of the last to expire valid claim of a licensed patent covering such product in such country, the expiration of regulatory exclusivity for such product in such country, or <span><ix:nonnumeric contextref="i7ab6df641ef14f30bb72bfffdd621f0a_D20200401-20210331" format="ixt-sec:duryear" name="myov:SupplyCommitmentAgreementTermafterFirstCommercialSale" id="fact-identifier-1151" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfMzczNw_62f2d905-b8a3-4045-9bd1-54124ee74afc" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">10</ix:nonnumeric></span> years after the first commercial sale of such product in such country. Under the Takeda License Agreement, there was no upfront payment and there are no payments upon the achievement of clinical development or marketing approval milestones. As the amount and timing of any potential future payments under the Takeda License Agreement are not probable and estimable, no such potential commitments have been included in the consolidated balance sheet.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Takeda License Agreement is terminated in its entirety or with respect to relugolix for prostate cancer, other than for safety reasons or by the Company for Takeda’s uncured material breach, prior to receipt of the first regulatory approval of relugolix for prostate cancer in Japan, then the Company must either reimburse Takeda for its out of pocket costs and expenses directly incurred in connection with Takeda’s completion of the relugolix development for prostate cancer, up to an agreed upon cap, or complete by itself the conduct of any clinical studies of relugolix for prostate cancer that are ongoing as of the effective date of such termination, at its cost and expense.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a Commercial Manufacturing and Supply Agreement with Takeda (the “Takeda Commercial Supply Agreement”) pursuant to which Takeda agreed to supply the Company and the Company agreed to obtain from Takeda certain quantities of relugolix drug substance according to agreed-upon quality specifications. For relugolix drug substance manufactured or delivered on or after December 31, 2019, the Company will pay Takeda a price per kilogram of relugolix drug substance to be agreed upon between the parties at the beginning of each fiscal year.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Takeda Commercial Supply Agreement began on May 30, 2018 and will continue for <span><ix:nonnumeric contextref="i05ed7cbc4a1b443fa804b7e7dd5511ce_D20180530-20180530" format="ixt-sec:durwordsen" name="myov:SupplyCommitmentInitialAgreementTerm" id="fact-identifier-1152" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfNTU0Mg_81dc3265-7a9c-45e1-b53b-a25dfc7de56c" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">five years</ix:nonnumeric></span>. At the end of the initial term, the Takeda Commercial Supply Agreement will automatically renew for successive <span><ix:nonnumeric contextref="i7ab6df641ef14f30bb72bfffdd621f0a_D20200401-20210331" format="ixt-sec:durwordsen" name="myov:SupplyCommitmentRenewalTerm" id="fact-identifier-1153" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfNjQ4OQ_3aaa1d14-6038-4916-b47f-8308a91be580" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">one-year</ix:nonnumeric></span> terms, unless either party gives notice of termination to the other at least <span><ix:nonnumeric contextref="i7ab6df641ef14f30bb72bfffdd621f0a_D20200401-20210331" format="ixt-sec:durmonth" name="myov:SupplyCommitmentTerminationNoticePeriod" id="fact-identifier-1154" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfNTc0Mg_f941288e-22b0-4cb3-948f-ea9520b4af96" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">12</ix:nonnumeric></span> months prior to the end of the then-current term. The Takeda Commercial Supply Agreement may be terminated by either party upon <span><ix:nonnumeric contextref="i7ab6df641ef14f30bb72bfffdd621f0a_D20200401-20210331" format="ixt-sec:durday" name="myov:SupplyCommitmentTerminationNoticePeriodUncuredMaterialBreach" id="fact-identifier-1155" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfNTg2Ng_cc756599-baf0-489b-94b6-6a6b4429fb39" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">90</ix:nonnumeric></span> days’ notice of an uncured material breach of its terms by the other party, or immediately upon notice to the other party of a party’s bankruptcy. Each party will also have the right to terminate the Takeda Commercial Supply Agreement, in whole or in part, for any reason upon <span><ix:nonnumeric contextref="i7ab6df641ef14f30bb72bfffdd621f0a_D20200401-20210331" format="ixt-sec:durday" name="myov:SupplyCommitmentTerminationNoticePeriodOpenPurchaseOrdersFilled" id="fact-identifier-1156" inside-table="false" data-original-id="id3VybDovL2RvY3MudjEvZG9jOmFkNTU4MThlNWQwOTRlNzBhMTcxYzI5ZjJhYWUyNTEyL3NlYzphZDU1ODE4ZTVkMDk0ZTcwYTE3MWMyOWYyYWFlMjUxMl82Ny9mcmFnOjM0Y2EwZmFmMjFiYzQzMjZiYzVhODFhNWY0ZWYzMWU4L3RleHRyZWdpb246MzRjYTBmYWYyMWJjNDMyNmJjNWE4MWE1ZjRlZjMxZThfNjE0MQ_3151ca2d-14db-431d-8814-1359b96c8438" continued-taxonomy="false" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isamountsonly="false" istextonly="true" iscalculationsonly="false" isnegativesonly="false" isadditionalitemsonly="false" isstandardonly="false" iscustomonly="true">180</ix:nonnumeric></span> days’ prior written notice to the other party, provided that any then-open purchase orders will remain in effect and be binding on both </span></div></ix:continuation></span><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span><ix:continuation id="i20b1bf6770a24c13ae4a91d05eb6bac7" inside-table="false" continued-taxonomy="true" enabled-taxonomy="true" highlight-taxonomy="false" selected-taxonomy="false" hover-taxonomy="false" onclick="Taxonomies.clickEvent(event, this)" onkeyup="Taxonomies.clickEvent(event, this)" onmouseenter="Taxonomies.enterElement(event, this);" onmouseleave="Taxonomies.leaveElement(event, this);" tabindex="18" isadditionalitemsonly="false">parties. The Takeda Commercial Supply Agreement, including any then-open purchase orders thereunder, will terminate immediately upon the termination of the Takeda License Agreement in accordance with its terms.</ix:continuation></span></span></div><div id="iad55818e5d094e70a171c29f2aae2512_1155"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.  Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1150"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.  Controls and Procedures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Annual Report on Form 10-K, have concluded that, based on such evaluation, our disclosure controls and procedures were effective. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) Management’s Annual Report on Internal Control Over Financial Reporting </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) and Rule 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pertain to maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the  assets of our company;</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of March&nbsp;31, 2021. In making this assessment, our management used the criteria in the Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO). Based on its assessment, our management has concluded that, as of March&nbsp;31, 2021, our internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm was not required to and did not express an opinion on the effectiveness of our internal control over financial reporting as of March&nbsp;31, 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously seek to improve the efficiency and effectiveness of our internal controls. No changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the fiscal quarter ended March&nbsp;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1145"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  Other Information</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_1163"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to file a definitive proxy statement for our 2021 Annual General Meeting of Shareholders (“2021 Proxy Statement”) with the SEC, pursuant to Regulation 14A, not later than 120 days after March&nbsp;31, 2021. Accordingly, certain information required by Part III has been omitted under General Instruction G(3) to Form 10-K. Only those sections of the 2021 Proxy Statement that specifically address the items set forth herein are incorporated by reference.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1169"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  Directors, Executive Officers and Corporate Governance</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our 2021 Proxy Statement under the captions “Election of Directors,” “Information Regarding the Board of Directors and Corporate Governance,” “Executive Officers” and, if applicable, “Delinquent Section 16(a) Reports” and is incorporated herein by reference.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1175"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  Executive Compensation</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our 2021 Proxy Statement under the captions “Information Regarding the Board of Directors and Corporate Governance,” “Executive Compensation” and “Director Compensation” and is incorporated herein by reference.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1181"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.  Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our 2021 Proxy Statement under the captions “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” and is incorporated herein by reference.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1187"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our 2021 Proxy Statement under the captions “Transactions with Related Persons” and “Information Regarding the Board of Directors and Corporate Governance” and is incorporated herein by reference.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1193"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Principal Accounting Fees and Services</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our 2021 Proxy Statement under the caption “Ratification of Selection of Independent Registered Public Accounting Firm, Appointment of Auditor for Statutory Purposes and Authorization for the Board to Set Auditor Remuneration” and is incorporated herein by reference.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1121"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV. FINANCIAL INFORMATION</span></div><div id="iad55818e5d094e70a171c29f2aae2512_142"></div><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  Exhibits and Financial Statement Schedules</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Documents filed as part of this Annual Report on Form 10-K: </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Financial Statements. Our audited consolidated financial statements and the Report of Independent Registered Public Accounting Firm are included herein on the pages indicated: </span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:92.018%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1138" tabindex="18">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1138" tabindex="18">87</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">Consolidated Balance Sheets as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">March 31, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">2021 and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">2020</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_16" tabindex="18">89</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">Consolidated Statements of Operations for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">Fiscal Year</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">s Ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18"> 31, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18"> and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_19" tabindex="18">90</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">Consolidated Statements of Comprehensive Loss for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">Fiscal </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">Year</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">s Ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18"> 31,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18"> 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18"> a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">nd</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18"> 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_22" tabindex="18">91</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">Consolidated Statements of Shareholders</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_76" tabindex="18">’</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">Equity (Deficit)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> for the</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> Fiscal Year</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">s Ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18"> 31, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">, 2020 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_25" tabindex="18">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_1099511629026" tabindex="18">92</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">Consolidated Statements of Cash Flows for the </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">Fisca</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">l Year</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">s Ended </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">March</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18"> 31, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18"> and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">19</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_28" tabindex="18">94</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_31" tabindex="18">Notes to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_31" tabindex="18">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_31" tabindex="18">95</a></span></div></td></tr></tbody></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Financial Statement Schedules. All financial statement schedules are omitted because they are not applicable or the required information is included in the audited consolidated financial statements or notes thereto.</span></div><div style="margin-top:9pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Exhibits.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&nbsp;of&nbsp;Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Schedule / Form</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex31.htm" tabindex="18">Certificate of Incorporation.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-213891</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/30/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex32.htm" tabindex="18">Memorandum of Association.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-213891</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/30/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000010/myovantex3312312019.htm" tabindex="18">Fifth Amended and Restated Bye-Laws.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex413312020.htm" tabindex="18">Description of Common Shares.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/18/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">See Exhibits 3.1 - 3.3.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000010/myovantex10112312019.htm" tabindex="18">Letter Agreement, dated October 31, 2019, by and between the Registrant and Sumitomo Dainippon Pharma Co., Ltd.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000010/myovantex10212312019.htm" tabindex="18">Loan Agreement, dated as of December 27, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd., as the Lender, the Registrant, as the Parent, and Myovant Sciences GmbH, as the Borrower.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000010/myovantex10312312019.htm" tabindex="18">Investor Rights Agreement, dated as of December 27, 2019, by and among the Registrant, Sumitovant Biopharma Ltd. and Sumitomo Dainippon Pharma Co., Ltd.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex103.htm" tabindex="18">Commitment Letter, dated August 5, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex104.htm" tabindex="18">Commitment Letter Amendment Letter, dated September 29, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex103_dspcommitmentletter.htm" tabindex="18">Commitment Letter Amendment Letter, dated December 22, 2020, by and between Sumitomo Dainippon Pharma Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/11/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000041/a06302020myovant10qex1.htm" tabindex="18">Consulting Agreement, dated May 18, 2020, by and between the Registrant and Sumitovant BioPharma Ltd.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/11/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex101_amendmentno1consulti.htm" tabindex="18">Amendment to Consulting Agreement, dated November 11, 2020, by and between the Registrant and Sumitovant BioPharma, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/11/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1043312020.htm" tabindex="18">License Agreement, dated April 29, 2016, by and between the Registrant and Takeda Pharmaceuticals International AG and Amendment No. 1 dated August 30, 2016.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/18/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1053312020.htm" tabindex="18">Amendment No. 2 to License Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1053312020.htm" tabindex="18">effec</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1053312020.htm" tabindex="18">tive</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1053312020.htm" tabindex="18"> as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1053312020.htm" tabindex="18">November 19, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1053312020.htm" tabindex="18">, by and between the Registrant and Takeda Pharmaceuticals International AG.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/18/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex102_amdno3tolicenseagree.htm" tabindex="18">Amendment No. 3 to License Agreement, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex102_amdno3tolicenseagree.htm" tabindex="18">effective as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex102_amdno3tolicenseagree.htm" tabindex="18"> December 15, 2020, by and between the Registrant and Takeda Pharmaceuticals International AG.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/11/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000026/myovantex1063312020.htm" tabindex="18">Agreement for the Manufacture and Supply of Clinical Trial Material, dated June 7, 2016, by and between the Registrant and Takeda Pharmaceuticals Company Limited, as amended.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/18/2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1013take.htm" tabindex="18">Commercial Manufacturing &amp; Supply Agreement, effective as of May 30, 2018, by and between Myovant Sciences GmbH and Takeda Pharmaceutical Company Limited.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex102.htm" tabindex="18">Commercial Manufacturing and Supply Agreement, dated April 4, 2019, by and between Excella GmbH &amp; Co. KG and Myovant Sciences GmbH.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex101.htm" tabindex="18">Market Access Services Agreement, dated as of August 1, 2020, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex104marketaccessserviceag.htm" tabindex="18">Amendment No.1 to Market Access Services Agreement, dated as of December 14, 2020, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/11/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1017amen.htm" tabindex="18">Amendment No.2 to Market Access Services Agreement, dated as of January 25, 2021, by and between Sunovion Pharmaceuticals Inc. and Myovant Sciences GmbH.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000009/ex105-collaborationandlice.htm" tabindex="18">Collaboration and License Agreement, dated December 26, 2020, by and between Myovant Sciences GmbH and Pfizer Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/11/2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312518105420/d555202dex11.htm" tabindex="18">Sales Agreement, dated as of April&nbsp;2, 2018, between Myovant Sciences Ltd. and Cowen and Company, LLC. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/03/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908218000036/exhibit101lynnseelyemploym.htm" tabindex="18">Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Lynn Seely, M.D. and Myovant Sciences, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/08/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myovantex1020-restrictedst.htm" tabindex="18">Restricted Stock Award Agreement, dated May 31, 2017, by and between Myovant Sciences Ltd. and Lynn Seely. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/24/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000167908218000036/exhibit102frankkarbeemploy.htm" tabindex="18">Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Frank Karbe and Myovant Sciences, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/08/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000167908218000036/exhibit103mattlangemployme.htm" tabindex="18">Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Matt Lang and Myovant Sciences, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/08/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000167908218000036/exhibit104juancamiloarjona.htm" tabindex="18">Amended and Restated Employment Agreement, dated as of November 7, 2018, by and between Juan Camilo Arjona Ferreira, M.D. and Myovant Sciences, Inc.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/08/2018</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1025davi.htm" tabindex="18">Employment Agreement, dated as of January 4, 2021, by and between David Marek and Myovant Sciences, Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1026lynn.htm" tabindex="18">Separation Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1026lynn.htm" tabindex="18"> and General Release</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1026lynn.htm" tabindex="18">, dated as of January 3, 2021, by and between Lynn Seely and Myovant Sciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1027laur.htm" tabindex="18">Employment Agreement, effective as of April 5, 2021, by and between Lauren Merendino and Myovant Sciences, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex108.htm" tabindex="18">Form of Indemnification Agreement with directors and executive officers.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-213891</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/30/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312516741919/d221801dex105.htm" tabindex="18">2016 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-213891</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex106.htm" tabindex="18">Forms of Option Grant Notice and Option Agreement under 2016 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-213891</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/30/2016</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000036/myovantex1019302019.htm" tabindex="18">Form of Amendment No.1 to the Stock Option Grant Notice and Option Agreement under 2016 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1679082/000119312516727309/d221801dex107.htm" tabindex="18">Form of Early Exercise Stock Purchase Agreement under 2016 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-213891</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/30/2016</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myovantex1029-formofrestri.htm" tabindex="18">Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/24/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000036/myovantex1029302019.htm" tabindex="18">Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (2019 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000036/myovantex1029302019.htm" tabindex="18">U</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000036/myovantex1029302019.htm" tabindex="18">.S. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000036/myovantex1029302019.htm" tabindex="18">Form).</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1035form.htm" tabindex="18">Form of Restricted Stock Unit Grant Notice and Award Agreement under 2016 Equity Incentive Plan, as amended (2019 Non-U.S. Form).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908219000019/myovantex1030-formofrestri.htm" tabindex="18">Form of Restricted Stock Award Agreement under 2016 Equity Incentive Plan, as amended.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">05/24/2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex105.htm" tabindex="18">2020 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex106.htm" tabindex="18">Form of Option Grant Notice and Option Agreement under 2020 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex107.htm" tabindex="18">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2020 Inducement Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex107.htm" tabindex="18"> (U.S. Form)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000051/a09302020myovantex107.htm" tabindex="18">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex10ormofr.htm" tabindex="18">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2020 Inducement Plan (Non-U.S. Form).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908220000010/myovant10q12312019.htm#s912D89019D825AADAC7D24CA1D67B9F4" tabindex="18">2020 Incentive Bonus Arrangements with Executive Officers.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37929</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part II -Item 5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/10/2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1042form.htm" tabindex="18">Form of 2021 Incentive Bonus Letter with Executive Officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex1043dire.htm" tabindex="18">Non-Employee Director Compensation Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex211.htm" tabindex="18">Subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†<br></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex231.htm" tabindex="18">Consent of independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†<br></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex311.htm" tabindex="18">Certification of Principal Executive Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">†<br></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex312.htm" tabindex="18">Certification of Principal Financial Officer pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">††**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex321.htm" tabindex="18">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">††**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1679082/000167908221000017/a03312021myovantex322.htm" tabindex="18">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.902%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File- the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">† Filed herewith.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">†† Furnished herewith.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Indicates management contract or compensatory plan.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Portions of this exhibit have been omitted from this exhibit (indicated by asterisks) as such portions are both (a) not material and (b) would likely cause competitive harm to the Registrant if publicly disclosed, or is the type of information that the Registrant treats as private or confidential.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** These certifications are being furnished solely to accompany this Annual Report on Form&nbsp;10-K pursuant to 18 U.S.C. Section&nbsp;1350, and are not being filed for purposes of Section&nbsp;18 of the Exchange Act, as amended, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div><div id="iad55818e5d094e70a171c29f2aae2512_1130"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.  Form 10-K Summary</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><div id="iad55818e5d094e70a171c29f2aae2512_145"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span><br></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:39.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MYOVANT SCIENCES LTD.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Marek</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Marek<br>(Principal Executive Officer and Director)</span></td></tr></tbody></table></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&nbsp;11, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">Table of Content</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iad55818e5d094e70a171c29f2aae2512_7" tabindex="18">s</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David Marek and Frank Karbe, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Annual Report on Form 10-K of Myovant Sciences Ltd., and any or all amendments (including post-effective amendments) thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his, her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:14pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:25.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Marek</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Marek<br></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Frank Karbe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Financial and Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Frank Karbe</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Myrtle Potter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Myrtle Potter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Terrie Curran</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Terrie Curran</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Guinan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Guinan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adele Gulfo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adele Gulfo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Hiroshi Nomura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hiroshi Nomura</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kathleen Sebelius</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathleen Sebelius</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div>

</body>
</html>